
<html lang="en"     class="pb-page"  data-request-id="716425d9-ea7f-4cdd-a464-4998e45841e3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c02218;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-13;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer" /></meta><meta name="dc.Creator" content="Shiou  Zhu" /></meta><meta name="dc.Creator" content="Minru  Liao" /></meta><meta name="dc.Creator" content="Huidan  Tan" /></meta><meta name="dc.Creator" content="Lingjuan  Zhu" /></meta><meta name="dc.Creator" content="Yi  Chen" /></meta><meta name="dc.Creator" content="Gu  He" /></meta><meta name="dc.Creator" content="Bo  Liu" /></meta><meta name="dc.Description" content="Eukaryotic elongation factor 2 kinase (eEF2K), a member of the atypical protein kinase family of alpha-kinases, is well-known as a negative regulator of protein synthesis by phosphorylating eEF2. N..." /></meta><meta name="Description" content="Eukaryotic elongation factor 2 kinase (eEF2K), a member of the atypical protein kinase family of alpha-kinases, is well-known as a negative regulator of protein synthesis by phosphorylating eEF2. N..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 24, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02218" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02218" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02218" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02218" /></link>
        
    
    

<title>Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02218" /></meta><meta property="og:title" content="Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0006.jpeg" /></meta><meta property="og:description" content="Eukaryotic elongation factor 2 kinase (eEF2K), a member of the atypical protein kinase family of alpha-kinases, is well-known as a negative regulator of protein synthesis by phosphorylating eEF2. Notably, eEF2K functions as a key regulator of several cellular processes, leading to tumorigenesis. To date, some small-molecule compounds have been reported as potential eEF2K inhibitors in cancer drug discovery. However, an ideal targeted drug design still faces huge challenges. Alternatively, other design strategies, such as repurposed drugs, dual-target drugs, and drug combination strategies, provide insights into the improvement of cancer treatment. Here, we summarize the crucial eEF2K-modulating pathways in cancer, including AMPK, REDD1, and Src. Moreover, we discuss the inhibition of eEF2K with single-target inhibitors, repurposed drugs, dual-target inhibitors, drug combination strategies, and other emerging technologies for therapeutic purposes. Together, these inspiring findings provide insights into a promising strategy for inhibiting eEF2K with small-molecule compounds to improve potential cancer therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02218"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02218">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02218&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02218&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02218&amp;href=/doi/10.1021/acs.jmedchem.0c02218" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 8870-8883</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01676" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00629" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Shiou Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shiou Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shiou++Zhu">Shiou Zhu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minru Liao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minru Liao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minru++Liao">Minru Liao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huidan Tan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huidan Tan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huidan++Tan">Huidan Tan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lingjuan Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lingjuan Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lingjuan++Zhu">Lingjuan Zhu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#65110a01011c060d040b255453564b060a08"><span class="__cf_email__" data-cfemail="0f7b606b6b766c676e614f3e393c216c6062">[email protected]</span></a>. Phone: (+86) 28-85164063.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi++Chen">Yi Chen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gu He</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gu He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3f575a584a7f4c5c4a115a5b4a115c51"><span class="__cf_email__" data-cfemail="5d35383a281d2e3e2873383928733e33">[email protected]</span></a>. Phone: (+86) 28-85164063.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gu++He">Gu He</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1536-8882" title="Orcid link">https://orcid.org/0000-0002-1536-8882</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Bo Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bo Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#117d7864737e23252121512027223f727e7c"><span class="__cf_email__" data-cfemail="a7cbced2c5c895939797e796919489c4c8ca">[email protected]</span></a>. Phone: (+86) 28-85164063.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Liu">Bo Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3900-9486" title="Orcid link">https://orcid.org/0000-0003-3900-9486</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02218&amp;href=/doi/10.1021%2Facs.jmedchem.0c02218" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 8870–8883</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 23, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 December 2020</li><li><span class="item_label"><b>Published</b> online</span>24 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02218" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02218</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8870%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DShiou%2BZhu%252C%2BMinru%2BLiao%252C%2BHuidan%2BTan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D13%26contentID%3Dacs.jmedchem.0c02218%26title%3DInhibiting%2BEukaryotic%2BElongation%2BFactor%2B2%2BKinase%253A%2BAn%2BUpdate%2Bon%2BPharmacological%2BSmall-Molecule%2BCompounds%2Bin%2BCancer%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8883%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02218"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">526</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02218" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Shiou&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Minru&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Huidan&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Lingjuan&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Yi&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Gu&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;8870-8883&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02218&quot;},&quot;abstract&quot;:&quot;Eukaryotic elongation factor 2 kinase (eEF2K), a member of the atypical protein kinase family of alpha-kinases, is well-known as a negative regulator of protein synthesis by phosphorylating eEF2. Notably, eEF2K functions as a key regulator of several cellular processes, leading to tumorigenesis. To date, some small-molecule compounds have been reported as potential eEF2K inhibitors in cancer drug discovery. However, an ideal targeted drug design still faces huge challenges. Alternatively, other design strategies, such as repurposed drugs, dual-target drugs, and drug combination strategies, provide insights into the improvement of cancer treatment. Here, we summarize the crucial eEF2K-modulating pathways in cancer, including AMPK, REDD1, and Src. Moreover, we discuss the inhibition of eEF2K with single-target inhibitors, repurposed drugs, dual-target inhibitors, drug combination strategies, and other emerging technologies for therapeutic purposes. Together, these inspiring findings provide insights into a prom&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02218&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02218" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02218&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02218" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02218&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02218" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02218&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02218&amp;href=/doi/10.1021/acs.jmedchem.0c02218" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02218" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02218" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02218%26sid%3Dliteratum%253Aachs%26pmid%3D34162208%26genre%3Darticle%26aulast%3DZhu%26date%3D2021%26atitle%3DInhibiting%2BEukaryotic%2BElongation%2BFactor%2B2%2BKinase%253A%2BAn%2BUpdate%2Bon%2BPharmacological%2BSmall-Molecule%2BCompounds%2Bin%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D13%26spage%3D8870%26epage%3D8883%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Eukaryotic elongation factor 2 kinase (eEF2K), a member of the atypical protein kinase family of alpha-kinases, is well-known as a negative regulator of protein synthesis by phosphorylating eEF2. Notably, eEF2K functions as a key regulator of several cellular processes, leading to tumorigenesis. To date, some small-molecule compounds have been reported as potential eEF2K inhibitors in cancer drug discovery. However, an ideal targeted drug design still faces huge challenges. Alternatively, other design strategies, such as repurposed drugs, dual-target drugs, and drug combination strategies, provide insights into the improvement of cancer treatment. Here, we summarize the crucial eEF2K-modulating pathways in cancer, including AMPK, REDD1, and Src. Moreover, we discuss the inhibition of eEF2K with single-target inhibitors, repurposed drugs, dual-target inhibitors, drug combination strategies, and other emerging technologies for therapeutic purposes. Together, these inspiring findings provide insights into a promising strategy for inhibiting eEF2K with small-molecule compounds to improve potential cancer therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84477" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84477" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Eukaryotic elongation factor 2 kinase (eEF2K) was first reported as an atypical alpha-kinase in 1985. As calcium/calmodulin-dependent protein kinase III (CaMKIII), eEF2K is a structurally and functionally unique protein kinase involved in calmodulin-mediated signaling pathways that phosphorylates eEF2 on Thr56 and thereby inhibits the regulation of protein synthesis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Notably, eEF2K consists of two main identifiable domains, with the catalytic domain located in the N-terminus and the SEL domain located near the C-terminus, while its key site for interaction with eEF2 is also located in the C-terminus.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). Currently, the whole three-dimensional structure of eEF2K has not been reported, but has been predicted, with the functional “domain” of eEF2K including an atypical cam binding domain (CBD) at the N-terminus (residues 79–95), followed by a special alpha-kinase catalytic domain (KD) between amino acids 116 and 326, and a long regulatory loop (R-loop) (residues 326–480) that connects to the C-terminal domain (CTD) (residues 490–725) and contains most of the regulatory phosphorylation sites<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). The major self-phosphorylation site, Thr348, is docked in the basic allosteric binding pocket (ABP) of KD to help create a conformation with kinase function, whose phosphorylation is pivotal for fully activating its substrate kinase.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Additionally, the junction region of eEF2K is highly conserved and therefore is crucial for its biological function.<a onclick="showRef(event, 'ref3 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref6">(3,6)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Molecular structure and post-translational modifications of eEF2K. (A) Domain organization of eEF2K. eEF2K consists two main identifiable domains: the catalytic domain lying in the N-terminus and the SEL domain near the C-terminus, with the R-loop region connecting them. (B) The predicted three-dimensional structure of eEF2K. eEF2K can be phosphorylated at different sites and lead to eEF2 inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More importantly, eEF2K may participate in different signaling pathways that play an essential role in different human cancers, such as glioma, breast cancer, and esophageal carcinoma. Overexpression of eEF2K is usually observed in different types of cancer and is crucial in the cancer network of signaling pathways, such as 5′ AMP-activated protein kinase (AMPK).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Moreover, a few of mutations in the <i>eEF2K</i> gene, including S366F and S369F, have also been reported in esophageal and urinary carcinomas and malignant melanoma.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Thus, the inhibition of eEF2K would be considered as a promising therapeutic strategy for cancer.</div><div class="NLM_p">Recently, a series of small-molecule compounds have been reported to affect the function of eEF2K by targeting its regulating oncogenic pathways, such as the single-target inhibitor 21L (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>1</b>), repurposed drug fluoxetine (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>2</b>), dual-target inhibitor 18i (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>3</b>), and combination strategy of the eEF2K inhibitor NH-125 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>4</b>) and Akt inhibitor MK-2206 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>5</b>). Interestingly, some new emerging strategies for inhibiting eEF2K have gradually been developed, such as the identification of eEF2K-regulated noncoding RNAs (ncRNAs) and the proteolytic target chimeras (PROTACs).</div><div class="NLM_p last">Thus, in this review, we focus on summarizing how eEF2K modulates some key pathways in tumorigenesis and further present the current cancer therapeutic strategy of inhibiting eEF2K with single-target inhibitors, repurposed drugs, dual-target inhibitors, and drug combination strategies, which might provide a novel avenue for exploiting more candidate small-molecule compounds that inhibit eEF2K for cancer drug discovery.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">The Oncogenic Roles of eEF2K</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The eEF2K phosphorylates eEF2 at Thr-56, which promotes ribosome translocation during protein translation. Overexpression of eEF2K has been widely reported in various types of cancer, including glioma, breast cancer, and esophageal squamous cell carcinoma (ESCC). <i>eEF2K</i> gene knockout has also been reported to restore the sensitivity of highly drug-resistant cancer cells to acute nutritional deficiency and to significantly affect the growth of MYCN-amplified neuroblastoma xenografts under caloric restriction, whereas overexpression of eEF2K results in the resistance to caloric restriction.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Additionally, knockdown of eEF2K has been shown to decrease cell viability and aggressive biological behaviors in MDA-MB-231 and MDA-MB-468 human breast carcinoma cells.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In addition, eEF2K has been shown to support breast cancer cell survival by promoting the Warburg effect, which is regulated by decreasing protein phosphatase 2A-A (PP2A-A) translation, thereby hindering the degradation of the c-Myc protein and increasing pyruvate kinase isozyme M2 (PKM2) expression.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Compared with normal tissues, ESCC tissues exhibit higher eEF2K expression and increased proliferation. In contrast, eEF2K silencing has been shown to reduce cell proliferation, migration and invasion.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In MD-MBA-231 cells and A549 human nonsmall cell lung cancer (NSCLC) cells, eEF2K reinforces migration and invasion by controlling the translation of mRNAs encoding proteins.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Moreover, some mutations in the <i>eEF2K</i> gene occur in solid tumors, including S366F in esophageal or urinary carcinomas and S396F in malignant melanoma, which have been shown to affect the ability of the protein to bind eEF2. Both Ser-to-Phe mutants and the S366A mutant displayed enhanced binding to eEF2, whereas the Phe variants display markedly higher activity than WT eEF2K, indicating the possible oncogenic role of mutant eEF2K.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Because the frequent overexpression of eEF2K promotes the development of different types of cancer, eEF2K inhibition may represent a promising therapeutic intervention in human cancers.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">The eEF2K-Regulated Signaling Network in Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Upstream Signaling Pathways of eEF2K</h3><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> AMPK/mTORC1/eEF2K</h4><div class="NLM_p">AMPK is well-known to phosphorylate a series of key regulators that ameliorate energy stress by promoting catabolism and inhibiting anabolism.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The activation of eEF2K signaling mediated by AMPK represents the main catabolic pathway. AMPK has been reported to activate eEF2K through direct phosphorylation of S398.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Additionally, the phosphorylation of eEF2K at Ser491/Ser492 is crucial for the regulation of protein synthesis independent of mammalian target of rapamycin complex 1 (mTORC1).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">On the one hand, the inhibition of translation prolongation caused by AMPK-mediated eEF2K activation is essential for the survival of normal and transformed cells under nutritional deprivation conditions. Liver kinase B1 (LKB1) is an upstream mediator that activates AMPK in response to energy pressure. The loss of the tumor suppressor LKB1 in A549 cells leads to the substantial attenuation of AMPK signaling, inducing apoptosis under energy stress triggered by benzobiguanide, which indicates that the loss of established upstream (LKB1) or downstream (eEF2K) targets of AMPK may underlie the susceptibility of cancer cells to starvation.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">On the other hand, the main mechanism underlying the AMPK mediated inhibition of anabolism is a blockade of mTORC1 signaling, which inactivates eEF2K through phosphorylation at Ser336 triggered by 70 kDa ribosomal protein S6 kinase.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Transformation events that lead to the abnormal activation of mTORC1 or extracellular signal-regulated kinase (ERK) signaling block the function of eEF2K for a long time without being affected by AMPK. mTORC1 signaling is inhibited by starvation through an AMPK-independent pathway<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The upstream and downstream signaling pathways of eEF2K in cancer. (A) Upstream signaling pathways of eEF2K. Upstreaming signaling such as AMPK and REDD1 can regulate mTOC1, thereby inhibiting eEF2K. Also, MAPK/ERK signaling can inhibit eEF2K through P90<sup>RSK</sup>, while FOXM1 activates eEF2K to induce downstream CyclinD1 signaling. (B) Downstream signaling pathways of eEF2K. eEF2 is the only known substrate of eEF2K, which can be inactivated by eEF2K. β-integrin, TG2, VEGF, and PI3K pathways can be activated by eEF2K and ultimately lead to tumorigenesis. The regulation of STAT3 by active eEF2K remains disputed, which is activated in liver cancer and inhibited in lung cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7"> REDD1/AKT/mTOR/eEF2K</h4><div class="NLM_p last">Regulated in development and DNA damage response-1 (REDD1) is a stress-related protein involved in cancer progression.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> High REDD1 expression has been reported to be correlated with the progression of bladder urothelial carcinoma (BUC).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> mTOR signaling promotes the degradation of eEF2K by phosphorylating its Ser78/Ser366 sites, which leads to a reduction in autophagy. As an mTOR inhibitor, REDD1 may activate eEF2K-induced autophagy by inhibiting the Akt/mTOR pathway at the early stage and then sustain BUC cell survival. Overexpression of REDD1 increases the expression of eEF2K and the autophagy marker LC3B in BUC cells, while the REDD1 knockout leads to an increase in eEF2K expression and a decrease in LC3B. The expression of REDD1 is induced by mitogen-activated protein kinases (MAPKs) and protein kinase A signaling pathways and negatively regulated by ezrin, T-cell acute leukemia 1, and interleukin 6. In addition, miR-22 enhances the Taxol chemosensitivity of BUC cells by inhibiting the recognized REDD1-eEF2K-autophagy axis.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Treatments inhibiting the REDD1-eEF2K-autophagy axis inhibit BUC cell proliferation. eEF2K-mediated phosphorylation of eEF2 at Thr56 induces autophagy in glioma cells and breast cancer cells,<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> while eEF2K inhibition enhances the efficacy of drugs in human gliomas by inhibiting autophagy<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A).</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> FOXM1/eEF2K/CyclinD1</h4><div class="NLM_p last">Forkhead box m1 (FOXM1) is a member of the fork-head box (FOX) protein family, which is one of the main regulators of tumor metastasis and promotes invasion and progression.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> FOXM1 regulates the expression of the cyclin D1 (CyclinD1) gene.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> CyclinD1 plays key roles in G1 phase, the G1/S transition, and tumorigenesis. Recently, increased FOXM1 expression has been detected in different types of cancer cells, and inhibition of the FOXM1/eEF2K/CyclinD1 axis significantly reduces survival, proliferation, invasion, and migration.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> A systemic intravenous injection of miR-34a nanoparticles has been shown to inhibit both eEF2K and FOXM1, thereby restraining proliferation and angiogenesis, inducing apoptosis, and delaying the development of tumor growth in triple-negative breast cancer (TNBC) xenograft mouse models.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The FOXM1/eEF2K/CyclinD1 axis is crucial for the progression of TNBC (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A).</div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> MAPK/ERK/eEF2K</h4><div class="NLM_p last">Mitogen-activated protein kinases/ERK (MAPK/ERK) signaling plays an important role in cancer cell proliferation.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> eEF2K inhibition disturbs the MAPK/ERK signaling pathway, thereby significantly arresting lung cancer cell proliferation, colony formation, migration, and invasion.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In addition, ERK is reported to phosphorylate eEF2K mainly on Ser359, while Ser396 may also represent a minor phosphorylation site, resulting in eEF2K inhibition<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A).</div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Downstream Signaling Pathways of eEF2K</h3><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> eEF2K/TG2/Src/uPAR</h4><div class="NLM_p">Proto-oncogene tyrosine protein kinase (Src), whose activation triggers invasion and proliferation, is a nonreceptor tyrosine kinase.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> eEF2K is reported to promote proliferation, migration, invasion, the epithelial-mesenchymal transition, and TNBC tumorigenesis and progression by activating the transglutaminase 2 (TG2)/β1 integrin/Src/urokinase-type plasminogen activator receptor (uPAR) axis.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In a TNBC xenograft mouse model, miR-603 induced the significant downregulation of eEF2K in parallel with tumor growth inhibition and was related to decreased Src activity, a downstream target of eEF2K.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Thymoquinone (TQ) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <b>6</b>), has shown to reduce the proliferation, invasion, and migration of MDA-MB-231 and MDA-MB-436 cells, by inducing miR-603 expression and inhibiting the eEF2K/Src/focal adhesion kinase (FAK) axis.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Considering the key roles of the eEF2K/Src/FAK axis in the progression of TNBC, its blockade may be a potential therapeutic strategy (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibiting eEF2K with Single-Target Small-Molecule Compounds in Cancer</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">method</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">cancer type</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>1</b></td><td class="colsep0 rowsep0">21L</td><td class="colsep0 rowsep0">apoptosis inducing</td><td class="colsep0 rowsep0">enzymatic assays followed by apoptosis assay</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 5.5 μM); MDA-MB-231 (IC<sub>50</sub> = 12.6 μM); MDA-MB-436 (IC<sub>50</sub> = 19.8 μM)</td><td class="colsep0 rowsep0">breast cancer; triple-negative breast cancer (<i>in vitro</i> and <i>in vivo</i>: xenograft mouse model of breast cancer)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>4</b></td><td class="colsep0 rowsep0">NH125</td><td class="colsep0 rowsep0">CaM competitive non-ATP competitive</td><td class="colsep0 rowsep0"><i>in vitro</i> eEF2K kinase assay followed by either a filter-based assay or immunoblotting</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 0.06 μM); T98G (IC<sub>50</sub> = 0.06 μM); PC3 (IC<sub>50</sub> = 1.29 μM); A-375 (IC<sub>50</sub> = 2.30 μM); Hela (IC<sub>50</sub> = 2.47 μM); MG63 (IC<sub>50</sub> = 2.89 μM); LoVo (IC<sub>50</sub> = 3.50 μM); MiaPaCa (IC<sub>50</sub> = 3.65 μM); SW620 (IC<sub>50</sub> = 6.96 μM); H1299 (IC<sub>50</sub> = 7.30 μM); H460 (IC<sub>50</sub> = 7.34 μM); H526 (IC<sub>50</sub> = 9.22 μM); U138 (IC<sub>50</sub> = 9.66 μM)</td><td class="colsep0 rowsep0">glioma; prostate cancer; melanoma; cervical cancer; osteosarcoma; colon cancer; pancreatic cancer; NSCLC; SCLC; glioblastoma (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>6</b></td><td class="colsep0 rowsep0">TQ</td><td class="colsep0 rowsep0">regulating the NF-κB/miR-603/eEF2K signal axis</td><td class="colsep0 rowsep0">Western blotting followed by miRNA and mRNA reverse transcription</td><td class="colsep0 rowsep0">MDA-MB-231 (IC<sub>50</sub> = 8.2 μM); MDA-MB-436 (IC<sub>50</sub> = 9.1 μM)</td><td class="colsep0 rowsep0">TNBC (<i>in vitro</i> and <i>in vivo</i>: orthotopic xenograft TNBC tumor mice model</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>7</b></td><td class="colsep0 rowsep0">Rottlerin</td><td class="colsep0 rowsep0">CaM antagonism ATP competitive</td><td class="colsep0 rowsep0"><i>in vitro</i> eEF2K kinase assay followed by autoradiography</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 5.3 μM)</td><td class="colsep0 rowsep0">breast cancer (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref39">(36−39)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>8</b></td><td class="colsep0 rowsep0">TS-2</td><td class="colsep0 rowsep0">inhibition of ATP-binding Inhibition of eEF2-binding</td><td class="colsep0 rowsep0"><i>in vitro</i> eEF2K kinase assay followed by autoradiography</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 0.36 μM)</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>9</b></td><td class="colsep0 rowsep0">TS-4</td><td class="colsep0 rowsep0">inhibition of ATP-binding Inhibition of eEF2-binding</td><td class="colsep0 rowsep0"><i>in vitro</i> eEF2K kinase assay followed by autoradiography</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 0.31 μM)</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>10</b></td><td class="colsep0 rowsep0">TX-1918</td><td class="colsep0 rowsep0">non-ATP competitive</td><td class="colsep0 rowsep0"><i>in vitro</i> eEF2K kinase assay followed by tumor cell growth assay using MTT</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 0.44 μM); HepG2(IC<sub>50</sub> = 2.07 μM)</td><td class="colsep0 rowsep0">liver cancer (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>11</b></td><td class="colsep0 rowsep0">compound <b>34</b></td><td class="colsep0 rowsep0">ATP competitive</td><td class="colsep0 rowsep0"><i>in vitro</i> fluorometric, coupled-enzyme assay</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 0.17 μM); HCT116(IC<sub>50</sub> = 17 μM)</td><td class="colsep0 rowsep0">colorectal cancer (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>12</b></td><td class="colsep0 rowsep0">10,11,27,28-tetrahydrotrisorbicillinone C</td><td class="colsep0 rowsep0">detail mechanism is unknown</td><td class="colsep0 rowsep0">fungal strain and fermentation followed by biomolecular interactions assay</td><td class="colsep0 rowsep0">eEF2K (<i>K</i><sub>d</sub> = 5.5 μM)</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>13</b></td><td class="colsep0 rowsep0">GA</td><td class="colsep0 rowsep0">disrupting EF-2-kinase/Hsp90 interactions</td><td class="colsep0 rowsep0"><i>in vitro</i> clonogenic assays followed by immunoprecipitations and Western blot analysis</td><td class="colsep0 rowsep0">C6 (IC<sub>50</sub> = 2 ± 0.1 μM); T95G (IC<sub>50</sub> = 3 ± 0.2 μM); SKNSH (IC<sub>50</sub> = 1 ± 0.1 μM); Daov (IC<sub>50</sub> = 1 ± 0.1 μM); TJY1-R (IC<sub>50</sub> = 0.4 ± 0.04 μM); TJY2-D (IC<sub>50</sub> = 2 ± 0.1 μM)</td><td class="colsep0 rowsep0">glioma (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>14</b></td><td class="colsep0 rowsep0">17-AAG</td><td class="colsep0 rowsep0">disrupting EF-2-kinase/Hsp90 interactions</td><td class="colsep0 rowsep0"><i>in vitro</i> clonogenic assays followed by immunoprecipitations and Western blot analysis</td><td class="colsep0 rowsep0">C6 (IC<sub>50</sub> = 13 ± 1.8 μM); T95G (IC<sub>50</sub> = 35 ± 4.0 μM)</td><td class="colsep0 rowsep0">glioma (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>15</b></td><td class="colsep0 rowsep0">SCH66336</td><td class="colsep0 rowsep0">induced eEF2 phosphorylation is independent of ras-MEK-eEF2K pathway</td><td class="colsep0 rowsep0">Western blot analysis followed by two-dimensional gel electrophoresis and metabolic labeling</td><td class="colsep0 rowsep0">eEF2K was inhibited from 2 to 8 μM</td><td class="colsep0 rowsep0">head and neck squamous carcinoma (<i>in vitro</i>; cell lines: UMSCC38)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>16</b></td><td class="colsep0 rowsep0">compounds <b>A1</b></td><td class="colsep0 rowsep0">detailed mechanism is unknown</td><td class="colsep0 rowsep0">homology modeling along with analysis</td><td class="colsep0 rowsep0">eEF2K was significantly inhibited at 1.0 μM</td><td class="colsep0 rowsep0">TNBC (<i>in vitro</i>; cell lines: MDA-MB-231 cell lines)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>17</b></td><td class="colsep0 rowsep0">compounds <b>A2</b></td><td class="colsep0 rowsep0">detailed mechanism is unknown</td><td class="colsep0 rowsep0">homology modeling along with analysis</td><td class="colsep0 rowsep0">eEF2K was significantly inhibited at 2.5 μM</td><td class="colsep0 rowsep0">TNBC (<i>in vitro</i>; cell lines: MDA-MB-231)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>18</b></td><td class="colsep0 rowsep0">A-484954</td><td class="colsep0 rowsep0">ATP-competitive and cell-permeable inhibitor of eEF2K</td><td class="colsep0 rowsep0"><i>in vitro</i> kinase assay using myelin basic protein as substrate</td><td class="colsep0 rowsep0">eEF-2K(IC<sub>50</sub> = 0.42 ± 0.01 μM); MDA-MB-231 (inhibit eEF2K at 75 μM)</td><td class="colsep0 rowsep0">TNBC (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>19</b></td><td class="colsep0 rowsep0">WNN0017-C003</td><td class="colsep0 rowsep0">promoting eEF2 phosphorylation</td><td class="colsep0 rowsep0">luminescence-based HTS assay for eEF2K</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 32.3 μM)</td><td class="colsep0 rowsep0">human breast cancer; human NSCLC (<i>in vitro</i>; cell lines: MDA-MB-453 H1299 HCT116)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>20</b></td><td class="colsep0 rowsep0">WNN0048-A002</td><td class="colsep0 rowsep0">promoting eEF2 phosphorylation</td><td class="colsep0 rowsep0">luminescence-based HTS assay for eEF2K</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 13.27 μM)</td><td class="colsep0 rowsep0">human breast cancer; human NSCLC (<i>in vitro</i>; cell lines: MDA-MB-453 H1299 HCT116)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>21</b></td><td class="colsep0 rowsep0">WNN0532-H011</td><td class="colsep0 rowsep0">detail mechanism is unknown</td><td class="colsep0 rowsep0">luminescence-based HTS assay for eEF2K</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 0.032 μM)</td><td class="colsep0 rowsep0">human breast cancer; human NSCLC (<i>in vitro</i>; cell lines: MDA-MB-453 H1299 HCT116)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>22</b></td><td class="colsep0 rowsep0">WNN0572-A011</td><td class="colsep0 rowsep0">detail mechanism is unknown</td><td class="colsep0 rowsep0">luminescence-based HTS assay for eEF2K</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 0.069 μM)</td><td class="colsep0 rowsep0">human breast cancer; human NSCLC (<i>in vitro</i>; cell lines: MDA-MB-453 H1299 HCT116)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>23</b></td><td class="colsep0 rowsep0">WNN0593-D007</td><td class="colsep0 rowsep0">detail mechanism is unknown</td><td class="colsep0 rowsep0">luminescence-based HTS assay for eEF2K</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 0.23 μM)</td><td class="colsep0 rowsep0">human breast cancer; human NSCLC (<i>in vitro</i>; cell lines: MDA-MB-453 H1299 HCT116)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>24</b></td><td class="colsep0 rowsep0">Cefatrizine</td><td class="colsep0 rowsep0">induces ER stress</td><td class="colsep0 rowsep0">network construction, functional clustering and enrichment analysis</td><td class="colsep0 rowsep0">MCF-7 (IC<sub>50</sub> = 30 μM); MDA-MB-436 (IC<sub>50</sub> = 30 μM)</td><td class="colsep0 rowsep0">human breast carcinoma (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></td></tr></tbody></table></div></div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> eEF2K/VEGF</h4><div class="NLM_p last">eEF2K regulates angiogenesis in liver cancer <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Inhibition of eEF2K reduces vascular endothelial growth factor (VEGF) mRNA expression and thereby impairs angiogenesis in MHCC97H and HepG2 hepatocellular carcinoma cells and mouse tumor models. Thus, eEF2K induces the expression of angiogenesis-related genes such as vascular endothelial growth factor receptor 2.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In addition, β-cryptoxanthin has been shown to downregulate the expression of eEF2K, thereby significantly reducing the levels of VEGF and ultimately inhibiting the viability of AGS and SGC-7901 human gastric carcinoma cells<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> eEF2K/PI3K/Akt</h4><div class="NLM_p last">eEF2K has been recently reported to activate the phosphoinositide 3-kinase/Akt (PI3K/Akt) pathway by phosphorylating PI3K at Tyr458 and Akt at Ser473 and Thr308. Interestingly, in MHCC97H cells, the results are paradoxical to the known role of the PI3K/Akt pathway in suppressing eEF2K. This paradox may stem from the reduction in the expression and secretion of growth factors from cancer cells or endothelial cells or other as yet uncovered feedback mechanisms<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div></div><div id="sec3_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> eEF2K/STAT3</h4><div class="NLM_p last">Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in human cancers and is important for the proliferation and survival of cancer cells. In liver cancer, eEF2K has been shown to promote the angiogenesis and tumor progression of liver cancer cells by stimulating STAT3 signaling, while eEF2K silencing inhibits tumor growth and angiogenesis.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In lung cancer, eEF2K inhibition increases STAT3 phosphorylation, which promotes cancer cell proliferation and tumor growth in mouse models. eEF2K is confirmed to form a complex with PKM2 and STAT3, followed by PKM2 phosphorylation at T129, consequently reducing its dimerization reaction. Subsequently, PKM2 blocks STAT3 phosphorylation and STAT3-dependent c-Myc expression<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Inhibiting eEF2K with Small-Molecule Compounds in Cancer Therapy</h3><div class="NLM_p last">eEF2K, as an atypical kinase, is different from other protein kinases, enabling the development of potently selective small-molecule inhibitors without affecting other kinases. However, as an atypical alpha-kinase, eEF2K is not inhibited by “classical” protein kinase inhibitors, rendering the development of small-molecule inhibitors more challenging and independent of experiences with previously known kinase inhibitors. Thus, the current cancer therapies associated with eEF2K inhibition, including targeted inhibitors, repurposed drugs, dual-target inhibitors, and combination strategies are summarized (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Single-Target Small-Molecule Inhibitors of eEF2K</h3><div class="NLM_p">Rottlerin (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>7</b>), derived from <i>Mallotus philippinensis</i>, is an inhibitor of eEF2K that blocks its phosphorylation with an IC<sub>50</sub> of 5.3 μM.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> However, rottlerin also inhibits other protein kinases with much stronger activity, indicating that rottlerin may not be sufficiently specific to affect eEF2K alone.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> TS-2 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>8</b>) and TS-4 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>9</b>) have been reported to be the first identified eEF2K-selective inhibitors, showing little activity toward CaMK-I and CaMK-II, in contrast to rottlerin. Thus, these compounds may be useful tools for studying the function of eEF2K.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Among the many analogs of tyrphostin AG17 that were designed and synthesized based upon the lead structure of a soft-acid-type electrophilic cyclopentene-1,3-dione moiety, TX-1918 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>10</b>) was discovered in a high-throughput screen. It has shown a significant activity against eEF2K with an IC<sub>50</sub> of 0.44 μM in human colorectal carcinoma HCT166 cells and HepG2 cells.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Moreover, several thieno[2-3-<i>b</i>] pyridine analogs possess inhibitory activity against eEF2K. Ring fusion adjacent to the nitrogen on the thiophene pyridine nucleus is imperative for the anti-eEF2K activity. Among these analogs, compound 34 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>11</b>) is the most effective, with an IC<sub>50</sub> of 170 nM for eEF2K <i>in vitro</i>, but its mechanism of suppressing eEF2K remains unclear.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Additionally, a new sorbic penicillin compound, 10,11,27,28-tetrahydrotrisorbicillinone C (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>12</b>), which was isolated from the sponge-derived fungus <i>Penicillium chrysogenum</i> 581F1, participates in biological interactions with eEF2K, with a <i>K</i><sub>d</sub> value of 0.0746 μM, making it a promising drug candidate.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Most of these eEF2K inhibitors lack sound data beyond kinase assays, and thus their mechanisms and efficacy <i>in vitro</i> and <i>in vivo</i> require further exploration.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Single-target inhibitors of eEF2K in cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Moreover, geldanamycin (GA) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>13</b>) and its less toxic and potent derivative 17-allylamino-17-demethyoxygeldanamycin (17-AAG) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>14</b>) exert cytotoxic effects on four glioma cell lines by disrupting the interaction of eEF2K and Hsp90. Only the effect of 17-AAG against C6 glioma has been tested in nude mice since it is less toxic than GA and highly lipid soluble, allowing it to penetrate the blood–brain barrier.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a><b>4</b> inhibits eEF2K kinase activity <i>in vitro</i> (IC<sub>50</sub> = 60 nM), blocks the phosphorylation of eEF2 in intact cells, and shows relative selectivity toward other protein kinases.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> However, an <b>4</b>-mediated increase in the phosphorylation of eEF2 was subsequently reported upon the coinhibition of AMPK and eEF2K signaling, and the anticancer property of <b>4</b> in PC3 cells is more likely related to the induction of eEF2 phosphorylation than the inhibition of eEF2K.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Inhibition of protein synthesis by eEF2 inactivation represents a new mechanism of SCH66336 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>15</b>)-mediated tumor growth inhibition that is independent of the RAS-MEK/p70S6K-eEF2K signal cascade.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Compounds A1 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>16</b>) and A2 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>17</b>) have been reported to be potent and selective inhibitors that show high efficacy in suppressing eEF2K at 1.0 and 2.5 μM doses, respectively, thereby impairing the growth of breast cancer cells.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">Additionally, other small-molecule inhibitors have been shown to affect the AMPK pathway and other relevant pathways thereby modulating eEF2K. A series of pyrido[2,3-<i>d</i>] pyrimidine-2,4-dione derivatives, compounds <b>6</b>–<b>16</b>, show inhibitory activities against eEF2K and the structure–activity relationships (SAR) of compound <b>6</b> (A-484954) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>18</b>). Compounds <b>6</b> (A-484954) and <b>9</b> inhibit AMPK-mediated activation of eEF2K in MDA-MB-231 cells, which provides a basis for the optimization of novel pyrido[2,3-<i>d</i>] pyrimidine analogs as new eEF2K inhibitors.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Additionally, human eEF2K was purified from an <i>E. coli</i> expression system, and a luminescence-based high-throughput screening (HTS) method was established using MH-1 peptide as a substrate. From 56,000 synthetic compounds, nine initial hits with inhibitory effects on eEF2K were identified, and five of the nine compounds (WNN0017-C003, WNN0048-A002, WNN0532- H011, WNN0572-A011, and WNN0593-D007) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>19</b>–<b>23</b>) exerted consistent effects (>30%) on inhibiting eEF2K. Interestingly, <b>19</b> and <b>20</b> promote eEF2 phosphorylation in MDA-MB-453 cells, in contrast to their positive control (compound <b>18</b>), which inhibited eEF2 phosphorylation.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Compound <b>6</b> has been reported to inhibit the growth, migration, and invasion of TNBC cells by partially regulating the nuclear factor kappa-light-chain-enhancer of activated B (NF-κB)/miR-603/eEF2K signaling axis.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p last">Moreover, a new eEF2K inhibitor (cefatrizine) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>24</b>) has been reported to induce endoplasmic reticulum (ER) stress in breast cancer cells, which may promote tumor cell death by regulating crosstalk between autophagy and apoptosis.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In addition, a β-phenylalanine scaffold was found, and 46 derivatives were designed and synthesized to assess their inhibitory effects on eEF2K and cytotoxicity. In addition, an eEF2K inhibitor <b>1</b> was shown to have the best enzymatic and antiproliferative activity (IC<sub>50</sub> = 5.5 ± 1.4 μM), inhibiting tumor growth by inducing apoptosis <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Inhibiting eEF2K with Repurposed Drugs</h3><div class="NLM_p">Compound <b>2</b>, a selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI) that is widely used in clinical practice, has been reported to induce autophagic cell death in MDA-MB-231 and MDA-MB-436 cells.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The mechanism by which fluoxetine induces autophagic cell death is related to the inhibition of eEF2K and activation of the AMPK-mTOR-ULK1 axis.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> In addition, four small-molecule compounds from the FDA-approved drug library have been screened as new hit compounds to inhibit eEF2K: pemetrexed (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>25</b>), entecavir (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>26</b>), calcium levofolinate (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>27</b>), and fosbretabulin (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>28</b>). All of them displayed a high binding affinity with eEF2K in SPR assays, with <i>K</i><sub>d</sub> values of 0.104 μM, 2.16 μM, 11.7 μM, and 34.5 μM. However, only entecavir and pemetrexed inhibited eEF2 phosphorylation in experimental validation studies, and further investigation is needed to verify their efficacy on breast cancer.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Mitoxantrone (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>29</b>) has been shown to be a new eEF2K inhibitor that directly binds to eEF2K and inhibits the phosphorylation of eEF2, followed by Akt inhibition.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Drug repurposing may expand the sources of eEF2K inhibitors while reducing costs and time compared to newly designed eEF2K inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Repurposed inhibitors targeting eEF2K in cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibiting eEF2K with Repurposed Drugs in Cancer</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">method</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">cancer type</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>2</b></td><td class="colsep0 rowsep0">fluoxetine</td><td class="colsep0 rowsep0">autophagic cell death triggered; activation of the AMPK-mTOR- ULK1 axis</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0">TNBC (<i>in vitro</i>; cell lines: MDA-MB-231, MDA-MB-468)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>25</b></td><td class="colsep0 rowsep0">pemetrexed</td><td class="colsep0 rowsep0">inhibiting eEF2 phosphorylation</td><td class="colsep0 rowsep0">homology modeling, QSAR, and molecular docking</td><td class="colsep0 rowsep0"><i>K</i><sub>d</sub> = 0.104 μM</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>26</b></td><td class="colsep0 rowsep0">entecavir</td><td class="colsep0 rowsep0">inhibiting eEF2 phosphorylation</td><td class="colsep0 rowsep0">homology modeling, QSAR, and molecular docking</td><td class="colsep0 rowsep0"><i>K</i><sub>d</sub> = 2.16 μM</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>27</b></td><td class="colsep0 rowsep0">calcium levofolinate</td><td class="colsep0 rowsep0">inhibiting eEF2 phosphorylation</td><td class="colsep0 rowsep0">homology modeling, QSAR and molecular docking</td><td class="colsep0 rowsep0"><i>K</i><sub>d</sub> = 11.7 μM</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>28</b></td><td class="colsep0 rowsep0">fosbretablin</td><td class="colsep0 rowsep0">inhibiting eEF2 phosphorylation</td><td class="colsep0 rowsep0">homology modeling, QSAR and molecular docking</td><td class="colsep0 rowsep0"><i>K</i><sub>d</sub> = 34.5 μM</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>29</b></td><td class="colsep0 rowsep0">mitoxantrone</td><td class="colsep0 rowsep0">phosphorylating eEF2</td><td class="colsep0 rowsep0">structure-based virtual screening</td><td class="colsep0 rowsep0"><i>K</i><sub>d</sub> = 9.11 μM</td><td class="colsep0 rowsep0">breast cancer; (<i>in vitro</i>, cell lines: MCE-7, MDA-MB-231)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></td></tr></tbody></table></div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Dual-Target Small-Molecule Inhibitors of eEF2K</h3><div class="NLM_p last">Both polo-like kinase 1 (PLK1) and eEF2K are serine threonine kinases that play important roles in the proliferation and programmed cell death of human cancers.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Based on the pharmacophore model of PLK1 and the homology model of eEF2K, a new dual-target inhibitor of PLK1/eEF2K, compound <b>3</b>, was identified.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Through molecular mechanistic studies of kinetic simulation, cell cycle, apoptosis, and autophagy, compound <b>3</b> was found to display adequate antitumor activity. Furthermore, nanoliposomal delivery of miR-34a inhibits tumor proliferation and angiogenesis, induces apoptosis, and delays tumor growth in two different TNBC orthotopic tumor transplantation models by directly binding to the 3′-untranslated region of eEF2K and FOXM1, thereby suppressing their expression.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> These dual-target eEF2K inhibitors may reduce the toxicity of traditional eEF2K inhibitors, thereby representing a new direction of drug discovery of eEF2K inhibitors.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Inhibiting eEF2K with Combination Strategies</h3><div class="NLM_p">The expression of heat shock protein 90 (HSP90) is increased in eEF2K-deficient human cells and eEF2K knockout (eEF2K–/−) mouse embryonic fibroblasts (MEFs). eEF2K dysfunction has been suggested to increase the expression of HSP90 chaperones and their collective effects on proper homeostasis, which makes their combined inhibition a promising strategy for cancer therapy.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> eEF2K determines the crosstalk between autophagy and pyroptosis in melanoma cells treated with adriamycin. Inhibition of eEF2K inhibits autophagy while activating pyroptosis, thereby increasing the sensitivity of melanoma cells to adriamycin, representing a new idea for combined tumor chemotherapy.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Additionally, the combination of the selective eEF2K inhibitor <b>4</b> and Akt inhibitor <b>5</b> showed good synergistic antitumor effects <i>in vivo</i>. Compared with <b>5</b> alone, a combination with an shRNA or <b>4</b> inhibits eEF2 kinase and enhances the effect of <b>5</b> on human nasopharyngeal carcinoma cells.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In addition, inhibiting the synergistic effect of eEF2K and <b>5</b> is similar to that of hydroxychloroquine and <b>5</b>.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> More recently, eEF2K has been reported to participate in Akt activation and autophagy evoked by mTOR inhibitors induces drug resistance in breast cancer, indicating that combination of an eEF2K inhibitor and mTOR inhibitor warrants further investigation. Subsequently, compound <b>29</b>, an FDA-approved drug, was shown to restrain the growth of breast cancer <i>in vitro</i> and <i>in vivo</i> when combined with the mTOR inhibitor rapamycin (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>30</b>).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> As mentioned above, combination strategies can enhance drug efficacy and reduce single drug doses to alleviate side effects, ultimately promoting the employment of eEF2K inhibitors in cancer treatment.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Other small-molecule inhibitors targeting/cotargeting eEF2K in cancer therapy. (A) The dual-target inhibitor of eEF2K and PLK1. (B) Combination strategies including one eEF2K inhibitor and the other drug. (C) eEF2K inhibitors identified with other emerging techniques. <b>31</b> is a PROTAC small-molecule inhibitor, and <b>32</b> and <b>33</b> are inhibitors identified using highly sensitive fluorescence analysis based upon Sox.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Emerging Therapeutic Strategies Targeting eEF2K in Cancer</h3><div class="NLM_p">The development of cutting-edge technologies may provide a new insight into eEF2K inhibition. Noncoding RNAs represent a promising field of eEF2K inhibition. The overexpression of long intergenic noncoding RNA (GAPLINC) is related to a poor prognosis for patients with NSCLC.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> GAPLINC silencing inhibits cell proliferation, promotes cell apoptosis, and induces cell cycle arrest in G0/G1 phase and has been recently shown to reduce the expression of the eEF2K protein <i>in vivo</i> and <i>in vitro.</i> Bioinformatics analysis and luciferase reporter assays confirmed that miR-661 targets GAPLINC and the eEF2K 3′-UTR and is negatively correlated with the expression of GAPLINC and eEF2K.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> A reduction in miR-603 expression was reported to induce the eEF2K overexpression in TNBC cells, while its overexpression inhibited TNBC growth, migration, and invasion through direct eEF2K inhibition by binding to the 3′-UTR. The expression of miR-449b is positively correlated with the radiosensitivity of cancer cells and is detected in patient tumor specimens.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Importantly, miR-449b mimics can inhibit the expression of eEF2K, leading to increased protein synthesis and depletion of cellular ATP.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> In addition, it is proved that miR-449b mimics an increase in sensitivity of cancer cells to ionizing radiation <i>in vitro</i> and <i>in vivo</i>, which is compromised by the inhibitor of protein synthesis cycloheximide or by direct delivery of ATP liposome, and this also supports the modulating roles of eEF2K in miR-449b-induced radio-sensitizing effects. Notably, miRNA-22-3p binds directly to the 3′-UTR of eEF2K and regulates the expression of the eEF2K mRNA, ultimately suppressing MDA-MB-231 cell proliferation, migration, and invasion and the growth of orthotopic TNBC xenografts in mice.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Given the regulatory relationship between different microRNAs and eEF2K, the employment of microRNA mimics may represent a new strategy to inhibit eEF2K.</div><div class="NLM_p">Polyethylenimine-modified gold nanoparticles (AuNPs-PEI)/eEF2K siRNA have been shown to be effective in downregulating gene expression <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Additionally, AuNP-PEI/eEF2K nanoparticles exert antitumor effects related to eEF2K gene silencing and inhibition of the Src and MAPK-ERK signaling pathways in TNBC.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The use of AuNP-PEI as an siRNA vector may be a potential therapeutic strategy for TNBC.</div><div class="NLM_p">Importantly, another novel technology to inhibit eEF2K is PROTAC technology, which uses the proteasome to degrade the target protein and inhibit the growth of cancer cells. PROTACs can target nontreatable targets, which may account for more than 80% of the human proteome.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Additionally, for many druggable targets, PROTAC is also a strategy used to address drug resistance and improve drug selectivity. Current eEF2K inhibitors lack inhibitory effects on cancer cells, and the use of the PROTAC strategy with compound <b>11L</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>31</b>) to degrade eEF2K in combination with the eEF2K inhibitor <b>18</b> and its potential derivatives has been shown to overcome the insufficient inhibitory effect of the existing eEF2K inhibitors.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Additionally, 2,6-diamino-4-(2-fluorophenyl)-4H-thiopyran-3,5-dicarbonitrile (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>32</b>) and 2-((3-cyano-4-(4-methoxyphenyl) pyridine-2-ylthio)-2-phenylacetic) acid (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>33</b>) are examples utilizing a highly sensitive fluorescence analysis based upon Sox.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p">Moreover, cancer exosomes have been recently reported to be capable of inducing eEF2K expression, revealing a new mechanism of its oncology.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> eEF2K also affects the immune response by positively regulating programmed death-ligand 1 expression in A549 cells, human prostate carcinoma PC3 cells, and MDA-MB-231 cells, rendering tumors resistant to immune attack.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Overall, these complex effects of eEF2K on tumorigenesis make its inhibition warrant further investigations.</div><div class="NLM_p">Interestingly, eEF2K silencing has been shown to generate cytoprotective autophagy in colon cancer cells via the AMPK-ULK1 pathway instead of the suppression of mTOR or reactive oxygen species production, suggesting that the upregulation of eEF2K may constitute a potentially new therapy for human colon cancer.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> More recently, eEF2K has been confirmed to suppress lung cancer cell proliferation by forming a complex with PKM2 and STAT3, followed by PKM2 phosphorylation at T129, thereby reducing its dimerization.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Nelfinavir, an antiviral drug approved by the FDA, shows effective anticancer activity in mice by eliciting eEF2K activation independent of mTORC1 inhibition, AMPK, or the integrated stress response.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a> Based on the discoveries of the possible tumor-suppressive role of eEF2K, designing eEF2K activators for specific tumor types might be another therapeutic strategy for cancer drug discovery (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Other Small Molecules to Inhibit eEF2K</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">method</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">cancer type</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>3</b></td><td class="colsep0 rowsep0">18i</td><td class="colsep0 rowsep0">inducing autophagy and mitochondrial apoptotic cell death</td><td class="colsep0 rowsep0">generation of multicomplexes-based pharmacophore model of PLK1 and homology modeling of eEF2K</td><td class="colsep0 rowsep0">PLK1 (<i>K</i><sub>d</sub> = 94.9 ± 9.3 μM); eEF2K (<i>K</i><sub>d</sub> = 82.7 ± 14.8 μM); MCF-7 (IC<sub>50</sub> = 1.24 ± 0.35 μM); BT-483 (IC<sub>50</sub> = 13.3 ± 2.86 μM)</td><td class="colsep0 rowsep0">breast cancer (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>5</b></td><td class="colsep0 rowsep0">MK-2206</td><td class="colsep0 rowsep0">inducing eEF2K-dependent autophagy</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>30</b></td><td class="colsep0 rowsep0">Rapamycin</td><td class="colsep0 rowsep0">enhancing mTOR-targeted cancer therapy through the eEF2K-induced activation of resistance signaling pathways</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>31</b></td><td class="colsep0 rowsep0"><b>11L</b></td><td class="colsep0 rowsep0">apoptosis-inducing</td><td class="colsep0 rowsep0">colony formation assay followed by immunoblotting analysis</td><td class="colsep0 rowsep0">MDA-MB-231 (IC<sub>50</sub> = 100 μM)</td><td class="colsep0 rowsep0">TNBC (<i>in vitro</i>)</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>32</b></td><td class="colsep0 rowsep0">2,6-diamino-4-(2-fluorophenyl)-4H-thiopyran-3,5-dicarbonitrile</td><td class="colsep0 rowsep0">non-ATP competitive</td><td class="colsep0 rowsep0">fluorescence-based assay that uses the phosphorylation of a Sox-based peptide (<i>in vitro</i>)</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 60 μM)</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>33</b></td><td class="colsep0 rowsep0">2-((3-cyano-4-(4-methoxyphenyl) pyridine-2-ylthio)-2-phenylacetic) acid</td><td class="colsep0 rowsep0">non-ATP competitive</td><td class="colsep0 rowsep0">luminescence-based assay that measures the amount of ATP remaining in the reaction (in vitro)</td><td class="colsep0 rowsep0">eEF2K (IC<sub>50</sub> = 77 μM)</td><td class="colsep0 rowsep0">–</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></td></tr></tbody></table></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46684" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46684" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Considering the importance of eEF2K in tumorigenesis, eEF2K represents a promising therapeutic target for cancer therapy. To date, fluoxetine and other FDA-approved drugs have been repurposed to inhibit eEF2K. Single-target inhibitors such as NH-125, TX-1918, AG, and 17-AAG have been developed, and dual-target inhibitors including 18i and drug combination strategies of NH125 (eEF2K inhibitor) and MK-2206 (Akt inhibitor) also show adequate activity. Meanwhile, some new emerging techniques, such as noncoding RNAs and PROTACs, may further accelerate the process of eEF2K-targeted cancer drug discovery.</div><div class="NLM_p">Interestingly, the currently available eEF2K inhibitors may display either adequate inhibitory kinase activity, such as A-484954, or potent antiproliferative activity, such as NH125; however, none of them can exhibit both properties to inhibit eEF2K and cancer cell proliferation simultaneously. Thus, the anticancer efficacy of eEF2K inhibitors has been disputed. We speculate that this property is attributed to the function of eEF2K itself as a weak oncogene, thereby making the drug combination strategies of eEF2K inhibitors more promising approaches. In addition, the whole three-dimensional structure of eEF2K has not been clearly solved to date, which limits the structure-based drug design of eEF2K inhibitors. Thus, a complete structural analysis of eEF2K is needed to promote the development of eEF2K inhibitors. Moreover, natural product libraries and new DNA-encoding libraries are worth considering as additional sources of leading compounds as eEF2K inhibitors, which may identify novel scaffolds for eEF2K inhibitors.</div><div class="NLM_p last">More importantly, genetic interventions using RNAi or clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas 9) are good methods to further investigate the biological function of eEF2K. For the pharmacological verification, most eEF2K inhibitors were solely investigated using multiple kinase assay; thus, in-depth investigations are needed for better translation to preclinical or even clinical practice. As an increasing number of new techniques, including PROTAC, gene editing, and noncoding RNAs, are being implemented for drug development, opportunities exist to discover more specific and potent small-molecule inhibitors of eEF2K as future cancer therapeutics.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02218" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi Chen</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center and Department of Gastrointestinal Surgery, West
China Hospital, Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6a1e050e0e1309020b042a5b5c5944090507"><span class="__cf_email__" data-cfemail="73071c17170a101b121d334245405d101c1e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gu He</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center and Department of Gastrointestinal Surgery, West
China Hospital, Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1536-8882" title="Orcid link">https://orcid.org/0000-0002-1536-8882</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9cf4f9fbe9dcefffe9b2f9f8e9b2fff2"><span class="__cf_email__" data-cfemail="fa929f9d8fba89998fd49f9e8fd49994">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Liu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center and Department of Gastrointestinal Surgery, West
China Hospital, Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3900-9486" title="Orcid link">https://orcid.org/0000-0003-3900-9486</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b2dedbc7d0dd80868282f28384819cd1dddf"><span class="__cf_email__" data-cfemail="e08c8995828fd2d4d0d0a0d1d6d3ce838f8d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shiou Zhu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center and Department of Gastrointestinal Surgery, West
China Hospital, Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minru Liao</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center and Department of Gastrointestinal Surgery, West
China Hospital, Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huidan Tan</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center and Department of Gastrointestinal Surgery, West
China Hospital, Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lingjuan Zhu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center and Department of Gastrointestinal Surgery, West
China Hospital, Sichuan University, Chengdu 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>These authors contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Shiou Zhu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=BIO-d7e2207-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Shiou Zhu</b> received her bachelor’s degree from Wuhan University of Science and Technology in 2020. She is now a graduate student at State Key Laboratory of Biotherapy and Cancer Center of West China Hospital in Sichuan University. Her research interest is focused on the designing and discovery of novel small-molecule inhibitors targeting eEF2K in breast cancer.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Minru Liao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=BIO-d7e2212-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Minru Liao</b> received her bachelor’s degree in clinical pharmacy from China Medical University in 2019. She is a graduate student at State Key Laboratory of Biotherapy and Cancer Center of West China Hospital in Sichuan University. Her research interest focuses on autophagic target identification and drug repurposing in triple negative breast cancer.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Huidan Tan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=BIO-d7e2217-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Huidan Tan</b> received her bachelor’s degree in clinical pharmacy from China Medical University in 2019. She is a graduate student at State Key Laboratory of Biotherapy and Cancer Center of West China Hospital in Sichuan University. Her research interest focuses on molecular mechanisms of RNAs and targeted drug discovery in triple negative breast cancer.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Lingjuan Zhu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=BIO-d7e2222-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lingjuan Zhu</b> received a degree in Traditional Chinese Medicines (TCMs) Resources and Development from the Shenyang Pharmaceutical University in 2008. She received her Ph.D. in 2013 in Natural Product Chemistry, with a thesis about the active ingredients and integrative mechanisms of TCMs, under advisor Prof. X. S Yao. In 2017, she was promoted to Associate Professor of Natural Product Chemistry at Shenyang Pharmaceutical University. In 2017, she also received a postdoctoral position at the State Key Laboratory of Biotherapy and Cancer Center of West China Hospital at Sichuan University. Her major research interests focus on elucidating molecular mechanisms of small-molecule compounds from natural products in triple negative breast cancer.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Yi Chen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=BIO-d7e2227-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yi Chen</b> received his Ph.D. degree from West China Hospital, Sichuan University in 2013. He is a full professor at State Key Laboratory of Biotherapy, West China Hospital at Sichuan University. His research interest focuses on multiomics-based target identification and relevant pathways in cancer therapy.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Gu He</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=BIO-d7e2232-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Gu He</b> received his Ph.D. degree from West China School of Pharmacy, Sichuan University in 2008. He is a full professor of State Key Lab of Biotherapy, West China Hospital, Sichuan University since 2016. To date, he has published more than 60 papers in peer-review journals indexed by the Science Citation Index, with the H-index of 27. His research interests are the identification of novel targets in programmed cell death and the structure-based discovery of both small-molecule and peptide drugs.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Bo Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=BIO-d7e2237-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Bo Liu</b> received his Ph.D. degree in Bioinformatics (drug design) from School of Life Sciences, Sichuan University in 2010. In 2012, he joined the faculty of State Key Laboratory of Biotherapy of West China Hospital in Sichuan University as a professor. His research interests include autophagic target identification and structure-based drug discovery in both breast cancer and Parkinson’s disease.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23585" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23585" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Prof. Heng Xu and Prof. Shengyong Yang (Sichuan University) for their good discussions on this manuscript. This work was supported in part by grants from National Natural Science Foundation of China (grant nos. 81673455, 21772131, and 31970374), Key R&D Program of Sichuan Province (grant no. 2021YFS0046), and National Science and Technology Major Project of the Ministry of Science and Technology of China (no. 2018ZX09735005).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptors</p></td></tr><tr><td class="NLM_term">ABP</td><td class="NLM_def"><p class="first last">allosteric binding pocket</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">5′ AMP-activated protein kinase</p></td></tr><tr><td class="NLM_term">AuNP-PEI</td><td class="NLM_def"><p class="first last">polyethylenimine-modified gold nanoparticles</p></td></tr><tr><td class="NLM_term">BUC</td><td class="NLM_def"><p class="first last">bladder urothelial carcinoma</p></td></tr><tr><td class="NLM_term">CaMK-III</td><td class="NLM_def"><p class="first last">calcium/calmodulin-dependent protein kinase III</p></td></tr><tr><td class="NLM_term">CBD</td><td class="NLM_def"><p class="first last">cam binding domain</p></td></tr><tr><td class="NLM_term">CRISPR/Cas 9</td><td class="NLM_def"><p class="first last">clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9</p></td></tr><tr><td class="NLM_term">CTD</td><td class="NLM_def"><p class="first last">C-terminal domain</p></td></tr><tr><td class="NLM_term">CyclinD1</td><td class="NLM_def"><p class="first last">Cyclin D1</p></td></tr><tr><td class="NLM_term">eEF2K</td><td class="NLM_def"><p class="first last">eukaryotic elongation factor 2 kinase</p></td></tr><tr><td class="NLM_term">eEF2</td><td class="NLM_def"><p class="first last">eukaryotic elongation factor 2</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">endoplasmic reticulum</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">ESCC</td><td class="NLM_def"><p class="first last">esophageal squamous cell carcinoma</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">FOX</td><td class="NLM_def"><p class="first last">fork-head box</p></td></tr><tr><td class="NLM_term">FOXM1</td><td class="NLM_def"><p class="first last">fork-head box m1</p></td></tr><tr><td class="NLM_term">HSP90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase domain</p></td></tr><tr><td class="NLM_term">LKB1</td><td class="NLM_def"><p class="first last">liver kinase B1</p></td></tr><tr><td class="NLM_term">GAPLINC</td><td class="NLM_def"><p class="first last">long intergenic noncoding RNA</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinases</p></td></tr><tr><td class="NLM_term">MEFs</td><td class="NLM_def"><p class="first last">mouse embryonic fibroblasts</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">mTORC1</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin complex 1</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor kappa-light-chain-enhancer of activated B</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">PLK1</td><td class="NLM_def"><p class="first last">polo-like kinase 1</p></td></tr><tr><td class="NLM_term">PKM2</td><td class="NLM_def"><p class="first last">pyruvate kinase isozymes M2</p></td></tr><tr><td class="NLM_term">PP2A-A</td><td class="NLM_def"><p class="first last">protein phosphatase 2A-A</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolytic target chimera</p></td></tr><tr><td class="NLM_term">QSAR</td><td class="NLM_def"><p class="first last">quantitative structure–activity relationship</p></td></tr><tr><td class="NLM_term">REDD1</td><td class="NLM_def"><p class="first last">DNA damage response-1</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">SNAP29</td><td class="NLM_def"><p class="first last">synaptosomal-associated protein 29</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">proto-oncogene tyrosine-protein kinase</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">TG2</td><td class="NLM_def"><p class="first last">transgultaminase 2</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">ULK</td><td class="NLM_def"><p class="first last">Unc-51-like autophagy activating kinase</p></td></tr><tr><td class="NLM_term">uPAR</td><td class="NLM_def"><p class="first last">urokinase-type plasminogen activator receptor</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 71 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nairn, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palfrey, H. C.</span></span> <span> </span><span class="NLM_article-title">Identification of the Major M(r) 100,000 Substrate for Calmodulin-Dependent Protein Kinase III in Mammalian Cells as Elongation Factor-2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>262</i></span>,  <span class="NLM_fpage">17299</span>– <span class="NLM_lpage">17303</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)45377-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2FS0021-9258%2818%2945377-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=3693353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADyaL2sXmtFCjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=1987&pages=17299-17303&author=A.+C.+Nairnauthor=H.+C.+Palfrey&title=Identification+of+the+Major+M%28r%29+100%2C000+Substrate+for+Calmodulin-Dependent+Protein+Kinase+III+in+Mammalian+Cells+as+Elongation+Factor-2&doi=10.1016%2FS0021-9258%2818%2945377-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the major Mr 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2</span></div><div class="casAuthors">Nairn, Angus C.; Palfrey, H. Clive</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">262</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">17299-303</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The major substrate for Ca2+/calmodulin (CaM)-dependent protein kinase III in mammalian cells, a species of mol. wt. (Mr) 100,000 with a primarily cytoplasmic localization, has been identified as elongation factor-2 (EF-2), the protein that catalyzes the translocation of peptidyl-tRNA on the ribosome.  The amino acid sequence of 18 residues from the N-terminal end of the Mr 100,000 CaM-dependent protein kinase III substrate purified from rat pancreas was identical to the N-terminal sequence of authentic rat EF-2 as previously deduced from nucleic acid sequencing of a cDNA (Kohno, K., et al., 1986).  CaM-dependent protein kinase III phosphorylated EF-2 in vitro with a stoichiometry of ∼1 mol/mol on a threonine residue.  Amino acid sequencing of the purified tryptic phosphopeptide revealed that this threonine residue lies within the sequence: Ala-Gly-Glu-Thr-Arg-Phe-Thr-Asp-Thr-Arg (residues 51-60 of EF-2).  The Mr 100,000 protein was stoichiometrically ADP-ribosylated in vitro by the diphtheria toxin and NAD.  The Mr 100,000 protein was photoaffinity labeled with a GTP analog and the protein had an endogenous GTPase activity that could be stimulated by the addn. of salt-washed ribosomes.  These properties are all characteristic of EF-2.  Dephospho-EF-2 could support poly(U)-directed polyphenylalanine synthesis in a reconstituted elongation system when combined with EF-1.  In the same system, phospho-EF-2 was virtually inactive in supporting polypeptide synthesis; this effect could be reversed by dephosphorylation of phospho-EF-2.  Thus, intracellular Ca2+ may inhibit protein synthesis in mammalian cells via CaM-dependent protein kinase III-catalyzed phosphorylation of EF-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDivJtOneWLVg90H21EOLACvtfcHk0ljDVS4GYKHRoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmtFCjtbo%253D&md5=70c6580fce10b2c696ed38a2357dbda5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2945377-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252945377-X%26sid%3Dliteratum%253Aachs%26aulast%3DNairn%26aufirst%3DA.%2BC.%26aulast%3DPalfrey%26aufirst%3DH.%2BC.%26atitle%3DIdentification%2520of%2520the%2520Major%2520M%2528r%2529%2520100%252C000%2520Substrate%2520for%2520Calmodulin-Dependent%2520Protein%2520Kinase%2520III%2520in%2520Mammalian%2520Cells%2520as%2520Elongation%2520Factor-2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1987%26volume%3D262%26spage%3D17299%26epage%3D17303%26doi%3D10.1016%2FS0021-9258%2818%2945377-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nairn, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picciotto, M.</span></span> <span> </span><span class="NLM_article-title">Calcium/Calmodulin-Dependent Protein Kinases</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=7803766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVyls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1994&pages=295-303&author=A.+C.+Nairnauthor=M.+Picciotto&title=Calcium%2FCalmodulin-Dependent+Protein+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium/calmodulin-dependent protein kinases</span></div><div class="casAuthors">Nairn, Angus C.; Picciotto, Marina R.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-303</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    </div><div class="casAbstract">A review, with 55 refs.  Ca2+ is widely recognized as an essential intracellular second messenger in eukaryotic systems regulating processes such as muscle contraction, neurotransmitter release, gene expression and cell proliferation.  The effects of Ca2+ are frequently mediated via interaction with calmodulin (CaM) and strong evidence indicates, in turn, that the effects of Ca2+/CaM are often achieved through the regulation of protein phosphorylation.  A family of CaM-dependent protein kinases has been identified that includes: myosin light chain kinase, phosphorylase kinase, CaM kinase I, CaM kinase II, EF-2 kinase (CaM kinase III) and CaM kinase IV.  The structure, regulation and function of this important family of second messenger-regulated protein kinases will be briefly reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU-McjOgcuHrVg90H21EOLACvtfcHk0limNxvIQCV_aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVyls7w%253D&md5=00a56ae0dba82de4eb8f34541fb4a1b6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNairn%26aufirst%3DA.%2BC.%26aulast%3DPicciotto%26aufirst%3DM.%26atitle%3DCalcium%252FCalmodulin-Dependent%2520Protein%2520Kinases%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D1994%26volume%3D5%26spage%3D295%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piserchio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajredini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, R.</span></span> <span> </span><span class="NLM_article-title">Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>431</i></span>,  <span class="NLM_fpage">2700</span>– <span class="NLM_lpage">2717</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2019.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.jmb.2019.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=31108082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVegtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2019&pages=2700-2717&author=A.+Piserchioauthor=N.+Willauthor=D.+H.+Gilesauthor=F.+Hajrediniauthor=K.+N.+Dalbyauthor=R.+Ghose&title=Solution+Structure+of+the+Carboxy-Terminal+Tandem+Repeat+Domain+of+Eukaryotic+Elongation+Factor+2+Kinase+and+Its+Role+in+Substrate+Recognition&doi=10.1016%2Fj.jmb.2019.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition</span></div><div class="casAuthors">Piserchio, Andrea; Will, Nathan; Giles, David H.; Hajredini, Fatlum; Dalby, Kevin N.; Ghose, Ranajeet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2700-2717</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF-2K), an atypical calmodulin-activated protein kinase, regulates translational elongation by phosphorylating its substrate, eukaryotic elongation factor 2 (eEF-2), thereby reducing its affinity for the ribosome.  The activation and activity of eEF-2K are crit. for survival under energy-deprived conditions and is implicated in a variety of essential physiol. processes.  Previous biochem. expts. have indicated that the binding site for the substrate eEF-2 is located in the C-terminal domain of eEF-2K, a region predicted to harbor several α-helical repeats.  Here, using NMR methodol., we have detd. the soln. structure of a C-terminal fragment of eEF-2K, eEF-2K562-725 that encodes two α-helical repeats.  The structure of eEF-2K562-725 shows signatures characteristic of TPR domains and of their SEL1-like sub-family.  Furthermore, using the analyses of NMR spectral perturbations and ITC measurements, we have localized the eEF-2 binding site on eEF-2K562-725.  We find that eEF-2K562-725 engages eEF-2 with an affinity comparable to that of the full-length enzyme.  Furthermore, eEF-2K562-725 is able to inhibit the phosphorylation of eEF-2 by full-length eEF-2K in trans.  Our present studies establish that eEF-2K562-725 encodes the major elements necessary to enable the eEF-2K/eEF-2 interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfdPhG8Gi58bVg90H21EOLACvtfcHk0limNxvIQCV_aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVegtrrF&md5=586a943a61f84c48b6af01f92bea122a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2019.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2019.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DPiserchio%26aufirst%3DA.%26aulast%3DWill%26aufirst%3DN.%26aulast%3DGiles%26aufirst%3DD.%2BH.%26aulast%3DHajredini%26aufirst%3DF.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26aulast%3DGhose%26aufirst%3DR.%26atitle%3DSolution%2520Structure%2520of%2520the%2520Carboxy-Terminal%2520Tandem%2520Repeat%2520Domain%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520and%2520Its%2520Role%2520in%2520Substrate%2520Recognition%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2019%26volume%3D431%26spage%3D2700%26epage%3D2717%26doi%3D10.1016%2Fj.jmb.2019.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, M.</span></span> <span> </span><span class="NLM_article-title">AMP-Activated Protein Kinase Stimulates Warburg-like Glycolysis and Activation of Satellite Cells during Muscle Regeneration</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">26445</span>– <span class="NLM_lpage">26456</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.665232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.M115.665232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=26370082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGisLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=26445-26456&author=X.+Fuauthor=M.+J.+Zhuauthor=M.+V.+Dodsonauthor=M.+Du&title=AMP-Activated+Protein+Kinase+Stimulates+Warburg-like+Glycolysis+and+Activation+of+Satellite+Cells+during+Muscle+Regeneration&doi=10.1074%2Fjbc.M115.665232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-activated protein kinase stimulates Warburg-like glycolysis and activation of satellite cells during muscle regeneration</span></div><div class="casAuthors">Fu, Xing; Zhu, Mei-Jun; Dodson, Mike V.; Du, Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">26445-26456</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Satellite cells are the major myogenic stem cells residing inside skeletal muscle and are indispensable for muscle regeneration.  Satellite cells remain largely quiescent, but are rapidly activated in response to muscle injury, and the derived myogenic cells then fuse to repair damaged muscle fibers or form new muscle fibers.  However, mechanisms eliciting metabolic activation, an inseparable step for satellite cell activation following muscle injury, have not been defined.  Here, the authors found that a noncanonical Sonic Hedgehog (Shh) pathway was rapidly activated in response to muscle injury, which activates AMPK and induces a Warburg-like glycolysis in satellite cells.  AMPKα1 was the dominant AMPKα isoform expressed in satellite cells, and AMPKα1 deficiency in satellite cells impaired their activation and myogenic differentiation during muscle regeneration.  Drugs activating noncanonical Shh promoted proliferation of satellite cells, which was abolished because of satellite cell-specific AMPKα1 knock-out.  Taken together, AMPKα1 is a crit. mediator linking the noncanonical Shh pathway to Warburg-like glycolysis in satellite cells, which is required for satellite activation and muscle regeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOAfzHI0wKAbVg90H21EOLACvtfcHk0lg8AH1CW_rUMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGisLnF&md5=2270df58b02919a3a4ef9f169577ce3d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.665232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.665232%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DM.%2BJ.%26aulast%3DDodson%26aufirst%3DM.%2BV.%26aulast%3DDu%26aufirst%3DM.%26atitle%3DAMP-Activated%2520Protein%2520Kinase%2520Stimulates%2520Warburg-like%2520Glycolysis%2520and%2520Activation%2520of%2520Satellite%2520Cells%2520during%2520Muscle%2520Regeneration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D26445%26epage%3D26456%26doi%3D10.1074%2Fjbc.M115.665232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regufe da Mota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajek, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">A Conserved Loop in the Catalytic Domain of Eukaryotic Elongation Factor 2 Kinase Plays a Key Role in Its Substrate Specificity</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2294</span>– <span class="NLM_lpage">2307</span>, <span class="refDoi"> DOI: 10.1128/MCB.00388-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1128%2FMCB.00388-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24732796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=2294-2307&author=C.+E.+Mooreauthor=S.+Regufe+da+Motaauthor=H.+Mikolajekauthor=C.+G.+Proud&title=A+Conserved+Loop+in+the+Catalytic+Domain+of+Eukaryotic+Elongation+Factor+2+Kinase+Plays+a+Key+Role+in+Its+Substrate+Specificity&doi=10.1128%2FMCB.00388-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A conserved loop in the catalytic domain of eukaryotic elongation factor 2 kinase plays a key role in its substrate specificity</span></div><div class="casAuthors">Moore, Claire E.; da Mota, Sergio Regufe; Mikolajek, Halina; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2294-2307, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) is the best-characterized member of the α-kinase family.  Within this group, only eEF2K and myosin heavy-chain kinases (MHCKs) have known substrates.  Here, the authors studied the roles of specific residues, selected on the basis of structural data for MHCK A and TRPM7, in the function of eEF2K.  The data provide the 1st information regarding the basis of the substrate specificity of α-kinases, in particular the roles of residues in the so-called N/D loop, which appears to occupy a position in the structure of α-kinases similar to that of the activation loop in other kinases.  Several mutations in the EEF2K gene occur in tumors, one of which (R303C) is at a highly conserved residue in the N/D loop.  This mutation greatly enhances eEF2K activity and may be cytoprotective.  The data supported the concept that the major autophosphorylation site (Thr-348 in eEF2K) docks into a binding pocket to help create the kinase-competent conformation.  This was similar to the situation for MHCK A and is consistent with this being a common feature of α-kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXzKcm_OB_H7Vg90H21EOLACvtfcHk0lgrSsjHaDfE8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksL3N&md5=bde77703c284c1f186aede461e50f61b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1128%2FMCB.00388-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00388-14%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DC.%2BE.%26aulast%3DRegufe%2Bda%2BMota%26aufirst%3DS.%26aulast%3DMikolajek%26aufirst%3DH.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DA%2520Conserved%2520Loop%2520in%2520the%2520Catalytic%2520Domain%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520Plays%2520a%2520Key%2520Role%2520in%2520Its%2520Substrate%2520Specificity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26spage%3D2294%26epage%3D2307%26doi%3D10.1128%2FMCB.00388-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Elongation Factor-2 Kinase (EEF2K): A Potential Therapeutic Target in Cancer</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1531</span>, <span class="refDoi"> DOI: 10.1007/s10495-014-1019-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1007%2Fs10495-014-1019-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25023961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCqtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1527-1531&author=L.+L.+Fuauthor=T.+Xieauthor=S.+Y.+Zhangauthor=B.+Liu&title=Eukaryotic+Elongation+Factor-2+Kinase+%28EEF2K%29%3A+A+Potential+Therapeutic+Target+in+Cancer&doi=10.1007%2Fs10495-014-1019-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer</span></div><div class="casAuthors">Fu, L. L.; Xie, T.; Zhang, S. Y.; Liu, B.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1527-1531</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Eukaryotic elongation factor-2 kinase (eEF2K), encoded by the EEF2K gene, is well-known to be a Ca2+/calmodulin (CaM)-dependent kinase which can neg. modulate protein synthesis.  It is highly conserved among eukaryotes from mammals to invertebrates, of which human and mouse may have 99 % overall amino acid identity.  This kinase can phosphorylate eukaryotic elongation factor-2 (eEF2) or undergo the process of autophosphorylation at multiple sites to inhibit its function in translation elongation.  Due to the fact that regulation of eEF2 by eEF2K is an evolutionarily conserved mechanism, eEF2K activity may confer tumor cell adaptation to metabolic stress under acute nutrient depletion, and the high expressed level of eEF2K has been found in several types of malignancies. eEF2K may modulate the expression of some apoptotic proteins such as XIAP, c-FLIPL, Bcl-XL, PI3KCI and p70S6K to inhibit apoptotic process in cancer.  On the other hand, it plays a regulatory role in autophagy involved in mTORC1, AMPK and Atg8, thereby promoting cancer cell survival.  Addnl., eEF2K may play a crucial role in the crosstalk between apoptosis and autophagy in cancer.  Collectively, these findings have led to the conclusions that eEF2K may contribute to carcinogenesis, and thus being utilized as a potential target for future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGeOYqgUkeurVg90H21EOLACvtfcHk0lgrSsjHaDfE8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCqtbrO&md5=07b5761eed07eaac9b5ef703077560c1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs10495-014-1019-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-014-1019-7%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.%2BL.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DEukaryotic%2520Elongation%2520Factor-2%2520Kinase%2520%2528EEF2K%2529%253A%2520A%2520Potential%2520Therapeutic%2520Target%2520in%2520Cancer%26jtitle%3DApoptosis%26date%3D2014%26volume%3D19%26spage%3D1527%26epage%3D1531%26doi%3D10.1007%2Fs10495-014-1019-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White-Gilbertson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voelkel-Johnson, C.</span></span> <span> </span><span class="NLM_article-title">The Role of Protein Synthesis in Cell Cycling and Cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2009.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.molonc.2009.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=19546037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFGjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=402-408&author=S.+White-Gilbertsonauthor=D.+T.+Kurtzauthor=C.+Voelkel-Johnson&title=The+Role+of+Protein+Synthesis+in+Cell+Cycling+and+Cancer&doi=10.1016%2Fj.molonc.2009.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The role of protein synthesis in cell cycling and cancer</span></div><div class="casAuthors">White-Gilbertson, Shai; Kurtz, David T.; Voelkel-Johnson, Christina</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">402-408</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cell cycling and protein synthesis are both key physiol. tasks for cancer cells.  Here we present a model for how the elongation phase of protein synthesis, governed by elongation factor 2 and elongation factor 2 kinase, both modulates and responds to cell cycling.  Within this framework we also discuss survivin, a protein with both pro-mitotic and anti-apoptotic roles whose persistence in the cell is tied to protein synthesis due to its short half-life.  Finally, we provide a brief overview of efforts of cancer researchers to target EF2 and EF2 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUmPpnb5kcybVg90H21EOLACvtfcHk0ljL_-pIeUXCPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFGjurk%253D&md5=1d47c7daadf76dc7b999a917bd04f55e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2009.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2009.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DWhite-Gilbertson%26aufirst%3DS.%26aulast%3DKurtz%26aufirst%3DD.%2BT.%26aulast%3DVoelkel-Johnson%26aufirst%3DC.%26atitle%3DThe%2520Role%2520of%2520Protein%2520Synthesis%2520in%2520Cell%2520Cycling%2520and%2520Cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2009%26volume%3D3%26spage%3D402%26epage%3D408%26doi%3D10.1016%2Fj.molonc.2009.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regufe da Mota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanucara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwala, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyr dit Ruys, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertommen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rider, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Elongation Factor 2 Kinase Activity Is Controlled by Multiple Inputs from Oncogenic Signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">4088</span>– <span class="NLM_lpage">4103</span>, <span class="refDoi"> DOI: 10.1128/MCB.01035-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1128%2FMCB.01035-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25182533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=4088-4103&author=X.+Wangauthor=S.+Regufe+da+Motaauthor=R.+Liuauthor=C.+E.+Mooreauthor=J.+Xieauthor=F.+Lanucaraauthor=U.+Agarwalaauthor=S.+Pyr+dit+Ruysauthor=D.+Vertommenauthor=M.+H.+Riderauthor=C.+E.+Eyersauthor=C.+G.+Proud&title=Eukaryotic+Elongation+Factor+2+Kinase+Activity+Is+Controlled+by+Multiple+Inputs+from+Oncogenic+Signaling&doi=10.1128%2FMCB.01035-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling</span></div><div class="casAuthors">Wang, Xuemin; Regufe da Mota, Sergio; Liu, Rui; Moore, Claire E.; Xie, Jianling; Lanucara, Francesco; Agarwala, Usha; Pyr dit Ruys, Sebastien; Vertommen, Didier; Rider, Mark H.; Eyers, Claire E.; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4088-4103, 17 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K), an atypical calmodulin-dependent protein kinase, phosphorylates and inhibits eEF2, slowing down translation elongation.  EEF2K contains an N-terminal catalytic domain, a C-terminal α-helical region and a linker contg. several regulatory phosphorylation sites.  EEF2K is expressed at high levels in certain cancers, where it may act to help cell survival, e.g., during nutrient starvation.  However, it is a neg. regulator of protein synthesis and thus cell growth, suggesting that cancer cells may possess mechanisms to inhibit eEF2K under good growth conditions, to allow protein synthesis to proceed.  We show here that the mTORC1 pathway and the oncogenic Ras/Raf/MEK/extracellular signal-regulated kinase (ERK) pathway cooperate to restrict eEF2K activity.  We identify multiple sites in eEF2K whose phosphorylation is regulated by mTORC1 and/or ERK, including new ones in the linker region.  We demonstrate that certain sites are phosphorylated directly by mTOR or ERK.  Our data reveal that glycogen synthase kinase 3 signaling also regulates eEF2 phosphorylation.  In addn., we show that phosphorylation sites remote from the N-terminal calmodulin-binding motif regulate the phosphorylation of N-terminal sites that control CaM binding.  Mutations in the former sites, which occur in cancer cells, cause the activation of eEF2K.  EEF2K is thus regulated by a network of oncogenic signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDO0LF9tOIo7Vg90H21EOLACvtfcHk0ljL_-pIeUXCPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSls7rO&md5=3874c9e5ee8f4aeccd4500722b7665e5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FMCB.01035-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01035-14%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRegufe%2Bda%2BMota%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DC.%2BE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLanucara%26aufirst%3DF.%26aulast%3DAgarwala%26aufirst%3DU.%26aulast%3DPyr%2Bdit%2BRuys%26aufirst%3DS.%26aulast%3DVertommen%26aufirst%3DD.%26aulast%3DRider%26aufirst%3DM.%2BH.%26aulast%3DEyers%26aufirst%3DC.%2BE.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DEukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520Activity%2520Is%2520Controlled%2520by%2520Multiple%2520Inputs%2520from%2520Oncogenic%2520Signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26spage%3D4088%26epage%3D4103%26doi%3D10.1128%2FMCB.01035-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delaidelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansonius, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Naggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarni Oo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leprivier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P. H.</span></span> <span> </span><span class="NLM_article-title">MYCN Amplified Neuroblastoma Requires the MRNA Translation Regulator EEF2 Kinase to Adapt to Nutrient Deprivation</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1564</span>– <span class="NLM_lpage">1576</span>, <span class="refDoi"> DOI: 10.1038/cdd.2017.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fcdd.2017.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28574509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Wrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1564-1576&author=A.+Delaidelliauthor=G.+L.+Negriauthor=A.+Janauthor=B.+Jansoniusauthor=A.+El-Naggarauthor=J.+K.+M.+Limauthor=D.+Khanauthor=H.+Zarni+Ooauthor=C.+J.+Carnieauthor=M.+Remkeauthor=J.+M.+Marisauthor=G.+Leprivierauthor=P.+H.+Sorensen&title=MYCN+Amplified+Neuroblastoma+Requires+the+MRNA+Translation+Regulator+EEF2+Kinase+to+Adapt+to+Nutrient+Deprivation&doi=10.1038%2Fcdd.2017.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation</span></div><div class="casAuthors">Delaidelli, Alberto; Negri, Gian Luca; Jan, Asad; Jansonius, Brandon; El-Naggar, Amal; Lim, Jonathan K. M.; Khan, Debjit; Zarni Oo, Htoo; Carnie, Christopher J.; Remke, Marc; Maris, John M.; Leprivier, Gabriel; Sorensen, Poul H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1564-1576</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">MYC family proteins are implicated in many human cancers, but their therapeutic targeting has proven challenging.  MYCN amplification in childhood neuroblastoma (NB) is assocd. with aggressive disease and high mortality.  Novel and effective therapeutic strategies are therefore urgently needed for these tumors.  MYC-driven oncogenic transformation impairs cell survival under nutrient deprivation (ND), a characteristic stress condition within the tumor microenvironment.  We recently identified eukaryotic Elongation Factor 2 Kinase (eEF2K) as a pivotal mediator of the adaptive response of tumor cells to ND.  We therefore hypothesized that eEF2K facilitates the adaptation of MYCN amplified NB to ND, and that inhibiting this pathway can impair MYCN-driven NB progression.  To test our hypothesis, we first analyzed publicly available genomic databases and tissue microarrays for eEF2K expression in NB, and for links between eEF2K, MYCN, and clin. outcome in NB.  Effects of eEF2K inhibition were evaluated on survival of MYCN amplified vs. non-amplified NB cell lines under ND.  Finally, NB xenograft mouse models were used to confirm in vitro observations.  Our results indicate that high eEF2K expression and activity are strongly predictive of poor outcome in NB, and correlates significantly with MYCN amplification.  Inhibition of eEF2K markedly decreases survival of MYCN amplified NB cell lines in vitro under ND.  Growth of MYCN amplified NB xenografts is markedly impaired by eEF2K knockdown, particularly under caloric restriction.  In summary, eEF2K protects MYCN overexpressing NB cells from ND in vitro and in vivo, highlighting this kinase as a crit. mediator of the adaptive response of MYCN amplified NB cells to metabolic stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo07GXfi1Pt-7Vg90H21EOLACvtfcHk0li5NVlnkYjy6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Wrsr8%253D&md5=5ea5f1f6610da7d813ecf86c185cd85d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2017.79%26sid%3Dliteratum%253Aachs%26aulast%3DDelaidelli%26aufirst%3DA.%26aulast%3DNegri%26aufirst%3DG.%2BL.%26aulast%3DJan%26aufirst%3DA.%26aulast%3DJansonius%26aufirst%3DB.%26aulast%3DEl-Naggar%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DJ.%2BK.%2BM.%26aulast%3DKhan%26aufirst%3DD.%26aulast%3DZarni%2BOo%26aufirst%3DH.%26aulast%3DCarnie%26aufirst%3DC.%2BJ.%26aulast%3DRemke%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DLeprivier%26aufirst%3DG.%26aulast%3DSorensen%26aufirst%3DP.%2BH.%26atitle%3DMYCN%2520Amplified%2520Neuroblastoma%2520Requires%2520the%2520MRNA%2520Translation%2520Regulator%2520EEF2%2520Kinase%2520to%2520Adapt%2520to%2520Nutrient%2520Deprivation%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2017%26volume%3D24%26spage%3D1564%26epage%3D1576%26doi%3D10.1038%2Fcdd.2017.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leprivier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotblat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubuc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, A. R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kool, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnihotri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Naggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash Somasekharan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faubert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barokas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korshunov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hielscher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcott, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galpin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahern, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delattre, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derry, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P. H.</span></span> <span> </span><span class="NLM_article-title">XThe EEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">1064</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2013.04.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.cell.2013.04.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=23706743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2013&pages=1064&author=G.+Leprivierauthor=M.+Remkeauthor=B.+Rotblatauthor=A.+Dubucauthor=A.+R.+F.+Mateoauthor=M.+Koolauthor=S.+Agnihotriauthor=A.+El-Naggarauthor=B.+Yuauthor=S.+Prakash+Somasekharanauthor=B.+Faubertauthor=G.+Bridonauthor=C.+E.+Tognonauthor=J.+Mathersauthor=R.+Thomasauthor=A.+Liauthor=A.+Barokasauthor=B.+Kwokauthor=M.+Bowdenauthor=S.+Smithauthor=X.+Wuauthor=A.+Korshunovauthor=T.+Hielscherauthor=P.+A.+Northcottauthor=J.+D.+Galpinauthor=C.+A.+Ahernauthor=Y.+Wangauthor=M.+G.+McCabeauthor=V.+P.+Collinsauthor=R.+G.+Jonesauthor=M.+Pollakauthor=O.+Delattreauthor=M.+E.+Gleaveauthor=E.+Janauthor=S.+M.+Pfisterauthor=C.+G.+Proudauthor=W.+B.+Derryauthor=M.+D.+Taylorauthor=P.+H.+Sorensen&title=XThe+EEF2+Kinase+Confers+Resistance+to+Nutrient+Deprivation+by+Blocking+Translation+Elongation&doi=10.1016%2Fj.cell.2013.04.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The eEF2 Kinase confers resistance to nutrient deprivation by blocking translation elongation</span></div><div class="casAuthors">Leprivier, Gabriel; Remke, Marc; Rotblat, Barak; Dubuc, Adrian; Mateo, Abigail-Rachele F.; Kool, Marcel; Agnihotri, Sameer; El-Naggar, Amal; Yu, Bin; Prakash Somasekharan, Syam; Faubert, Brandon; Bridon, Gaelle; Tognon, Cristina E.; Mathers, Joan; Thomas, Ryan; Li, Amy; Barokas, Adi; Kwok, Brian; Bowden, Mary; Smith, Stephanie; Wu, Xiaochong; Korshunov, Andrey; Hielscher, Thomas; Northcott, Paul A.; Galpin, Jason D.; Ahern, Christopher A.; Wang, Ye; McCabe, Martin G.; Collins, V. Peter; Jones, Russell G.; Pollak, Michael; Delattre, Olivier; Gleave, Martin E.; Jan, Eric; Pfister, Stefan M.; Proud, Christopher G.; Derry, W. Brent; Taylor, Michael D.; Sorensen, Poul H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1064-1079</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Metabolic adaptation is essential for cell survival during nutrient deprivation.  We report that eukaryotic elongation factor 2 kinase (eEF2K), which is activated by AMP-kinase (AMPK), confers cell survival under acute nutrient depletion by blocking translation elongation.  Tumor cells exploit this pathway to adapt to nutrient deprivation by reactivating the AMPK-eEF2K axis.  Adaptation of transformed cells to nutrient withdrawal is severely compromised in cells lacking eEF2K.  Moreover, eEF2K knockdown restored sensitivity to acute nutrient deprivation in highly resistant human tumor cell lines.  In vivo, overexpression of eEF2K rendered murine tumors remarkably resistant to caloric restriction.  Expression of eEF2K strongly correlated with overall survival in human medulloblastoma and glioblastoma multiforme.  Finally, C. elegans strains deficient in efk-1, the eEF2K ortholog, were severely compromised in their response to nutrient depletion.  Our data highlight a conserved role for eEF2K in protecting cells from nutrient deprivation and in conferring tumor cell adaptation to metabolic stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpP5d3R_4drVg90H21EOLACvtfcHk0ljaOrCBKR7OEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGltLg%253D&md5=a0e527178fcfd8de9b5c9aa724e35542</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.04.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.04.055%26sid%3Dliteratum%253Aachs%26aulast%3DLeprivier%26aufirst%3DG.%26aulast%3DRemke%26aufirst%3DM.%26aulast%3DRotblat%26aufirst%3DB.%26aulast%3DDubuc%26aufirst%3DA.%26aulast%3DMateo%26aufirst%3DA.%2BR.%2BF.%26aulast%3DKool%26aufirst%3DM.%26aulast%3DAgnihotri%26aufirst%3DS.%26aulast%3DEl-Naggar%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DPrakash%2BSomasekharan%26aufirst%3DS.%26aulast%3DFaubert%26aufirst%3DB.%26aulast%3DBridon%26aufirst%3DG.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DMathers%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DBarokas%26aufirst%3DA.%26aulast%3DKwok%26aufirst%3DB.%26aulast%3DBowden%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKorshunov%26aufirst%3DA.%26aulast%3DHielscher%26aufirst%3DT.%26aulast%3DNorthcott%26aufirst%3DP.%2BA.%26aulast%3DGalpin%26aufirst%3DJ.%2BD.%26aulast%3DAhern%26aufirst%3DC.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMcCabe%26aufirst%3DM.%2BG.%26aulast%3DCollins%26aufirst%3DV.%2BP.%26aulast%3DJones%26aufirst%3DR.%2BG.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DDelattre%26aufirst%3DO.%26aulast%3DGleave%26aufirst%3DM.%2BE.%26aulast%3DJan%26aufirst%3DE.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DDerry%26aufirst%3DW.%2BB.%26aulast%3DTaylor%26aufirst%3DM.%2BD.%26aulast%3DSorensen%26aufirst%3DP.%2BH.%26atitle%3DXThe%2520EEF2%2520Kinase%2520Confers%2520Resistance%2520to%2520Nutrient%2520Deprivation%2520by%2520Blocking%2520Translation%2520Elongation%26jtitle%3DCell%26date%3D2013%26volume%3D153%26spage%3D1064%26doi%3D10.1016%2Fj.cell.2013.04.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.-M.</span></span> <span> </span><span class="NLM_article-title">EEF2 Kinase Mediated Autophagy as a Potential Therapeutic Target for Paclitaxel-Resistant Triple-Negative Breast Cancer</span>. <i>Annals of Translational Medicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.21037/atm.2019.11.39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.21037%2Fatm.2019.11.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=32042799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1KntLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=783-783&author=R.-X.+Wangauthor=X.-E.+Xuauthor=L.+Huangauthor=S.+Chenauthor=Z.-M.+Shao&title=EEF2+Kinase+Mediated+Autophagy+as+a+Potential+Therapeutic+Target+for+Paclitaxel-Resistant+Triple-Negative+Breast+Cancer&doi=10.21037%2Fatm.2019.11.39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer</span></div><div class="casAuthors">Wang, Ruo-Xi; Xu, Xiao-En; Huang, Liang; Chen, Sheng; Shao, Zhi-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">783</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">In this study, we aimed to investigate the role of autophagy and its regulator, eukaryotic elongation factor 2 kinase (eEF2K), in detg. the biol. nature of TNBC.  Methods: We used in vitro models of TNBC, namely, paclitaxel-resistant cell lines derived from sensitive cell lines.  Various approaches to measuring autophagy flux were applied.  We assessed the effects of inhibiting autophagy and silencing eEF2K on cell viability, tumor formation and invasion.  We also collected residual tumor samples from 222 breast cancer patients who underwent neoadjuvant chemotherapy and measured eEF2K and LC3 expression levels by immunohistochem. (IHC).  Multivariate survival anal. was used to det. prognostic variables.  Results: Compared to the parental lines, the chemoresistant lines exhibited enhanced starvation-stimulated autophagy and showed significant decreases in cell viability, growth and invasion upon treatment with autophagy inhibitors. eEF2K silencing also resulted in the suppression of autophagic activity and in aggressive biol. behavior.  In the survival anal., residual tumor LC3 (P=0.001) and eEF2K (P=0.027) expression levels were independent prognostic factors for patients who underwent neoadjuvant chemotherapy, esp. in those with TNBC.  Conclusions: Our study indicated that eEF2K and autophagy play key roles in the maintenance of aggressive tumor behavior and chemoresistance in resistant TNBC. eEF2K silencing may be a novel strategy for the treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF94kK_mrZ77Vg90H21EOLACvtfcHk0lhHQDjtRbsbRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1KntLvJ&md5=31e71ad46a97a905f1ee0010442e2e1c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.21037%2Fatm.2019.11.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2019.11.39%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.-X.%26aulast%3DXu%26aufirst%3DX.-E.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DZ.-M.%26atitle%3DEEF2%2520Kinase%2520Mediated%2520Autophagy%2520as%2520a%2520Potential%2520Therapeutic%2520Target%2520for%2520Paclitaxel-Resistant%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DAnnals%2520of%2520Translational%2520Medicine%26date%3D2019%26volume%3D7%26spage%3D783%26epage%3D783%26doi%3D10.21037%2Fatm.2019.11.39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryazanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span> <span> </span><span class="NLM_article-title">EEF-2 Kinase Is a Critical Regulator of Warburg Effect through Controlling PP2A-A Synthesis</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">6293</span>– <span class="NLM_lpage">6308</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fonc.2016.166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=27181208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFSisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=6293-6308&author=Y.+Chengauthor=X.+Renauthor=Y.+Yuanauthor=Y.+Shanauthor=L.+Liauthor=X.+Chenauthor=L.+Zhangauthor=Y.+Takahashiauthor=J.+W.+Yangauthor=B.+Hanauthor=J.+Liaoauthor=Y.+Liauthor=H.+Harveyauthor=A.+Ryazanovauthor=G.+P.+Robertsonauthor=G.+Wanauthor=D.+Liuauthor=A.+F.+Chenauthor=Y.+Taoauthor=J.+M.+Yang&title=EEF-2+Kinase+Is+a+Critical+Regulator+of+Warburg+Effect+through+Controlling+PP2A-A+Synthesis&doi=10.1038%2Fonc.2016.166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis</span></div><div class="casAuthors">Cheng, Y.; Ren, X.; Yuan, Y.; Shan, Y.; Li, L.; Chen, X.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Ryazanov, A.; Robertson, G. P.; Wan, G.; Liu, D.; Chen, A. F.; Tao, Y.; Yang, J.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">6293-6308</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells predominantly metabolize glucose by glycolysis to produce energy in order to meet their metabolic requirement, a phenomenon known as Warburg effect.  Although Warburg effect is considered a peculiarity crit. for survival and proliferation of cancer cells, the regulatory mechanisms behind this phenomenon remain incompletely understood.  We report here that eukaryotic elongation factor-2 kinase (eEF-2K), a neg. regulator of protein synthesis, has a crit. role in promoting glycolysis in cancer cells.  We showed that deficiency in eEF-2K significantly reduced the uptake of glucose and decreased the productions of lactate and ATP in tumor cells and in the Ras-transformed mouse embryonic fibroblasts.  We further demonstrated that the promotive effect of eEF-2K on glycolysis resulted from the kinase-mediated restriction of synthesis of the protein phosphatase 2A-A (PP2A-A), a key factor that facilitates the ubiquitin-proteasomal degrdn. of c-Myc protein, as knockdown of eEF-2K expression led to a significant increase in PP2A-A protein synthesis and remarkable downregulation of c-Myc and pyruvate kinase M2 isoform, the key glycolytic enzyme transcriptionally activated by c-Myc.  In addn., depletion of eEF-2K reduced the ability of the transformed cells to proliferate and enhanced the sensitivity of tumor cells to chemotherapy both in vitro and in vivo.  These results, which uncover a role of the eEF-2K-mediated control of PP2A-A in tumor cell glycolysis, provide new insights into the regulation of the Warburg effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJGJ4r_M_gIrVg90H21EOLACvtfcHk0lhHQDjtRbsbRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFSisLs%253D&md5=2a997bb0f17e697440b2d447bc2b8aa5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.166%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BW.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHarvey%26aufirst%3DH.%26aulast%3DRyazanov%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DG.%2BP.%26aulast%3DWan%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DA.%2BF.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26atitle%3DEEF-2%2520Kinase%2520Is%2520a%2520Critical%2520Regulator%2520of%2520Warburg%2520Effect%2520through%2520Controlling%2520PP2A-A%2520Synthesis%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26spage%3D6293%26epage%3D6308%26doi%3D10.1038%2Fonc.2016.166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span> <span> </span><span class="NLM_article-title">EEF2K Promotes Progression and Radioresistance of Esophageal Squamous Cell Carcinoma</span>. <i>Radiother. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1016/j.radonc.2017.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.radonc.2017.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28431753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVygt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=439-447&author=H.+Zhuauthor=H.+Songauthor=G.+Chenauthor=X.+Yangauthor=J.+Liuauthor=Y.+Geauthor=J.+Luauthor=Q.+Qinauthor=C.+Zhangauthor=L.+Xuauthor=X.+Diauthor=J.+Caiauthor=J.+Maauthor=S.+Zhangauthor=X.+Sun&title=EEF2K+Promotes+Progression+and+Radioresistance+of+Esophageal+Squamous+Cell+Carcinoma&doi=10.1016%2Fj.radonc.2017.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma</span></div><div class="casAuthors">Zhu, Hongcheng; Song, Hongmei; Chen, Guangzong; Yang, Xi; Liu, Jia; Ge, Yangyang; Lu, Jing; Qin, Qin; Zhang, Chi; Xu, Liping; Di, Xiaoke; Cai, Jing; Ma, Jianxin; Zhang, Shu; Sun, Xinchen</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-447</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">To investigate the biol. function of eEF2K in esophageal squamous cell carcinoma (ESCC).Tissue microarrays contg. 100 pairs of ESCC tumor and adjacent normal tissues were completed.  Overexpression and knockdown of eEF2K were constructed in ECA-109 and TE-13 ESCC cells.  DNA damage, cell viability, migration and invasion, radioresistance, apoptosis and autophagy were detd. by immunofluorescence, CCK-8, transwell assay, colony formation assay, flow cytometry and western blot, resp.  Tumor growth and radioresistance were also evaluated using xenograft models created in nude mice.eEF2K expression was higher in ESCC tissues compared with matched non-tumor tissues (P < 0.05).  Proliferation was increased in eEF2K overexpressing cells compared with controls (P < 0.05), while silencing eEF2K reduced cell proliferation (P < 0.05).  Furthermore, lower levels of eEF2K expression correlated with slower migration and invasion rates (P < 0.05), while higher levels of eEF2K expression with faster migration and invasion rates (P < 0.05). eEF2K overexpression resulted in radioresistance and radiation-induced autophagy, and reduced radiation-induced apoptosis compared with controls, but silencing eEF2K promoted radiosensitivity and apoptosis, and reduced autophagy.  In addn., eEF2K overexpression promoted the tumor growth in vivo (P < 0.01).  Combined treatment of NH125 (a pharmacol. inhibitor of eEF2K) and radiation was more effective at delaying xenograft tumor growth than NH125 and radiation alone (P < 0.05).eEF2K induced progression and radioresistance in ESCC, which may be a novel therapeutic target for ESCC to increase radiosensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqreqW2KO6dgrVg90H21EOLACvtfcHk0ljY8N2maKSATQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVygt78%253D&md5=ef5b7c2873cf7ed430d51df652372963</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.radonc.2017.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.radonc.2017.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDi%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DX.%26atitle%3DEEF2K%2520Promotes%2520Progression%2520and%2520Radioresistance%2520of%2520Esophageal%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DRadiother.%2520Oncol.%26date%3D2017%26volume%3D124%26spage%3D439%26epage%3D447%26doi%3D10.1016%2Fj.radonc.2017.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashour, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbuz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpay, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, A. A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Elongation Factor-2 Kinase Regulates TG2/B1 Integrin/Src/UPAR Pathway and Epithelial-Mesenchymal Transition Mediating Pancreatic Cancer Cells Invasion</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2235</span>– <span class="NLM_lpage">2251</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1111%2Fjcmm.12361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25215932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCgsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=2235-2251&author=A.+A.+Ashourauthor=N.+Gurbuzauthor=S.+N.+Alpayauthor=A.+A.+H.+Abdel-Azizauthor=A.+M.+Mansourauthor=L.+Huoauthor=B.+Ozpolat&title=Elongation+Factor-2+Kinase+Regulates+TG2%2FB1+Integrin%2FSrc%2FUPAR+Pathway+and+Epithelial-Mesenchymal+Transition+Mediating+Pancreatic+Cancer+Cells+Invasion&doi=10.1111%2Fjcmm.12361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion</span></div><div class="casAuthors">Ashour, Ahmed A.; Gurbuz, Nilgun; Alpay, Sultan Neslihan; Abdel-Aziz, Abdel-Aziz H.; Mansour, Ahmed M.; Huo, Longfei; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2235-2251</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma is one of the lethal cancers with extensive local tumor invasion, metastasis, early systemic dissemination and poorest prognosis.  Thus, understanding the mechanisms regulating invasion/metastasis and epithelial-mesenchymal transition (EMT), is the key for developing effective therapeutic strategies for pancreatic cancer (PaCa).  Eukaryotic elongation factor-2 kinase (eEF-2K) is an atypical kinase that we found to be highly up-regulated in PaCa cells.  However, its role in PaCa invasion/progression remains unknown.  Here, we investigated the role of eEF-2K in cellular invasion, and we found that down-regulation of eEF-2K, by siRNA or rottlerin, displays impairment of PaCa cells invasion/migration, with significant decreases in the expression of tissue transglutaminase (TG2), the multifunctional enzyme implicated in regulation of cell attachment, motility and survival.  These events were assocd. with redns. in β1 integrin/uPAR/MMP-2 expressions as well as decrease in Src activity.  Furthermore, inhibition of eEF-2K/TG2 axis suppresses the EMT, as demonstrated by the modulation of the zinc finger transcription factors, ZEB1/Snail, and the tight junction proteins, claudins.  Importantly, while eEF-2K silencing recapitulates the rottlerin-induced inhibition of invasion and correlated events, eEF-2K overexpression, by lentivirus-based expression system, suppresses such rottlerin effects and potentiates PaCa cells invasion/migration capability.  Collectively, our results show, for the first time, that eEF-2K is involved in regulation of the invasive phenotype of PaCa cells through promoting a new signalling pathway, which is mediated by TG2/β1 integrin/Src/uPAR/MMP-2, and the induction of EMT biomarkers which enhance cancer cell motility and metastatic potential.  Thus, eEF-2K could represent a novel potential therapeutic target in pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVRwJEw_q7s7Vg90H21EOLACvtfcHk0ljY8N2maKSATQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCgsbzE&md5=817f7237ec5e42fbe33902b406b9b6d4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12361%26sid%3Dliteratum%253Aachs%26aulast%3DAshour%26aufirst%3DA.%2BA.%26aulast%3DGurbuz%26aufirst%3DN.%26aulast%3DAlpay%26aufirst%3DS.%2BN.%26aulast%3DAbdel-Aziz%26aufirst%3DA.%2BA.%2BH.%26aulast%3DMansour%26aufirst%3DA.%2BM.%26aulast%3DHuo%26aufirst%3DL.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DElongation%2520Factor-2%2520Kinase%2520Regulates%2520TG2%252FB1%2520Integrin%252FSrc%252FUPAR%2520Pathway%2520and%2520Epithelial-Mesenchymal%2520Transition%2520Mediating%2520Pancreatic%2520Cancer%2520Cells%2520Invasion%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2014%26volume%3D18%26spage%3D2235%26epage%3D2251%26doi%3D10.1111%2Fjcmm.12361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span> <span> </span><span class="NLM_article-title">Adaptation to Starvation: Translating a Matter of Life or Death</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">715</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ccr.2013.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=23763997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFOmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=713-715&author=B.+D.+Manning&title=Adaptation+to+Starvation%3A+Translating+a+Matter+of+Life+or+Death&doi=10.1016%2Fj.ccr.2013.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptation to Starvation: Translating a Matter of Life or Death</span></div><div class="casAuthors">Manning, Brendan D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">713-715</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  There is much interest in defining the nutrient dependencies of cancer cells and their mechanisms of adaptation to nutrient depletion.  In a recent issue of Cell, Leprivier and colleagues demonstrate that eEF2K, which can inhibit translation elongation acutely during protein synthesis, is a crit. switch in the survival vs. death fate of starved cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq63wCC24n-LbVg90H21EOLACvtfcHk0ljY8N2maKSATQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFOmt7w%253D&md5=1062f6473c546509da0cb11be7c1be71</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26atitle%3DAdaptation%2520to%2520Starvation%253A%2520Translating%2520a%2520Matter%2520of%2520Life%2520or%2520Death%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D713%26epage%3D715%26doi%3D10.1016%2Fj.ccr.2013.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Browne, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Stimulation of the AMP-Activated Protein Kinase Leads to Activation of Eukaryotic Elongation Factor 2 Kinase and to Its Phosphorylation at a Novel Site, Serine 398</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">12220</span>– <span class="NLM_lpage">12231</span>, <span class="refDoi"> DOI: 10.1074/jbc.M309773200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.M309773200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=14709557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitl2hu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=12220-12231&author=G.+J.+Browneauthor=S.+G.+Finnauthor=C.+G.+Proud&title=Stimulation+of+the+AMP-Activated+Protein+Kinase+Leads+to+Activation+of+Eukaryotic+Elongation+Factor+2+Kinase+and+to+Its+Phosphorylation+at+a+Novel+Site%2C+Serine+398&doi=10.1074%2Fjbc.M309773200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of the AMP-activated Protein Kinase Leads to Activation of Eukaryotic Elongation Factor 2 Kinase and to Its Phosphorylation at a Novel Site, Serine 398</span></div><div class="casAuthors">Browne, Gareth J.; Finn, Stephen G.; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">12220-12231</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein synthesis consumes a high proportion of the metabolic energy of mammalian cells, and most of this is used by peptide chain elongation.  An important regulator of energy supply and demand in eukaryotic cells is the AMP-activated protein kinase (AMPK).  The rate of peptide chain elongation can be modulated through the phosphorylation of eukaryotic elongation factor (eEF) 2, which inhibits its activity and is catalyzed by a specific calcium/calmodulin-dependent protein kinase termed eEF2 kinase.  Here the authors show that AMPK directly phosphorylates eEF2 kinase, and the authors identify the major site of phosphorylation as Ser-398 in a regulatory domain of eEF2 kinase.  AMPK also phosphorylates two other sites (Ser-78 and Ser-366) in eEF2 kinase in vitro.  The authors develop appropriate phosphospecific antisera and show that phosphorylation of Ser-398 in eEF2 kinase is enhanced in intact cells under a range of conditions that activate AMPK and increase the phosphorylation of eEF2.  Ser-78 and Ser-366 do not appear to be phosphorylated by AMPK within cells.  Although cardiomyocytes appear to contain a distinct isoform of eEF2 kinase, it also contains a site corresponding to Ser-398 that is phosphorylated by AMPK in vitro.  Stimuli that activate AMPK and increase eEF2 phosphorylation within cells increase the activity of eEF2 kinase.  Thus, AMPK and eEF2 kinase may provide a key link between cellular energy status and the inhibition of protein synthesis, a major consumer of metabolic energy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpmIy4X0YYjbVg90H21EOLACvtfcHk0lj5YYoOQw5Vew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitl2hu7k%253D&md5=4860e96e2e335be247ad153b9af60d07</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M309773200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M309773200%26sid%3Dliteratum%253Aachs%26aulast%3DBrowne%26aufirst%3DG.%2BJ.%26aulast%3DFinn%26aufirst%3DS.%2BG.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DStimulation%2520of%2520the%2520AMP-Activated%2520Protein%2520Kinase%2520Leads%2520to%2520Activation%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520and%2520to%2520Its%2520Phosphorylation%2520at%2520a%2520Novel%2520Site%252C%2520Serine%2520398%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D12220%26epage%3D12231%26doi%3D10.1074%2Fjbc.M309773200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johanns, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyr dit Ruys, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houddane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertommen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herinckx, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rider, M. H.</span></span> <span> </span><span class="NLM_article-title">Direct and Indirect Activation of Eukaryotic Elongation Factor 2 Kinase by AMP-Activated Protein Kinase</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2017.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.cellsig.2017.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28502587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=212-221&author=M.+Johannsauthor=S.+Pyr+dit+Ruysauthor=A.+Houddaneauthor=D.+Vertommenauthor=G.+Herinckxauthor=L.+Hueauthor=C.+G.+Proudauthor=M.+H.+Rider&title=Direct+and+Indirect+Activation+of+Eukaryotic+Elongation+Factor+2+Kinase+by+AMP-Activated+Protein+Kinase&doi=10.1016%2Fj.cellsig.2017.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Direct and indirect activation of eukaryotic elongation factor 2 kinase by AMP-activated protein kinase</span></div><div class="casAuthors">Johanns, M.; Pyr dit Ruys, S.; Houddane, A.; Vertommen, D.; Herinckx, G.; Hue, L.; Proud, C. G.; Rider, M. H.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">212-221</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 (eEF2) kinase (eEF2K) is a key regulator of protein synthesis in mammalian cells.  It phosphorylates and inhibits eEF2, the translation factor necessary for peptide translocation during the elongation phase of protein synthesis.  When cellular energy demand outweighs energy supply, AMP-activated protein kinase (AMPK) and eEF2K become activated, leading to eEF2 phosphorylation, which reduces the rate of protein synthesis, a process that consumes a large proportion of cellular energy under optimal conditions.  The goal of the present study was to elucidate the mechanisms by which AMPK activation leads to increased eEF2 phosphorylation to decrease protein synthesis.  Using genetically modified mouse embryo fibroblasts (MEFs), effects of treatments with commonly used AMPK activators to increase eEF2 phosphorylation were compared with that of the novel compd. 991.  Bacterially expressed recombinant eEF2K was phosphorylated in vitro by recombinant activated AMPK for phosphorylation site-identification by mass spectrometry followed by site-directed mutagenesis of the identified sites to alanine residues to study effects on the kinetic properties of eEF2K.  Wild-type eEF2K and a Ser491/Ser492 mutant were retrovirally re-introduced in eEF2K-deficient MEFs and effects of 991 treatment on eEF2 phosphorylation and protein synthesis rates were studied in these cells.  AMPK activation leads to increased eEF2 phosphorylation in MEFs mainly by direct activation of eEF2K and partly by inhibition of mammalian target of rapamycin complex 1 (mTORC1) signaling.  Treatment of MEFs with AMPK activators can also lead to eEF2K activation independently of AMPK probably via a rise in intracellular Ca2+.  AMPK activates eEF2K by multi-site phosphorylation and the newly identified Ser491/Ser492 is important for activation, leading to mTOR-independent inhibition of protein synthesis.  Our study provides new insights into the control of eEF2K by AMPK, with implications for linking metabolic stress to decreased protein synthesis to conserve energy reserves, a pathway that is of major importance in cancer cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSUtKY-XXPX7Vg90H21EOLACvtfcHk0lj5YYoOQw5Vew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGms74%253D&md5=8e6e849a6e25fbf3a10f55de41016222</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2017.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2017.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DJohanns%26aufirst%3DM.%26aulast%3DPyr%2Bdit%2BRuys%26aufirst%3DS.%26aulast%3DHouddane%26aufirst%3DA.%26aulast%3DVertommen%26aufirst%3DD.%26aulast%3DHerinckx%26aufirst%3DG.%26aulast%3DHue%26aufirst%3DL.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DRider%26aufirst%3DM.%2BH.%26atitle%3DDirect%2520and%2520Indirect%2520Activation%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520by%2520AMP-Activated%2520Protein%2520Kinase%26jtitle%3DCell.%2520Signalling%26date%3D2017%26volume%3D36%26spage%3D212%26epage%3D221%26doi%3D10.1016%2Fj.cellsig.2017.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerken, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbein, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czernin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, R. J.</span></span> <span> </span><span class="NLM_article-title">LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ccr.2012.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=23352126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=143-158&author=D.+B.+Shackelfordauthor=E.+Abtauthor=L.+Gerkenauthor=D.+S.+Vasquezauthor=A.+Sekiauthor=M.+Leblancauthor=L.+Weiauthor=M.+C.+Fishbeinauthor=J.+Czerninauthor=P.+S.+Mischelauthor=R.+J.+Shaw&title=LKB1+Inactivation+Dictates+Therapeutic+Response+of+Non-Small+Cell+Lung+Cancer+to+the+Metabolism+Drug+Phenformin&doi=10.1016%2Fj.ccr.2012.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin</span></div><div class="casAuthors">Shackelford, David B.; Abt, Evan; Gerken, Laurie; Vasquez, Debbie S.; Seki, Atsuko; Leblanc, Mathias; Wei, Liu; Fishbein, Michael C.; Czernin, Johannes; Mischel, Paul S.; Shaw, Reuben J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-158</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in ∼20% of non-small cell lung cancers (NSCLC).  LKB1 is the major upstream kinase activating the energy-sensing kinase AMPK, making LKB1-deficient cells unable to appropriately sense metabolic stress.  We tested the therapeutic potential of metabolic drugs in NSCLC and identified phenformin, a mitochondrial inhibitor and analog of the diabetes therapeutic metformin, as selectively inducing apoptosis in LKB1-deficient NSCLC cells.  Therapeutic trials in Kras-dependent mouse models of NSCLC revealed that tumors with Kras and Lkb1 mutations, but not those with Kras and p53 mutations, showed selective response to phenformin as a single agent, resulting in prolonged survival.  This study suggests phenformin as a cancer metab.-based therapeutic to selectively target LKB1-deficient tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFxHW2QvmnVbVg90H21EOLACvtfcHk0lj5YYoOQw5Vew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGitro%253D&md5=42f9e3b69b797a3bcfe73eb5392b6298</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DShackelford%26aufirst%3DD.%2BB.%26aulast%3DAbt%26aufirst%3DE.%26aulast%3DGerken%26aufirst%3DL.%26aulast%3DVasquez%26aufirst%3DD.%2BS.%26aulast%3DSeki%26aufirst%3DA.%26aulast%3DLeblanc%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DFishbein%26aufirst%3DM.%2BC.%26aulast%3DCzernin%26aufirst%3DJ.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DShaw%26aufirst%3DR.%2BJ.%26atitle%3DLKB1%2520Inactivation%2520Dictates%2520Therapeutic%2520Response%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520to%2520the%2520Metabolism%2520Drug%2520Phenformin%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D143%26epage%3D158%26doi%3D10.1016%2Fj.ccr.2012.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Signalling to Translation: How Signal Transduction Pathways Control the Protein Synthetic Machinery</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>403</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1042/BJ20070024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1042%2FBJ20070024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=17376031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=403&publication_year=2007&pages=217-234&author=C.+G.+Proud&title=Signalling+to+Translation%3A+How+Signal+Transduction+Pathways+Control+the+Protein+Synthetic+Machinery&doi=10.1042%2FBJ20070024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling to translation: how signal transduction pathways control the protein synthetic machinery</span></div><div class="casAuthors">Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">403</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-234</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent advances in our understanding of both the regulation of components of the translational machinery and the upstream signalling pathways that modulate them have provided important new insights into the mechanisms by which hormones, growth factors, nutrients and cellular energy status control protein synthesis in mammalian cells.  The importance of proper control of mRNA translation is strikingly illustrated by the fact that defects in this process or its control are implicated in a no. of disease states, such as cancer, tissue hypertrophy and neurodegeneration.  Signalling pathways such as those involving mTOR (mammalian target of rapamycin) and mitogen-activated protein kinases modulate the phosphorylation of translation factors, the activities of the protein kinases that act upon them and the assocn. of RNA-binding proteins with specific mRNAs.  These effects contribute both to the overall control of protein synthesis (which is linked to cell growth) and to the modulation of the translation or stability of specific mRNAs.  However, important questions remain about both the contributions of individual regulatory events to the control of general protein synthesis and the mechanisms by which the translation of specific mRNAs is controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprRqs7aO9DL7Vg90H21EOLACvtfcHk0ljK9IL0thCj-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWrtrg%253D&md5=234023d8d36d6bd7b55d8268ca55a56b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1042%2FBJ20070024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070024%26sid%3Dliteratum%253Aachs%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DSignalling%2520to%2520Translation%253A%2520How%2520Signal%2520Transduction%2520Pathways%2520Control%2520the%2520Protein%2520Synthetic%2520Machinery%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D403%26spage%3D217%26epage%3D234%26doi%3D10.1042%2FBJ20070024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span> <span> </span><span class="NLM_article-title">Methylseleninic Acid Elevates REDD1 and Inhibits Prostate Cancer Cell Growth despite AKT Activation and MTOR Dysregulation in Hypoxia</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1002/cam4.198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1002%2Fcam4.198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24515947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFyhurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=252-264&author=I.+Sinhaauthor=J.+E.+Allenauthor=J.+T.+Pintoauthor=R.+Sinha&title=Methylseleninic+Acid+Elevates+REDD1+and+Inhibits+Prostate+Cancer+Cell+Growth+despite+AKT+Activation+and+MTOR+Dysregulation+in+Hypoxia&doi=10.1002%2Fcam4.198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia</span></div><div class="casAuthors">Sinha, Indu; Allen, Joshua E.; Pinto, John T.; Sinha, Raghu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">252-264</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Methylseleninic acid (MSeA) is a monomethylated selenium metabolite theor. derived from subsequent β-lyase or transamination reactions of dietary Se-methylselenocysteine that has potent antitumor activity by inhibiting cell proliferation of several cancers.  Our previous studies showed that MSeA promotes apoptosis in invasive prostate cancer cells in part by downregulating hypoxia-inducible factor HIF-1α.  We have now extended these studies to evaluate the impact of MSeA on REDD1 (an mTOR inhibitor) in inducing cell death of invasive prostate cancer cells in hypoxia.  In both PTEN+ and PTEN- prostate cancer cells we show that MSeA elevates REDD1 and phosphorylation of AKT along with p70S6K in hypoxia.  Furthermore, REDD1 induction by MSeA is independent of AKT and the mTOR inhibition in prostate cancer cells causes partial resistance to MSeA-induced growth redn. in hypoxia.  Our data suggest that MSeA induces REDD1 and inhibits prostate cancer cell growth in hypoxia despite activation of AKT and dysregulation of mTOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtsaAeKEa6v7Vg90H21EOLACvtfcHk0ljK9IL0thCj-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFyhurY%253D&md5=7e4715db199787b144eb9cf72cf8b304</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fcam4.198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.198%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DI.%26aulast%3DAllen%26aufirst%3DJ.%2BE.%26aulast%3DPinto%26aufirst%3DJ.%2BT.%26aulast%3DSinha%26aufirst%3DR.%26atitle%3DMethylseleninic%2520Acid%2520Elevates%2520REDD1%2520and%2520Inhibits%2520Prostate%2520Cancer%2520Cell%2520Growth%2520despite%2520AKT%2520Activation%2520and%2520MTOR%2520Dysregulation%2520in%2520Hypoxia%26jtitle%3DCancer%2520Med.%26date%3D2014%26volume%3D3%26spage%3D252%26epage%3D264%26doi%3D10.1002%2Fcam4.198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-0419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F1078-0432.CCR-17-0419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29084921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=445-459&author=Q.+Zengauthor=J.+Liuauthor=P.+Caoauthor=J.+Liauthor=X.+Liuauthor=X.+Fanauthor=L.+Liuauthor=Y.+Chengauthor=W.+Xiongauthor=J.+Liauthor=H.+Boauthor=Y.+Zhuauthor=F.+Yangauthor=J.+Huauthor=M.+Zhouauthor=Y.+Zhouauthor=Q.+Zouauthor=J.+Zhouauthor=K.+Cao&title=Inhibition+of+REDD1+Sensitizes+Bladder+Urothelial+Carcinoma+to+Paclitaxel+by+Inhibiting+Autophagy&doi=10.1158%2F1078-0432.CCR-17-0419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy</span></div><div class="casAuthors">Zeng, Qinghai; Liu, Jianye; Cao, Peiguo; Li, Jingjing; Liu, Xiaoming; Fan, Xiaojun; Liu, Ling; Cheng, Yan; Xiong, Wei; Li, Jigang; Bo, Hao; Zhu, Yuxing; Yang, Fei; Hu, Jun; Zhou, Ming; Zhou, Yanhong; Zou, Qiong; Zhou, Jianda; Cao, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">445-459</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Regulated in development and DNA damage response-1 (REDD1) is a stress-related protein and is involved in the progression of cancer.  The role and regulatory mechanism of REDD1 in bladder urothelial carcinoma (BUC), however, is yet unidentified.  Exptl. Design: The expression of REDD1 in BUC was detected by Western blot anal. and immunohistochem. (IHC).  The correlation between REDD1 expression and clin. features in patients with BUC were assessed.  The effects of REDD1 on cellular proliferation, apoptosis, autophagy, and paclitaxel sensitivity were detd. both in vitro and in vivo.  Then the targeted-regulating mechanism of REDD1 by miRNAs was explored.  Results: Here the significant increase of REDD1 expression is detected in BUC tissue, and REDD1 is first reported as an independent prognostic factor in patients with BUC.  Silencing REDD1 expression in T24 and EJ cells decreased cell proliferation, increased apoptosis, and decreased autophagy, whereas the ectopic expression of REDD1 in RT4 and BIU87 cells had the opposite effect.  In addn., the REDD1-mediated proliferation, apoptosis, and autophagy are found to be neg. regulated by miR-22 in vitro, which intensify the paclitaxel sensitivity via inhibition of the well-acknowledged REDD1-EEF2K-autophagy axis.  AKT/mTOR signaling initially activated or inhibited in response to silencing or enhancing REDD1 expression and then recovered rapidly.  Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a s.c. transplant carcinoma model in vivo.  Conclusions: REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel.  Clin Cancer Res; 24(2); 445-59. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLgP6n1ilj0rVg90H21EOLACvtfcHk0ljK9IL0thCj-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslGitQ%253D%253D&md5=41195e1c0b00c042bfaaddf6fb1e9a00</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-0419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-0419%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBo%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520REDD1%2520Sensitizes%2520Bladder%2520Urothelial%2520Carcinoma%2520to%2520Paclitaxel%2520by%2520Inhibiting%2520Autophagy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D445%26epage%3D459%26doi%3D10.1158%2F1078-0432.CCR-17-0419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tekedereli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpay, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, C. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobanoglu, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaoud, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e41171</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0041171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1371%2Fjournal.pone.0041171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=22911754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSkt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e41171&author=I.+Tekedereliauthor=S.+N.+Alpayauthor=C.+D.+J.+Tavaresauthor=Z.+E.+Cobanogluauthor=T.+S.+Kaoudauthor=I.+Sahinauthor=A.+K.+Soodauthor=G.+Lopez-Beresteinauthor=K.+N.+Dalbyauthor=B.+Ozpolat&title=Targeted+Silencing+of+Elongation+Factor+2+Kinase+Suppresses+Growth+and+Sensitizes+Tumors+to+Doxorubicin+in+an+Orthotopic+Model+of+Breast+Cancer&doi=10.1371%2Fjournal.pone.0041171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer</span></div><div class="casAuthors">Tekedereli, Ibrahim; Alpay, S. Neslihan; Tavares, Clint D. J.; Cobanoglu, Zehra E.; Kaoud, Tamer S.; Sahin, Ibrahim; Sood, Anil K.; Lopez-Berestein, Gabriel; Dalby, Kevin N.; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e41171</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF-2K), through its phosphorylation of elongation factor 2 (eEF2), provides a mechanism by which cells can control the rate of the elongation phase of protein synthesis.  The activity of eEF-2K is increased in rapidly proliferating malignant cells, is inhibited during mitosis, and may contribute to the promotion of autophagy in response to anti-cancer therapies.  The purpose of this study was to examine the therapeutic potential of targeting eEF-2K in breast cancer tumors.  Through the systemic administration of liposomal eEF-2K siRNA (twice a week, i.v. 150 μg/kg), the expression of eEF-2K was down-regulated in vivo in an orthotopic xenograft mouse model of a highly aggressive triple neg. MDA-MB-231 tumor.  This targeting resulted in a substantial decrease in eEF2 phosphorylation in the tumors, and led to the inhibition of tumor growth, the induction of apoptosis and the sensitization of tumors to the chemotherapy agent doxorubicin.  EEF-2K down-modulation in vitro resulted in a decrease in the expression of c-Myc and cyclin D1 with a concomitant increase in the expression of p27Kip1.  A decrease in the basal activity of c-Src (phospho-Tyr-416), focal adhesion kinase (phospho-Tyr-397), and Akt (phospho-Ser-473) was also detected following eEF-2K down-regulation in MDA-MB-231 cells, as detd. by Western blotting.  Where tested, similar results were seen in ER-pos. MCF-7 cells.  These effects were also accompanied by a decrease in the obsd. invasive phenotype of the MDA-MB-231 cells.  These data support the notion that the disruption of eEF-2K expression in breast cancer cells results in the down-regulation of signaling pathways affecting growth, survival and resistance and has potential as a therapeutic approach for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOuuDE83QkhrVg90H21EOLACvtfcHk0lgiAkLhFG46tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSkt73P&md5=e1966dce4ec43a5fb26998653af4aaa6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0041171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0041171%26sid%3Dliteratum%253Aachs%26aulast%3DTekedereli%26aufirst%3DI.%26aulast%3DAlpay%26aufirst%3DS.%2BN.%26aulast%3DTavares%26aufirst%3DC.%2BD.%2BJ.%26aulast%3DCobanoglu%26aufirst%3DZ.%2BE.%26aulast%3DKaoud%26aufirst%3DT.%2BS.%26aulast%3DSahin%26aufirst%3DI.%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DTargeted%2520Silencing%2520of%2520Elongation%2520Factor%25202%2520Kinase%2520Suppresses%2520Growth%2520and%2520Sensitizes%2520Tumors%2520to%2520Doxorubicin%2520in%2520an%2520Orthotopic%2520Model%2520of%2520Breast%2520Cancer%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De41171%26doi%3D10.1371%2Fjournal.pone.0041171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span> <span> </span><span class="NLM_article-title">EEF-2 Kinase: Another Meddler in the “Yin and Yang” of Akt-Mediated Cell Fate?</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.4161/auto.7.6.15385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.4161%2Fauto.7.6.15385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=21460616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1ymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=660-661&author=Y.+Chengauthor=L.+Yanauthor=X.+Renauthor=J.+M.+Yang&title=EEF-2+Kinase%3A+Another+Meddler+in+the+%E2%80%9CYin+and+Yang%E2%80%9D+of+Akt-Mediated+Cell+Fate%3F&doi=10.4161%2Fauto.7.6.15385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">eEF-2 kinase: Another meddler in the yin and yang of Akt-mediated cell fate?</span></div><div class="casAuthors">Cheng, Yan; Yan, Li; Ren, Xingcong; Yang, Jin-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">660-661</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Eukaryotic elongation factor-2 (eEF-2) kinase, also known as calmodulin-dependent protein kinase III, is a unique calcium/calmodulin-dependent enzyme.  EEF-2 kinase can act as a neg. regulator of protein synthesis and a pos. regulator of autophagy under environmental or metabolic stresses.  Akt, a key downstream effector of the PI3K signaling pathway that regulates cell survival and proliferation, is an attractive therapeutic target for anticancer treatment.  Akt inhibition leads to activation of both apoptosis, type I programmed cell death and autophagy, a cellular degrdn. process via lysosomal machinery (also termed type II programmed cell death).  However, the underlying mechanisms that dictate functional relationship between autophagy and apoptosis in response to Akt inhibition remain to be delineated.  Our recent study demonstrated that inhibition of eEF-2 kinase can suppress autophagy but promote apoptosis in tumor cells subjected to Akt inhibition, indicating a role of eEF-2 kinase as a controller in the crosstalk between autophagy and apoptosis.  Furthermore, inhibition of eEF-2 kinase can reinforce the efficacy of a novel Akt inhibitor, MK-2206, against human glioma.  These findings may help optimize the use of Akt inhibitors in the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ERIa08yUVrVg90H21EOLACvtfcHk0lgiAkLhFG46tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1ymtw%253D%253D&md5=c19bea03bc74fe5368d633bec7e00ed9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4161%2Fauto.7.6.15385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.7.6.15385%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26atitle%3DEEF-2%2520Kinase%253A%2520Another%2520Meddler%2520in%2520the%2520%25E2%2580%259CYin%2520and%2520Yang%25E2%2580%259D%2520of%2520Akt-Mediated%2520Cell%2520Fate%253F%26jtitle%3DAutophagy%26date%3D2011%26volume%3D7%26spage%3D660%26epage%3D661%26doi%3D10.4161%2Fauto.7.6.15385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span> <span> </span><span class="NLM_article-title">FoxM1: A Master Regulator of Tumor Metastasis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4329</span>– <span class="NLM_lpage">4333</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-0640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F0008-5472.CAN-11-0640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=21712406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4329-4333&author=P.+Raychaudhuriauthor=H.+J.+Park&title=FoxM1%3A+A+Master+Regulator+of+Tumor+Metastasis&doi=10.1158%2F0008-5472.CAN-11-0640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FoxM1: A Master Regulator of Tumor Metastasis</span></div><div class="casAuthors">Raychaudhuri, Pradip; Park, Hyun Jung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4329-4333</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The FoxM1 transcription factor gene is overexpressed in cancer.  Its expression is stimulated by oncogenic signaling pathways and reactive oxygen species.  It is also a target of regulation by the tumor suppressor genes.  The transcriptional activity of FoxM1 depends upon activation by cyclin and cyclin-dependent kinases as well as Plk1.  FoxM1 stimulates expression of several genes involved in the cell cycle progression.  Moreover, it supports proliferation of tumor cells by stimulating expression of the antioxidant genes and reducing oxidative stress.  A new study provides evidence that FoxM1, in the absence of its inhibitor, the tumor suppressor Arf, drives metastasis of hepatocellular carcinoma (HCC).  It induces an epithelial-mesenchymal-like transition phenotype in HCC cells, increases cell migration, and induces premetastatic niche at the distal organ of metastasis.  FoxM1 directly activates genes involved in multiple steps of metastasis.  In this review, the authors discuss the evidence for a master regulatory role of FoxM1 in tumor metastasis.  Cancer Res; 71(13); 4329-33.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaeWChChl5hrVg90H21EOLACvtfcHk0lgiAkLhFG46tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersL4%253D&md5=7230f9e5cef8374fdbc1e93138767c1f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-0640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-0640%26sid%3Dliteratum%253Aachs%26aulast%3DRaychaudhuri%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26atitle%3DFoxM1%253A%2520A%2520Master%2520Regulator%2520of%2520Tumor%2520Metastasis%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4329%26epage%3D4333%26doi%3D10.1158%2F0008-5472.CAN-11-0640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupczak-Hollis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennewitz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adami, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, R. H.</span></span> <span> </span><span class="NLM_article-title">Increased Hepatic Forkhead Box M1B (FoxM1B) Levels in Old-Aged Mice Stimulated Liver Regeneration through Diminished P27Kip1 Protein Levels and Increased Cdc25B Expression</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">44310</span>– <span class="NLM_lpage">44316</span>, <span class="refDoi"> DOI: 10.1074/jbc.M207510200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.M207510200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=12221098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1aktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=44310-44316&author=X.+Wangauthor=K.+Krupczak-Hollisauthor=Y.+Tanauthor=M.+B.+Dennewitzauthor=G.+R.+Adamiauthor=R.+H.+Costa&title=Increased+Hepatic+Forkhead+Box+M1B+%28FoxM1B%29+Levels+in+Old-Aged+Mice+Stimulated+Liver+Regeneration+through+Diminished+P27Kip1+Protein+Levels+and+Increased+Cdc25B+Expression&doi=10.1074%2Fjbc.M207510200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Hepatic Forkhead Box M1B (FoxM1B) Levels in Old-aged Mice Stimulated Liver Regeneration through Diminished p27Kip1 Protein Levels and Increased Cdc25B Expression</span></div><div class="casAuthors">Wang, Xinhe; Krupczak-Hollis, Katherine; Tan, Yongjun; Dennewitz, Margaret B.; Adami, Guy R.; Costa, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">44310-44316</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Recent liver regeneration studies indicate that maintaining hepatic Forkhead Box M1B (FoxM1B) expression in 12-mo-old (old-aged) Transthyretin-FoxM1B transgenic mice increases hepatocyte proliferation and expression of cell cycle regulatory genes.  Because these transgenic CD-1 mice maintain FoxM1B levels during the aging process, we conducted the current study to det. whether adenovirus delivery of the FoxM1B gene (AdFoxM1B) is sufficient to stimulate liver regeneration in old-aged Balb/c mice.  Here we show that AdFoxM1B infection of old-aged mice caused a significant increase in FoxM1B expression, hepatocyte DNA replication, and mitosis following partial hepatectomy.  This stimulation in hepatocyte S-phase progression was assocd. with diminished protein expression and perinuclear localization of cyclin-dependent kinase (Cdk) inhibitor p27Kip1 (p27) protein following partial hepatectomy.  In contrast, old-aged mice infected with control virus displayed high hepatocyte levels of p27 protein, which had been localized to the nucleus prior to S-phase.  Furthermore, we found that restoring FoxM1B expression did not influence p27 mRNA levels, and this new finding implicates FoxM1B in regulation of p27 protein levels.  Likewise, AdFoxM1B-infected regenerating livers displayed elevated S-phase levels of Cdk2 kinase activity compared with old-aged mice infected with control virus.  Furthermore, restoring FoxM1B expression in old-aged mice caused elevated levels of Cyclin B1, Cyclin B2, Cdc25B, Cdk1, and p55CDC mRNA as well as stimulating Cdc25B nuclear localization during liver regeneration, all of which are required for mitosis.  These studies indicated that an acute delivery of the FoxM1B gene in old-aged mice is sufficient to re-establish proliferation of regenerating hepatocytes, suggesting that FoxM1B can be used for therapeutic intervention to alleviate the redn. in cellular proliferation obsd. in the elderly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpof6jVzwCPnLVg90H21EOLACvtfcHk0lgtQcZun6buzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1aktL4%253D&md5=75897091171110f57381f42608e4932f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207510200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207510200%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKrupczak-Hollis%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DDennewitz%26aufirst%3DM.%2BB.%26aulast%3DAdami%26aufirst%3DG.%2BR.%26aulast%3DCosta%26aufirst%3DR.%2BH.%26atitle%3DIncreased%2520Hepatic%2520Forkhead%2520Box%2520M1B%2520%2528FoxM1B%2529%2520Levels%2520in%2520Old-Aged%2520Mice%2520Stimulated%2520Liver%2520Regeneration%2520through%2520Diminished%2520P27Kip1%2520Protein%2520Levels%2520and%2520Increased%2520Cdc25B%2520Expression%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D44310%26epage%3D44316%26doi%3D10.1074%2Fjbc.M207510200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamurcu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">FOXM1 Regulates Expression of Eukaryotic Elongation Factor 2 Kinase and Promotes Proliferation, Invasion and Tumorgenesis of Human Triple Negative Breast Cancer Cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">16619</span>– <span class="NLM_lpage">16635</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.18632%2Foncotarget.7672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=26918606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A280%3ADC%252BC28jks1ehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=16619-16635&author=Z.+Hamurcuauthor=A.+Ashourauthor=N.+Kahramanauthor=B.+Ozpolat&title=FOXM1+Regulates+Expression+of+Eukaryotic+Elongation+Factor+2+Kinase+and+Promotes+Proliferation%2C+Invasion+and+Tumorgenesis+of+Human+Triple+Negative+Breast+Cancer+Cells&doi=10.18632%2Foncotarget.7672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells</span></div><div class="casAuthors">Hamurcu Zuhal; Ashour Ahmed; Kahraman Nermin; Ozpolat Bulent; Hamurcu Zuhal; Hamurcu Zuhal; Ozpolat Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">16619-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K), an emerging molecular target for cancer therapy, contributes to cancer proliferation, cell survival, tumorigenesis, and invasion, disease progression and drug resistance.  Although eEF2K is highly up-regulated in various cancers, the mechanism of gene regulation has not been elucidated.  In this study, we examined the role of Forkhead Box M1 (FOXM1) proto-oncogenic transcription factor in triple negative breast cancer (TNBC) cells and the regulation of eEF2K.  We found that FOXM1 is highly upregulated in TNBC and its knockdown by RNA interference (siRNA) significantly inhibited eEF2K expression and suppressed cell proliferation, colony formation, migration, invasion and induced apoptotic cell death, recapitulating the effects of eEF2K inhibition.  Knockdown of FOXM1 inhibited regulators of cell cycle, migration/invasion and survival, including cyclin D1, Src and MAPK-ERK signaling pathways, respectively.  We also demonstrated that FOXM1 (1B and 1C isoforms) directly binds to and transcriptionally regulates eEF2K gene expression by chromatin immunoprecipitation (ChIP) and luciferase gene reporter assays.  Furthermore, in vivo inhibition of FOXM1 by liposomal siRNA-nanoparticles suppressed growth of MDA-MB-231 TNBC tumor xenografts in orthotopic models.  In conclusion, our study provides the first evidence about the transcriptional regulation of eEF2K in TNBC and the role of FOXM1 in mediating breast cancer cell proliferation, survival, migration/invasion, progression and tumorgenesis and highlighting the potential of FOXM1/eEF2K axis as a molecular target in breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnE1pTgfQWEySm0e6ZOaemfW6udTcc2ebQIYnjQi-X07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jks1ehuw%253D%253D&md5=01078417f171868a3f71be29a9fcca60</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7672%26sid%3Dliteratum%253Aachs%26aulast%3DHamurcu%26aufirst%3DZ.%26aulast%3DAshour%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DFOXM1%2520Regulates%2520Expression%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520and%2520Promotes%2520Proliferation%252C%2520Invasion%2520and%2520Tumorgenesis%2520of%2520Human%2520Triple%2520Negative%2520Breast%2520Cancer%2520Cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D16619%26epage%3D16635%26doi%3D10.18632%2Foncotarget.7672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanlikilicer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhlis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Aguayo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Dual Suppressive Effect of MiR-34A on the FOXM1/EEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4225</span>– <span class="NLM_lpage">4241</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F1078-0432.CCR-17-1959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29748184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVahs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4225-4241&author=R.+Bayraktarauthor=C.+Ivanauthor=E.+Bayraktarauthor=P.+Kanlikilicerauthor=N.+N.+Kabilauthor=N.+Kahramanauthor=H.+A.+Mokhlisauthor=D.+Karakasauthor=C.+Rodriguez-Aguayoauthor=A.+Arslanauthor=J.+Shengauthor=S.+Wongauthor=G.+Lopez-Beresteinauthor=G.+A.+Calinauthor=B.+Ozpolat&title=Dual+Suppressive+Effect+of+MiR-34A+on+the+FOXM1%2FEEF2-Kinase+Axis+Regulates+Triple-Negative+Breast+Cancer+Growth+and+Invasion&doi=10.1158%2F1078-0432.CCR-17-1959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Dual suppressive effect of miR-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion</span></div><div class="casAuthors">Bayraktar, Recep; Ivan, Cristina; Bayraktar, Emine; Kanlikilicer, Pinar; Kabil, Nashwa N.; Kahraman, Nermin; Mokhlis, Hamada A.; Karakas, Didem; Rodriguez-Aguayo, Cristian; Arslan, Ahmet; Sheng, Jianting; Wong, Stephen; Lopez-Berestein, Gabriel; Calin, George A.; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4225-4241</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent studies indicated that dysregulation of noncoding RNAs (ncRNA) such as miRNAs is involved in pathogenesis of various human cancers.  However, the mol. mechanisms underlying miR-34a are not fully understood in triple-neg. breast cancer (TNBC).  We performed in vitro functional assays on TNBC cell lines to investigate the role of miR-34a in FOXM1/eEF2K signaling axis.  TNBC tumor xenograft models were used for in vivo therapeutic delivery of miR-34a.  In this study, we investigated the role of p53-driven ncRNA miR-34a and found that miR-34a is assocd. with significantly longer patient survival in TNBC and inversely correlated with levels of proto-oncogenic eEF2K, which was assocd. with significantly shorter overall patient survival.  We showed that miR-34a directly binds to the 3'-untranslated region of eEF2K and FOXM1 mRNAs and suppresses their expression, leading to inhibition of TNBC cell proliferation, motility, and invasion.  Notably, restoring miR-34a expression recapitulated the effects of inhibition of eEF2K and FOXM1, the transcription factor for eEF2K and the direct target of p53, in TNBC cell lines, whereas overexpression of eEF2K and FOXM1 rescued the effects and signaling pathways mediated by miR-34a.  Moreover, in vivo therapeutic delivery of miR-34a nanoparticles by systemic i.v. administration delayed tumor growth of two different orthotopic TNBC tumor xenograft models by inhibiting eEF2K and FOXM1, intratumoral proliferation and angiogenesis, and inducing apoptosis.  Overall, our findings provide new insights into the tumor suppressor role of miR-34a by dual-targeting of FOXM1/eEF2K signaling axis and suggest that miR-34a-based gene therapy may be a potential therapeutic strategy in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxfq_aB9mBmLVg90H21EOLACvtfcHk0liJJC9eIudH_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVahs7Y%253D&md5=12d48c9e740094b5dc49fccffa995349</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1959%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DKanlikilicer%26aufirst%3DP.%26aulast%3DKabil%26aufirst%3DN.%2BN.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DMokhlis%26aufirst%3DH.%2BA.%26aulast%3DKarakas%26aufirst%3DD.%26aulast%3DRodriguez-Aguayo%26aufirst%3DC.%26aulast%3DArslan%26aufirst%3DA.%26aulast%3DSheng%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DCalin%26aufirst%3DG.%2BA.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DDual%2520Suppressive%2520Effect%2520of%2520MiR-34A%2520on%2520the%2520FOXM1%252FEEF2-Kinase%2520Axis%2520Regulates%2520Triple-Negative%2520Breast%2520Cancer%2520Growth%2520and%2520Invasion%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D4225%26epage%3D4241%26doi%3D10.1158%2F1078-0432.CCR-17-1959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vicent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Picazo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Corchón, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Algarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montuenga, L. M.</span></span> <span> </span><span class="NLM_article-title">ERK 1/2 Is Activated in Non-Small-Cell Lung Cancer and Associated with Advanced Tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1052</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fsj.bjc.6601644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=14997206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslWrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=1047-1052&author=S.+Vicentauthor=J.+M.+L%C3%B3pez-Picazoauthor=G.+Toledoauthor=M.+D.+Lozanoauthor=W.+Torreauthor=C.+Garcia-Corch%C3%B3nauthor=C.+Queroauthor=J.+C.+Soriaauthor=S.+Mart%C3%ADn-Algarraauthor=R.+G.+Manzanoauthor=L.+M.+Montuenga&title=ERK+1%2F2+Is+Activated+in+Non-Small-Cell+Lung+Cancer+and+Associated+with+Advanced+Tumours&doi=10.1038%2Fsj.bjc.6601644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours</span></div><div class="casAuthors">Vicent, S.; Lopez-Picazo, J. M.; Toledo, G.; Lozano, M. D.; Torre, W.; Garcia-Corchon, C.; Quero, C.; Soria, J-C.; Martin-Algarra, S.; Manzano, R. G.; Montuenga, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1047-1052</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the ERK1/2 pathway is involved in malignant transformation both in vitro and in vivo.  Little is known about the role of activated ERK1/2 in non-small cell lung cancer (NSCLC).  The purpose of this study was to characterize the extent of the activation of ERK1/2 by immunohistochem. in patients with NSCLC, and to det. the relationship of ERK1/2 activation with clinicopathol. variables.  Specimens from 111 patients with NSCLC (stages I-IV) were stained for P-ERK.  Staining for epidermal growth factor receptor (EGFR) and Ki-67 was also performed.  In all, 34% of the tumor specimens showed activation for ERK1/2, while normal lung epithelial tissue was consistently neg.  There was a strong statistical correlation between nuclear and cytoplasmic P-ERK staining and advanced stages (P<0.05 and P<0.001, resp.), metastatic hilar or mediastinal lymph nodes (P<0.01, P<0.001), and higher T stages (P<0.01, P<0.001).  We did not find correlation of nuclear or cytoplasmic P-ERK staining with either EGFR expression or Ki-67 expression.  Total ERK1/2 expression was evaluated with a specific ERK1/2 antibody and showed that P-ERK staining was not due to ERK overexpression but rather to hyperactivation of ERK1/2.  Patients with a pos. P-ERK cytoplasmic staining had a significant lower survival (P<0.05).  However, multivariate anal. did not show significant survival difference.  Our study indicates that nuclear and cytoplasmic ERK1/2 activation pos. correlates with stage, T and lymph node metastases, and thus, is assocd. with advanced and aggressive NSCLC tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDzCC8cfDByrVg90H21EOLACvtfcHk0liJJC9eIudH_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslWrsbw%253D&md5=62ddfb9aadeb5d8d7086f6eb7cf0656b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601644%26sid%3Dliteratum%253Aachs%26aulast%3DVicent%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez-Picazo%26aufirst%3DJ.%2BM.%26aulast%3DToledo%26aufirst%3DG.%26aulast%3DLozano%26aufirst%3DM.%2BD.%26aulast%3DTorre%26aufirst%3DW.%26aulast%3DGarcia-Corch%25C3%25B3n%26aufirst%3DC.%26aulast%3DQuero%26aufirst%3DC.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DManzano%26aufirst%3DR.%2BG.%26aulast%3DMontuenga%26aufirst%3DL.%2BM.%26atitle%3DERK%25201%252F2%2520Is%2520Activated%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%2520and%2520Associated%2520with%2520Advanced%2520Tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26spage%3D1047%26epage%3D1052%26doi%3D10.1038%2Fsj.bjc.6601644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bircan, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbuz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pataer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdogan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Elongation Factor-2 Kinase (EEF-2K) Expression Is Associated with Poor Patient Survival and Promotes Proliferation, Invasion and Tumor Growth of Lung Cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.07.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.lungcan.2018.07.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30268477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A280%3ADC%252BB3czktV2luw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=31-39&author=H.+A.+Bircanauthor=N.+Gurbuzauthor=A.+Pataerauthor=A.+Canerauthor=N.+Kahramanauthor=E.+Bayraktarauthor=R.+Bayraktarauthor=M.+A.+Erdoganauthor=N.+Kabilauthor=B.+Ozpolat&title=Elongation+Factor-2+Kinase+%28EEF-2K%29+Expression+Is+Associated+with+Poor+Patient+Survival+and+Promotes+Proliferation%2C+Invasion+and+Tumor+Growth+of+Lung+Cancer&doi=10.1016%2Fj.lungcan.2018.07.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer</span></div><div class="casAuthors">Bircan Haci Ahmet; Gurbuz Nilgun; Pataer Apar; Caner Ayse; Kahraman Nermin; Bayraktar Emine; Bayraktar Recep; Erdogan Mumin Alper; Kabil Nashwa; Ozpolat Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Lung cancer is the leading cause of cancer related deaths in worldwide.  Despite recent advances in treatment options, patient survival has not improved substantially due to lack of commonly expressed molecular targets and effective targeted therapeutics.  Thus, better understanding of the biology of lung cancer and identification of novel therapeutic targets are urgently needed for development of highly effective molecularly targeted therapies.  MATERIALS AND METHODS:  Viability, proliferation and metastatic ability of lung cancer cells were evaluated using methylthiazoltetrazolium (MTT), colony formation and matrigel invasion assays, respectively.  Western blotting, RT-PCR, and gene knockdown by siRNA transfections were carried out to investigate the effects of eEF-2K on lung cancer cells.  Athymic Nu/Nu mice were treated with liposomal eEF-2KeEF-2K or control siRNA and tumor growth was evaluated in tumor xenograft models of lung cancer.  RESULTS AND DISCUSSION:  Here, we report that Eukaryotic Elongation Factor-2 kinase (eEF-2K), a member of an atypical alpha kinases family, is significantly upregulated in lung cancer cell lines and its expression is associated with shorter overall patient survival in lung cancer.  Inhibition eEF-2K expression by siRNA or a chemical inhibitorsignificantly suppressed lung cancer cell proliferation, colony formation, survival, migration/invasion and tumorigenesis by inhibiting cyclin D1, Src and Mitogen-Activated Protein Kinases/Extracellular Signal-Regulated Kinase (MAPK/ERK) signaling.  In vivo targeting of eEF-2K by systemically injected nanoliposomal eEF-2K siRNA resulted in a significant inhibition of lung cancer tumor xenografts in nude mice.  Our results suggest, for the first time, that expression of eEF-2K is associated with poor patient prognosis and involved in regulation of critical pathways, including Src and MAPK/ERK and cyclin D1, promoting tumor growth and progression, and thus may be a novel potential therapeutic target in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQh6lCdjmngrhgd2Wuil24tfW6udTcc2eZRDzbTB6TK7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czktV2luw%253D%253D&md5=f5be504835970740ac9449ae852c697c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.07.027%26sid%3Dliteratum%253Aachs%26aulast%3DBircan%26aufirst%3DH.%2BA.%26aulast%3DGurbuz%26aufirst%3DN.%26aulast%3DPataer%26aufirst%3DA.%26aulast%3DCaner%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DErdogan%26aufirst%3DM.%2BA.%26aulast%3DKabil%26aufirst%3DN.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DElongation%2520Factor-2%2520Kinase%2520%2528EEF-2K%2529%2520Expression%2520Is%2520Associated%2520with%2520Poor%2520Patient%2520Survival%2520and%2520Promotes%2520Proliferation%252C%2520Invasion%2520and%2520Tumor%2520Growth%2520of%2520Lung%2520Cancer%26jtitle%3DLung%2520Cancer%26date%3D2018%26volume%3D124%26spage%3D31%26epage%3D39%26doi%3D10.1016%2Fj.lungcan.2018.07.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dehm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonham, K.</span></span> <span> </span><span class="NLM_article-title">SRC Gene Expression in Human Cancer: The Role of Transcriptional Activation</span>. <i>Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1139/o03-077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1139%2Fo03-077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=15060621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2004&pages=263-274&author=S.+M.+Dehmauthor=K.+Bonham&title=SRC+Gene+Expression+in+Human+Cancer%3A+The+Role+of+Transcriptional+Activation&doi=10.1139%2Fo03-077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">SRC gene expression in human cancer: The role of transcriptional activation</span></div><div class="casAuthors">Dehm, Scott M.; Bonham, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">BCBIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0829-8211</span>.
    
            (<span class="NLM_cas:orgname">National Research Council of Canada</span>)
        </div><div class="casAbstract">A review.  Human pp60c-Src (or c-Src) is a 60 kDa non-receptor tyrosine kinase encoded by the SRC gene and is the cellular homolog to the potent transforming v-Src viral oncogene.  C-Src functions at the hub of a vast array of signal transduction cascades that influence cellular proliferation, differentiation, motility, and survival.  C-Src activation has been documented in upwards of 50% of tumors derived from the colon, liver, lung, breast, and pancreas.  Therefore, a major focus has been to understand the mechanisms of c-Src activation in human cancer.  Early studies concd. on post-translational mechanisms that lead to increased c-Src kinase activity, which often correlated with overexpression of c-Src protein.  More recently, the discovery of an activating SRC mutation in a small subset of advanced colon tumors has been reported.  In addn., elevated SRC transcription has been identified as yet another mechanism contributing significantly to c-Src activation in a subset of human colon cancer cell lines.  Interestingly, histone deacetylase (HDAC) inhibitors, agents with well-documented anti-cancer activity, repress SRC transcription in a wide variety of human cancer cell lines.  Anal. of the mechanisms behind HDAC inhibitor mediated repression could be utilized in the future to specifically inhibit SRC gene expression in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi4CZWd0vRL7Vg90H21EOLACvtfcHk0lgIfS1Xxt4Bhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFChsb8%253D&md5=3693d1b64959feb8218339c72e2c7b25</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1139%2Fo03-077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fo03-077%26sid%3Dliteratum%253Aachs%26aulast%3DDehm%26aufirst%3DS.%2BM.%26aulast%3DBonham%26aufirst%3DK.%26atitle%3DSRC%2520Gene%2520Expression%2520in%2520Human%2520Cancer%253A%2520The%2520Role%2520of%2520Transcriptional%2520Activation%26jtitle%3DBiochem.%2520Cell%2520Biol.%26date%3D2004%26volume%3D82%26spage%3D263%26epage%3D274%26doi%3D10.1139%2Fo03-077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanlikilicer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguztuzun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulasli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">MicroRNA 603 Acts as a Tumor Suppressor and Inhibits Triplenegative Breast Cancer Tumorigenesis by Targeting Elongation Factor 2 Kinase</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11641</span>– <span class="NLM_lpage">11658</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.18632%2Foncotarget.14264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28036267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A280%3ADC%252BC1c7gs1eisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=11641-11658&author=R.+Bayraktarauthor=M.+Pichlerauthor=P.+Kanlikilicerauthor=C.+Ivanauthor=E.+Bayraktarauthor=N.+Kahramanauthor=B.+Aslanauthor=S.+Oguztuzunauthor=M.+Ulasliauthor=A.+Arslanauthor=G.+Calinauthor=G.+Lopez-Beresteinauthor=B.+Ozpolat&title=MicroRNA+603+Acts+as+a+Tumor+Suppressor+and+Inhibits+Triplenegative+Breast+Cancer+Tumorigenesis+by+Targeting+Elongation+Factor+2+Kinase&doi=10.18632%2Foncotarget.14264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase</span></div><div class="casAuthors">Bayraktar Recep; Kanlikilicer Pinar; Ivan Cristina; Bayraktar Emine; Kahraman Nermin; Aslan Burcu; Calin George; Lopez-Berestein Gabriel; Ozpolat Bulent; Bayraktar Recep; Bayraktar Emine; Ulasli Mustafa; Arslan Ahmet; Pichler Martin; Ivan Cristina; Calin George; Lopez-Berestein Gabriel; Ozpolat Bulent; Oguztuzun Serpil</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">11641-11658</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by the absence of defined molecular targets, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and is associated with high rates of relapse and distant metastasis despite surgery and adjuvant chemotherapy.  The lack of effective targeted therapies for TNBC represents an unmet therapeutic challenge.  Eukaryotic elongation factor 2 kinase (eEF2K) is an atypical calcium/calmodulin-dependent serine/threonine kinase that promotes TNBC tumorigenesis, progression, and drug resistance, representing a potential novel molecular target.  However, the mechanisms regulating eEF2K expression are unknown.  Here, we report that eEF2K protein expression is highly up-regulated in TNBC cells and patient tumors and it is associated with poor patient survival and clinical outcome.  We found that loss/reduced expression of miR-603 leads to eEF2K overexpression in TNBC cell lines.  Its expression results in inhibition of eEF2K by directly targeting the 3-UTR and the inhibition of tumor cell growth, migration and invasion in TNBC.  In vivo therapeutic gene delivery of miR-603 into TNBC xenograft mouse models by systemic administration of miR-603-nanoparticles led to a significant inhibition of eEF2K expression and tumor growth, which was associated with decreased activity of the downstream targets of eEF2K, including Src, Akt, cyclin D1 and c-myc.  Our findings suggest that miR-603 functions as a tumor suppressor and loss of miR-603 expression leads to increase in eEF2K expression and contributes to the growth, invasion, and progression of TNBC.  Taken together, our data suggest that miR-603-based gene therapy is a potential strategy against TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-_T1YwZchiaNc3HjJRoFAfW6udTcc2eajWBsILensBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7gs1eisA%253D%253D&md5=629328be6dd8244a4b8183d7c0b1bf18</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14264%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DPichler%26aufirst%3DM.%26aulast%3DKanlikilicer%26aufirst%3DP.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DAslan%26aufirst%3DB.%26aulast%3DOguztuzun%26aufirst%3DS.%26aulast%3DUlasli%26aufirst%3DM.%26aulast%3DArslan%26aufirst%3DA.%26aulast%3DCalin%26aufirst%3DG.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DMicroRNA%2520603%2520Acts%2520as%2520a%2520Tumor%2520Suppressor%2520and%2520Inhibits%2520Triplenegative%2520Breast%2520Cancer%2520Tumorigenesis%2520by%2520Targeting%2520Elongation%2520Factor%25202%2520Kinase%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D11641%26epage%3D11658%26doi%3D10.18632%2Foncotarget.14264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhlis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Thymoquinone Inhibits Cell Proliferation, Migration, and Invasion by Regulating the Elongation Factor 2 Kinase (EEF-2K) Signaling Axis in Triple-Negative Breast Cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1007/s10549-018-4847-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1007%2Fs10549-018-4847-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29971628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yksLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2018&pages=593-605&author=N.+Kabilauthor=R.+Bayraktarauthor=N.+Kahramanauthor=H.+A.+Mokhlisauthor=G.+A.+Calinauthor=G.+Lopez-Beresteinauthor=B.+Ozpolat&title=Thymoquinone+Inhibits+Cell+Proliferation%2C+Migration%2C+and+Invasion+by+Regulating+the+Elongation+Factor+2+Kinase+%28EEF-2K%29+Signaling+Axis+in+Triple-Negative+Breast+Cancer&doi=10.1007%2Fs10549-018-4847-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer</span></div><div class="casAuthors">Kabil, Nashwa; Bayraktar, Recep; Kahraman, Nermin; Mokhlis, Hamada A.; Calin, George A.; Lopez-Berestein, Gabriel; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">593-605</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background/purpose: Triple-neg. breast cancer (TNBC) is the most aggressive and chemoresistant subtype of breast cancer.  Therefore, new mol. targets and treatments need to be developed to improve poor patient prognosis and survival.  We have previously shown that eukaryotic elongation factor 2 kinase (eEF-2K) is highly expressed in TNBC cells, is assocd. with poor patient survival and prognosis, and promotes cell proliferation, migration, and invasion.  In vivo targeting of eEF-2K significantly reduces the tumor growth of orthotopic TNBC xenograft mouse models, suggesting that eEF-2K may serve as a potential novel therapeutic target.  Methods/results: In the current study, we identified thymoquinone (TQ), an active ingredient of Nigella sativa, as a potential safe and effective eEF-2K inhibitor in TNBC.  We demonstrated for the first time that TQ inhibits the protein and mRNA expression of eEF-2K, as well as the clin. relevant downstream targets, including Src/FAK and Akt, and induces the tumor suppressor miR-603, in response to NF-kB inhibition.  This effect was assocd. with a significant decrease in the proliferation, colony formation, migration, and invasion of TNBC cells.  Furthermore, systemic in vivo injection of TQ (20 and 100 mg/kg) significantly reduced the growth of MDA-MB-231 tumors and inhibited the eEF-2K expression in an orthotopic tumor model in mice.  Conclusion: Our study provides first evidence that TQ treatment inhibits cell proliferation, migration/invasion, and tumor growth, in part through the inhibition of eEF-2K signaling in TNBC.  Thus, our findings suggest that systemic TQ treatment may be used as a targeted therapeutic strategy for the inhibition of eEF-2K in TNBC tumor growth and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8kyxIVXtRLVg90H21EOLACvtfcHk0lgIfS1Xxt4Bhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yksLbL&md5=0bbf638cfefa85c33f9c4bc4f8c492c8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs10549-018-4847-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-018-4847-2%26sid%3Dliteratum%253Aachs%26aulast%3DKabil%26aufirst%3DN.%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DMokhlis%26aufirst%3DH.%2BA.%26aulast%3DCalin%26aufirst%3DG.%2BA.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DThymoquinone%2520Inhibits%2520Cell%2520Proliferation%252C%2520Migration%252C%2520and%2520Invasion%2520by%2520Regulating%2520the%2520Elongation%2520Factor%25202%2520Kinase%2520%2528EEF-2K%2529%2520Signaling%2520Axis%2520in%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2018%26volume%3D171%26spage%3D593%26epage%3D605%26doi%3D10.1007%2Fs10549-018-4847-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Elongation Factor 2 Kinase Promotes Angiogenesis in Hepatocellular Carcinoma via PI3K/Akt and STAT3</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1002/ijc.32560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1002%2Fijc.32560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=31286509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWgtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=1383-1395&author=Y.+Zhouauthor=Y.+Liauthor=S.+Xuauthor=J.+Luauthor=Z.+Zhuauthor=S.+Chenauthor=Y.+Tanauthor=P.+Heauthor=J.+Xuauthor=C.+G.+Proudauthor=J.+Xieauthor=K.+Shen&title=Eukaryotic+Elongation+Factor+2+Kinase+Promotes+Angiogenesis+in+Hepatocellular+Carcinoma+via+PI3K%2FAkt+and+STAT3&doi=10.1002%2Fijc.32560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3</span></div><div class="casAuthors">Zhou, Ying; Li, Yaoting; Xu, Shihao; Lu, Jing; Zhu, Ziyi; Chen, Shaoli; Tan, Yuan; He, Peng; Xu, Jin; Proud, Christopher G.; Xie, Jianling; Shen, Kaikai</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1383-1395</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is an aggressive malignancy with increasing mortality in China.  Angiogenesis is crucial for tumor formation, development and metastasis in HCC.  Previous studies indicated that high expression levels of elongation factor 2 kinase (eEF2K), a protein kinase that neg. regulates the elongation stage of translation, were assocd. with poor prognosis of HCC.  This study show that pharmacol. inhibition or knockdown of eEF2K in highly metastatic liver cancer cells inhibits their colony forming and migratory capacities, as well as reducing their invasiveness.  Importantly, knocking down eEF2K by lentiviral directed shRNA prevented tumor growth and angiogenesis of HCC in mice.  Silencing of eEF2K in endothelial cells (HUVECs) led to a redn. in vascularization, evidenced by a decrease in capillary-like structures in the matrigel.  Notably, knocking down eEF2K reduced the expression of angiogenesis-related growth factors in liver cancer cells and the expression of growth factor receptors on HUVECs, and thus restricted signaling crosstalk that promotes angiogenesis between HCC cells and endothelial cells.  This study also showed that silencing of eEF2K effectively reduced protein levels of SP1/KLF5 transcription factors and hence decreased the levels of bound SP1/KLF5 to the VEGF promoter, resulted in a decrease in VEGF mRNA expression.  Knocking down eEF2K also led to a striking decrease in the phosphorylation of PI3K/Akt and STAT3, indicating inactivation of these tumorigenic pathways.  Taken together, our data suggest that eEF2K contributes to angiogenesis and tumor progression in HCC via SP1/KLF5-mediated VEGF expression, as well as the subsequent stimulation of PI3K/Akt and STAT3 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG91ZjVeu0FrVg90H21EOLACvtfcHk0ljeIk5kJ3tSCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWgtrjO&md5=344cdf63f7bcc4cd5919ed2b73564a6f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fijc.32560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32560%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26atitle%3DEukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520Promotes%2520Angiogenesis%2520in%2520Hepatocellular%2520Carcinoma%2520via%2520PI3K%252FAkt%2520and%2520STAT3%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2020%26volume%3D146%26spage%3D1383%26epage%3D1395%26doi%3D10.1002%2Fijc.32560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, C.</span></span> <span> </span><span class="NLM_article-title">β-Cryptoxanthin Induced Anti-Proliferation and Apoptosis by G0/G1 Arrest and AMPK Signal Inactivation in Gastric Cancer</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>859</i></span>,  <span class="NLM_fpage">172528</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2019.172528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ejphar.2019.172528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=31288004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGns7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=859&publication_year=2019&pages=172528&author=M.+Gaoauthor=F.+Dangauthor=C.+Deng&title=%CE%B2-Cryptoxanthin+Induced+Anti-Proliferation+and+Apoptosis+by+G0%2FG1+Arrest+and+AMPK+Signal+Inactivation+in+Gastric+Cancer&doi=10.1016%2Fj.ejphar.2019.172528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">β-Cryptoxanthin induced anti-proliferation and apoptosis by G0/G1 arrest and AMPK signal inactivation in gastric cancer</span></div><div class="casAuthors">Gao, Meili; Dang, Fan; Deng, Chun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">859</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172528</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A β-Cryptoxanthin has been assocd. with reduced-risk of some cancers.  However, the mechanisms of β-cryptoxanthin still remain unclearly understood in gastric cancer (GC).  In this study, we examd. the effect of β-cryptoxanthin on AMPK signal in human gastric cancer cells.  AGS and SGC-7901 cells were treated with β-cryptoxanthin (0-40μM) and AGS cells were injected in BALB/c (nu/nu) mice to analyze the effect of β-cryptoxanthin on GC.  We found that β-cryptoxanthin induced inhibitory effect on the cell viability in a time- and concn.-dependent manner.  The no. of migrated cells and protein levels of matrix metalloproteinase (MMP) -2 and MMP-9 were obviously decreased.  β-Cryptoxanthin treatment induced G0/G1 arrest, and reduced the expression of Cyclin E, Cyclin D1, cyclin-dependent kinases (CDK) of CDK4 and CDK6, and increased the expression of p53 and p21 in the two GC cells.  Addnl., β-cryptoxanthin induced apoptosis and increased the expression of cleaved caspase-3, -8, -9 as well as cytochrome C (cyt C).  β-Cryptoxanthin induced AMP-activated protein kinase (AMPK) signal inactivation by the down-regulation of protein kinase A (PKA), p-AMPK, eukaryotic elongation factor 2 kinase (eEF2k).  Furthermore, β-cryptoxanthin inhibited tumor growth through suppressing the tumor vol. and wt., inducing apoptotic cells.  Besides, β-cryptoxanthin induced significant redns. of vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).  In conclusion, our data provide the novel evidence to understand the mechanism of anti-pcancer of β-cryptoxanthin and indicate that β-cryptoxanthin can serve as a promising chemopreventive agent against gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKVdtY9022bVg90H21EOLACvtfcHk0ljeIk5kJ3tSCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGns7rE&md5=baa2786739dc745b0d159b44586cb5c6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2019.172528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2019.172528%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DDang%26aufirst%3DF.%26aulast%3DDeng%26aufirst%3DC.%26atitle%3D%25CE%25B2-Cryptoxanthin%2520Induced%2520Anti-Proliferation%2520and%2520Apoptosis%2520by%2520G0%252FG1%2520Arrest%2520and%2520AMPK%2520Signal%2520Inactivation%2520in%2520Gastric%2520Cancer%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D859%26spage%3D172528%26doi%3D10.1016%2Fj.ejphar.2019.172528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakhill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">The EEF2 Kinase-Induced STAT3 Inactivation Inhibits Lung Cancer Cell Proliferation by Phosphorylation of PKM2</span>. <i>Cell Commun. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi"> DOI: 10.1186/s12964-020-0528-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1186%2Fs12964-020-0528-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=32054489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVGhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=25&author=M.+Xiaoauthor=J.+Xieauthor=Y.+Wuauthor=G.+Wangauthor=X.+Qiauthor=Z.+Liuauthor=Y.+Wangauthor=X.+Wangauthor=A.+Hoqueauthor=J.+Oakhillauthor=C.+G.+Proudauthor=J.+Li&title=The+EEF2+Kinase-Induced+STAT3+Inactivation+Inhibits+Lung+Cancer+Cell+Proliferation+by+Phosphorylation+of+PKM2&doi=10.1186%2Fs12964-020-0528-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The eEF2 kinase-induced STAT3 inactivation inhibits lung cancer cell proliferation by phosphorylation of PKM2</span></div><div class="casAuthors">Xiao, Min; Xie, Jianling; Wu, Yu; Wang, Genzhu; Qi, Xin; Liu, Zailiang; Wang, Yuying; Wang, Xuemin; Hoque, Ashfaqul; Oakhill, Jon; Proud, Christopher G.; Li, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Cell Communication and Signaling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">CCSEC6</span>;
        ISSN:<span class="NLM_cas:issn">1478-811X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Abstr.: Background: Eukaryotic elongation factor-2 kinase (eEF2K) is a Ca 2+ /calmodulin (CaM)-dependent protein kinase that inhibits protein synthesis.  However, the role of eEF2K in cancer development was reported paradoxically and remains to be elucidated.  Methods: Herein, A549 cells with eEF2K depletion or overexpression by stably transfected lentivirus plasmids were used in vitro and in vivo study.  MTT and colony assays were used to detect cell proliferation and growth.  Results: We demonstrated that eEF2K inhibited lung cancer cells proliferation and affected the inhibitory effects of EGFR inhibitor gefitinib.  Mechanistically, we showed that eEF2K formed a complex with PKM2 and STAT3, thereby phosphorylated PKM2 at T129, leading to reduced dimerization of PKM2.  Subsequently, PKM2 impeded STAT3 phosphorylation and STAT3-dependent c-Myc expression. eEF2K depletion promoted the nuclear translocation of PKM2 and increased aerobic glycolysis reflected by increased lactate secretion and glucose.  Conclusions: Our findings define a novel mechanism underlying the regulation of cancer cell proliferation by eEF2K independent of its role in protein synthesis, disclosing the diverse roles of eEF2K in cell biol., which lays foundation for the development of new anticancer therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhD9KBFSLrcLVg90H21EOLACvtfcHk0ljeIk5kJ3tSCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVGhtLY%253D&md5=1265794a975ac8d45c0d50ee5bc089a5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2Fs12964-020-0528-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12964-020-0528-y%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHoque%26aufirst%3DA.%26aulast%3DOakhill%26aufirst%3DJ.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DThe%2520EEF2%2520Kinase-Induced%2520STAT3%2520Inactivation%2520Inhibits%2520Lung%2520Cancer%2520Cell%2520Proliferation%2520by%2520Phosphorylation%2520of%2520PKM2%26jtitle%3DCell%2520Commun.%2520Signaling%26date%3D2020%26volume%3D18%26spage%3D25%26doi%3D10.1186%2Fs12964-020-0528-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gschwendt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kittstein, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, F.</span></span> <span> </span><span class="NLM_article-title">Elongation Factor-2 Kinase: Effective Inhibition by the Novel Protein Kinase Inhibitor Rottlerin and Relative Insensitivity towards Staurosporine</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(94)80121-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2F0014-5793%2894%2980121-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=8307162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFOgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=1994&pages=85-88&author=M.+Gschwendtauthor=W.+Kittsteinauthor=F.+Marks&title=Elongation+Factor-2+Kinase%3A+Effective+Inhibition+by+the+Novel+Protein+Kinase+Inhibitor+Rottlerin+and+Relative+Insensitivity+towards+Staurosporine&doi=10.1016%2F0014-5793%2894%2980121-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Elongation factor-2 kinase: effective inhibition by the novel protein kinase inhibitor rottlerin and relative insensitivity towards staurosporine</span></div><div class="casAuthors">Gschwendt, Michael; Kittstein, Walter; Marks, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-8</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">The elongation factor-2 (eEF-2) is selectively phosphorylated by the eEF-2 kinase (calmodulin-dependent kinase III).  This phosphorylation can be inhibited by calmodulin antagonists, such as CGS 9343B (IC50 = 4 μM).  The novel protein kinase inhibitor rottlerin is shown to suppress eEF-2 phosphorylation with an IC50 of 5.3 μM.  By contrast, the eEF-2 kinase is rather resistant towards the potent but non-selective protein kinase inhibitor staurosporine (IC50 > 50 μM) and thus can be differentiated from most other protein kinases that are suppressed by staurosporine in the nM range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcka0nTmZgk7Vg90H21EOLACvtfcHk0li7-LYvUN6uwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFOgtr4%253D&md5=98b0abf8a08408167ea63200aab9731d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2980121-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252980121-5%26sid%3Dliteratum%253Aachs%26aulast%3DGschwendt%26aufirst%3DM.%26aulast%3DKittstein%26aufirst%3DW.%26aulast%3DMarks%26aufirst%3DF.%26atitle%3DElongation%2520Factor-2%2520Kinase%253A%2520Effective%2520Inhibition%2520by%2520the%2520Novel%2520Protein%2520Kinase%2520Inhibitor%2520Rottlerin%2520and%2520Relative%2520Insensitivity%2520towards%2520Staurosporine%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D338%26spage%3D85%26epage%3D88%26doi%3D10.1016%2F0014-5793%2894%2980121-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caivano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1042/bj3510095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1042%2Fbj3510095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10998351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=95-105&author=S.+P.+Daviesauthor=H.+Reddyauthor=M.+Caivanoauthor=P.+Cohen&title=Specificity+and+Mechanism+of+Action+of+Some+Commonly+Used+Protein+Kinase+Inhibitors&doi=10.1042%2Fbj3510095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span></div><div class="casAuthors">Davies, Stephen P.; Reddy, Helen; Caivano, Matilde; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 28 com. available compds. reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examd. against a large panel of protein kinases.  The compds. KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based expts. are likely to be erroneous.  Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency.  LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase.  The compds. with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190.  U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.  Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one addnl. protein kinase.  Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure.  The authors propose guidelines for the use of protein kinase inhibitors in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs5LPDkzaGrVg90H21EOLACvtfcHk0li7-LYvUN6uwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D&md5=e14eb47a52dc43afca7373c276b2d147</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1042%2Fbj3510095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3510095%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DReddy%26aufirst%3DH.%26aulast%3DCaivano%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DSpecificity%2520and%2520Mechanism%2520of%2520Action%2520of%2520Some%2520Commonly%2520Used%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26spage%3D95%26epage%3D105%26doi%3D10.1042%2Fbj3510095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R. K.</span></span> <span> </span><span class="NLM_article-title">Rottlerin-Induced Autophagy Leads to the Apoptosis in Breast Cancer Stem Cells: Molecular Mechanisms</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">171</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-12-171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1186%2F1476-4598-12-171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24359639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Wgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=171&author=D.+Kumarauthor=S.+Shankarauthor=R.+K.+Srivastava&title=Rottlerin-Induced+Autophagy+Leads+to+the+Apoptosis+in+Breast+Cancer+Stem+Cells%3A+Molecular+Mechanisms&doi=10.1186%2F1476-4598-12-171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms</span></div><div class="casAuthors">Kumar, Dhruv; Shankar, Sharmila; Srivastava, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171/1-171/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Autophagy is an indispensable lysosomal self-digestion process involved in the degrdn. of aggregated proteins and damaged organelles.  Autophagy is assocd. with the several pathol. processes, including cancer.  Cancer stem cells (CSCs) play significant roles in cancer initiation, progression and drug resistance.  Recent studies have demonstrated the antitumor activities of plant-derived chemopreventive agent rottlerin (Rott).  However, the mol. mechanism by which Rott induces autophagy in breast CSCs has not been investigated.  Results: The objectives of this study were to examine the mol. mechanism by which Rott induces autophagy which leads to apoptosis in breast CSCs.  Treatment of breast CSCs with Rott for 24 h resulted in a concn. dependent induction of autophagy, followed by apoptosis as measured by flow cytometry.  Electron microscopy confirmed the presence of autophagosomes in Rott treated breast CSCs.  Western blot anal. showed that Rott treatment increased the expression of LC3, Beclin-1 and Atg12 that are accumulated during autophagy.  Prolonged exposure of breast CSCs to Rott caused apoptosis which was assocd. with the suppression of phosphorylated Akt and mTOR, upregulation of phosphorylated AMPK, and downregulation of anti-apoptosis Bcl-2, Bcl-XL, XIAP and cIAP-1.  Knock-down of Atg7 or Beclin-1 by shRNA inhibited Rott-induced autophagy at 24 h.  Our study also demonstrates that pre-treatment of breast CSCs with autophagosome inhibitors 3-methyladenine and Bafilomycin, as well as protein synthesis inhibitor cycloheximide inhibited Rott-induced autophagy and apoptosis.  Rott induces autophagy via extensive cytoplasmic vacuolization in breast CSCs.  Mol. docking results between C2-domain of protein kinase C-delta and Rott indicated that both hydrogen bonding and hydrophobic interactions contributed significantly for ligand binding with min. binding affinity of ≈ 7.5 Kcal/mol.  Although, autophagy inhibitors suppress the formation of cytoplasmic vacuolization and autophagy in breast CSCs, the potency of Rott to induce autophagy and apoptosis might be based on its capability to activate several pathways such as AMPK and proteasome inhibition.  Conclusions: A better understanding of the relationship between autophagy and apoptosis would eventually allow us to discover novel drugs for the treatment of breast cancer by eliminating CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKFUtFnPynvrVg90H21EOLACvtfcHk0li7-LYvUN6uwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Wgs78%253D&md5=77358f30a3d6eed30e2dacf0a90738c5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-12-171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-12-171%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DR.%2BK.%26atitle%3DRottlerin-Induced%2520Autophagy%2520Leads%2520to%2520the%2520Apoptosis%2520in%2520Breast%2520Cancer%2520Stem%2520Cells%253A%2520Molecular%2520Mechanisms%26jtitle%3DMol.%2520Cancer%26date%3D2013%26volume%3D12%26spage%3D171%26doi%3D10.1186%2F1476-4598-12-171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koketsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nairn, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span> <span> </span><span class="NLM_article-title">Novel Compounds, “1,3-Selenazine Derivatives” as Specific Inhibitors of Eukaryotic Elongation Factor-2 Kinase</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1475</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1016/S0304-4165(00)00061-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2FS0304-4165%2800%2900061-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVOls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1475&publication_year=2000&pages=207-215&author=S.+I.+Choauthor=M.+Koketsuauthor=H.+Ishiharaauthor=M.+Matsushitaauthor=A.+C.+Nairnauthor=H.+Fukazawaauthor=Y.+Uehara&title=Novel+Compounds%2C+%E2%80%9C1%2C3-Selenazine+Derivatives%E2%80%9D+as+Specific+Inhibitors+of+Eukaryotic+Elongation+Factor-2+Kinase&doi=10.1016%2FS0304-4165%2800%2900061-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Novel compounds, '1,3-selenazine derivatives' as specific inhibitors of eukaryotic elongation factor-2 kinase</span></div><div class="casAuthors">Cho, S. I.; Koketsu, M.; Ishihara, H.; Matsushita, M.; Nairn, A. C.; Fukazawa, H.; Uehara, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1475</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-215</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The inhibitory activities of 5,6-dihydro-4H-1,3-selenazine derivs. on protein kinases were investigated.  In a multiple protein kinase assay using a postnuclear fraction of v-src-transformed NIH3T3 cells, 4-ethyl-4-hydroxy-2-p-tolyl-5,6-dihydro-4H-1,3-selenazine (TS-2) and 4-hydroxy-6-isopropyl-4-methyl-2-p-tolyl-5,6-dihydro-4H-1,3-selenazine (TS-4) exhibited selective inhibitory activity against eukaryotic elongation factor-2 kinase (eEF-2K) over protein kinase A (PKA), protein kinase C (PKC) and protein tyrosine kinase (PTK).  In further expts. using purified kinases, TS-2 (IC50=0.36 μM) and TS-4 (IC50=0.31 μM) inhibited eEF-2K about 25-fold more effectively than calmodulin-dependent protein kinase-I (CaMK-I), and about 6-fold (TS-2) or 33-fold (TS-4) more effectively than calmodulin-dependent protein kinase-II (CaMK-II), resp.  TS-2 and TS-4 showed much weaker inhibitory activity toward PKA and PKC, while TS-4, but not TS-2, moderately inhibited immunopptd. v-src kinase.  TS-2 (10.7-fold) and TS-4 (12.5-fold) demonstrated more potent and more specific eEF-2K inhibitory activity than rottlerin, a previously identified eEF-2K inhibitor.  TS-2 inhibited ATP or eEF-2 binding to eEF-2K in a competitive or non-competitive manner, resp.  In cultured v-src-transformed NIH3T3 cells, TS-2 also decreased phospho-eEF-2 protein level (IC50=4.7 μM) without changing the total eEF-2 protein level.  Taken together, these results suggest that TS-2 and TS-4 are the first identified selective eEF-2K inhibitors and should be useful tools for studying the function of eEF-2K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfsLRua-VEfrVg90H21EOLACvtfcHk0lgu9hlE7BPOeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVOls7w%253D&md5=3a58d81422a8a354474c4ff51c95fb99</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0304-4165%2800%2900061-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-4165%252800%252900061-1%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BI.%26aulast%3DKoketsu%26aufirst%3DM.%26aulast%3DIshihara%26aufirst%3DH.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DNairn%26aufirst%3DA.%2BC.%26aulast%3DFukazawa%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DY.%26atitle%3DNovel%2520Compounds%252C%2520%25E2%2580%259C1%252C3-Selenazine%2520Derivatives%25E2%2580%259D%2520as%2520Specific%2520Inhibitors%2520of%2520Eukaryotic%2520Elongation%2520Factor-2%2520Kinase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2000%26volume%3D1475%26spage%3D207%26epage%3D215%26doi%3D10.1016%2FS0304-4165%2800%2900061-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span> <span> </span><span class="NLM_article-title">TX-1123: An Antitumor 2-Hydroxyarylidene-4-Cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor Having Low Mitochondrial Toxicity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3257</span>– <span class="NLM_lpage">3265</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(02)00160-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2FS0968-0896%2802%2900160-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=12150871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVemsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=3257-3265&author=H.+Horiauthor=H.+Nagasawaauthor=M.+Ishibashiauthor=Y.+Utoauthor=A.+Hirataauthor=K.+Saijoauthor=K.+Ohkuraauthor=K.+L.+Kirkauthor=Y.+Uehara&title=TX-1123%3A+An+Antitumor+2-Hydroxyarylidene-4-Cyclopentene-1%2C3-Dione+as+a+Protein+Tyrosine+Kinase+Inhibitor+Having+Low+Mitochondrial+Toxicity&doi=10.1016%2FS0968-0896%2802%2900160-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">TX-1123: an antitumor 2-hydroxyarylidene-4-cyclopentene-1,3-dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity</span></div><div class="casAuthors">Hori, Hitoshi; Nagasawa, Hideko; Ishibashi, Masaki; Uto, Yoshihiro; Hirata, Akihiko; Saijo, Kouichi; Ohkura, Kazuto; Kirk, Kenneth L.; Uehara, Yoshimasa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3257-3265</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of 2-hydroxyarylidene-4-cyclopentene-1,3-diones were designed, synthesized, and evaluated with respect to protein tyrosine kinase (PTK) inhibition, mitochondrial toxicity, and antitumor activity.  Our results show that the cyclopentenedione-derived TX-1123 is a more potent antitumor tyrphostin and also shows lower mitochondrial toxicity than the malononitrile-derived AG17, a potent antitumor tyrphostin.  The O-methylation product of TX-1123 (TX-1925) retained its tyrphostin-like properties, including mitochondrial toxicity and antitumor activities.  However, the methylation product of AG17 (TX-1927) retained its tyrphostin-like antitumor activities, but lost its mitochondrial toxicity.  Our comprehensive evaluation of these agents with respect to protein tyrosine kinase inhibition, mitochondrial inhibition, antitumor activity, and hepatotoxicity demonstrates that PTK inhibitors TX-1123 and TX-1925 are more promising candidates for antitumor agents than tyrphostin AG17.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt-bAAuqLXw7Vg90H21EOLACvtfcHk0lgu9hlE7BPOeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVemsrk%253D&md5=e544ca06e36b48d58c9fc38ec88ea225</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900160-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900160-8%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DH.%26aulast%3DNagasawa%26aufirst%3DH.%26aulast%3DIshibashi%26aufirst%3DM.%26aulast%3DUto%26aufirst%3DY.%26aulast%3DHirata%26aufirst%3DA.%26aulast%3DSaijo%26aufirst%3DK.%26aulast%3DOhkura%26aufirst%3DK.%26aulast%3DKirk%26aufirst%3DK.%2BL.%26aulast%3DUehara%26aufirst%3DY.%26atitle%3DTX-1123%253A%2520An%2520Antitumor%25202-Hydroxyarylidene-4-Cyclopentene-1%252C3-Dione%2520as%2520a%2520Protein%2520Tyrosine%2520Kinase%2520Inhibitor%2520Having%2520Low%2520Mitochondrial%2520Toxicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D3257%26epage%3D3265%26doi%3D10.1016%2FS0968-0896%2802%2900160-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lockman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeder, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostanin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhoite, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baichwal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam Willardsen, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of EEF2-K by Thieno[2,3-b]Pyridine Analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2283</span>– <span class="NLM_lpage">2286</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.bmcl.2010.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=20189382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslGmtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2283-2286&author=J.+W.+Lockmanauthor=M.+D.+Reederauthor=K.+Suzukiauthor=K.+Ostaninauthor=R.+Hoffauthor=L.+Bhoiteauthor=H.+Austinauthor=V.+Baichwalauthor=J.+Adam+Willardsen&title=Inhibition+of+EEF2-K+by+Thieno%5B2%2C3-b%5DPyridine+Analogues&doi=10.1016%2Fj.bmcl.2010.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eEF2-K by thieno[2,3-b]pyridine analogues</span></div><div class="casAuthors">Lockman, Jeffrey W.; Reeder, Matthew D.; Suzuki, Kazuyuki; Ostanin, Kirill; Hoff, Ryan; Bhoite, Leena; Austin, Harry; Baichwal, Vijay; Adam Willardsen, J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2283-2286</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Several series of thieno[2-3-b]pyridine analogs were synthesized and screened for inhibitory activity against eukaryotic elongation factor-2 kinase (eEF2-K).  Modifications around several regions of the lead mols. were made, with a ring fusion adjacent to the nitrogen on the thienopyridine core being crit. for activity.  The most active compd. 34 shows an IC50 of 170 nM against eEF2-K in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfkbsgYtCHIrVg90H21EOLACvtfcHk0lgu9hlE7BPOeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslGmtb4%253D&md5=dd50cf5427d106d9e361349de04ca0ad</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DLockman%26aufirst%3DJ.%2BW.%26aulast%3DReeder%26aufirst%3DM.%2BD.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DOstanin%26aufirst%3DK.%26aulast%3DHoff%26aufirst%3DR.%26aulast%3DBhoite%26aufirst%3DL.%26aulast%3DAustin%26aufirst%3DH.%26aulast%3DBaichwal%26aufirst%3DV.%26aulast%3DAdam%2BWillardsen%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520EEF2-K%2520by%2520Thieno%255B2%252C3-b%255DPyridine%2520Analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2283%26epage%3D2286%26doi%3D10.1016%2Fj.bmcl.2010.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. W.</span></span> <span> </span><span class="NLM_article-title">New Sorbicillinoid Derivatives with GLP-1R and EEF2K Affinities from a Sponge-Derived Fungus Penicillium Chrysogenum 581F1</span>. <i>Nat. Prod. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2880</span>– <span class="NLM_lpage">2886</span>, <span class="refDoi"> DOI: 10.1080/14786419.2019.1596099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1080%2F14786419.2019.1596099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30990084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVersbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=2880-2886&author=M.+J.+Caoauthor=T.+Zhuauthor=J.+T.+Liuauthor=L.+Ouyangauthor=F.+Yangauthor=H.+W.+Lin&title=New+Sorbicillinoid+Derivatives+with+GLP-1R+and+EEF2K+Affinities+from+a+Sponge-Derived+Fungus+Penicillium+Chrysogenum+581F1&doi=10.1080%2F14786419.2019.1596099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">New sorbicillinoid derivatives with GLP-1R and eEF2K affinities from a sponge-derived fungus Penicillium chrysogenum 581F1</span></div><div class="casAuthors">Cao, Min-Jia; Zhu, Tao; Liu, Jing-Tang; Ouyang, Liang; Yang, Fan; Lin, Hou-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2880-2886</span>CODEN:
                <span class="NLM_cas:coden">NPRAAT</span>;
        ISSN:<span class="NLM_cas:issn">1478-6419</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Two new sorbicillinoids, 13-hydroxy-dihydrotrichodermolide (I) and 10,11,27,28-tetrahydrotrisorbicillinone C (II), were isolated from the sponge-derived fungus Penicillium chrysogenum 581F1.  Their structures were detd. on the basis of spectroscopic anal.  I and II displayed high affinities to target proteins GLP-1R (diabetes) and eEF2K (cancer) with Kd values of 0.0285μM and 0.0162μM for GLP-1R and 0.118μM and 0.0746μM for eEF2K, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXYwA0lR9hsLVg90H21EOLACvtfcHk0lgk2zG6QepUHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVersbk%253D&md5=66925b12d745b89d53eca16d36cba300</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1080%2F14786419.2019.1596099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14786419.2019.1596099%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DM.%2BJ.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%2BT.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DH.%2BW.%26atitle%3DNew%2520Sorbicillinoid%2520Derivatives%2520with%2520GLP-1R%2520and%2520EEF2K%2520Affinities%2520from%2520a%2520Sponge-Derived%2520Fungus%2520Penicillium%2520Chrysogenum%2520581F1%26jtitle%3DNat.%2520Prod.%2520Res.%26date%3D2020%26volume%3D34%26spage%3D2880%26epage%3D2886%26doi%3D10.1080%2F14786419.2019.1596099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hait, W. N.</span></span> <span> </span><span class="NLM_article-title">Disruption of the EF-2 Kinase/Hsp90 Protein Complex: A Possible Mechanism to Inhibit Glioblastoma by Geldanamycin</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4010</span>– <span class="NLM_lpage">4016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=11358819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVWqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4010-4016&author=J.+Yangauthor=J.+M.+Yangauthor=M.+Iannoneauthor=W.+J.+Shihauthor=Y.+Linauthor=W.+N.+Hait&title=Disruption+of+the+EF-2+Kinase%2FHsp90+Protein+Complex%3A+A+Possible+Mechanism+to+Inhibit+Glioblastoma+by+Geldanamycin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin</span></div><div class="casAuthors">Yang, Jun; Yang, Jin-Ming; Iannone, Marie; Shih, Weichung Joe; Lin, Yong; Hait, William N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4010-4016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glioblastoma multiforme is the most treatment-resistant brain tumor.  Elongation factor-2 (EF-2) kinase (calmodulin kinase III) is a unique protein kinase that is overexpressed in glioma cell lines and in human surgical specimens.  Several mitogens activate this kinase and inhibitors block mitogen activation and produce cell death.  Geldanamycin (GA) is a benzoquinone ansamycin antibiotic that disrupts Hsp90-protein interactions.  Because EF-2 kinase is chaperoned by Hsp90, we investigated the effects of GA on the viability of glioma cells, the expression of EF-2 kinase protein, and the interaction between Hsp90 and EF-2 kinase.  GA was a potent inhibitor of the clonogenicity of four glioma cells lines with IC50s ranging from 1 to 3 nM.  17-Allylamino-17-demethoxygeldanamycin (17-AAG), a less toxic and less potent deriv. of GA, inhibited the clonogenicity of glioma cells with IC50 values of 13 nM in C6 cells and 35 nM in T98G cells.  Treatment of cell lines for 24-48 h of GA or 17-AAG disrupted EF-2-kinase/Hsp90 interactions as measured by coimmunopptn., resulting in a decreased amt. of recoverable kinase in cell lysates.  The ability of GA to inhibit the growth of glioma cells was abrogated by overexpressing EF-2 kinase.  In addn., 17-AAG significantly inhibited the growth of a glioma xenograft in nude mice.  These studies demonstrate for the first time the activity of GAs against human gliomas in vitro and in vivo and suggest that destruction of EF-2 kinase may be an important cytotoxic mechanism of this unique class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-vSj_gRoatLVg90H21EOLACvtfcHk0lgk2zG6QepUHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVWqsbs%253D&md5=892bf41051344cf793533b741de9747a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DIannone%26aufirst%3DM.%26aulast%3DShih%26aufirst%3DW.%2BJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHait%26aufirst%3DW.%2BN.%26atitle%3DDisruption%2520of%2520the%2520EF-2%2520Kinase%252FHsp90%2520Protein%2520Complex%253A%2520A%2520Possible%2520Mechanism%2520to%2520Inhibit%2520Glioblastoma%2520by%2520Geldanamycin%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4010%26epage%3D4016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzy, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hait, W. N.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of an Inhibitor of Eukaryotic Elongation Factor 2 Kinase against Human Cancer Cell Lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6894</span>– <span class="NLM_lpage">6899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=14583488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVGns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=6894-6899&author=S.+Aroraauthor=J.+M.+Yangauthor=T.+G.+Kinzyauthor=R.+Utsumiauthor=T.+Okamotoauthor=T.+Kitayamaauthor=P.+A.+Ortizauthor=W.+N.+Hait&title=Identification+and+Characterization+of+an+Inhibitor+of+Eukaryotic+Elongation+Factor+2+Kinase+against+Human+Cancer+Cell+Lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of an Inhibitor of Eukaryotic Elongation Factor 2 Kinase against Human Cancer Cell Lines</span></div><div class="casAuthors">Arora, Sonia; Yang, Jin-Ming; Kinzy, Terri Goss; Utsumi, Ryutaro; Okamoto, Tadashi; Kitayama, Takashi; Ortiz, Pedro A.; Hait, William N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6894-6899</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent evidence suggests that the machinery of protein synthesis may provide novel targets for anticancer drugs.  For example, aberrations in protein synthesis are commonly encountered in established cancers, and disruption by mutation or overexpression of translation factors can cause cellular transformation.  We previously demonstrated that the activity of eukaryotic elongation factor 2 (eEF-2) kinase was markedly increased in several forms of malignancy and that nonspecific inhibitors of this enzyme promoted cell death.  On the basis of the predicted amino acid sequence of eEF-2 kinase deduced from the cloned cDNA, we hypothesized that inhibitors of prokaryotic histidine kinases might also inhibit the activity of eEF-2 kinase.  We describe herein the screening of a series of imidazolium histidine kinase inhibitors and the identification of an active lead compd., NH125.  NH125 inhibited eEF-2 kinase activity (IC50 = 60 nM) in vitro, blocked the phosphorylation of eEF-2 in intact cells, and showed relative selectivity over other protein kinases: protein kinase C (IC50 = 7.5 μM), protein kinase A (IC50 = 80 μM), and calmodulin-dependent kinase II (IC50 > 100 μM).  NH125 decreased the viability of 10 cancer cell lines with IC50s ranging from 0.7 to 4.7 μM.  Forced overexpression of eEF-2 kinase in a glioma cell line produced 10-fold resistance to NH125.  In conclusion, these results suggest that identification of potent inhibitors of eEF-2 kinase may lead to the development of new types of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEyQVDmEkPp7Vg90H21EOLACvtfcHk0lgk2zG6QepUHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVGns7g%253D&md5=3fc89947782a76d6e522898a57f00aa5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DKinzy%26aufirst%3DT.%2BG.%26aulast%3DUtsumi%26aufirst%3DR.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DKitayama%26aufirst%3DT.%26aulast%3DOrtiz%26aufirst%3DP.%2BA.%26aulast%3DHait%26aufirst%3DW.%2BN.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520an%2520Inhibitor%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520against%2520Human%2520Cancer%2520Cell%2520Lines%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D6894%26epage%3D6899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishnan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrior, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, K. B.</span></span> <span> </span><span class="NLM_article-title">1-Benzyl-3-Cetyl-2-Methylimidazolium Iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (EEF2): A Cautionary Note on the Anticancer Mechanism of an EEF2 Kinase Inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">43951</span>– <span class="NLM_lpage">43958</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.301291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.M111.301291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=22020937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=43951-43958&author=Z.+Chenauthor=S.+M.+Gopalakrishnanauthor=M.+H.+Buiauthor=N.+B.+Soniauthor=U.+Warriorauthor=E.+F.+Johnsonauthor=J.+B.+Donnellyauthor=K.+B.+Glaser&title=1-Benzyl-3-Cetyl-2-Methylimidazolium+Iodide+%28NH125%29+Induces+Phosphorylation+of+Eukaryotic+Elongation+Factor-2+%28EEF2%29%3A+A+Cautionary+Note+on+the+Anticancer+Mechanism+of+an+EEF2+Kinase+Inhibitor&doi=10.1074%2Fjbc.M111.301291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (eEF2): A CAUTIONARY NOTE ON THE ANTICANCER MECHANISM OF AN eEF2 KINASE INHIBITOR</span></div><div class="casAuthors">Chen, Zehan; Gopalakrishnan, Sujatha M.; Bui, Mai-Ha; Soni, Niru B.; Warrior, Usha; Johnson, Eric F.; Donnelly, Jennifer B.; Glaser, Keith B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">43951-43958</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF2K) relays growth and stress signals to protein synthesis through phosphorylation and inactivation of eukaryotic elongation factor 2 (eEF2). 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) is a widely accepted inhibitor of mammalian eEF2K and an efficacious anti-proliferation agent against different cancer cells.  It implied that eEF2K could be an efficacious anticancer target.  However, eEF2K siRNA was ineffective against cancer cells including those sensitive to NH125.  To test if pharmacol. intervention differs from siRNA interference, we identified a highly selective small mol. eEF2K inhibitor A-484954.  Like siRNA, A-484954 had little effect on cancer cell growth.  We carefully examd. the effect of NH125 and A-484954 on phosphorylation of eEF2, the known cellular substrate of eEF2K.  Surprisingly, NH125 increased eEF2 phosphorylation, whereas A-484954 inhibited the phosphorylation as expected for an eEF2K inhibitor.  Both A-484954 and eEF2K siRNA inhibited eEF2K and reduced eEF2 phosphorylation with little effect on cancer cell growth.  These data demonstrated clearly that the anticancer activity of NH125 was more correlated with induction of eEF2 phosphorylation than inhibition of eEF2K.  Actually, induction of eEF2 phosphorylation was reported to correlate with inhibition of cancer cell growth.  We compared several known inducers of eEF2 phosphorylation including AMPK activators and an mTOR inhibitor.  Interestingly, stronger induction of eEF2 phosphorylation correlated with more effective growth inhibition.  We also explored signal transduction pathways leading to NH125-induced eEF2 phosphorylation.  Preliminary data suggested that NH125-induced eEF2 phosphorylation was likely mediated through multiple pathways.  These observations identified an opportunity for a new multipathway approach to anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGI7DoizNH17Vg90H21EOLACvtfcHk0lg7chKnac4RoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtbjM&md5=9cb0e962892fe086c0d0ca77b8fa0730</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.301291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.301291%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGopalakrishnan%26aufirst%3DS.%2BM.%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DWarrior%26aufirst%3DU.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonnelly%26aufirst%3DJ.%2BB.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26atitle%3D1-Benzyl-3-Cetyl-2-Methylimidazolium%2520Iodide%2520%2528NH125%2529%2520Induces%2520Phosphorylation%2520of%2520Eukaryotic%2520Elongation%2520Factor-2%2520%2528EEF2%2529%253A%2520A%2520Cautionary%2520Note%2520on%2520the%2520Anticancer%2520Mechanism%2520of%2520an%2520EEF2%2520Kinase%2520Inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D43951%26epage%3D43958%26doi%3D10.1074%2Fjbc.M111.301291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span> <span> </span><span class="NLM_article-title">Farnesyltransferase Inhibitor SCH66336 Induces Rapid Phosphorylation of Eukaryotic Translation Elongation Factor 2 in Head and Neck Squamous Cell Carcinoma Cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">5841</span>– <span class="NLM_lpage">5847</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-3141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F0008-5472.CAN-04-3141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=15994961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlslOqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=5841-5847&author=H.+Renauthor=S.+K.+Taiauthor=F.+Khuriauthor=Z.+Chuauthor=L.+Mao&title=Farnesyltransferase+Inhibitor+SCH66336+Induces+Rapid+Phosphorylation+of+Eukaryotic+Translation+Elongation+Factor+2+in+Head+and+Neck+Squamous+Cell+Carcinoma+Cells&doi=10.1158%2F0008-5472.CAN-04-3141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase Inhibitor SCH66336 Induces Rapid Phosphorylation of Eukaryotic Translation Elongation Factor 2 in Head and Neck Squamous Cell Carcinoma Cells</span></div><div class="casAuthors">Ren, Hening; Tai, Shyh-Kuan; Khuri, Fadlo; Chu, Zuming; Mao, Li</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5841-5847</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Farnesyltransferase inhibitors (FTI) are a class of therapeutic agents designed to target tumors with mutations of the ras oncogene.  However, the biol. effect of FTIs is often independent of ras mutation status, which suggests the existence of addnl. mechanisms.  In this study, we investigated the mol. effects of SCH66336 an FTI, in head and neck squamous cell carcinoma cells using proteomic approaches.  We showed that SCH66336 induced phosphorylation (inactivation) of eukaryotic translation elongation factor 2 (eEF2), an important mol. for protein synthesis, as early as 3 h after SCH66336 administration.  Protein synthesis was subsequently reduced in the cells.  Paradoxically, activation of eEF2 kinase (eEF2K), the only known kinase that regulates eEF2, was obsd. only at 12 h after SCH66336 treatment.  Consistent with this observation, the inhibition of phosphorylated-MEK and phosphorylated-p70S6K, the two key signaling mols. responsible for activation of eEF2K, also occurred at least 12 h after SCH66336 administration.  Our data suggest that inhibition of protein synthesis through inactivation of eEF2 is a novel mechanism of SCH66336 mediated growth inhibition and that this effect is independent of ras-MEK/p70S6K-eEF2K signaling cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuKdDvft_rabVg90H21EOLACvtfcHk0lg7chKnac4RoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlslOqtr0%253D&md5=1be705ee1ac1baa26ff28313d758748d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3141%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTai%26aufirst%3DS.%2BK.%26aulast%3DKhuri%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DZ.%26aulast%3DMao%26aufirst%3DL.%26atitle%3DFarnesyltransferase%2520Inhibitor%2520SCH66336%2520Induces%2520Rapid%2520Phosphorylation%2520of%2520Eukaryotic%2520Translation%2520Elongation%2520Factor%25202%2520in%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D5841%26epage%3D5847%26doi%3D10.1158%2F0008-5472.CAN-04-3141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comert
Onder, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durdagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ay, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as EEF-2K Inhibitors</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1766</span>– <span class="NLM_lpage">1778</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.9b01083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.9b01083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitl2qt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2020&pages=1766-1778&author=F.+Comert%0AOnderauthor=S.+Durdagiauthor=K.+Sahinauthor=B.+Ozpolatauthor=M.+Ay&title=Design%2C+Synthesis%2C+and+Molecular+Modeling+Studies+of+Novel+Coumarin+Carboxamide+Derivatives+as+EEF-2K+Inhibitors&doi=10.1021%2Facs.jcim.9b01083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors</span></div><div class="casAuthors">Comert Onder, Ferah; Durdagi, Serdar; Sahin, Kader; Ozpolat, Bulent; Ay, Mehmet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1766-1778</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF-2K) is an unusual alpha kinase commonly upregulated in various human cancers, including breast, pancreatic, lung, and brain tumors.  We have demonstrated that eEF-2K is relevant to poor prognosis and shorter patient survival in breast and lung cancers and validated it as a mol. target using genetic methods in related in vivo tumor models.  Although several eEF-2K inhibitors have been published, none of them have shown to be potent and specific enough for translation into clin. trials.  Therefore, development of highly effective novel inhibitors targeting eEF-2K is needed for clin. applications.  However, currently, the crystal structure of eEF-2K is not known, limiting the efforts for designing novel inhibitor compds.  Therefore, using homol. modeling of eEF-2K, we designed and synthesized novel coumarin-3-carboxamides including compds. (I) and (II) and evaluated their activity by performing in silico anal. and in vitro biol. assays in breast cancer cells (structures contained within.  The Mol. Mechanics/Generalized Born Surface Area (MM/GBSA) area results showed that I have interaction energies with eEF-2K better than those of II compds.  Our in vitro results indicated that compds. I were highly effective in inhibiting eEF-2K at 1.0 and 2.5μM concns. compared to compds. II, supporting the in silico findings.  In conclusion, the results of this study suggest that our homol. modeling along with in silico anal. may be effectively used to design inhibitors for eEF-2K.  Our newly synthesized compds. I may be used as novel eEF-2K inhibitors with potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt2bUQbz7aE7Vg90H21EOLACvtfcHk0lg7chKnac4RoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitl2qt7g%253D&md5=61fbbd9df1f63e4e2a5d32fb2cfc4492</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.9b01083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.9b01083%26sid%3Dliteratum%253Aachs%26aulast%3DComert%2BOnder%26aufirst%3DF.%26aulast%3DDurdagi%26aufirst%3DS.%26aulast%3DSahin%26aufirst%3DK.%26aulast%3DOzpolat%26aufirst%3DB.%26aulast%3DAy%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Molecular%2520Modeling%2520Studies%2520of%2520Novel%2520Coumarin%2520Carboxamide%2520Derivatives%2520as%2520EEF-2K%2520Inhibitors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2020%26volume%3D60%26spage%3D1766%26epage%3D1778%26doi%3D10.1021%2Facs.jcim.9b01083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edupuganti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, C. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitjian, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anslyn, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Pyrido[2,3-d]Pyrimidine-2,4-Dione Derivatives as EEF-2K Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4910</span>– <span class="NLM_lpage">4916</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.06.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.bmc.2014.06.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25047940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyms7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4910-4916&author=R.+Edupugantiauthor=Q.+Wangauthor=C.+D.+J.+Tavaresauthor=C.+A.+Chitjianauthor=J.+L.+Bachmanauthor=P.+Renauthor=E.+V.+Anslynauthor=K.+N.+Dalby&title=Synthesis+and+Biological+Evaluation+of+Pyrido%5B2%2C3-d%5DPyrimidine-2%2C4-Dione+Derivatives+as+EEF-2K+Inhibitors&doi=10.1016%2Fj.bmc.2014.06.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors</span></div><div class="casAuthors">Edupuganti, Ramakrishna; Wang, Qiantao; Tavares, Clint D. J.; Chitjian, Catrina A.; Bachman, James L.; Ren, Pengyu; Anslyn, Eric V.; Dalby, Kevin N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4910-4916</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A small mol. library of pyrido[2,3-d]pyrimidine-2,4-diones was synthesized from 6-amino-1,3-disubstituted uracils, characterized, and screened for inhibitory activity against eukaryotic elongation factor-2 kinase (eEF-2K).  To understand the binding pocket of eEF-2K, structural modifications of the pyrido[2,3-d]pyrimidine were made at three regions.  A homol. model of eEF-2K was created, and compd. I (A-484954, Abbott labs.) was docked in the catalytic domain of eEF-2K.  Compds. I (IC50 = 420 nM) and II (IC50 = 930 nM) are found to be better mols. in this preliminary series of pyrido[2,3-d]pyrimidine analogs.  EEF-2K activity in MDA-MB-231 breast cancer cells is significantly reduced by compd. I, to a lesser extent by compd. II, and is unaffected by thioamide analog.  Similar inhibitory results are obsd. when eEF-2K activity is stimulated by 2-deoxy-D-glucose (2-DOG) treatment, suggesting that compds. I and II are able to inhibit AMPK-mediated activation of eEF-2K to a notable extent.  The results of this work will shed light on the further design and optimization of novel pyrido[2,3-d]pyrimidine analogs as eEF-2K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1DNRahjmvArVg90H21EOLACvtfcHk0lj788p8Xq7PmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyms7vP&md5=cba3bfaa20b7eb1076c3ee6c1afbb956</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.06.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.06.050%26sid%3Dliteratum%253Aachs%26aulast%3DEdupuganti%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DTavares%26aufirst%3DC.%2BD.%2BJ.%26aulast%3DChitjian%26aufirst%3DC.%2BA.%26aulast%3DBachman%26aufirst%3DJ.%2BL.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAnslyn%26aufirst%3DE.%2BV.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Pyrido%255B2%252C3-d%255DPyrimidine-2%252C4-Dione%2520Derivatives%2520as%2520EEF-2K%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4910%26epage%3D4916%26doi%3D10.1016%2Fj.bmc.2014.06.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-W. W.</span></span> <span> </span><span class="NLM_article-title">A High-Throughput Screening Assay for Eukaryotic Elongation Factor 2 Kinase Inhibitors</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2016.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.apsb.2016.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=27818922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A280%3ADC%252BC2snjsFGmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=557-563&author=T.+Xiaoauthor=R.+Liuauthor=C.+G.+Proudauthor=M.-W.+W.+Wang&title=A+High-Throughput+Screening+Assay+for+Eukaryotic+Elongation+Factor+2+Kinase+Inhibitors&doi=10.1016%2Fj.apsb.2016.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput screening assay for eukaryotic elongation factor 2 kinase inhibitors</span></div><div class="casAuthors">Xiao Ting; Liu Rui; Proud Christopher G; Wang Ming-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">557-563</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) inhibitors may aid in the development of new therapeutic agents to combat cancer.  Purified human eEF2K was obtained from an Escherichia coli expression system and a luminescence-based high-throughput screening (HTS) assay was developed using MH-1 peptide as the substrate.  The luminescent readouts correlated with the amount of adenosine triphosphate remaining in the kinase reaction.  This method was applied to a large-scale screening campaign against a diverse compound library and subsequent confirmation studies.  Nine initial hits showing inhibitory activities on eEF2K were identified from 56,000 synthetic compounds during the HTS campaign, of which, five were chosen to test their effects in cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRu2RD154rBG4hLSh9fo81bfW6udTcc2eZJNCEG8x9onLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snjsFGmtQ%253D%253D&md5=163aef48d7062502ec335c4c0dd67b46</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2016.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2016.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DM.-W.%2BW.%26atitle%3DA%2520High-Throughput%2520Screening%2520Assay%2520for%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520Inhibitors%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2016%26volume%3D6%26spage%3D557%26epage%3D563%26doi%3D10.1016%2Fj.apsb.2016.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span> <span> </span><span class="NLM_article-title">Integrative Bioinformatics and Proteomics-Based Discovery of an EEF2K Inhibitor (Cefatrizine) with ER Stress Modulation in Breast Cancer Cells</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1039/C5MB00848D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1039%2FC5MB00848D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=26776155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=729-736&author=Z.+Yaoauthor=J.+Liauthor=Z.+Liuauthor=L.+Zhengauthor=N.+Fanauthor=Y.+Zhangauthor=N.+Jiaauthor=J.+Lvauthor=N.+Liuauthor=X.+Zhuauthor=J.+Duauthor=C.+Lvauthor=F.+Xieauthor=Y.+Liuauthor=X.+Wangauthor=Z.+Feiauthor=C.+Gao&title=Integrative+Bioinformatics+and+Proteomics-Based+Discovery+of+an+EEF2K+Inhibitor+%28Cefatrizine%29+with+ER+Stress+Modulation+in+Breast+Cancer+Cells&doi=10.1039%2FC5MB00848D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells</span></div><div class="casAuthors">Yao, Zhiqiang; Li, Juntang; Liu, Zhongyu; Zheng, Lu; Fan, Naijun; Zhang, Ying; Jia, Nan; Lv, Jingjing; Liu, Ningning; Zhu, Xiaoshan; Du, Jiangbo; Lv, Ci; Xie, Feng; Liu, Yigang; Wang, Xingke; Fei, Zhou; Gao, Chunfang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">729-736</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF2K), a unique calcium/calmodulin-dependent protein kinase, is well known to regulate apoptosis, autophagy and ER stress in many types of human cancers.  Therefore, eEF2K would be regarded as a promising therapeutic target; however, the eEF2K-regulated mechanism and its targeted inhibitor still remain to be discovered in cancer.  Herein, we constructed a protein-protein interaction (PPI) network of eEF2K and achieved an eEF2K-regulated ER stress subnetwork by bioinformatics prediction.  Then, we found that the differential protein expressions involved in ER stress in the context of si-eEF2K-treated MCF-7 and MDA-MB-436 cells by iTRAQ-based analyses, resp.  Integrated into these aforementioned results, we constructed a core eEF2K-regulated ER stress subnetwork in breast cancer cells.  Subsequently, we screened a series of candidate compds. targeting eEF2K and discovered a novel eEF2K inhibitor (cefatrizine) with an anti-proliferative activity toward breast cancer cells.  Moreover, we found that cefatrizine induced ER stress in both MCF-7 and MDA-MB-436 cells.  Interestingly, we demonstrated that the mechanism of cefatrizine-induced ER stress was in good agreement with our bioinformatics and proteomics-based results.  In conclusion, these results demonstrate that a novel eEF2K inhibitor (cefatrizine) induces ER stress in breast cancer cells by integrating bioinformatics prediction, proteomics analyses and exptl. validation, which would provide a clue for exploring more mechanisms of eEF2K and its targeted inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDQPIGrQ6947Vg90H21EOLACvtfcHk0lj788p8Xq7PmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGhuw%253D%253D&md5=84c2bbd60d8c71479e98f426db5fbb5b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1039%2FC5MB00848D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MB00848D%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DN.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFei%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DC.%26atitle%3DIntegrative%2520Bioinformatics%2520and%2520Proteomics-Based%2520Discovery%2520of%2520an%2520EEF2K%2520Inhibitor%2520%2528Cefatrizine%2529%2520with%2520ER%2520Stress%2520Modulation%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DMol.%2520BioSyst.%26date%3D2016%26volume%3D12%26spage%3D729%26epage%3D736%26doi%3D10.1039%2FC5MB00848D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Structure-Activity Relationship of a Focused Library of β-Phenylalanine Derivatives as Novel EEF2K Inhibitors with Apoptosis-Inducing Mechanisms in Breast Cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ejmech.2017.11.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29202403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=402-418&author=Y.+Guoauthor=Y.+Zhaoauthor=G.+Wangauthor=Y.+Chenauthor=Y.+Jiangauthor=L.+Ouyangauthor=B.+Liu&title=Design%2C+Synthesis+and+Structure-Activity+Relationship+of+a+Focused+Library+of+%CE%B2-Phenylalanine+Derivatives+as+Novel+EEF2K+Inhibitors+with+Apoptosis-Inducing+Mechanisms+in+Breast+Cancer&doi=10.1016%2Fj.ejmech.2017.11.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer</span></div><div class="casAuthors">Guo, Yongzhi; Zhao, Yuqian; Wang, Guan; Chen, Yi; Jiang, Yingnan; Ouyang, Liang; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">402-418</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca2+/calmudulin-dependent protein kinase, belonging to a small family of an atypical Ser/Thr-protein kinase.  EEF2K has been recently reported to be highly activated or over-expressed in many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target.  In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivs. with assessment of inhibition activity against eEF2K and cytotoxicity.  After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K inhibitor (I) with best eEF2K enzymic activity (IC50 of 5.5 μM) and anti-proliferative activity (MDA-MB-231 cells, IC50 of 12.6 μM, MDA-MB-436 cells, IC50 of 19.8 μM).  Moreover, we found that I could induce cell death via the apoptotic pathways in MDA-MB-231 and MDA-MB-436 cells.  Subsequently, we evaluated its anti-tumor activity and apoptosis-inducing mechanisms in vivo.  These results suggested that I inhibited tumor growth by apoptosis in the xenograft mouse model of breast cancer (MDA-MB-231 and MDA-MB-436).  Collectively, our results demonstrate a novel small-mol. inhibitor targeting eEF2K with mechanism of apoptosis and a therapeutic potential in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHKgIUg85n1LVg90H21EOLACvtfcHk0lgcenpYHDZjkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FM&md5=d5017cf0b61bbd2cc2962d3ded11dda3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.065%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Structure-Activity%2520Relationship%2520of%2520a%2520Focused%2520Library%2520of%2520%25CE%25B2-Phenylalanine%2520Derivatives%2520as%2520Novel%2520EEF2K%2520Inhibitors%2520with%2520Apoptosis-Inducing%2520Mechanisms%2520in%2520Breast%2520Cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D402%26epage%3D418%26doi%3D10.1016%2Fj.ejmech.2017.11.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine Induces Autophagic Cell Death via EEF2K-AMPK-MTOR-ULK Complex Axis in Triple Negative Breast Cancer</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">e12402</span>, <span class="refDoi"> DOI: 10.1111/cpr.12402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1111%2Fcpr.12402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29094413" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=e12402&author=D.+Sunauthor=L.+Zhuauthor=Y.+Zhaoauthor=Y.+Jiangauthor=L.+Chenauthor=Y.+Yuauthor=L.+Ouyang&title=Fluoxetine+Induces+Autophagic+Cell+Death+via+EEF2K-AMPK-MTOR-ULK+Complex+Axis+in+Triple+Negative+Breast+Cancer&doi=10.1111%2Fcpr.12402"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fcpr.12402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcpr.12402%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DFluoxetine%2520Induces%2520Autophagic%2520Cell%2520Death%2520via%2520EEF2K-AMPK-MTOR-ULK%2520Complex%2520Axis%2520in%2520Triple%2520Negative%2520Breast%2520Cancer%26jtitle%3DCell%2520Proliferation%26date%3D2018%26volume%3D51%26spage%3De12402%26doi%3D10.1111%2Fcpr.12402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y. Di</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D. S.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening and Experimental Validation of EEF2K Inhibitors by Combining Homology Modeling, QSAR and Molecular Docking from FDA Approved Drugs</span>. <i>New J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">19097</span>– <span class="NLM_lpage">19106</span>, <span class="refDoi"> DOI: 10.1039/C9NJ02600B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1039%2FC9NJ02600B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2gt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2019&pages=19097-19106&author=W.+L.+Yeauthor=L.+X.+Zhangauthor=Y.+Di+Guanauthor=W.+W.+Xueauthor=A.+F.+Chenauthor=Q.+Caoauthor=Y.+Chengauthor=D.+S.+Cao&title=Virtual+Screening+and+Experimental+Validation+of+EEF2K+Inhibitors+by+Combining+Homology+Modeling%2C+QSAR+and+Molecular+Docking+from+FDA+Approved+Drugs&doi=10.1039%2FC9NJ02600B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual screening and experimental validation of eEF2K inhibitors by combining homology modeling, QSAR and molecular docking from FDA approved drugs</span></div><div class="casAuthors">Ye, Wen-Ling; Zhang, Liu-Xia; Guan, Yi-Di; Xue, Wei-Wei; Chen, Alex F.; Cao, Qian; Cheng, Yan; Cao, Dong-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">New Journal of Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">19097-19106</span>CODEN:
                <span class="NLM_cas:coden">NJCHE5</span>;
        ISSN:<span class="NLM_cas:issn">1144-0546</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF2K), a calcium/calmodulin-dependent protein kinase, is a potential target for treating cancer. eEF2K can reduce the binding ability of eEF2 to ribosomes by phosphorylating eEF2, thereby inhibiting peptide chain extension and neg. regulating protein synthesis, which provides a cytoprotective mechanism for the development of cancer. eEF2K has been reported to be overexpressed in various types of cancers.  Therefore, it is of high importance to discover new eEF2K inhibitors for cancer therapy.  Here, we proposed a three-step screening strategy to seek eEF2K inhibitors from the FDA approved drug library: homol. modeling of eEF2K protein, SAR-based virtual screening, and docking-based virtual screening.  Based on the screening strategy, 13 drugs with high evaluation scores were purchased to measure their binding affinity (KD) to eEF2K by using the SPR assay.  The assay results suggested that 4 drugs may be potential eEF2K inhibitors, which are Pemetrexed (KD = 0.104 μM), Entecavir (KD = 2.16 μM), calcium levofolinate (KD = 11.7 μM), and Fosbretabulin (KD = 34.5 μM).  To further validate whether these drugs act on eEF2K, Western blot (WB) anal. was performed, which showed that Pemetrexed and Entecavir could inhibit the eEF2K activity.  Furthermore, mol. dynamics (MD) simulation was carried out to further demonstrate the interaction of eEF2K with Pemetrexed, the most bioactive drug.  The specific in vitro/in vivo interaction mechanisms between these drugs and eEF2K are under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofGwzBm2RnzbVg90H21EOLACvtfcHk0lgcenpYHDZjkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2gt73K&md5=fc20c7884a186c66628594882330f7b4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1039%2FC9NJ02600B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9NJ02600B%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DW.%2BL.%26aulast%3DZhang%26aufirst%3DL.%2BX.%26aulast%3DGuan%26aufirst%3DY.%2BDi%26aulast%3DXue%26aufirst%3DW.%2BW.%26aulast%3DChen%26aufirst%3DA.%2BF.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DD.%2BS.%26atitle%3DVirtual%2520Screening%2520and%2520Experimental%2520Validation%2520of%2520EEF2K%2520Inhibitors%2520by%2520Combining%2520Homology%2520Modeling%252C%2520QSAR%2520and%2520Molecular%2520Docking%2520from%2520FDA%2520Approved%2520Drugs%26jtitle%3DNew%2520J.%2520Chem.%26date%3D2019%26volume%3D43%26spage%3D19097%26epage%3D19106%26doi%3D10.1039%2FC9NJ02600B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span> <span> </span><span class="NLM_article-title">Combined Treatment of Mitoxantrone Sensitizes Breast Cancer Cells to Rapalogs through Blocking EEF-2K-Mediated Activation of Akt and Autophagy</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">948</span>, <span class="refDoi"> DOI: 10.1038/s41419-020-03153-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fs41419-020-03153-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=33144562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlCqur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=948&author=Y.+Guanauthor=S.+Jiangauthor=W.+Yeauthor=X.+Renauthor=X.+Wangauthor=Y.+Zhangauthor=M.+Yinauthor=K.+Wangauthor=Y.+Taoauthor=J.+M.+Yangauthor=D.+Caoauthor=Y.+Cheng&title=Combined+Treatment+of+Mitoxantrone+Sensitizes+Breast+Cancer+Cells+to+Rapalogs+through+Blocking+EEF-2K-Mediated+Activation+of+Akt+and+Autophagy&doi=10.1038%2Fs41419-020-03153-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy</span></div><div class="casAuthors">Guan, Yidi; Jiang, Shilong; Ye, Wenling; Ren, Xingcong; Wang, Xinluan; Zhang, Yi; Yin, Mingzhu; Wang, Kuansong; Tao, Yongguang; Yang, JinMing; Cao, Dongsheng; Cheng, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">948</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Oncogenic activation of the mTOR signaling pathway occurs frequently in tumor cells and contributes to the devastating features of cancer, including breast cancer. mTOR inhibitors rapalogs are promising anticancer agents in clin. trials; however, rapalogs resistance remains an unresolved clin. challenge.  In this study, we found that eEF-2K, which is overexpressed in cancer cells and is required for survival of stressed cells, was involved in the neg.-feedback activation of Akt and cytoprotective autophagy induction in breast cancer cells in response to mTOR inhibitors.  Therefore, disruption of eEF-2K simultaneously abrogates the two crit. resistance signaling pathways, sensitizing breast cancer cells to rapalogs.  Importantly, we identified mitoxantrone, an admitted anticancer drug for a wide range of tumors, as a potential inhibitor of eEF-2K via a structure-based virtual screening strategy.  We further demonstrated that mitoxantrone binds to eEF-2K and inhibits its activity, and the combination treatment of mitoxantrone and mTOR inhibitor resulted in significant synergistic cytotoxicity in breast cancer.  In conclusion, we report that eEF-2K contributes to the activation of resistance signaling pathways of mTOR inhibitor, suggesting a novel strategy to enhance mTOR-targeted cancer therapy through combining mitoxantrone, an eEF-2K inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmZBm2wJhJJbVg90H21EOLACvtfcHk0li1Jgm7ISkvbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlCqur7M&md5=7bb44468fcbef7b2a5f15f3c4938c062</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fs41419-020-03153-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-020-03153-x%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DY.%26atitle%3DCombined%2520Treatment%2520of%2520Mitoxantrone%2520Sensitizes%2520Breast%2520Cancer%2520Cells%2520to%2520Rapalogs%2520through%2520Blocking%2520EEF-2K-Mediated%2520Activation%2520of%2520Akt%2520and%2520Autophagy%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2020%26volume%3D11%26spage%3D948%26doi%3D10.1038%2Fs41419-020-03153-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhola, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bafna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meszoely, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">Kinome-Wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F0008-5472.CAN-14-2475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25480943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=405-414&author=N.+E.+Bholaauthor=V.+M.+Jansenauthor=S.+Bafnaauthor=J.+M.+Giltnaneauthor=J.+M.+Balkoauthor=M.+V.+Estradaauthor=I.+Meszoelyauthor=I.+Mayerauthor=V.+Abramsonauthor=F.+Yeauthor=M.+Sandersauthor=T.+C.+Duggerauthor=E.+V.+Allenauthor=C.+L.+Arteaga&title=Kinome-Wide+Functional+Screen+Identifies+Role+of+PLK1+in+Hormone-Independent%2C+ER-Positive+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-14-2475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer</span></div><div class="casAuthors">Bhola, Neil E.; Jansen, Valerie M.; Bafna, Sangeeta; Giltnane, Jennifer M.; Balko, Justin M.; Estrada, Monica V.; Meszoely, Ingrid; Mayer, Ingrid; Abramson, Vandana; Ye, Fei; Sanders, Melinda; Dugger, Teresa C.; Allen, Eliezer V.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">405-414</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings suggest that breast cancers that recur in a hormone-independent form may be sensitive to attack by exptl. small mol. inhibitors that target the mitotic kinase PLK1, the most advanced of which is currently in phase III trials for acute myeloid leukemias.  Estrogen receptor (ER) α-pos. breast cancers initially respond to antiestrogens but eventually become estrogen independent and recur.  ER+ breast cancer cells resistant to long-term estrogen deprivation (LTED) exhibit hormone-independent ER transcriptional activity and growth.  A kinome-wide siRNA screen using a library targeting 720 kinases identified Polo-like kinase 1 (PLK1) as one of the top genes whose downregulation resulted in inhibition of estrogen-independent ER transcriptional activity and growth of LTED cells.  High PLK1 mRNA and protein correlated with a high Ki-67 score in primary ER+ breast cancers after treatment with the aromatase inhibitor letrozole.  RNAi-mediated knockdown of PLK1 inhibited ER expression, estrogen-independent growth, and ER transcription in MCF7 and HCC1428 LTED cells.  Pharmacol. inhibition of PLK1 with volasertib, a small-mol. ATP-competitive PLK1 inhibitor, decreased LTED cell growth, ER transcriptional activity, and ER expression.  Volasertib in combination with the ER antagonist, fulvestrant, decreased MCF7 xenograft growth in ovariectomized mice more potently than each drug alone.  JUNB, a component of the AP-1 complex, was expressed 16-fold higher in MCF7/LTED compared with parental MCF7 cells.  Furthermore, JUNB and BCL2L1 (which encodes antiapoptotic BCL-xL) mRNA levels were markedly reduced upon volasertib treatment in MCF7/LTED cells, while they were increased in parental MCF7 cells.  Finally, JUNB knockdown decreased ER expression and transcriptional activity in MCF7/LTED cells, suggesting that PLK1 drives ER expression and estrogen-independent growth via JUNB.  These data support a crit. role of PLK1 in acquired hormone-independent growth of ER+ human breast cancer and is therefore a promising target in tumors that have escaped estrogen deprivation therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotBYnbgcIjm7Vg90H21EOLACvtfcHk0li1Jgm7ISkvbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWiug%253D%253D&md5=d33d1b9954337951c31a0e316191332b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2475%26sid%3Dliteratum%253Aachs%26aulast%3DBhola%26aufirst%3DN.%2BE.%26aulast%3DJansen%26aufirst%3DV.%2BM.%26aulast%3DBafna%26aufirst%3DS.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DEstrada%26aufirst%3DM.%2BV.%26aulast%3DMeszoely%26aufirst%3DI.%26aulast%3DMayer%26aufirst%3DI.%26aulast%3DAbramson%26aufirst%3DV.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DSanders%26aufirst%3DM.%26aulast%3DDugger%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DE.%2BV.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DKinome-Wide%2520Functional%2520Screen%2520Identifies%2520Role%2520of%2520PLK1%2520in%2520Hormone-Independent%252C%2520ER-Positive%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D405%26epage%3D414%26doi%3D10.1158%2F0008-5472.CAN-14-2475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Polo-like Kinase 1/Eukaryotic Elongation Factor 2 Kinase (PLK1/EEF2K) Dual Inhibitors for Regulating Breast Cancer Cells Apoptosis and Autophagy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ejmech.2017.12.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29288948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Kmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=517-528&author=Z.+Panauthor=Y.+Chenauthor=J.+Liuauthor=Q.+Jiangauthor=S.+Yangauthor=L.+Guoauthor=G.+He&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Polo-like+Kinase+1%2FEukaryotic+Elongation+Factor+2+Kinase+%28PLK1%2FEEF2K%29+Dual+Inhibitors+for+Regulating+Breast+Cancer+Cells+Apoptosis+and+Autophagy&doi=10.1016%2Fj.ejmech.2017.12.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy</span></div><div class="casAuthors">Pan, Zhaoping; Chen, Yujuan; Liu, Jingyan; Jiang, Qinglin; Yang, Shengyong; Guo, Li; He, Gu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Both PLK1 and EEF2K are serine/threonine kinases that play important roles in the proliferation and programmed cell death of various types of cancer.  They are highly expressed in breast cancer tissues.  Based on the multiple-complexes generated pharmacophore models of PLK1 and homol. models of EEF2K, the integrated virtual screening is performed to discover novel PLK1/EEF2K dual inhibitors.  The top ten hit compds. are selected and tested in vitro, and five of them display PLK1 and EEF2K inhibition in vitro.  Based on the docking modes of the most potent hit compd., a series of derivs. are synthesized, characterized and biol. assayed on the PLK1, EEF2K as well as breast cancer cell proliferation models.  Compd. I with satisfied inhibitory potency are shifted to mol. mechanism studies contained mol. dynamics simulations, cell cycles, apoptosis and autophagy assays.  Our results suggested that these novel PLK1/EEF2K dual inhibitors can be used as lead compds. for further development breast cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW3GfRJEilVbVg90H21EOLACvtfcHk0li1Jgm7ISkvbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Kmsw%253D%253D&md5=21a2433b436edc4c3cfae89389fdfd6e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Polo-like%2520Kinase%25201%252FEukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520%2528PLK1%252FEEF2K%2529%2520Dual%2520Inhibitors%2520for%2520Regulating%2520Breast%2520Cancer%2520Cells%2520Apoptosis%2520and%2520Autophagy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D517%26epage%3D528%26doi%3D10.1016%2Fj.ejmech.2017.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Ablation of Elongation Factor 2 Kinase Enhances Heat-Shock Protein 90 Chaperone Expression and Protects Cells under Proteotoxic Stress</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">7169</span>– <span class="NLM_lpage">7176</span>, <span class="refDoi"> DOI: 10.1074/jbc.AC119.008036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.AC119.008036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30890561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWiu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=7169-7176&author=J.+Xieauthor=P.+Van+Dammeauthor=D.+Fangauthor=C.+G.+Proud&title=Ablation+of+Elongation+Factor+2+Kinase+Enhances+Heat-Shock+Protein+90+Chaperone+Expression+and+Protects+Cells+under+Proteotoxic+Stress&doi=10.1074%2Fjbc.AC119.008036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Ablation of elongation factor 2 kinase enhances heat-shock protein 90 chaperone expression and protects cells under proteotoxic stress</span></div><div class="casAuthors">Xie, Jianling; Van Damm, Petra; Fang, Danielle; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7169-7177</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) neg. regulates the elongation stage of mRNA translation and is activated under different stress conditions to slow down protein synthesis.  One effect of eEF2K is to alter the repertoire of expressed proteins, perhaps to aid survival of stressed cells.  Here, we applied pulsed stable isotope labeling with amino acids in cell culture (SILAC) to study changes in the synthesis of specific proteins in human lung adenocarcinoma (A549) cells in which eEF2K had been depleted by an inducible shRNA.  We discovered that levels of heat-shock protein 90 (HSP90) are increased in eEF2K-depleted human cells as well as in eEF2K-knockout (eEF2K-/-) mouse embryonic fibroblasts (MEFs).  This rise in HSP90 coincided with an increase in the fraction of HSP90 mRNAs assocd. with translationally active polysomes, irresp. of unchanged total HSP90 levels.  These results indicate that blocking eEF2K function can enhance expression of HSP90 chaperones.  In eEF2K-/- mouse embryonic fibroblasts (MEFs), inhibition of HSP90 by its specific inhibitor AUY922 promoted the accumulation of ubiquitinated proteins.  Notably, HSP90 inhibition promoted apoptosis of eEF2K-/- MEFs under proteostatic stress induced by the proteasome inhibitor MG132.  Up-regulation of HSP90 likely protects cells from protein folding stress, arising, for example, from faster rates of polypeptide synthesis due to the lack of eEF2K.  Our findings indicate that eEF2K and HSPs closely cooperate to maintain proper proteostasis and suggest that concomitant inhibition of HSP90 and eEF2K could be a strategy to decrease cancer cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUSdrHKdrom7Vg90H21EOLACvtfcHk0lhCwEP2L8pNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWiu7vF&md5=884bc4568b694807921b6a4bb4037b46</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.AC119.008036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.AC119.008036%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DAblation%2520of%2520Elongation%2520Factor%25202%2520Kinase%2520Enhances%2520Heat-Shock%2520Protein%252090%2520Chaperone%2520Expression%2520and%2520Protects%2520Cells%2520under%2520Proteotoxic%2520Stress%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D7169%26epage%3D7176%26doi%3D10.1074%2Fjbc.AC119.008036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.-x.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Elongation Factor-2 Kinase Regulates the Cross-Talk between Autophagy and Pyroptosis in Doxorubicin-Treated Human Melanoma Cells in Vitro</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1038/s41401-019-0222-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fs41401-019-0222-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30914761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslKktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=1237-1244&author=P.+Yuauthor=H.-y.+Wangauthor=M.+Tianauthor=A.-x.+Liauthor=X.-s.+Chenauthor=X.-l.+Wangauthor=Y.+Zhangauthor=Y.+Cheng&title=Eukaryotic+Elongation+Factor-2+Kinase+Regulates+the+Cross-Talk+between+Autophagy+and+Pyroptosis+in+Doxorubicin-Treated+Human+Melanoma+Cells+in+Vitro&doi=10.1038%2Fs41401-019-0222-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro</span></div><div class="casAuthors">Yu, Pian; Wang, Hai-yan; Tian, Min; Li, Ao-xue; Chen, Xi-sha; Wang, Xin-luan; Zhang, Yi; Cheng, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1237-1244</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF-2K), a neg. regulator of protein synthesis, has been shown to play an important role in modulating autophagy and apoptosis in tumor cells under various stresses.  In this study, we investigated the regulatory role of eEF-2K in pyroptosis (a new form of programmed necrosis) in doxorubicin-treated human melanoma cells.  We found that doxorubicin (0.5-5μmol/L) induced pyroptosis in melanoma cell lines SK-MEL-5, SK-MEL-28, and A-375 with high expression of DFNA5, but not in human breast cancer cell line MCF-7 with little expression of DFNA5.  On the other hand, doxorubicin treatment activated autophagy in the melanoma cells; inhibition of autophagy by transfecting the cells with siRNA targeting Beclin1 or by pretreatment with chloroquine (20μmol/L) significantly augmented pyroptosis, thus sensitizing the melanoma cells to doxorubicin.  We further demonstrated that doxorubicin treatment activated eEF-2K in the melanoma cells, and silencing of eEF-2K blunted autophagic responses, but promoted doxorubicin-induced pyroptotic cell death.  Taken together, the above results demonstrate that eEF-2K dictates the cross-talk between pyroptosis and autophagy in doxorubicin-treated human melanoma cells; suppression of eEF-2K results in inhibiting autophagy and augmenting pyroptosis, thus modulating the sensitivity of melanoma cells to doxorubicin, suggesting that targeting eEF-2K may reinforce the antitumor efficacy of doxorubicin, offering a new insight into tumor chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEj3G3I-UI1rVg90H21EOLACvtfcHk0lhCwEP2L8pNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslKktLY%253D&md5=26984675c5f05a6628e59b3bbc2bc037</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fs41401-019-0222-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-019-0222-z%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DH.-y.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DA.-x.%26aulast%3DChen%26aufirst%3DX.-s.%26aulast%3DWang%26aufirst%3DX.-l.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DY.%26atitle%3DEukaryotic%2520Elongation%2520Factor-2%2520Kinase%2520Regulates%2520the%2520Cross-Talk%2520between%2520Autophagy%2520and%2520Pyroptosis%2520in%2520Doxorubicin-Treated%2520Human%2520Melanoma%2520Cells%2520in%2520Vitro%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D1237%26epage%3D1244%26doi%3D10.1038%2Fs41401-019-0222-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Inhibiting EEF-2 Kinase-Mediated Autophagy Enhanced the Cytocidal Effect of AKT Inhibitor on Human Nasopharyngeal Carcinoma</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2655</span>– <span class="NLM_lpage">2663</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S169952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.2147%2FDDDT.S169952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30214154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGru77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=2655-2663&author=Y.+Y.+Zhaoauthor=Y.+Tianauthor=L.+Liuauthor=J.+H.+Zhanauthor=X.+Houauthor=X.+Chenauthor=T.+Zhouauthor=Y.+Huangauthor=L.+Zhang&title=Inhibiting+EEF-2+Kinase-Mediated+Autophagy+Enhanced+the+Cytocidal+Effect+of+AKT+Inhibitor+on+Human+Nasopharyngeal+Carcinoma&doi=10.2147%2FDDDT.S169952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma</span></div><div class="casAuthors">Zhao, Yuan-yuan; Tian, Ying; Liu, Lin; Zhan, Jian-hua; Hou, Xue; Chen, Xi; Zhou, Ting; Huang, Yan; Zhang, Li</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2655-2663</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Aim: Our previous research showed that AKT inactivation via small mol. inhibitors did not induce significant apoptosis, but rather markedly increased autophagy in nasopharyngeal carcinoma (NPC).  The purpose of the current study was to det. whether autophagy inhibition can enhance the anticancer efficacy of an AKT inhibitor (MK-2206).  Materials and methods: NPC cell lines CNE-2 (Epstein-Barr virus neg.) and C666-1 (Epstein-Barr virus pos.) were used to conduct the research.  Autophagy induction effects were evaluated via Western blotting.  Eukaryotic elongation factor-2 (eEF-2) kinase was specifically and stably knocked down using shRNA.  The growth and proliferation of the cells were assessed by Cell Counting Kit-8.  In CNE-2 xenograft tumors, the antitumor effects of an AKT inhibitor (MK-2206) combined with an eEF-2 kinase inhibitor (NH125) were tested.  Results: MK-2206 induced eEF-2 kinase-dependent autophagy in NPC cell lines.  Knockdown of eEF-2 kinase using shRNA blunted the autophagy activated by MK-2206.  Compared with treatment with MK-2206 alone, shRNA or NH125 suppressed eEF-2 kinase and increased the growth-inhibitory effect of MK-2206 on the human NPC cell lines.  The synergistic effects of eEF-2 kinase inhibition and MK-2206 were similar to those of the combination of hydroxychloroquine and MK-2206.  Moreover, NH125 showed good synergistic effects with MK-2206 in vivo.  Conclusion: eEF-2 kinase-mediated autophagy induced by AKT inhibition played a protective role in NPC cells.  Inhibition of eEF-2 kinase may be an effective method for increasing the efficacy of an AKT inhibitor such as MK-2206 in NPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroi6eXROUFC7Vg90H21EOLACvtfcHk0lhCwEP2L8pNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGru77N&md5=3e5fcf3993f95bc0a70df2a902fa35a6</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S169952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S169952%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BY.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DJ.%2BH.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DInhibiting%2520EEF-2%2520Kinase-Mediated%2520Autophagy%2520Enhanced%2520the%2520Cytocidal%2520Effect%2520of%2520AKT%2520Inhibitor%2520on%2520Human%2520Nasopharyngeal%2520Carcinoma%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2018%26volume%3D12%26spage%3D2655%26epage%3D2663%26doi%3D10.2147%2FDDDT.S169952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span> <span> </span><span class="NLM_article-title">Gastric Adenocarcinoma Predictive Long Intergenic Non-Coding RNA Promotes Tumor Occurrence and Progression in Non-Small Cell Lung Cancer via Regulation of the MiR-661/EEF2K Signaling Pathway</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2136</span>– <span class="NLM_lpage">2147</span>, <span class="refDoi"> DOI: 10.1159/000495831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1159%2F000495831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30522114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWrt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=2136-2147&author=H.+Guauthor=J.+Chenauthor=Y.+Songauthor=H.+Shao&title=Gastric+Adenocarcinoma+Predictive+Long+Intergenic+Non-Coding+RNA+Promotes+Tumor+Occurrence+and+Progression+in+Non-Small+Cell+Lung+Cancer+via+Regulation+of+the+MiR-661%2FEEF2K+Signaling+Pathway&doi=10.1159%2F000495831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Gastric Adenocarcinoma Predictive Long Intergenic Non-Coding RNA Promotes Tumor Occurrence and Progression in Non-Small Cell Lung Cancer via Regulation of the miR-661/eEF2K Signaling Pathway</span></div><div class="casAuthors">Gu, Haiting; Chen, Junfeng; Song, Yukang; Shao, Haiyan</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2136-2147</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: Long non-coding RNAs (lncRNAs) play vital roles in carcinogenesis as oncogenes or tumor suppressor genes.  This study explored the biol. function of lncRNA gastric adenocarcinoma predictive long intergenic non-coding RNA (GAPLINC) in human non-small cell lung cancer (NSCLC).  Methods: GAPLINC expression in NSCLC specimens and cell lines was detected by qRT-PCR and Western blot.  The effect of GAPLINC on cell proliferation was investigated using CCK8-assay, colony formation assay, and xenograft model.  The effects of GAPLINC on apoptosis and cell cycle were detd. using flow cytometry.  The mechanism of GAPLINC involved in NSCLC was explored using Western blot, luciferase reporter assay, and RNA fluorescence in situ hybridization.  Results: We found that GAPLINC expression was up-regulated in NSCLC tissues and cell lines.  Overexpression of GAPLINC was assocd. with poor prognosis in patients with NSCLC.  Silencing of GAPLINC significantly inhibited cell proliferation, promoted apoptosis, and induced cell cycle arrest in the G0/G1 phase.  Results from xenograft transplantation showed that GAPLINC silencing inhibited the tumor growth in vivo.  Interestingly, GAPLINC silencing decreased the expression of eukaryotic elongation factor-2 kinase (eEF2K) protein both in vivo and in vitro.  Bioinformatic anal. and luciferase reporter confirmed that miR-661 targeted GAPLINC and eEF2K 3'-UTR and was neg. correlated with the expression of GAPLINC and eEF2K.  Conclusion: Our findings indicate that GAPLINC promotes NSCLC tumorigenesis by regulating miR-661/eEF2K cascade and provide new insights for the pathogenesis underlying NSCLC and potential targets for therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5N70wrpv2srVg90H21EOLACvtfcHk0lidpKXERAxM4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWrt7vI&md5=b199620ca03d39f1e866ab69af258639</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1159%2F000495831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000495831%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DShao%26aufirst%3DH.%26atitle%3DGastric%2520Adenocarcinoma%2520Predictive%2520Long%2520Intergenic%2520Non-Coding%2520RNA%2520Promotes%2520Tumor%2520Occurrence%2520and%2520Progression%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520via%2520Regulation%2520of%2520the%2520MiR-661%252FEEF2K%2520Signaling%2520Pathway%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2018%26volume%3D51%26spage%3D2136%26epage%3D2147%26doi%3D10.1159%2F000495831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">EEF-2 Kinase-Targeted MiR-449b Confers Radiation Sensitivity to Cancer Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.canlet.2018.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29331413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2018&pages=64-74&author=C.+Jiauthor=Q.+H.+Xuauthor=L.+C.+Guoauthor=X.+H.+Wangauthor=Y.+J.+Renauthor=H.+H.+Zhangauthor=W.+D.+Zhuauthor=Z.+J.+Mingauthor=Y.+S.+Yuanauthor=X.+C.+Renauthor=J.+X.+Songauthor=Y.+Chengauthor=J.+M.+Yangauthor=Y.+Zhang&title=EEF-2+Kinase-Targeted+MiR-449b+Confers+Radiation+Sensitivity+to+Cancer+Cells&doi=10.1016%2Fj.canlet.2018.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">eEF-2 Kinase-targeted miR-449b confers radiation sensitivity to cancer cells</span></div><div class="casAuthors">Ji, Cheng; Xu, Qiong Hua; Guo, Ling Chuan; Wang, Xiao Hui; Ren, Yi Jie; Zhang, Hong Han; Zhu, Wei Dong; Ming, Zhi Jun; Yuan, Yun Sheng; Ren, Xing Cong; Song, Jian Xun; Cheng, Yan; Yang, Jin Ming; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64-74</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The roles of microRNA in regulation of various biol. processes and in modulation of therapeutic effects have been widely appreciated.  In this study, we found a pos. correlation between miR-449 b expression and radiation sensitivity in cancer cells and in tumor specimens from patients.  We showed that eEF-2 kinase, a neg. regulator of global protein synthesis, is a target of miR-449 b.  Introducing a miR-449 b mimic into cancer cells led to suppression of eEF-2 kinase expression, leading to increases of protein synthesis and depletion of cellular ATP.  Further, we demonstrated that the miR-449 b mimic rendered the cancer cells more sensitive to ionizing radiation both in vitro (cell culture) and in vivo (animal xenograft model).  Moreover, the radiation sensitivity conferred by miR-449 b could be blunted by cycloheximide, an inhibitor of protein synthesis, or by direct delivery of ATP liposome, supporting eEF-2 kinase as a mediator of the radio-sensitizing effects of miR-449 b.  These results indicate that miR-449 b, which is frequently down-regulated in radio-resistant cancers, may represent a new crit. determinant of radio-sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN1ld40ST8ILVg90H21EOLACvtfcHk0lidpKXERAxM4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOnu7g%253D&md5=6dd7545c470bb2317f69323163eb39ec</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DQ.%2BH.%26aulast%3DGuo%26aufirst%3DL.%2BC.%26aulast%3DWang%26aufirst%3DX.%2BH.%26aulast%3DRen%26aufirst%3DY.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%2BH.%26aulast%3DZhu%26aufirst%3DW.%2BD.%26aulast%3DMing%26aufirst%3DZ.%2BJ.%26aulast%3DYuan%26aufirst%3DY.%2BS.%26aulast%3DRen%26aufirst%3DX.%2BC.%26aulast%3DSong%26aufirst%3DJ.%2BX.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DEEF-2%2520Kinase-Targeted%2520MiR-449b%2520Confers%2520Radiation%2520Sensitivity%2520to%2520Cancer%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D418%26spage%3D64%26epage%3D74%26doi%3D10.1016%2Fj.canlet.2018.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhlis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanlikilicer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">NcRNA Therapy with MiRNA-22–3p Suppresses the Growth of Triple-Negative Breast Cancer</span>. <i>Mol. Ther.--Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1016/j.omtn.2021.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.omtn.2021.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=33614241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjs1yiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2021&pages=930-943&author=A.+Gorurauthor=R.+Bayraktarauthor=C.+Ivanauthor=H.+A.+Mokhlisauthor=E.+Bayraktarauthor=N.+Kahramanauthor=D.+Karakasauthor=S.+Karamilauthor=N.+N.+Kabilauthor=P.+Kanlikilicerauthor=B.+Aslanauthor=L.+Tamerauthor=Z.+Wangauthor=V.+Cristiniauthor=G.+Lopez-Beresteinauthor=G.+Calinauthor=B.+Ozpolat&title=NcRNA+Therapy+with+MiRNA-22%E2%80%933p+Suppresses+the+Growth+of+Triple-Negative+Breast+Cancer&doi=10.1016%2Fj.omtn.2021.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer</span></div><div class="casAuthors">Gorur, Aysegul; Bayraktar, Recep; Ivan, Cristina; Mokhlis, Hamada Ahmed; Bayraktar, Emine; Kahraman, Nermin; Karakas, Didem; Karamil, Selda; Kabil, Nashwa N.; Kanlikilicer, Pinar; Aslan, Burcu; Tamer, Lulufer; Wang, Zhihui; Cristini, Vittorio; Lopez-Berestein, Gabriel; Calin, George; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy--Nucleic Acids</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">930-943</span>CODEN:
                <span class="NLM_cas:coden">MTAOC5</span>;
        ISSN:<span class="NLM_cas:issn">2162-2531</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Deregulation of noncoding RNAs, including microRNAs (miRs), is implicated in the pathogenesis of many human cancers, including breast cancer.  Through extensive anal. of The Cancer Genome Atlas, we found that expression of miR-22-3p is markedly lower in triple-neg. breast cancer (TNBC) than in normal breast tissue.  The restoration of miR-22-3p expression led to significant inhibition of TNBC cell proliferation, colony formation, migration, and invasion.  We demonstrated that miR-22-3p reduces eukaryotic elongation factor 2 kinase (eEF2K) expression by directly binding to the 3' untranslated region of eEF2K mRNA.  Inhibition of EF2K expression recapitulated the effects of miR-22-3p on TNBC cell proliferation, motility, invasion, and suppression of phosphatidylinositol 3-kinase/Akt and Src signaling.  Systemic administration of miR-22-3p in single-lipid nanoparticles significantly suppressed tumor growth in orthotopic MDA-MB-231 and MDA-MB-436 TNBC models.  Evaluation of the tumor response, following miR-22-3p therapy in these models using a novel math. model factoring in various in vivo parameters, demonstrated that the therapy is highly effective against TNBC.  These findings suggest that miR-22-3p functions as a tumor suppressor by targeting clin. significant oncogenic pathways and that miR-22-3p loss contributes to TNBC growth and progression.  The restoration of miR-22-3p expression is a potential novel noncoding RNA-based therapy for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeKCFNM1OYs7Vg90H21EOLACvtfcHk0lidpKXERAxM4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjs1yiu70%253D&md5=9566fa8d23b98d6d398303f12d7b2bdc</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.omtn.2021.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.omtn.2021.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DGorur%26aufirst%3DA.%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DMokhlis%26aufirst%3DH.%2BA.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DKarakas%26aufirst%3DD.%26aulast%3DKaramil%26aufirst%3DS.%26aulast%3DKabil%26aufirst%3DN.%2BN.%26aulast%3DKanlikilicer%26aufirst%3DP.%26aulast%3DAslan%26aufirst%3DB.%26aulast%3DTamer%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCristini%26aufirst%3DV.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DCalin%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DNcRNA%2520Therapy%2520with%2520MiRNA-22%25E2%2580%25933p%2520Suppresses%2520the%2520Growth%2520of%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DMol.%2520Ther.--Nucleic%2520Acids%26date%3D2021%26volume%3D23%26spage%3D930%26epage%3D943%26doi%3D10.1016%2Fj.omtn.2021.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shahbazi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulubayram, K.</span></span> <span> </span><span class="NLM_article-title">Modified Gold-Based SiRNA Nanotherapeutics for Targeted Therapy of Triple-Negative Breast Cancer</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1961</span>– <span class="NLM_lpage">1973</span>, <span class="refDoi"> DOI: 10.2217/nnm-2017-0081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.2217%2Fnnm-2017-0081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28745127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GhtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1961-1973&author=R.+Shahbaziauthor=E.+Asikauthor=N.+Kahramanauthor=M.+Turkauthor=B.+Ozpolatauthor=K.+Ulubayram&title=Modified+Gold-Based+SiRNA+Nanotherapeutics+for+Targeted+Therapy+of+Triple-Negative+Breast+Cancer&doi=10.2217%2Fnnm-2017-0081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Modified gold-based sirna nanotherapeutics for targeted therapy of triple-negative breast cancer</span></div><div class="casAuthors">Shahbazi, Reza; Asik, Elif; Kahraman, Nermin; Turk, Mustafa; Ozpolat, Bulent; Ulubayram, Kezban</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1961-1973</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1748-6963</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aim: In this study, we aimed to therapeutically target eukaryotic elongation factor 2 kinase (eEF-2K) in an in vivo triple-neg. breast cancer (TNBC) tumor model.  Materials & methods: We synthesized a highly monodisperse nanoformulation using polyethylenimine-modified gold nanoparticles (AuNP-PEI) as siRNA delivery vehicle and evaluated gene downregulation.  Results: We found that AuNP-PEI/eEF-2K nanoformulation was highly effective for in vitro and in vivo gene downregulation and showed remarkable antitumor efficacy that was assocd. with eEF-2K knockdown, inhibition of Src and MAPK-ERK signaling pathways in a TNBC orthotopic tumor model.  Conclusion: Our study suggests that eEF-2K plays an important role in TNBC tumorigenesis and its inhibition by AuNP-PEI/eEF-2K siRNA-based nanotherapeutics may be a potential therapeutic strategy for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripOvKyjzSbLVg90H21EOLACvtfcHk0lh-l_Pfc4V1yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GhtbbO&md5=587825bab8fc793fe3fc34f4a36e8a92</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.2217%2Fnnm-2017-0081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm-2017-0081%26sid%3Dliteratum%253Aachs%26aulast%3DShahbazi%26aufirst%3DR.%26aulast%3DAsik%26aufirst%3DE.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DTurk%26aufirst%3DM.%26aulast%3DOzpolat%26aufirst%3DB.%26aulast%3DUlubayram%26aufirst%3DK.%26atitle%3DModified%2520Gold-Based%2520SiRNA%2520Nanotherapeutics%2520for%2520Targeted%2520Therapy%2520of%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DNanomedicine%26date%3D2017%26volume%3D12%26spage%3D1961%26epage%3D1973%26doi%3D10.2217%2Fnnm-2017-0081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poganik, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aye, Y.</span></span> <span> </span><span class="NLM_article-title">On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">3610</span>– <span class="NLM_lpage">3622</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b12608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b12608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVCis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=3610-3622&author=M.+J.+C.+Longauthor=J.+R.+Poganikauthor=Y.+Aye&title=On-Demand+Targeting%3A+Investigating+Biology+with+Proximity-Directed+Chemistry&doi=10.1021%2Fjacs.5b12608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry</span></div><div class="casAuthors">Long, Marcus J. C.; Poganik, Jesse R.; Aye, Yimon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3610-3622</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proximity enhancement is a central chem. tenet underpinning an exciting suite of small-mol. toolsets that have allowed us to unravel many biol. complexities.  The leitmotif of this opus is "tethering"-a strategy in which a multifunctional small mol. serves as a template to bring proteins/biomols. together.  Scaffolding approaches have been powerfully applied to control diverse biol. outcomes such as protein-protein assocn., protein stability, activity, and improve imaging capabilities.  A new twist on this strategy has recently appeared, in which the small-mol. probe is engineered to unleash controlled amts. of reactive chem. signals within the microenvironment of a target protein.  Modification of a specific target elicits a precisely timed and spatially controlled gain-of-function (or dominant loss-of-function) signaling response.  Presented herein is a unique personal outlook conceptualizing the powerful proximity-enhanced chem. biol. toolsets into two paradigms: "multifunctional scaffolding" vs. "on-demand targeting".  By addressing the latest advances and challenges in the established yet constantly evolving multifunctional scaffolding strategies as well as in the emerging on-demand precision targeting (and related) systems, this Perspective is aimed at choosing when it is best to employ each of the two strategies, with an emphasis toward further promoting novel applications and discoveries stemming from these innovative chem. biol. platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6dKG5laUM7Vg90H21EOLACvtfcHk0lh-l_Pfc4V1yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVCis7g%253D&md5=40fa3d02e8de215dd7c596aa7a32af78</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b12608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b12608%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DPoganik%26aufirst%3DJ.%2BR.%26aulast%3DAye%26aufirst%3DY.%26atitle%3DOn-Demand%2520Targeting%253A%2520Investigating%2520Biology%2520with%2520Proximity-Directed%2520Chemistry%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D3610%26epage%3D3622%26doi%3D10.1021%2Fjacs.5b12608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Designing an EEF2K-Targeting PROTAC Small Molecule That Induces Apoptosis in MDA-MB-231 Cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">112505</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ejmech.2020.112505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=32717479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVyjur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2020&pages=112505&author=Y.+Liuauthor=Y.+Zhenauthor=G.+Wangauthor=G.+Yangauthor=L.+Fuauthor=B.+Liuauthor=L.+Ouyang&title=Designing+an+EEF2K-Targeting+PROTAC+Small+Molecule+That+Induces+Apoptosis+in+MDA-MB-231+Cells&doi=10.1016%2Fj.ejmech.2020.112505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells</span></div><div class="casAuthors">Liu, Yao; Zhen, Yongqi; Wang, Guan; Yang, Gaoxia; Fu, Leilei; Liu, Bo; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112505</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) is a key α-kinase that neg. regulates the extension step of protein synthesis, which consumes most of the energy and amino acids required for protein synthesis.  Studies have found that eEF2K protein is related to the breast cancer.  However, existing inhibitor effect has not achieved the desired effect in cancer therapy.  Proteolysis target chimeric (PROTAC) technol. is uses proteasome to degrade target protein to achieve the purpose of inhibiting tumor cell growth.  Here, we reported that the use of PROTAC strategy in combining with star eEF2K inhibitor A484954 and its potential derivs.  Consequently, candidate compd. 11l was found to degrade eEF2K and induce apoptosis in human breast carcinoma MDA-MB-231 cells.  Together, these findings demonstrate that our eEF2K-targeting PROTAC small mol. would be a potential new strategy for future breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjwO5jWHiZhLVg90H21EOLACvtfcHk0lh-l_Pfc4V1yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVyjur7E&md5=76b64831dc135a5c75438b527ee5a8d8</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112505%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDesigning%2520an%2520EEF2K-Targeting%2520PROTAC%2520Small%2520Molecule%2520That%2520Induces%2520Apoptosis%2520in%2520MDA-MB-231%2520Cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D204%26spage%3D112505%26doi%3D10.1016%2Fj.ejmech.2020.112505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devkota, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warthaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edupuganti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, C. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Screens for EEF-2 Kinase</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1177/1087057113505204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1177%2F1087057113505204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24078616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWgsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=445-452&author=A.+K.+Devkotaauthor=M.+Warthakaauthor=R.+Edupugantiauthor=C.+D.+J.+Tavaresauthor=W.+H.+Johnsonauthor=B.+Ozpolatauthor=E.+J.+Choauthor=K.+N.+Dalby&title=High-Throughput+Screens+for+EEF-2+Kinase&doi=10.1177%2F1087057113505204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput screens for eEF-2 kinase</span></div><div class="casAuthors">Devkota, Ashwini K.; Warthaka, Mangalika; Edupuganti, Ramakrishna; Tavares, Clint D. J.; Johnson, William H.; Ozpolat, Bulent; Cho, Eun Jeong; Dalby, Kevin N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">445-452, 8</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">EEF-2 kinase is a potential therapeutic target for breast cancer, gliomas, and depression.  No potent inhibitors of eEF-2K have been reported, and thus development of high-throughput assay systems may expedite the process.  Two high-throughput assays are described for eEF-2K using recombinant, tag-free enzyme purified from bacteria.  The first is a fluorescence-based assay that uses the phosphorylation of a Sox-based peptide substrate by eEF-2K, which results in a 5-fold increase in fluorescence emission, allowing for continuous monitoring of the kinase activity.  The second is a luminescence-based assay that produces a luminescence signal, which correlates with the amt. of ATP remaining in the kinase reaction.  Both assays have been optimized and miniaturized for a 384-well plate format and validated in screens.  In conclusion, we demonstrated that a traditional radiolabeled assay can be readily transferred to universal spectroscopic assays that are robust and will facilitate high-throughput screening of larger size libraries for the identification of small-mol. inhibitors and significantly contribute to the development of therapies for targeting eEF2K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxD6CqjJyXRLVg90H21EOLACvtfcHk0li3wZRPSlDeMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWgsrnF&md5=fb49c1e0a2cda168e1b0ee82e728e3cb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1177%2F1087057113505204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057113505204%26sid%3Dliteratum%253Aachs%26aulast%3DDevkota%26aufirst%3DA.%2BK.%26aulast%3DWarthaka%26aufirst%3DM.%26aulast%3DEdupuganti%26aufirst%3DR.%26aulast%3DTavares%26aufirst%3DC.%2BD.%2BJ.%26aulast%3DJohnson%26aufirst%3DW.%2BH.%26aulast%3DOzpolat%26aufirst%3DB.%26aulast%3DCho%26aufirst%3DE.%2BJ.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26atitle%3DHigh-Throughput%2520Screens%2520for%2520EEF-2%2520Kinase%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2014%26volume%3D19%26spage%3D445%26epage%3D452%26doi%3D10.1177%2F1087057113505204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qadir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sari, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raithatha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Silva, L. G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poorkasreiy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waseem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teh, M.-T. T.</span></span> <span> </span><span class="NLM_article-title">Transcriptome Reprogramming by Cancer Exosomes: Identification of Novel Molecular Targets in Matrix and Immune Modulation</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">97</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1186%2Fs12943-018-0846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30008265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFektbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=97&author=F.+Qadirauthor=M.+A.+Azizauthor=C.+P.+Sariauthor=H.+Maauthor=H.+Daiauthor=X.+Wangauthor=D.+Raithathaauthor=L.+G.+L.+Da+Silvaauthor=M.+Hussainauthor=S.+P.+Poorkasreiyauthor=I.+L.+Hutchisonauthor=A.+Waseemauthor=M.-T.+T.+Teh&title=Transcriptome+Reprogramming+by+Cancer+Exosomes%3A+Identification+of+Novel+Molecular+Targets+in+Matrix+and+Immune+Modulation&doi=10.1186%2Fs12943-018-0846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptome reprogramming by cancer exosomes: identification of novel molecular targets in matrix and immune modulation</span></div><div class="casAuthors">Qadir, Fatima; Aziz, Mohammad Arshad; Sari, Chrisdina Puspita; Ma, Hong; Dai, Haiyan; Wang, Xun; Raithatha, Dhiresh; Lagreca Da Silva, Lucas Girotto; Hussain, Muhammad; Poorkasreiy, Seyedeh P.; Hutchison, Iain L.; Waseem, Ahmad; Teh, Muy-Teck</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97/1-97/16</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Exosomes are extracellular vesicles released by almost all cell types, including cancer cells, into bodily fluids such as saliva, plasma, breast milk, semen, urine, cerebrospinal fluid, amniotic fluid, synovial fluid and sputum.  Their key function being intercellular communication with both neighboring as well as distant cells.  Cancer exosomes have been shown to regulate organ-specific metastasis.  However, little is known about the functional differences and mol. consequences of normal cells responding to exosomes derived from normal cells compared to those derived from cancer cells.  Methods: Here, we characterised and compared the transcriptome profiles of primary human normal oral keratinocytes (HNOK) in response to exosomes isolated from either primary HNOK or head and neck squamous cell carcinoma (HNSCC) cell lines.  Results: In recipient HNOK cells, we found that regardless of normal or cancer derived, exosomes altered mol. programs involved in matrix modulation (MMP9), cytoskeletal remodelling (TUBB6, FEZ1, CCT6A), viral/dsRNAinduced interferon (OAS1, IFI6), anti-inflammatory (TSC22D3), deubiquitin (OTUD1), lipid metab. and membrane trafficking (BBOX1, LRP11, RAB6A).  Interestingly, cancer exosomes, but not normal exosomes, modulated expression of matrix remodelling (EFEMP1, DDK3, SPARC), cell cycle (EEF2K), membrane remodelling (LAMP2, SRPX), differentiation (SPRR2E), apoptosis (CTSC), transcription/translation (KLF6, PUS7).  We have also identified CEP55 as a potential cancer exosomal marker.  Conclusions: In conclusion, both normal and cancer exosomes modulated unique gene expression pathways in normal recipient cells.  Cancer cells may exploit exosomes to confer transcriptome reprogramming that leads to cancer-assocd. pathologies such as angiogenesis, immune evasion/modulation, cell fate alteration and metastasis.  Mol. pathways and biomarkers identified in this study may be clin. exploitable for developing novel liq.-biopsy based diagnostics and immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeGoFIOFpPCbVg90H21EOLACvtfcHk0li3wZRPSlDeMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFektbk%253D&md5=02961fc9f1f549a1a2246c6ab0554935</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0846-5%26sid%3Dliteratum%253Aachs%26aulast%3DQadir%26aufirst%3DF.%26aulast%3DAziz%26aufirst%3DM.%2BA.%26aulast%3DSari%26aufirst%3DC.%2BP.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRaithatha%26aufirst%3DD.%26aulast%3DDa%2BSilva%26aufirst%3DL.%2BG.%2BL.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DPoorkasreiy%26aufirst%3DS.%2BP.%26aulast%3DHutchison%26aufirst%3DI.%2BL.%26aulast%3DWaseem%26aufirst%3DA.%26aulast%3DTeh%26aufirst%3DM.-T.%2BT.%26atitle%3DTranscriptome%2520Reprogramming%2520by%2520Cancer%2520Exosomes%253A%2520Identification%2520of%2520Novel%2520Molecular%2520Targets%2520in%2520Matrix%2520and%2520Immune%2520Modulation%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D97%26doi%3D10.1186%2Fs12943-018-0846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenchine, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassar, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">EEF2K Enhances Expression of PD-L1 by Promoting the Translation of Its MRNA</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>477</i></span>,  <span class="NLM_fpage">4367</span>– <span class="NLM_lpage">4381</span>, <span class="refDoi"> DOI: 10.1042/BCJ20200697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1042%2FBCJ20200697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=33094805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1amtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2020&pages=4367-4381&author=Y.+Wuauthor=J.+Xieauthor=X.+Jinauthor=R.+V.+Lenchineauthor=X.+Wangauthor=D.+M.+Fangauthor=Z.+D.+Nassarauthor=L.+M.+Butlerauthor=J.+Liauthor=C.+G.+Proud&title=EEF2K+Enhances+Expression+of+PD-L1+by+Promoting+the+Translation+of+Its+MRNA&doi=10.1042%2FBCJ20200697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor-2 kinase enhances expression of PD-L1 by promoting the translation of its mRNA</span></div><div class="casAuthors">Wu, Yu; Xie, Jianling; Jin, Xin; Lenchine, Roman V.; Wang, Xuemin; Fang, Danielle M.; Nassar, Zeyad D.; Butler, Lisa M.; Li, Jing; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">477</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4367-4381</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Emerging advances in cancer therapy have transformed the landscape towards cancer immunotherapy regimens.  Recent discoveries have resulted in the development of clin. immune checkpoint inhibitors that are 'game-changers' for cancer immunotherapy.  Here we show that eEF2K, an atypical protein kinase that neg. modulates the elongation stage of protein synthesis, promotes the synthesis of PD-L1, an immune checkpoint protein which helps cancer cells to escape from immunosurveillance.  Ablation of eEF2K in prostate and lung cancer cells markedly reduced the expression levels of the PD-L1 protein.  We show that eEF2K promotes the assocn. of PD-L1 mRNAs with translationally active polyribosomes and that translation of the PD-L1 mRNA is regulated by a uORF (upstream open reading-frame) within its 5 ' -UTR (5 '-untranslated region) which starts with a non-canonical CUG as the initiation codon.  This inhibitory effect is attenuated by eEF2K thereby allowing higher levels of translation of the PD-L1 coding region and enhanced expression of the PD-L1 protein.  Moreover, eEF2K-depleted cancer cells are more vulnerable to immune attack by natural killer cells.  Therefore, control of translation elongation can modulate the translation of this specific mRNA, one which contains an uORF that starts with CUG, and perhaps others that contain a similar feature.  Taken together, our data reveal that eEF2K regulates PD-L1 expression at the level of the translation of its mRNA by virtue of a uORF in its 5 '-region.  This, and other roles of eEF2K in cancer cell biol. (e.g. in cell survival and migration), may be exploited for the design of future therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZDBV_deQprVg90H21EOLACvtfcHk0li3wZRPSlDeMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1amtLbF&md5=993d1f55781c94e0dbabd3e0ba7f1609</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1042%2FBCJ20200697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBCJ20200697%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DLenchine%26aufirst%3DR.%2BV.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DD.%2BM.%26aulast%3DNassar%26aufirst%3DZ.%2BD.%26aulast%3DButler%26aufirst%3DL.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DEEF2K%2520Enhances%2520Expression%2520of%2520PD-L1%2520by%2520Promoting%2520the%2520Translation%2520of%2520Its%2520MRNA%26jtitle%3DBiochem.%2520J.%26date%3D2020%26volume%3D477%26spage%3D4367%26epage%3D4381%26doi%3D10.1042%2FBCJ20200697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, K. W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. H. K.</span></span> <span> </span><span class="NLM_article-title">Silencing of EEF2K (Eukaryotic Elongation Factor-2 Kinase) Reveals AMPK-ULK1-Dependent Autophagy in Colon Cancer Cells</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.4161/auto.29164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.4161%2Fauto.29164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24955726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFGltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1495-1508&author=C.+M.+Xieauthor=X.+Y.+Liuauthor=K.+W.+Y.+Shamauthor=J.+M.+Y.+Laiauthor=C.+H.+K.+Cheng&title=Silencing+of+EEF2K+%28Eukaryotic+Elongation+Factor-2+Kinase%29+Reveals+AMPK-ULK1-Dependent+Autophagy+in+Colon+Cancer+Cells&doi=10.4161%2Fauto.29164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells</span></div><div class="casAuthors">Xie, Chuan-Ming; Liu, Xiao-Yu; Sham, Kathy W. Y.; Lai, Josie M. Y.; Cheng, Christopher H. K.</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1495-1508</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">EEF2K (eukaryotic elongation factor-2 kinase), also known as Ca2+/calmodulin-dependent protein kinase III, functions in downregulating peptide chain elongation through inactivation of EEF2 (eukaryotic translation elongation factor 2).  Currently, there is a limited amt. of information on the promotion of autophagic survival by EEF2K in breast and glioblastoma cell lines.  However, the precise role of EEF2K in carcinogenesis as well as the underlying mechanism involved is still poorly understood.  In this study, contrary to the reported autophagy-promoting activity of EEF2K in certain cancer cells, EEF2K is shown to neg. regulate autophagy in human colon cancer cells as indicated by the increase of LC3-II levels, the accumulation of LC3 dots per cell, and the promotion of autophagic flux in EEF2K knockdown cells.  EEF2K neg. regulates cell viability, clonogenicity, cell proliferation, and cell size in colon cancer cells.  Autophagy induced by EEF2K silencing promotes cell survival and does not potentiate the anticancer efficacy of the AKT inhibitor MK-2206.  In addn., autophagy induced by silencing of EEF2K is attributed to induction of protein synthesis and activation of the AMPK-ULK1 pathway, independent of the suppression of MTOR activity and ROS generation.  Knockdown of AMPK or ULK1 significantly abrogates EEF2K silencing-induced increase of LC3-II levels, accumulation of LC3 dots per cell as well as cell proliferation in colon cancer cells.  In conclusion, silencing of EEF2K promotes autophagic survival via activation of the AMPK-ULK1 pathway in colon cancer cells.  This finding suggests that upregulation of EEF2K activity may constitute a novel approach for the treatment of human colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonLybXr6EsQ7Vg90H21EOLACvtfcHk0lgW-DE6h7pgzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFGltLY%253D&md5=5d57a50e2f06d807e9bcae2be80cdecc</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.4161%2Fauto.29164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.29164%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DSham%26aufirst%3DK.%2BW.%2BY.%26aulast%3DLai%26aufirst%3DJ.%2BM.%2BY.%26aulast%3DCheng%26aufirst%3DC.%2BH.%2BK.%26atitle%3DSilencing%2520of%2520EEF2K%2520%2528Eukaryotic%2520Elongation%2520Factor-2%2520Kinase%2529%2520Reveals%2520AMPK-ULK1-Dependent%2520Autophagy%2520in%2520Colon%2520Cancer%2520Cells%26jtitle%3DAutophagy%26date%3D2014%26volume%3D10%26spage%3D1495%26epage%3D1508%26doi%3D10.4161%2Fauto.29164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Gassart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinon, F.</span></span> <span> </span><span class="NLM_article-title">Translating the Anticancer Properties of EEF2K</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1080/15384101.2016.1254974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1080%2F15384101.2016.1254974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=27830984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOhurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=299-300&author=A.+De%0AGassartauthor=F.+Martinon&title=Translating+the+Anticancer+Properties+of+EEF2K&doi=10.1080%2F15384101.2016.1254974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Translating the anticancer properties of eEF2K</span></div><div class="casAuthors">De Gassart, Aude; Martinon, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-300</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyMnrS4xFNLrVg90H21EOLACvtfcHk0liZAu84y7lJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOhurjF&md5=b10bbe7748e6ecb580166fbd8f34e20d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1254974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1254974%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BGassart%26aufirst%3DA.%26aulast%3DMartinon%26aufirst%3DF.%26atitle%3DTranslating%2520the%2520Anticancer%2520Properties%2520of%2520EEF2K%26jtitle%3DCell%2520Cycle%26date%3D2017%26volume%3D16%26spage%3D299%26epage%3D300%26doi%3D10.1080%2F15384101.2016.1254974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Gassart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demaria, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffalon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryazanov, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinon, F.</span></span> <span> </span><span class="NLM_article-title">Pharmacological EEF 2K Activation Promotes Cell Death and Inhibits Cancer Progression</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1484</span>, <span class="refDoi"> DOI: 10.15252/embr.201642194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.15252%2Fembr.201642194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=27572820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWmurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=1471-1484&author=A.+De%0AGassartauthor=O.+Demariaauthor=R.+Panesauthor=L.+Zaffalonauthor=A.+G.+Ryazanovauthor=M.+Gillietauthor=F.+Martinon&title=Pharmacological+EEF+2K+Activation+Promotes+Cell+Death+and+Inhibits+Cancer+Progression&doi=10.15252%2Fembr.201642194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological eEF2K activation promotes cell death and inhibits cancer progression</span></div><div class="casAuthors">De Gassart, Aude; Demaria, Olivier; Panes, Rebecca; Zaffalon, Lea; Ryazanov, Alexey G.; Gilliet, Michel; Martinon, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1471-1484</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Activation of the elongation factor 2 kinase (eEF2K) leads to the phosphorylation and inhibition of the elongation factor eEF2, reducing mRNA translation rates.  Emerging evidence indicates that the regulation of factors involved in protein synthesis may be crit. for controlling diverse biol. processes including cancer progression.  Here we show that inhibitors of the HIV aspartyl protease (HIV-PIs), nelfinavir in particular, trigger a robust activation of eEF2K leading to the phosphorylation of eEF2.  Beyond its anti-viral effects, nelfinavir has antitumoral activity and promotes cell death.  We show that nelfinavir-resistant cells specifically evade eEF2 inhibition.  Decreased cell viability induced by nelfinavir is impaired in cells lacking eEF2K.  Moreover, nelfinavir-mediated anti-tumoral activity is severely compromised in eEF2K-deficient engrafted tumors in vivo.  Our findings imply that exacerbated activation of eEF2K is detrimental for tumor survival and describe a mechanism explaining the anti-tumoral properties of HIV-PIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdE4_sM_Sl_rVg90H21EOLACvtfcHk0liZAu84y7lJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWmurjN&md5=48b7e8276ee905859484b73af23efac5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.15252%2Fembr.201642194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201642194%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BGassart%26aufirst%3DA.%26aulast%3DDemaria%26aufirst%3DO.%26aulast%3DPanes%26aufirst%3DR.%26aulast%3DZaffalon%26aufirst%3DL.%26aulast%3DRyazanov%26aufirst%3DA.%2BG.%26aulast%3DGilliet%26aufirst%3DM.%26aulast%3DMartinon%26aufirst%3DF.%26atitle%3DPharmacological%2520EEF%25202K%2520Activation%2520Promotes%2520Cell%2520Death%2520and%2520Inhibits%2520Cancer%2520Progression%26jtitle%3DEMBO%2520Rep.%26date%3D2016%26volume%3D17%26spage%3D1471%26epage%3D1484%26doi%3D10.15252%2Fembr.201642194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Molecular structure and post-translational modifications of eEF2K. (A) Domain organization of eEF2K. eEF2K consists two main identifiable domains: the catalytic domain lying in the N-terminus and the SEL domain near the C-terminus, with the R-loop region connecting them. (B) The predicted three-dimensional structure of eEF2K. eEF2K can be phosphorylated at different sites and lead to eEF2 inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The upstream and downstream signaling pathways of eEF2K in cancer. (A) Upstream signaling pathways of eEF2K. Upstreaming signaling such as AMPK and REDD1 can regulate mTOC1, thereby inhibiting eEF2K. Also, MAPK/ERK signaling can inhibit eEF2K through P90<sup>RSK</sup>, while FOXM1 activates eEF2K to induce downstream CyclinD1 signaling. (B) Downstream signaling pathways of eEF2K. eEF2 is the only known substrate of eEF2K, which can be inactivated by eEF2K. β-integrin, TG2, VEGF, and PI3K pathways can be activated by eEF2K and ultimately lead to tumorigenesis. The regulation of STAT3 by active eEF2K remains disputed, which is activated in liver cancer and inhibited in lung cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Single-target inhibitors of eEF2K in cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Repurposed inhibitors targeting eEF2K in cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/medium/jm0c02218_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Other small-molecule inhibitors targeting/cotargeting eEF2K in cancer therapy. (A) The dual-target inhibitor of eEF2K and PLK1. (B) Combination strategies including one eEF2K inhibitor and the other drug. (C) eEF2K inhibitors identified with other emerging techniques. <b>31</b> is a PROTAC small-molecule inhibitor, and <b>32</b> and <b>33</b> are inhibitors identified using highly sensitive fluorescence analysis based upon Sox.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.0c02218/20210629/images/large/jm0c02218_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02218&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 71 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nairn, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palfrey, H. C.</span></span> <span> </span><span class="NLM_article-title">Identification of the Major M(r) 100,000 Substrate for Calmodulin-Dependent Protein Kinase III in Mammalian Cells as Elongation Factor-2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>262</i></span>,  <span class="NLM_fpage">17299</span>– <span class="NLM_lpage">17303</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)45377-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2FS0021-9258%2818%2945377-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=3693353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADyaL2sXmtFCjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=1987&pages=17299-17303&author=A.+C.+Nairnauthor=H.+C.+Palfrey&title=Identification+of+the+Major+M%28r%29+100%2C000+Substrate+for+Calmodulin-Dependent+Protein+Kinase+III+in+Mammalian+Cells+as+Elongation+Factor-2&doi=10.1016%2FS0021-9258%2818%2945377-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the major Mr 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2</span></div><div class="casAuthors">Nairn, Angus C.; Palfrey, H. Clive</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">262</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">17299-303</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The major substrate for Ca2+/calmodulin (CaM)-dependent protein kinase III in mammalian cells, a species of mol. wt. (Mr) 100,000 with a primarily cytoplasmic localization, has been identified as elongation factor-2 (EF-2), the protein that catalyzes the translocation of peptidyl-tRNA on the ribosome.  The amino acid sequence of 18 residues from the N-terminal end of the Mr 100,000 CaM-dependent protein kinase III substrate purified from rat pancreas was identical to the N-terminal sequence of authentic rat EF-2 as previously deduced from nucleic acid sequencing of a cDNA (Kohno, K., et al., 1986).  CaM-dependent protein kinase III phosphorylated EF-2 in vitro with a stoichiometry of ∼1 mol/mol on a threonine residue.  Amino acid sequencing of the purified tryptic phosphopeptide revealed that this threonine residue lies within the sequence: Ala-Gly-Glu-Thr-Arg-Phe-Thr-Asp-Thr-Arg (residues 51-60 of EF-2).  The Mr 100,000 protein was stoichiometrically ADP-ribosylated in vitro by the diphtheria toxin and NAD.  The Mr 100,000 protein was photoaffinity labeled with a GTP analog and the protein had an endogenous GTPase activity that could be stimulated by the addn. of salt-washed ribosomes.  These properties are all characteristic of EF-2.  Dephospho-EF-2 could support poly(U)-directed polyphenylalanine synthesis in a reconstituted elongation system when combined with EF-1.  In the same system, phospho-EF-2 was virtually inactive in supporting polypeptide synthesis; this effect could be reversed by dephosphorylation of phospho-EF-2.  Thus, intracellular Ca2+ may inhibit protein synthesis in mammalian cells via CaM-dependent protein kinase III-catalyzed phosphorylation of EF-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDivJtOneWLVg90H21EOLACvtfcHk0ljIpZe1B2tvsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmtFCjtbo%253D&md5=70c6580fce10b2c696ed38a2357dbda5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2945377-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252945377-X%26sid%3Dliteratum%253Aachs%26aulast%3DNairn%26aufirst%3DA.%2BC.%26aulast%3DPalfrey%26aufirst%3DH.%2BC.%26atitle%3DIdentification%2520of%2520the%2520Major%2520M%2528r%2529%2520100%252C000%2520Substrate%2520for%2520Calmodulin-Dependent%2520Protein%2520Kinase%2520III%2520in%2520Mammalian%2520Cells%2520as%2520Elongation%2520Factor-2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1987%26volume%3D262%26spage%3D17299%26epage%3D17303%26doi%3D10.1016%2FS0021-9258%2818%2945377-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nairn, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picciotto, M.</span></span> <span> </span><span class="NLM_article-title">Calcium/Calmodulin-Dependent Protein Kinases</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=7803766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVyls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1994&pages=295-303&author=A.+C.+Nairnauthor=M.+Picciotto&title=Calcium%2FCalmodulin-Dependent+Protein+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium/calmodulin-dependent protein kinases</span></div><div class="casAuthors">Nairn, Angus C.; Picciotto, Marina R.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-303</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    </div><div class="casAbstract">A review, with 55 refs.  Ca2+ is widely recognized as an essential intracellular second messenger in eukaryotic systems regulating processes such as muscle contraction, neurotransmitter release, gene expression and cell proliferation.  The effects of Ca2+ are frequently mediated via interaction with calmodulin (CaM) and strong evidence indicates, in turn, that the effects of Ca2+/CaM are often achieved through the regulation of protein phosphorylation.  A family of CaM-dependent protein kinases has been identified that includes: myosin light chain kinase, phosphorylase kinase, CaM kinase I, CaM kinase II, EF-2 kinase (CaM kinase III) and CaM kinase IV.  The structure, regulation and function of this important family of second messenger-regulated protein kinases will be briefly reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU-McjOgcuHrVg90H21EOLACvtfcHk0liEnJfrB6jDzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVyls7w%253D&md5=00a56ae0dba82de4eb8f34541fb4a1b6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNairn%26aufirst%3DA.%2BC.%26aulast%3DPicciotto%26aufirst%3DM.%26atitle%3DCalcium%252FCalmodulin-Dependent%2520Protein%2520Kinases%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D1994%26volume%3D5%26spage%3D295%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piserchio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajredini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, R.</span></span> <span> </span><span class="NLM_article-title">Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>431</i></span>,  <span class="NLM_fpage">2700</span>– <span class="NLM_lpage">2717</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2019.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.jmb.2019.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=31108082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVegtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2019&pages=2700-2717&author=A.+Piserchioauthor=N.+Willauthor=D.+H.+Gilesauthor=F.+Hajrediniauthor=K.+N.+Dalbyauthor=R.+Ghose&title=Solution+Structure+of+the+Carboxy-Terminal+Tandem+Repeat+Domain+of+Eukaryotic+Elongation+Factor+2+Kinase+and+Its+Role+in+Substrate+Recognition&doi=10.1016%2Fj.jmb.2019.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition</span></div><div class="casAuthors">Piserchio, Andrea; Will, Nathan; Giles, David H.; Hajredini, Fatlum; Dalby, Kevin N.; Ghose, Ranajeet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2700-2717</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF-2K), an atypical calmodulin-activated protein kinase, regulates translational elongation by phosphorylating its substrate, eukaryotic elongation factor 2 (eEF-2), thereby reducing its affinity for the ribosome.  The activation and activity of eEF-2K are crit. for survival under energy-deprived conditions and is implicated in a variety of essential physiol. processes.  Previous biochem. expts. have indicated that the binding site for the substrate eEF-2 is located in the C-terminal domain of eEF-2K, a region predicted to harbor several α-helical repeats.  Here, using NMR methodol., we have detd. the soln. structure of a C-terminal fragment of eEF-2K, eEF-2K562-725 that encodes two α-helical repeats.  The structure of eEF-2K562-725 shows signatures characteristic of TPR domains and of their SEL1-like sub-family.  Furthermore, using the analyses of NMR spectral perturbations and ITC measurements, we have localized the eEF-2 binding site on eEF-2K562-725.  We find that eEF-2K562-725 engages eEF-2 with an affinity comparable to that of the full-length enzyme.  Furthermore, eEF-2K562-725 is able to inhibit the phosphorylation of eEF-2 by full-length eEF-2K in trans.  Our present studies establish that eEF-2K562-725 encodes the major elements necessary to enable the eEF-2K/eEF-2 interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfdPhG8Gi58bVg90H21EOLACvtfcHk0liEnJfrB6jDzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVegtrrF&md5=586a943a61f84c48b6af01f92bea122a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2019.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2019.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DPiserchio%26aufirst%3DA.%26aulast%3DWill%26aufirst%3DN.%26aulast%3DGiles%26aufirst%3DD.%2BH.%26aulast%3DHajredini%26aufirst%3DF.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26aulast%3DGhose%26aufirst%3DR.%26atitle%3DSolution%2520Structure%2520of%2520the%2520Carboxy-Terminal%2520Tandem%2520Repeat%2520Domain%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520and%2520Its%2520Role%2520in%2520Substrate%2520Recognition%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2019%26volume%3D431%26spage%3D2700%26epage%3D2717%26doi%3D10.1016%2Fj.jmb.2019.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, M.</span></span> <span> </span><span class="NLM_article-title">AMP-Activated Protein Kinase Stimulates Warburg-like Glycolysis and Activation of Satellite Cells during Muscle Regeneration</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">26445</span>– <span class="NLM_lpage">26456</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.665232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.M115.665232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=26370082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGisLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=26445-26456&author=X.+Fuauthor=M.+J.+Zhuauthor=M.+V.+Dodsonauthor=M.+Du&title=AMP-Activated+Protein+Kinase+Stimulates+Warburg-like+Glycolysis+and+Activation+of+Satellite+Cells+during+Muscle+Regeneration&doi=10.1074%2Fjbc.M115.665232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-activated protein kinase stimulates Warburg-like glycolysis and activation of satellite cells during muscle regeneration</span></div><div class="casAuthors">Fu, Xing; Zhu, Mei-Jun; Dodson, Mike V.; Du, Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">26445-26456</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Satellite cells are the major myogenic stem cells residing inside skeletal muscle and are indispensable for muscle regeneration.  Satellite cells remain largely quiescent, but are rapidly activated in response to muscle injury, and the derived myogenic cells then fuse to repair damaged muscle fibers or form new muscle fibers.  However, mechanisms eliciting metabolic activation, an inseparable step for satellite cell activation following muscle injury, have not been defined.  Here, the authors found that a noncanonical Sonic Hedgehog (Shh) pathway was rapidly activated in response to muscle injury, which activates AMPK and induces a Warburg-like glycolysis in satellite cells.  AMPKα1 was the dominant AMPKα isoform expressed in satellite cells, and AMPKα1 deficiency in satellite cells impaired their activation and myogenic differentiation during muscle regeneration.  Drugs activating noncanonical Shh promoted proliferation of satellite cells, which was abolished because of satellite cell-specific AMPKα1 knock-out.  Taken together, AMPKα1 is a crit. mediator linking the noncanonical Shh pathway to Warburg-like glycolysis in satellite cells, which is required for satellite activation and muscle regeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOAfzHI0wKAbVg90H21EOLACvtfcHk0liEnJfrB6jDzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGisLnF&md5=2270df58b02919a3a4ef9f169577ce3d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.665232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.665232%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DM.%2BJ.%26aulast%3DDodson%26aufirst%3DM.%2BV.%26aulast%3DDu%26aufirst%3DM.%26atitle%3DAMP-Activated%2520Protein%2520Kinase%2520Stimulates%2520Warburg-like%2520Glycolysis%2520and%2520Activation%2520of%2520Satellite%2520Cells%2520during%2520Muscle%2520Regeneration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D26445%26epage%3D26456%26doi%3D10.1074%2Fjbc.M115.665232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regufe da Mota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajek, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">A Conserved Loop in the Catalytic Domain of Eukaryotic Elongation Factor 2 Kinase Plays a Key Role in Its Substrate Specificity</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2294</span>– <span class="NLM_lpage">2307</span>, <span class="refDoi"> DOI: 10.1128/MCB.00388-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1128%2FMCB.00388-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24732796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=2294-2307&author=C.+E.+Mooreauthor=S.+Regufe+da+Motaauthor=H.+Mikolajekauthor=C.+G.+Proud&title=A+Conserved+Loop+in+the+Catalytic+Domain+of+Eukaryotic+Elongation+Factor+2+Kinase+Plays+a+Key+Role+in+Its+Substrate+Specificity&doi=10.1128%2FMCB.00388-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A conserved loop in the catalytic domain of eukaryotic elongation factor 2 kinase plays a key role in its substrate specificity</span></div><div class="casAuthors">Moore, Claire E.; da Mota, Sergio Regufe; Mikolajek, Halina; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2294-2307, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) is the best-characterized member of the α-kinase family.  Within this group, only eEF2K and myosin heavy-chain kinases (MHCKs) have known substrates.  Here, the authors studied the roles of specific residues, selected on the basis of structural data for MHCK A and TRPM7, in the function of eEF2K.  The data provide the 1st information regarding the basis of the substrate specificity of α-kinases, in particular the roles of residues in the so-called N/D loop, which appears to occupy a position in the structure of α-kinases similar to that of the activation loop in other kinases.  Several mutations in the EEF2K gene occur in tumors, one of which (R303C) is at a highly conserved residue in the N/D loop.  This mutation greatly enhances eEF2K activity and may be cytoprotective.  The data supported the concept that the major autophosphorylation site (Thr-348 in eEF2K) docks into a binding pocket to help create the kinase-competent conformation.  This was similar to the situation for MHCK A and is consistent with this being a common feature of α-kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXzKcm_OB_H7Vg90H21EOLACvtfcHk0ljanNy9ttjHaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksL3N&md5=bde77703c284c1f186aede461e50f61b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1128%2FMCB.00388-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00388-14%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DC.%2BE.%26aulast%3DRegufe%2Bda%2BMota%26aufirst%3DS.%26aulast%3DMikolajek%26aufirst%3DH.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DA%2520Conserved%2520Loop%2520in%2520the%2520Catalytic%2520Domain%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520Plays%2520a%2520Key%2520Role%2520in%2520Its%2520Substrate%2520Specificity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26spage%3D2294%26epage%3D2307%26doi%3D10.1128%2FMCB.00388-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Elongation Factor-2 Kinase (EEF2K): A Potential Therapeutic Target in Cancer</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1531</span>, <span class="refDoi"> DOI: 10.1007/s10495-014-1019-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1007%2Fs10495-014-1019-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25023961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCqtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1527-1531&author=L.+L.+Fuauthor=T.+Xieauthor=S.+Y.+Zhangauthor=B.+Liu&title=Eukaryotic+Elongation+Factor-2+Kinase+%28EEF2K%29%3A+A+Potential+Therapeutic+Target+in+Cancer&doi=10.1007%2Fs10495-014-1019-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer</span></div><div class="casAuthors">Fu, L. L.; Xie, T.; Zhang, S. Y.; Liu, B.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1527-1531</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Eukaryotic elongation factor-2 kinase (eEF2K), encoded by the EEF2K gene, is well-known to be a Ca2+/calmodulin (CaM)-dependent kinase which can neg. modulate protein synthesis.  It is highly conserved among eukaryotes from mammals to invertebrates, of which human and mouse may have 99 % overall amino acid identity.  This kinase can phosphorylate eukaryotic elongation factor-2 (eEF2) or undergo the process of autophosphorylation at multiple sites to inhibit its function in translation elongation.  Due to the fact that regulation of eEF2 by eEF2K is an evolutionarily conserved mechanism, eEF2K activity may confer tumor cell adaptation to metabolic stress under acute nutrient depletion, and the high expressed level of eEF2K has been found in several types of malignancies. eEF2K may modulate the expression of some apoptotic proteins such as XIAP, c-FLIPL, Bcl-XL, PI3KCI and p70S6K to inhibit apoptotic process in cancer.  On the other hand, it plays a regulatory role in autophagy involved in mTORC1, AMPK and Atg8, thereby promoting cancer cell survival.  Addnl., eEF2K may play a crucial role in the crosstalk between apoptosis and autophagy in cancer.  Collectively, these findings have led to the conclusions that eEF2K may contribute to carcinogenesis, and thus being utilized as a potential target for future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGeOYqgUkeurVg90H21EOLACvtfcHk0ljanNy9ttjHaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCqtbrO&md5=07b5761eed07eaac9b5ef703077560c1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs10495-014-1019-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-014-1019-7%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.%2BL.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DEukaryotic%2520Elongation%2520Factor-2%2520Kinase%2520%2528EEF2K%2529%253A%2520A%2520Potential%2520Therapeutic%2520Target%2520in%2520Cancer%26jtitle%3DApoptosis%26date%3D2014%26volume%3D19%26spage%3D1527%26epage%3D1531%26doi%3D10.1007%2Fs10495-014-1019-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White-Gilbertson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voelkel-Johnson, C.</span></span> <span> </span><span class="NLM_article-title">The Role of Protein Synthesis in Cell Cycling and Cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2009.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.molonc.2009.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=19546037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFGjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=402-408&author=S.+White-Gilbertsonauthor=D.+T.+Kurtzauthor=C.+Voelkel-Johnson&title=The+Role+of+Protein+Synthesis+in+Cell+Cycling+and+Cancer&doi=10.1016%2Fj.molonc.2009.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The role of protein synthesis in cell cycling and cancer</span></div><div class="casAuthors">White-Gilbertson, Shai; Kurtz, David T.; Voelkel-Johnson, Christina</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">402-408</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cell cycling and protein synthesis are both key physiol. tasks for cancer cells.  Here we present a model for how the elongation phase of protein synthesis, governed by elongation factor 2 and elongation factor 2 kinase, both modulates and responds to cell cycling.  Within this framework we also discuss survivin, a protein with both pro-mitotic and anti-apoptotic roles whose persistence in the cell is tied to protein synthesis due to its short half-life.  Finally, we provide a brief overview of efforts of cancer researchers to target EF2 and EF2 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUmPpnb5kcybVg90H21EOLACvtfcHk0ljanNy9ttjHaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFGjurk%253D&md5=1d47c7daadf76dc7b999a917bd04f55e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2009.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2009.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DWhite-Gilbertson%26aufirst%3DS.%26aulast%3DKurtz%26aufirst%3DD.%2BT.%26aulast%3DVoelkel-Johnson%26aufirst%3DC.%26atitle%3DThe%2520Role%2520of%2520Protein%2520Synthesis%2520in%2520Cell%2520Cycling%2520and%2520Cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2009%26volume%3D3%26spage%3D402%26epage%3D408%26doi%3D10.1016%2Fj.molonc.2009.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regufe da Mota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanucara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwala, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyr dit Ruys, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertommen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rider, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Elongation Factor 2 Kinase Activity Is Controlled by Multiple Inputs from Oncogenic Signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">4088</span>– <span class="NLM_lpage">4103</span>, <span class="refDoi"> DOI: 10.1128/MCB.01035-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1128%2FMCB.01035-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25182533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=4088-4103&author=X.+Wangauthor=S.+Regufe+da+Motaauthor=R.+Liuauthor=C.+E.+Mooreauthor=J.+Xieauthor=F.+Lanucaraauthor=U.+Agarwalaauthor=S.+Pyr+dit+Ruysauthor=D.+Vertommenauthor=M.+H.+Riderauthor=C.+E.+Eyersauthor=C.+G.+Proud&title=Eukaryotic+Elongation+Factor+2+Kinase+Activity+Is+Controlled+by+Multiple+Inputs+from+Oncogenic+Signaling&doi=10.1128%2FMCB.01035-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling</span></div><div class="casAuthors">Wang, Xuemin; Regufe da Mota, Sergio; Liu, Rui; Moore, Claire E.; Xie, Jianling; Lanucara, Francesco; Agarwala, Usha; Pyr dit Ruys, Sebastien; Vertommen, Didier; Rider, Mark H.; Eyers, Claire E.; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4088-4103, 17 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K), an atypical calmodulin-dependent protein kinase, phosphorylates and inhibits eEF2, slowing down translation elongation.  EEF2K contains an N-terminal catalytic domain, a C-terminal α-helical region and a linker contg. several regulatory phosphorylation sites.  EEF2K is expressed at high levels in certain cancers, where it may act to help cell survival, e.g., during nutrient starvation.  However, it is a neg. regulator of protein synthesis and thus cell growth, suggesting that cancer cells may possess mechanisms to inhibit eEF2K under good growth conditions, to allow protein synthesis to proceed.  We show here that the mTORC1 pathway and the oncogenic Ras/Raf/MEK/extracellular signal-regulated kinase (ERK) pathway cooperate to restrict eEF2K activity.  We identify multiple sites in eEF2K whose phosphorylation is regulated by mTORC1 and/or ERK, including new ones in the linker region.  We demonstrate that certain sites are phosphorylated directly by mTOR or ERK.  Our data reveal that glycogen synthase kinase 3 signaling also regulates eEF2 phosphorylation.  In addn., we show that phosphorylation sites remote from the N-terminal calmodulin-binding motif regulate the phosphorylation of N-terminal sites that control CaM binding.  Mutations in the former sites, which occur in cancer cells, cause the activation of eEF2K.  EEF2K is thus regulated by a network of oncogenic signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDO0LF9tOIo7Vg90H21EOLACvtfcHk0ljanNy9ttjHaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSls7rO&md5=3874c9e5ee8f4aeccd4500722b7665e5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FMCB.01035-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01035-14%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRegufe%2Bda%2BMota%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DC.%2BE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLanucara%26aufirst%3DF.%26aulast%3DAgarwala%26aufirst%3DU.%26aulast%3DPyr%2Bdit%2BRuys%26aufirst%3DS.%26aulast%3DVertommen%26aufirst%3DD.%26aulast%3DRider%26aufirst%3DM.%2BH.%26aulast%3DEyers%26aufirst%3DC.%2BE.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DEukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520Activity%2520Is%2520Controlled%2520by%2520Multiple%2520Inputs%2520from%2520Oncogenic%2520Signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26spage%3D4088%26epage%3D4103%26doi%3D10.1128%2FMCB.01035-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delaidelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansonius, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Naggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarni Oo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leprivier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P. H.</span></span> <span> </span><span class="NLM_article-title">MYCN Amplified Neuroblastoma Requires the MRNA Translation Regulator EEF2 Kinase to Adapt to Nutrient Deprivation</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1564</span>– <span class="NLM_lpage">1576</span>, <span class="refDoi"> DOI: 10.1038/cdd.2017.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fcdd.2017.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28574509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Wrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1564-1576&author=A.+Delaidelliauthor=G.+L.+Negriauthor=A.+Janauthor=B.+Jansoniusauthor=A.+El-Naggarauthor=J.+K.+M.+Limauthor=D.+Khanauthor=H.+Zarni+Ooauthor=C.+J.+Carnieauthor=M.+Remkeauthor=J.+M.+Marisauthor=G.+Leprivierauthor=P.+H.+Sorensen&title=MYCN+Amplified+Neuroblastoma+Requires+the+MRNA+Translation+Regulator+EEF2+Kinase+to+Adapt+to+Nutrient+Deprivation&doi=10.1038%2Fcdd.2017.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation</span></div><div class="casAuthors">Delaidelli, Alberto; Negri, Gian Luca; Jan, Asad; Jansonius, Brandon; El-Naggar, Amal; Lim, Jonathan K. M.; Khan, Debjit; Zarni Oo, Htoo; Carnie, Christopher J.; Remke, Marc; Maris, John M.; Leprivier, Gabriel; Sorensen, Poul H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1564-1576</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">MYC family proteins are implicated in many human cancers, but their therapeutic targeting has proven challenging.  MYCN amplification in childhood neuroblastoma (NB) is assocd. with aggressive disease and high mortality.  Novel and effective therapeutic strategies are therefore urgently needed for these tumors.  MYC-driven oncogenic transformation impairs cell survival under nutrient deprivation (ND), a characteristic stress condition within the tumor microenvironment.  We recently identified eukaryotic Elongation Factor 2 Kinase (eEF2K) as a pivotal mediator of the adaptive response of tumor cells to ND.  We therefore hypothesized that eEF2K facilitates the adaptation of MYCN amplified NB to ND, and that inhibiting this pathway can impair MYCN-driven NB progression.  To test our hypothesis, we first analyzed publicly available genomic databases and tissue microarrays for eEF2K expression in NB, and for links between eEF2K, MYCN, and clin. outcome in NB.  Effects of eEF2K inhibition were evaluated on survival of MYCN amplified vs. non-amplified NB cell lines under ND.  Finally, NB xenograft mouse models were used to confirm in vitro observations.  Our results indicate that high eEF2K expression and activity are strongly predictive of poor outcome in NB, and correlates significantly with MYCN amplification.  Inhibition of eEF2K markedly decreases survival of MYCN amplified NB cell lines in vitro under ND.  Growth of MYCN amplified NB xenografts is markedly impaired by eEF2K knockdown, particularly under caloric restriction.  In summary, eEF2K protects MYCN overexpressing NB cells from ND in vitro and in vivo, highlighting this kinase as a crit. mediator of the adaptive response of MYCN amplified NB cells to metabolic stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo07GXfi1Pt-7Vg90H21EOLACvtfcHk0lhwu416fY39Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Wrsr8%253D&md5=5ea5f1f6610da7d813ecf86c185cd85d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2017.79%26sid%3Dliteratum%253Aachs%26aulast%3DDelaidelli%26aufirst%3DA.%26aulast%3DNegri%26aufirst%3DG.%2BL.%26aulast%3DJan%26aufirst%3DA.%26aulast%3DJansonius%26aufirst%3DB.%26aulast%3DEl-Naggar%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DJ.%2BK.%2BM.%26aulast%3DKhan%26aufirst%3DD.%26aulast%3DZarni%2BOo%26aufirst%3DH.%26aulast%3DCarnie%26aufirst%3DC.%2BJ.%26aulast%3DRemke%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DLeprivier%26aufirst%3DG.%26aulast%3DSorensen%26aufirst%3DP.%2BH.%26atitle%3DMYCN%2520Amplified%2520Neuroblastoma%2520Requires%2520the%2520MRNA%2520Translation%2520Regulator%2520EEF2%2520Kinase%2520to%2520Adapt%2520to%2520Nutrient%2520Deprivation%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2017%26volume%3D24%26spage%3D1564%26epage%3D1576%26doi%3D10.1038%2Fcdd.2017.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leprivier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotblat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubuc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, A. R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kool, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnihotri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Naggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash Somasekharan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faubert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barokas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korshunov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hielscher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcott, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galpin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahern, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delattre, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derry, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, P. H.</span></span> <span> </span><span class="NLM_article-title">XThe EEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">1064</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2013.04.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.cell.2013.04.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=23706743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2013&pages=1064&author=G.+Leprivierauthor=M.+Remkeauthor=B.+Rotblatauthor=A.+Dubucauthor=A.+R.+F.+Mateoauthor=M.+Koolauthor=S.+Agnihotriauthor=A.+El-Naggarauthor=B.+Yuauthor=S.+Prakash+Somasekharanauthor=B.+Faubertauthor=G.+Bridonauthor=C.+E.+Tognonauthor=J.+Mathersauthor=R.+Thomasauthor=A.+Liauthor=A.+Barokasauthor=B.+Kwokauthor=M.+Bowdenauthor=S.+Smithauthor=X.+Wuauthor=A.+Korshunovauthor=T.+Hielscherauthor=P.+A.+Northcottauthor=J.+D.+Galpinauthor=C.+A.+Ahernauthor=Y.+Wangauthor=M.+G.+McCabeauthor=V.+P.+Collinsauthor=R.+G.+Jonesauthor=M.+Pollakauthor=O.+Delattreauthor=M.+E.+Gleaveauthor=E.+Janauthor=S.+M.+Pfisterauthor=C.+G.+Proudauthor=W.+B.+Derryauthor=M.+D.+Taylorauthor=P.+H.+Sorensen&title=XThe+EEF2+Kinase+Confers+Resistance+to+Nutrient+Deprivation+by+Blocking+Translation+Elongation&doi=10.1016%2Fj.cell.2013.04.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The eEF2 Kinase confers resistance to nutrient deprivation by blocking translation elongation</span></div><div class="casAuthors">Leprivier, Gabriel; Remke, Marc; Rotblat, Barak; Dubuc, Adrian; Mateo, Abigail-Rachele F.; Kool, Marcel; Agnihotri, Sameer; El-Naggar, Amal; Yu, Bin; Prakash Somasekharan, Syam; Faubert, Brandon; Bridon, Gaelle; Tognon, Cristina E.; Mathers, Joan; Thomas, Ryan; Li, Amy; Barokas, Adi; Kwok, Brian; Bowden, Mary; Smith, Stephanie; Wu, Xiaochong; Korshunov, Andrey; Hielscher, Thomas; Northcott, Paul A.; Galpin, Jason D.; Ahern, Christopher A.; Wang, Ye; McCabe, Martin G.; Collins, V. Peter; Jones, Russell G.; Pollak, Michael; Delattre, Olivier; Gleave, Martin E.; Jan, Eric; Pfister, Stefan M.; Proud, Christopher G.; Derry, W. Brent; Taylor, Michael D.; Sorensen, Poul H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1064-1079</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Metabolic adaptation is essential for cell survival during nutrient deprivation.  We report that eukaryotic elongation factor 2 kinase (eEF2K), which is activated by AMP-kinase (AMPK), confers cell survival under acute nutrient depletion by blocking translation elongation.  Tumor cells exploit this pathway to adapt to nutrient deprivation by reactivating the AMPK-eEF2K axis.  Adaptation of transformed cells to nutrient withdrawal is severely compromised in cells lacking eEF2K.  Moreover, eEF2K knockdown restored sensitivity to acute nutrient deprivation in highly resistant human tumor cell lines.  In vivo, overexpression of eEF2K rendered murine tumors remarkably resistant to caloric restriction.  Expression of eEF2K strongly correlated with overall survival in human medulloblastoma and glioblastoma multiforme.  Finally, C. elegans strains deficient in efk-1, the eEF2K ortholog, were severely compromised in their response to nutrient depletion.  Our data highlight a conserved role for eEF2K in protecting cells from nutrient deprivation and in conferring tumor cell adaptation to metabolic stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpP5d3R_4drVg90H21EOLACvtfcHk0lhwu416fY39Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGltLg%253D&md5=a0e527178fcfd8de9b5c9aa724e35542</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.04.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.04.055%26sid%3Dliteratum%253Aachs%26aulast%3DLeprivier%26aufirst%3DG.%26aulast%3DRemke%26aufirst%3DM.%26aulast%3DRotblat%26aufirst%3DB.%26aulast%3DDubuc%26aufirst%3DA.%26aulast%3DMateo%26aufirst%3DA.%2BR.%2BF.%26aulast%3DKool%26aufirst%3DM.%26aulast%3DAgnihotri%26aufirst%3DS.%26aulast%3DEl-Naggar%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DPrakash%2BSomasekharan%26aufirst%3DS.%26aulast%3DFaubert%26aufirst%3DB.%26aulast%3DBridon%26aufirst%3DG.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DMathers%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DBarokas%26aufirst%3DA.%26aulast%3DKwok%26aufirst%3DB.%26aulast%3DBowden%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKorshunov%26aufirst%3DA.%26aulast%3DHielscher%26aufirst%3DT.%26aulast%3DNorthcott%26aufirst%3DP.%2BA.%26aulast%3DGalpin%26aufirst%3DJ.%2BD.%26aulast%3DAhern%26aufirst%3DC.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMcCabe%26aufirst%3DM.%2BG.%26aulast%3DCollins%26aufirst%3DV.%2BP.%26aulast%3DJones%26aufirst%3DR.%2BG.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DDelattre%26aufirst%3DO.%26aulast%3DGleave%26aufirst%3DM.%2BE.%26aulast%3DJan%26aufirst%3DE.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DDerry%26aufirst%3DW.%2BB.%26aulast%3DTaylor%26aufirst%3DM.%2BD.%26aulast%3DSorensen%26aufirst%3DP.%2BH.%26atitle%3DXThe%2520EEF2%2520Kinase%2520Confers%2520Resistance%2520to%2520Nutrient%2520Deprivation%2520by%2520Blocking%2520Translation%2520Elongation%26jtitle%3DCell%26date%3D2013%26volume%3D153%26spage%3D1064%26doi%3D10.1016%2Fj.cell.2013.04.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.-M.</span></span> <span> </span><span class="NLM_article-title">EEF2 Kinase Mediated Autophagy as a Potential Therapeutic Target for Paclitaxel-Resistant Triple-Negative Breast Cancer</span>. <i>Annals of Translational Medicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.21037/atm.2019.11.39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.21037%2Fatm.2019.11.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=32042799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1KntLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=783-783&author=R.-X.+Wangauthor=X.-E.+Xuauthor=L.+Huangauthor=S.+Chenauthor=Z.-M.+Shao&title=EEF2+Kinase+Mediated+Autophagy+as+a+Potential+Therapeutic+Target+for+Paclitaxel-Resistant+Triple-Negative+Breast+Cancer&doi=10.21037%2Fatm.2019.11.39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer</span></div><div class="casAuthors">Wang, Ruo-Xi; Xu, Xiao-En; Huang, Liang; Chen, Sheng; Shao, Zhi-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">783</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">In this study, we aimed to investigate the role of autophagy and its regulator, eukaryotic elongation factor 2 kinase (eEF2K), in detg. the biol. nature of TNBC.  Methods: We used in vitro models of TNBC, namely, paclitaxel-resistant cell lines derived from sensitive cell lines.  Various approaches to measuring autophagy flux were applied.  We assessed the effects of inhibiting autophagy and silencing eEF2K on cell viability, tumor formation and invasion.  We also collected residual tumor samples from 222 breast cancer patients who underwent neoadjuvant chemotherapy and measured eEF2K and LC3 expression levels by immunohistochem. (IHC).  Multivariate survival anal. was used to det. prognostic variables.  Results: Compared to the parental lines, the chemoresistant lines exhibited enhanced starvation-stimulated autophagy and showed significant decreases in cell viability, growth and invasion upon treatment with autophagy inhibitors. eEF2K silencing also resulted in the suppression of autophagic activity and in aggressive biol. behavior.  In the survival anal., residual tumor LC3 (P=0.001) and eEF2K (P=0.027) expression levels were independent prognostic factors for patients who underwent neoadjuvant chemotherapy, esp. in those with TNBC.  Conclusions: Our study indicated that eEF2K and autophagy play key roles in the maintenance of aggressive tumor behavior and chemoresistance in resistant TNBC. eEF2K silencing may be a novel strategy for the treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF94kK_mrZ77Vg90H21EOLACvtfcHk0lgwCArQS8NeGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1KntLvJ&md5=31e71ad46a97a905f1ee0010442e2e1c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.21037%2Fatm.2019.11.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2019.11.39%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.-X.%26aulast%3DXu%26aufirst%3DX.-E.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DZ.-M.%26atitle%3DEEF2%2520Kinase%2520Mediated%2520Autophagy%2520as%2520a%2520Potential%2520Therapeutic%2520Target%2520for%2520Paclitaxel-Resistant%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DAnnals%2520of%2520Translational%2520Medicine%26date%3D2019%26volume%3D7%26spage%3D783%26epage%3D783%26doi%3D10.21037%2Fatm.2019.11.39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryazanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span> <span> </span><span class="NLM_article-title">EEF-2 Kinase Is a Critical Regulator of Warburg Effect through Controlling PP2A-A Synthesis</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">6293</span>– <span class="NLM_lpage">6308</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fonc.2016.166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=27181208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFSisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=6293-6308&author=Y.+Chengauthor=X.+Renauthor=Y.+Yuanauthor=Y.+Shanauthor=L.+Liauthor=X.+Chenauthor=L.+Zhangauthor=Y.+Takahashiauthor=J.+W.+Yangauthor=B.+Hanauthor=J.+Liaoauthor=Y.+Liauthor=H.+Harveyauthor=A.+Ryazanovauthor=G.+P.+Robertsonauthor=G.+Wanauthor=D.+Liuauthor=A.+F.+Chenauthor=Y.+Taoauthor=J.+M.+Yang&title=EEF-2+Kinase+Is+a+Critical+Regulator+of+Warburg+Effect+through+Controlling+PP2A-A+Synthesis&doi=10.1038%2Fonc.2016.166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis</span></div><div class="casAuthors">Cheng, Y.; Ren, X.; Yuan, Y.; Shan, Y.; Li, L.; Chen, X.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Ryazanov, A.; Robertson, G. P.; Wan, G.; Liu, D.; Chen, A. F.; Tao, Y.; Yang, J.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">6293-6308</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells predominantly metabolize glucose by glycolysis to produce energy in order to meet their metabolic requirement, a phenomenon known as Warburg effect.  Although Warburg effect is considered a peculiarity crit. for survival and proliferation of cancer cells, the regulatory mechanisms behind this phenomenon remain incompletely understood.  We report here that eukaryotic elongation factor-2 kinase (eEF-2K), a neg. regulator of protein synthesis, has a crit. role in promoting glycolysis in cancer cells.  We showed that deficiency in eEF-2K significantly reduced the uptake of glucose and decreased the productions of lactate and ATP in tumor cells and in the Ras-transformed mouse embryonic fibroblasts.  We further demonstrated that the promotive effect of eEF-2K on glycolysis resulted from the kinase-mediated restriction of synthesis of the protein phosphatase 2A-A (PP2A-A), a key factor that facilitates the ubiquitin-proteasomal degrdn. of c-Myc protein, as knockdown of eEF-2K expression led to a significant increase in PP2A-A protein synthesis and remarkable downregulation of c-Myc and pyruvate kinase M2 isoform, the key glycolytic enzyme transcriptionally activated by c-Myc.  In addn., depletion of eEF-2K reduced the ability of the transformed cells to proliferate and enhanced the sensitivity of tumor cells to chemotherapy both in vitro and in vivo.  These results, which uncover a role of the eEF-2K-mediated control of PP2A-A in tumor cell glycolysis, provide new insights into the regulation of the Warburg effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJGJ4r_M_gIrVg90H21EOLACvtfcHk0lgwCArQS8NeGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFSisLs%253D&md5=2a997bb0f17e697440b2d447bc2b8aa5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.166%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BW.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHarvey%26aufirst%3DH.%26aulast%3DRyazanov%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DG.%2BP.%26aulast%3DWan%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DA.%2BF.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26atitle%3DEEF-2%2520Kinase%2520Is%2520a%2520Critical%2520Regulator%2520of%2520Warburg%2520Effect%2520through%2520Controlling%2520PP2A-A%2520Synthesis%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26spage%3D6293%26epage%3D6308%26doi%3D10.1038%2Fonc.2016.166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span> <span> </span><span class="NLM_article-title">EEF2K Promotes Progression and Radioresistance of Esophageal Squamous Cell Carcinoma</span>. <i>Radiother. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1016/j.radonc.2017.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.radonc.2017.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28431753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVygt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=439-447&author=H.+Zhuauthor=H.+Songauthor=G.+Chenauthor=X.+Yangauthor=J.+Liuauthor=Y.+Geauthor=J.+Luauthor=Q.+Qinauthor=C.+Zhangauthor=L.+Xuauthor=X.+Diauthor=J.+Caiauthor=J.+Maauthor=S.+Zhangauthor=X.+Sun&title=EEF2K+Promotes+Progression+and+Radioresistance+of+Esophageal+Squamous+Cell+Carcinoma&doi=10.1016%2Fj.radonc.2017.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma</span></div><div class="casAuthors">Zhu, Hongcheng; Song, Hongmei; Chen, Guangzong; Yang, Xi; Liu, Jia; Ge, Yangyang; Lu, Jing; Qin, Qin; Zhang, Chi; Xu, Liping; Di, Xiaoke; Cai, Jing; Ma, Jianxin; Zhang, Shu; Sun, Xinchen</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-447</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">To investigate the biol. function of eEF2K in esophageal squamous cell carcinoma (ESCC).Tissue microarrays contg. 100 pairs of ESCC tumor and adjacent normal tissues were completed.  Overexpression and knockdown of eEF2K were constructed in ECA-109 and TE-13 ESCC cells.  DNA damage, cell viability, migration and invasion, radioresistance, apoptosis and autophagy were detd. by immunofluorescence, CCK-8, transwell assay, colony formation assay, flow cytometry and western blot, resp.  Tumor growth and radioresistance were also evaluated using xenograft models created in nude mice.eEF2K expression was higher in ESCC tissues compared with matched non-tumor tissues (P < 0.05).  Proliferation was increased in eEF2K overexpressing cells compared with controls (P < 0.05), while silencing eEF2K reduced cell proliferation (P < 0.05).  Furthermore, lower levels of eEF2K expression correlated with slower migration and invasion rates (P < 0.05), while higher levels of eEF2K expression with faster migration and invasion rates (P < 0.05). eEF2K overexpression resulted in radioresistance and radiation-induced autophagy, and reduced radiation-induced apoptosis compared with controls, but silencing eEF2K promoted radiosensitivity and apoptosis, and reduced autophagy.  In addn., eEF2K overexpression promoted the tumor growth in vivo (P < 0.01).  Combined treatment of NH125 (a pharmacol. inhibitor of eEF2K) and radiation was more effective at delaying xenograft tumor growth than NH125 and radiation alone (P < 0.05).eEF2K induced progression and radioresistance in ESCC, which may be a novel therapeutic target for ESCC to increase radiosensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqreqW2KO6dgrVg90H21EOLACvtfcHk0lgwCArQS8NeGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVygt78%253D&md5=ef5b7c2873cf7ed430d51df652372963</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.radonc.2017.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.radonc.2017.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDi%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DX.%26atitle%3DEEF2K%2520Promotes%2520Progression%2520and%2520Radioresistance%2520of%2520Esophageal%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DRadiother.%2520Oncol.%26date%3D2017%26volume%3D124%26spage%3D439%26epage%3D447%26doi%3D10.1016%2Fj.radonc.2017.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashour, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbuz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpay, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, A. A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Elongation Factor-2 Kinase Regulates TG2/B1 Integrin/Src/UPAR Pathway and Epithelial-Mesenchymal Transition Mediating Pancreatic Cancer Cells Invasion</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2235</span>– <span class="NLM_lpage">2251</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1111%2Fjcmm.12361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25215932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCgsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=2235-2251&author=A.+A.+Ashourauthor=N.+Gurbuzauthor=S.+N.+Alpayauthor=A.+A.+H.+Abdel-Azizauthor=A.+M.+Mansourauthor=L.+Huoauthor=B.+Ozpolat&title=Elongation+Factor-2+Kinase+Regulates+TG2%2FB1+Integrin%2FSrc%2FUPAR+Pathway+and+Epithelial-Mesenchymal+Transition+Mediating+Pancreatic+Cancer+Cells+Invasion&doi=10.1111%2Fjcmm.12361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion</span></div><div class="casAuthors">Ashour, Ahmed A.; Gurbuz, Nilgun; Alpay, Sultan Neslihan; Abdel-Aziz, Abdel-Aziz H.; Mansour, Ahmed M.; Huo, Longfei; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2235-2251</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma is one of the lethal cancers with extensive local tumor invasion, metastasis, early systemic dissemination and poorest prognosis.  Thus, understanding the mechanisms regulating invasion/metastasis and epithelial-mesenchymal transition (EMT), is the key for developing effective therapeutic strategies for pancreatic cancer (PaCa).  Eukaryotic elongation factor-2 kinase (eEF-2K) is an atypical kinase that we found to be highly up-regulated in PaCa cells.  However, its role in PaCa invasion/progression remains unknown.  Here, we investigated the role of eEF-2K in cellular invasion, and we found that down-regulation of eEF-2K, by siRNA or rottlerin, displays impairment of PaCa cells invasion/migration, with significant decreases in the expression of tissue transglutaminase (TG2), the multifunctional enzyme implicated in regulation of cell attachment, motility and survival.  These events were assocd. with redns. in β1 integrin/uPAR/MMP-2 expressions as well as decrease in Src activity.  Furthermore, inhibition of eEF-2K/TG2 axis suppresses the EMT, as demonstrated by the modulation of the zinc finger transcription factors, ZEB1/Snail, and the tight junction proteins, claudins.  Importantly, while eEF-2K silencing recapitulates the rottlerin-induced inhibition of invasion and correlated events, eEF-2K overexpression, by lentivirus-based expression system, suppresses such rottlerin effects and potentiates PaCa cells invasion/migration capability.  Collectively, our results show, for the first time, that eEF-2K is involved in regulation of the invasive phenotype of PaCa cells through promoting a new signalling pathway, which is mediated by TG2/β1 integrin/Src/uPAR/MMP-2, and the induction of EMT biomarkers which enhance cancer cell motility and metastatic potential.  Thus, eEF-2K could represent a novel potential therapeutic target in pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVRwJEw_q7s7Vg90H21EOLACvtfcHk0lhQTeiFcWdQ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCgsbzE&md5=817f7237ec5e42fbe33902b406b9b6d4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12361%26sid%3Dliteratum%253Aachs%26aulast%3DAshour%26aufirst%3DA.%2BA.%26aulast%3DGurbuz%26aufirst%3DN.%26aulast%3DAlpay%26aufirst%3DS.%2BN.%26aulast%3DAbdel-Aziz%26aufirst%3DA.%2BA.%2BH.%26aulast%3DMansour%26aufirst%3DA.%2BM.%26aulast%3DHuo%26aufirst%3DL.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DElongation%2520Factor-2%2520Kinase%2520Regulates%2520TG2%252FB1%2520Integrin%252FSrc%252FUPAR%2520Pathway%2520and%2520Epithelial-Mesenchymal%2520Transition%2520Mediating%2520Pancreatic%2520Cancer%2520Cells%2520Invasion%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2014%26volume%3D18%26spage%3D2235%26epage%3D2251%26doi%3D10.1111%2Fjcmm.12361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span> <span> </span><span class="NLM_article-title">Adaptation to Starvation: Translating a Matter of Life or Death</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">715</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ccr.2013.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=23763997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFOmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=713-715&author=B.+D.+Manning&title=Adaptation+to+Starvation%3A+Translating+a+Matter+of+Life+or+Death&doi=10.1016%2Fj.ccr.2013.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptation to Starvation: Translating a Matter of Life or Death</span></div><div class="casAuthors">Manning, Brendan D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">713-715</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  There is much interest in defining the nutrient dependencies of cancer cells and their mechanisms of adaptation to nutrient depletion.  In a recent issue of Cell, Leprivier and colleagues demonstrate that eEF2K, which can inhibit translation elongation acutely during protein synthesis, is a crit. switch in the survival vs. death fate of starved cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq63wCC24n-LbVg90H21EOLACvtfcHk0lhQTeiFcWdQ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFOmt7w%253D&md5=1062f6473c546509da0cb11be7c1be71</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26atitle%3DAdaptation%2520to%2520Starvation%253A%2520Translating%2520a%2520Matter%2520of%2520Life%2520or%2520Death%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D713%26epage%3D715%26doi%3D10.1016%2Fj.ccr.2013.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Browne, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Stimulation of the AMP-Activated Protein Kinase Leads to Activation of Eukaryotic Elongation Factor 2 Kinase and to Its Phosphorylation at a Novel Site, Serine 398</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">12220</span>– <span class="NLM_lpage">12231</span>, <span class="refDoi"> DOI: 10.1074/jbc.M309773200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.M309773200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=14709557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitl2hu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=12220-12231&author=G.+J.+Browneauthor=S.+G.+Finnauthor=C.+G.+Proud&title=Stimulation+of+the+AMP-Activated+Protein+Kinase+Leads+to+Activation+of+Eukaryotic+Elongation+Factor+2+Kinase+and+to+Its+Phosphorylation+at+a+Novel+Site%2C+Serine+398&doi=10.1074%2Fjbc.M309773200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of the AMP-activated Protein Kinase Leads to Activation of Eukaryotic Elongation Factor 2 Kinase and to Its Phosphorylation at a Novel Site, Serine 398</span></div><div class="casAuthors">Browne, Gareth J.; Finn, Stephen G.; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">12220-12231</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein synthesis consumes a high proportion of the metabolic energy of mammalian cells, and most of this is used by peptide chain elongation.  An important regulator of energy supply and demand in eukaryotic cells is the AMP-activated protein kinase (AMPK).  The rate of peptide chain elongation can be modulated through the phosphorylation of eukaryotic elongation factor (eEF) 2, which inhibits its activity and is catalyzed by a specific calcium/calmodulin-dependent protein kinase termed eEF2 kinase.  Here the authors show that AMPK directly phosphorylates eEF2 kinase, and the authors identify the major site of phosphorylation as Ser-398 in a regulatory domain of eEF2 kinase.  AMPK also phosphorylates two other sites (Ser-78 and Ser-366) in eEF2 kinase in vitro.  The authors develop appropriate phosphospecific antisera and show that phosphorylation of Ser-398 in eEF2 kinase is enhanced in intact cells under a range of conditions that activate AMPK and increase the phosphorylation of eEF2.  Ser-78 and Ser-366 do not appear to be phosphorylated by AMPK within cells.  Although cardiomyocytes appear to contain a distinct isoform of eEF2 kinase, it also contains a site corresponding to Ser-398 that is phosphorylated by AMPK in vitro.  Stimuli that activate AMPK and increase eEF2 phosphorylation within cells increase the activity of eEF2 kinase.  Thus, AMPK and eEF2 kinase may provide a key link between cellular energy status and the inhibition of protein synthesis, a major consumer of metabolic energy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpmIy4X0YYjbVg90H21EOLACvtfcHk0lhQTeiFcWdQ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitl2hu7k%253D&md5=4860e96e2e335be247ad153b9af60d07</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M309773200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M309773200%26sid%3Dliteratum%253Aachs%26aulast%3DBrowne%26aufirst%3DG.%2BJ.%26aulast%3DFinn%26aufirst%3DS.%2BG.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DStimulation%2520of%2520the%2520AMP-Activated%2520Protein%2520Kinase%2520Leads%2520to%2520Activation%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520and%2520to%2520Its%2520Phosphorylation%2520at%2520a%2520Novel%2520Site%252C%2520Serine%2520398%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D12220%26epage%3D12231%26doi%3D10.1074%2Fjbc.M309773200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johanns, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyr dit Ruys, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houddane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertommen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herinckx, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rider, M. H.</span></span> <span> </span><span class="NLM_article-title">Direct and Indirect Activation of Eukaryotic Elongation Factor 2 Kinase by AMP-Activated Protein Kinase</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2017.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.cellsig.2017.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28502587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=212-221&author=M.+Johannsauthor=S.+Pyr+dit+Ruysauthor=A.+Houddaneauthor=D.+Vertommenauthor=G.+Herinckxauthor=L.+Hueauthor=C.+G.+Proudauthor=M.+H.+Rider&title=Direct+and+Indirect+Activation+of+Eukaryotic+Elongation+Factor+2+Kinase+by+AMP-Activated+Protein+Kinase&doi=10.1016%2Fj.cellsig.2017.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Direct and indirect activation of eukaryotic elongation factor 2 kinase by AMP-activated protein kinase</span></div><div class="casAuthors">Johanns, M.; Pyr dit Ruys, S.; Houddane, A.; Vertommen, D.; Herinckx, G.; Hue, L.; Proud, C. G.; Rider, M. H.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">212-221</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 (eEF2) kinase (eEF2K) is a key regulator of protein synthesis in mammalian cells.  It phosphorylates and inhibits eEF2, the translation factor necessary for peptide translocation during the elongation phase of protein synthesis.  When cellular energy demand outweighs energy supply, AMP-activated protein kinase (AMPK) and eEF2K become activated, leading to eEF2 phosphorylation, which reduces the rate of protein synthesis, a process that consumes a large proportion of cellular energy under optimal conditions.  The goal of the present study was to elucidate the mechanisms by which AMPK activation leads to increased eEF2 phosphorylation to decrease protein synthesis.  Using genetically modified mouse embryo fibroblasts (MEFs), effects of treatments with commonly used AMPK activators to increase eEF2 phosphorylation were compared with that of the novel compd. 991.  Bacterially expressed recombinant eEF2K was phosphorylated in vitro by recombinant activated AMPK for phosphorylation site-identification by mass spectrometry followed by site-directed mutagenesis of the identified sites to alanine residues to study effects on the kinetic properties of eEF2K.  Wild-type eEF2K and a Ser491/Ser492 mutant were retrovirally re-introduced in eEF2K-deficient MEFs and effects of 991 treatment on eEF2 phosphorylation and protein synthesis rates were studied in these cells.  AMPK activation leads to increased eEF2 phosphorylation in MEFs mainly by direct activation of eEF2K and partly by inhibition of mammalian target of rapamycin complex 1 (mTORC1) signaling.  Treatment of MEFs with AMPK activators can also lead to eEF2K activation independently of AMPK probably via a rise in intracellular Ca2+.  AMPK activates eEF2K by multi-site phosphorylation and the newly identified Ser491/Ser492 is important for activation, leading to mTOR-independent inhibition of protein synthesis.  Our study provides new insights into the control of eEF2K by AMPK, with implications for linking metabolic stress to decreased protein synthesis to conserve energy reserves, a pathway that is of major importance in cancer cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSUtKY-XXPX7Vg90H21EOLACvtfcHk0ljn-RaUHe9FDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGms74%253D&md5=8e6e849a6e25fbf3a10f55de41016222</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2017.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2017.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DJohanns%26aufirst%3DM.%26aulast%3DPyr%2Bdit%2BRuys%26aufirst%3DS.%26aulast%3DHouddane%26aufirst%3DA.%26aulast%3DVertommen%26aufirst%3DD.%26aulast%3DHerinckx%26aufirst%3DG.%26aulast%3DHue%26aufirst%3DL.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DRider%26aufirst%3DM.%2BH.%26atitle%3DDirect%2520and%2520Indirect%2520Activation%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520by%2520AMP-Activated%2520Protein%2520Kinase%26jtitle%3DCell.%2520Signalling%26date%3D2017%26volume%3D36%26spage%3D212%26epage%3D221%26doi%3D10.1016%2Fj.cellsig.2017.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerken, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbein, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czernin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, R. J.</span></span> <span> </span><span class="NLM_article-title">LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ccr.2012.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=23352126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=143-158&author=D.+B.+Shackelfordauthor=E.+Abtauthor=L.+Gerkenauthor=D.+S.+Vasquezauthor=A.+Sekiauthor=M.+Leblancauthor=L.+Weiauthor=M.+C.+Fishbeinauthor=J.+Czerninauthor=P.+S.+Mischelauthor=R.+J.+Shaw&title=LKB1+Inactivation+Dictates+Therapeutic+Response+of+Non-Small+Cell+Lung+Cancer+to+the+Metabolism+Drug+Phenformin&doi=10.1016%2Fj.ccr.2012.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin</span></div><div class="casAuthors">Shackelford, David B.; Abt, Evan; Gerken, Laurie; Vasquez, Debbie S.; Seki, Atsuko; Leblanc, Mathias; Wei, Liu; Fishbein, Michael C.; Czernin, Johannes; Mischel, Paul S.; Shaw, Reuben J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-158</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in ∼20% of non-small cell lung cancers (NSCLC).  LKB1 is the major upstream kinase activating the energy-sensing kinase AMPK, making LKB1-deficient cells unable to appropriately sense metabolic stress.  We tested the therapeutic potential of metabolic drugs in NSCLC and identified phenformin, a mitochondrial inhibitor and analog of the diabetes therapeutic metformin, as selectively inducing apoptosis in LKB1-deficient NSCLC cells.  Therapeutic trials in Kras-dependent mouse models of NSCLC revealed that tumors with Kras and Lkb1 mutations, but not those with Kras and p53 mutations, showed selective response to phenformin as a single agent, resulting in prolonged survival.  This study suggests phenformin as a cancer metab.-based therapeutic to selectively target LKB1-deficient tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFxHW2QvmnVbVg90H21EOLACvtfcHk0ljn-RaUHe9FDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGitro%253D&md5=42f9e3b69b797a3bcfe73eb5392b6298</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DShackelford%26aufirst%3DD.%2BB.%26aulast%3DAbt%26aufirst%3DE.%26aulast%3DGerken%26aufirst%3DL.%26aulast%3DVasquez%26aufirst%3DD.%2BS.%26aulast%3DSeki%26aufirst%3DA.%26aulast%3DLeblanc%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DFishbein%26aufirst%3DM.%2BC.%26aulast%3DCzernin%26aufirst%3DJ.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DShaw%26aufirst%3DR.%2BJ.%26atitle%3DLKB1%2520Inactivation%2520Dictates%2520Therapeutic%2520Response%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520to%2520the%2520Metabolism%2520Drug%2520Phenformin%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D143%26epage%3D158%26doi%3D10.1016%2Fj.ccr.2012.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Signalling to Translation: How Signal Transduction Pathways Control the Protein Synthetic Machinery</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>403</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1042/BJ20070024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1042%2FBJ20070024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=17376031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=403&publication_year=2007&pages=217-234&author=C.+G.+Proud&title=Signalling+to+Translation%3A+How+Signal+Transduction+Pathways+Control+the+Protein+Synthetic+Machinery&doi=10.1042%2FBJ20070024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling to translation: how signal transduction pathways control the protein synthetic machinery</span></div><div class="casAuthors">Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">403</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-234</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent advances in our understanding of both the regulation of components of the translational machinery and the upstream signalling pathways that modulate them have provided important new insights into the mechanisms by which hormones, growth factors, nutrients and cellular energy status control protein synthesis in mammalian cells.  The importance of proper control of mRNA translation is strikingly illustrated by the fact that defects in this process or its control are implicated in a no. of disease states, such as cancer, tissue hypertrophy and neurodegeneration.  Signalling pathways such as those involving mTOR (mammalian target of rapamycin) and mitogen-activated protein kinases modulate the phosphorylation of translation factors, the activities of the protein kinases that act upon them and the assocn. of RNA-binding proteins with specific mRNAs.  These effects contribute both to the overall control of protein synthesis (which is linked to cell growth) and to the modulation of the translation or stability of specific mRNAs.  However, important questions remain about both the contributions of individual regulatory events to the control of general protein synthesis and the mechanisms by which the translation of specific mRNAs is controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprRqs7aO9DL7Vg90H21EOLACvtfcHk0ljn-RaUHe9FDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWrtrg%253D&md5=234023d8d36d6bd7b55d8268ca55a56b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1042%2FBJ20070024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070024%26sid%3Dliteratum%253Aachs%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DSignalling%2520to%2520Translation%253A%2520How%2520Signal%2520Transduction%2520Pathways%2520Control%2520the%2520Protein%2520Synthetic%2520Machinery%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D403%26spage%3D217%26epage%3D234%26doi%3D10.1042%2FBJ20070024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span> <span> </span><span class="NLM_article-title">Methylseleninic Acid Elevates REDD1 and Inhibits Prostate Cancer Cell Growth despite AKT Activation and MTOR Dysregulation in Hypoxia</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1002/cam4.198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1002%2Fcam4.198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24515947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFyhurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=252-264&author=I.+Sinhaauthor=J.+E.+Allenauthor=J.+T.+Pintoauthor=R.+Sinha&title=Methylseleninic+Acid+Elevates+REDD1+and+Inhibits+Prostate+Cancer+Cell+Growth+despite+AKT+Activation+and+MTOR+Dysregulation+in+Hypoxia&doi=10.1002%2Fcam4.198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia</span></div><div class="casAuthors">Sinha, Indu; Allen, Joshua E.; Pinto, John T.; Sinha, Raghu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">252-264</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Methylseleninic acid (MSeA) is a monomethylated selenium metabolite theor. derived from subsequent β-lyase or transamination reactions of dietary Se-methylselenocysteine that has potent antitumor activity by inhibiting cell proliferation of several cancers.  Our previous studies showed that MSeA promotes apoptosis in invasive prostate cancer cells in part by downregulating hypoxia-inducible factor HIF-1α.  We have now extended these studies to evaluate the impact of MSeA on REDD1 (an mTOR inhibitor) in inducing cell death of invasive prostate cancer cells in hypoxia.  In both PTEN+ and PTEN- prostate cancer cells we show that MSeA elevates REDD1 and phosphorylation of AKT along with p70S6K in hypoxia.  Furthermore, REDD1 induction by MSeA is independent of AKT and the mTOR inhibition in prostate cancer cells causes partial resistance to MSeA-induced growth redn. in hypoxia.  Our data suggest that MSeA induces REDD1 and inhibits prostate cancer cell growth in hypoxia despite activation of AKT and dysregulation of mTOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtsaAeKEa6v7Vg90H21EOLACvtfcHk0lhCZPvVtUvcOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFyhurY%253D&md5=7e4715db199787b144eb9cf72cf8b304</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fcam4.198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.198%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DI.%26aulast%3DAllen%26aufirst%3DJ.%2BE.%26aulast%3DPinto%26aufirst%3DJ.%2BT.%26aulast%3DSinha%26aufirst%3DR.%26atitle%3DMethylseleninic%2520Acid%2520Elevates%2520REDD1%2520and%2520Inhibits%2520Prostate%2520Cancer%2520Cell%2520Growth%2520despite%2520AKT%2520Activation%2520and%2520MTOR%2520Dysregulation%2520in%2520Hypoxia%26jtitle%3DCancer%2520Med.%26date%3D2014%26volume%3D3%26spage%3D252%26epage%3D264%26doi%3D10.1002%2Fcam4.198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-0419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F1078-0432.CCR-17-0419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29084921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=445-459&author=Q.+Zengauthor=J.+Liuauthor=P.+Caoauthor=J.+Liauthor=X.+Liuauthor=X.+Fanauthor=L.+Liuauthor=Y.+Chengauthor=W.+Xiongauthor=J.+Liauthor=H.+Boauthor=Y.+Zhuauthor=F.+Yangauthor=J.+Huauthor=M.+Zhouauthor=Y.+Zhouauthor=Q.+Zouauthor=J.+Zhouauthor=K.+Cao&title=Inhibition+of+REDD1+Sensitizes+Bladder+Urothelial+Carcinoma+to+Paclitaxel+by+Inhibiting+Autophagy&doi=10.1158%2F1078-0432.CCR-17-0419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy</span></div><div class="casAuthors">Zeng, Qinghai; Liu, Jianye; Cao, Peiguo; Li, Jingjing; Liu, Xiaoming; Fan, Xiaojun; Liu, Ling; Cheng, Yan; Xiong, Wei; Li, Jigang; Bo, Hao; Zhu, Yuxing; Yang, Fei; Hu, Jun; Zhou, Ming; Zhou, Yanhong; Zou, Qiong; Zhou, Jianda; Cao, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">445-459</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Regulated in development and DNA damage response-1 (REDD1) is a stress-related protein and is involved in the progression of cancer.  The role and regulatory mechanism of REDD1 in bladder urothelial carcinoma (BUC), however, is yet unidentified.  Exptl. Design: The expression of REDD1 in BUC was detected by Western blot anal. and immunohistochem. (IHC).  The correlation between REDD1 expression and clin. features in patients with BUC were assessed.  The effects of REDD1 on cellular proliferation, apoptosis, autophagy, and paclitaxel sensitivity were detd. both in vitro and in vivo.  Then the targeted-regulating mechanism of REDD1 by miRNAs was explored.  Results: Here the significant increase of REDD1 expression is detected in BUC tissue, and REDD1 is first reported as an independent prognostic factor in patients with BUC.  Silencing REDD1 expression in T24 and EJ cells decreased cell proliferation, increased apoptosis, and decreased autophagy, whereas the ectopic expression of REDD1 in RT4 and BIU87 cells had the opposite effect.  In addn., the REDD1-mediated proliferation, apoptosis, and autophagy are found to be neg. regulated by miR-22 in vitro, which intensify the paclitaxel sensitivity via inhibition of the well-acknowledged REDD1-EEF2K-autophagy axis.  AKT/mTOR signaling initially activated or inhibited in response to silencing or enhancing REDD1 expression and then recovered rapidly.  Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a s.c. transplant carcinoma model in vivo.  Conclusions: REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel.  Clin Cancer Res; 24(2); 445-59. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLgP6n1ilj0rVg90H21EOLACvtfcHk0lhCZPvVtUvcOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslGitQ%253D%253D&md5=41195e1c0b00c042bfaaddf6fb1e9a00</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-0419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-0419%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBo%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520REDD1%2520Sensitizes%2520Bladder%2520Urothelial%2520Carcinoma%2520to%2520Paclitaxel%2520by%2520Inhibiting%2520Autophagy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D445%26epage%3D459%26doi%3D10.1158%2F1078-0432.CCR-17-0419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tekedereli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpay, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, C. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobanoglu, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaoud, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e41171</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0041171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1371%2Fjournal.pone.0041171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=22911754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSkt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e41171&author=I.+Tekedereliauthor=S.+N.+Alpayauthor=C.+D.+J.+Tavaresauthor=Z.+E.+Cobanogluauthor=T.+S.+Kaoudauthor=I.+Sahinauthor=A.+K.+Soodauthor=G.+Lopez-Beresteinauthor=K.+N.+Dalbyauthor=B.+Ozpolat&title=Targeted+Silencing+of+Elongation+Factor+2+Kinase+Suppresses+Growth+and+Sensitizes+Tumors+to+Doxorubicin+in+an+Orthotopic+Model+of+Breast+Cancer&doi=10.1371%2Fjournal.pone.0041171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer</span></div><div class="casAuthors">Tekedereli, Ibrahim; Alpay, S. Neslihan; Tavares, Clint D. J.; Cobanoglu, Zehra E.; Kaoud, Tamer S.; Sahin, Ibrahim; Sood, Anil K.; Lopez-Berestein, Gabriel; Dalby, Kevin N.; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e41171</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF-2K), through its phosphorylation of elongation factor 2 (eEF2), provides a mechanism by which cells can control the rate of the elongation phase of protein synthesis.  The activity of eEF-2K is increased in rapidly proliferating malignant cells, is inhibited during mitosis, and may contribute to the promotion of autophagy in response to anti-cancer therapies.  The purpose of this study was to examine the therapeutic potential of targeting eEF-2K in breast cancer tumors.  Through the systemic administration of liposomal eEF-2K siRNA (twice a week, i.v. 150 μg/kg), the expression of eEF-2K was down-regulated in vivo in an orthotopic xenograft mouse model of a highly aggressive triple neg. MDA-MB-231 tumor.  This targeting resulted in a substantial decrease in eEF2 phosphorylation in the tumors, and led to the inhibition of tumor growth, the induction of apoptosis and the sensitization of tumors to the chemotherapy agent doxorubicin.  EEF-2K down-modulation in vitro resulted in a decrease in the expression of c-Myc and cyclin D1 with a concomitant increase in the expression of p27Kip1.  A decrease in the basal activity of c-Src (phospho-Tyr-416), focal adhesion kinase (phospho-Tyr-397), and Akt (phospho-Ser-473) was also detected following eEF-2K down-regulation in MDA-MB-231 cells, as detd. by Western blotting.  Where tested, similar results were seen in ER-pos. MCF-7 cells.  These effects were also accompanied by a decrease in the obsd. invasive phenotype of the MDA-MB-231 cells.  These data support the notion that the disruption of eEF-2K expression in breast cancer cells results in the down-regulation of signaling pathways affecting growth, survival and resistance and has potential as a therapeutic approach for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOuuDE83QkhrVg90H21EOLACvtfcHk0lhCZPvVtUvcOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSkt73P&md5=e1966dce4ec43a5fb26998653af4aaa6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0041171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0041171%26sid%3Dliteratum%253Aachs%26aulast%3DTekedereli%26aufirst%3DI.%26aulast%3DAlpay%26aufirst%3DS.%2BN.%26aulast%3DTavares%26aufirst%3DC.%2BD.%2BJ.%26aulast%3DCobanoglu%26aufirst%3DZ.%2BE.%26aulast%3DKaoud%26aufirst%3DT.%2BS.%26aulast%3DSahin%26aufirst%3DI.%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DTargeted%2520Silencing%2520of%2520Elongation%2520Factor%25202%2520Kinase%2520Suppresses%2520Growth%2520and%2520Sensitizes%2520Tumors%2520to%2520Doxorubicin%2520in%2520an%2520Orthotopic%2520Model%2520of%2520Breast%2520Cancer%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De41171%26doi%3D10.1371%2Fjournal.pone.0041171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span> <span> </span><span class="NLM_article-title">EEF-2 Kinase: Another Meddler in the “Yin and Yang” of Akt-Mediated Cell Fate?</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.4161/auto.7.6.15385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.4161%2Fauto.7.6.15385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=21460616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1ymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=660-661&author=Y.+Chengauthor=L.+Yanauthor=X.+Renauthor=J.+M.+Yang&title=EEF-2+Kinase%3A+Another+Meddler+in+the+%E2%80%9CYin+and+Yang%E2%80%9D+of+Akt-Mediated+Cell+Fate%3F&doi=10.4161%2Fauto.7.6.15385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">eEF-2 kinase: Another meddler in the yin and yang of Akt-mediated cell fate?</span></div><div class="casAuthors">Cheng, Yan; Yan, Li; Ren, Xingcong; Yang, Jin-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">660-661</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Eukaryotic elongation factor-2 (eEF-2) kinase, also known as calmodulin-dependent protein kinase III, is a unique calcium/calmodulin-dependent enzyme.  EEF-2 kinase can act as a neg. regulator of protein synthesis and a pos. regulator of autophagy under environmental or metabolic stresses.  Akt, a key downstream effector of the PI3K signaling pathway that regulates cell survival and proliferation, is an attractive therapeutic target for anticancer treatment.  Akt inhibition leads to activation of both apoptosis, type I programmed cell death and autophagy, a cellular degrdn. process via lysosomal machinery (also termed type II programmed cell death).  However, the underlying mechanisms that dictate functional relationship between autophagy and apoptosis in response to Akt inhibition remain to be delineated.  Our recent study demonstrated that inhibition of eEF-2 kinase can suppress autophagy but promote apoptosis in tumor cells subjected to Akt inhibition, indicating a role of eEF-2 kinase as a controller in the crosstalk between autophagy and apoptosis.  Furthermore, inhibition of eEF-2 kinase can reinforce the efficacy of a novel Akt inhibitor, MK-2206, against human glioma.  These findings may help optimize the use of Akt inhibitors in the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ERIa08yUVrVg90H21EOLACvtfcHk0lhzOKSXuZNxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1ymtw%253D%253D&md5=c19bea03bc74fe5368d633bec7e00ed9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4161%2Fauto.7.6.15385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.7.6.15385%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26atitle%3DEEF-2%2520Kinase%253A%2520Another%2520Meddler%2520in%2520the%2520%25E2%2580%259CYin%2520and%2520Yang%25E2%2580%259D%2520of%2520Akt-Mediated%2520Cell%2520Fate%253F%26jtitle%3DAutophagy%26date%3D2011%26volume%3D7%26spage%3D660%26epage%3D661%26doi%3D10.4161%2Fauto.7.6.15385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span> <span> </span><span class="NLM_article-title">FoxM1: A Master Regulator of Tumor Metastasis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4329</span>– <span class="NLM_lpage">4333</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-0640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F0008-5472.CAN-11-0640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=21712406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4329-4333&author=P.+Raychaudhuriauthor=H.+J.+Park&title=FoxM1%3A+A+Master+Regulator+of+Tumor+Metastasis&doi=10.1158%2F0008-5472.CAN-11-0640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FoxM1: A Master Regulator of Tumor Metastasis</span></div><div class="casAuthors">Raychaudhuri, Pradip; Park, Hyun Jung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4329-4333</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The FoxM1 transcription factor gene is overexpressed in cancer.  Its expression is stimulated by oncogenic signaling pathways and reactive oxygen species.  It is also a target of regulation by the tumor suppressor genes.  The transcriptional activity of FoxM1 depends upon activation by cyclin and cyclin-dependent kinases as well as Plk1.  FoxM1 stimulates expression of several genes involved in the cell cycle progression.  Moreover, it supports proliferation of tumor cells by stimulating expression of the antioxidant genes and reducing oxidative stress.  A new study provides evidence that FoxM1, in the absence of its inhibitor, the tumor suppressor Arf, drives metastasis of hepatocellular carcinoma (HCC).  It induces an epithelial-mesenchymal-like transition phenotype in HCC cells, increases cell migration, and induces premetastatic niche at the distal organ of metastasis.  FoxM1 directly activates genes involved in multiple steps of metastasis.  In this review, the authors discuss the evidence for a master regulatory role of FoxM1 in tumor metastasis.  Cancer Res; 71(13); 4329-33.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaeWChChl5hrVg90H21EOLACvtfcHk0lhzOKSXuZNxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersL4%253D&md5=7230f9e5cef8374fdbc1e93138767c1f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-0640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-0640%26sid%3Dliteratum%253Aachs%26aulast%3DRaychaudhuri%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26atitle%3DFoxM1%253A%2520A%2520Master%2520Regulator%2520of%2520Tumor%2520Metastasis%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4329%26epage%3D4333%26doi%3D10.1158%2F0008-5472.CAN-11-0640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupczak-Hollis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennewitz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adami, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, R. H.</span></span> <span> </span><span class="NLM_article-title">Increased Hepatic Forkhead Box M1B (FoxM1B) Levels in Old-Aged Mice Stimulated Liver Regeneration through Diminished P27Kip1 Protein Levels and Increased Cdc25B Expression</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">44310</span>– <span class="NLM_lpage">44316</span>, <span class="refDoi"> DOI: 10.1074/jbc.M207510200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.M207510200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=12221098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1aktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=44310-44316&author=X.+Wangauthor=K.+Krupczak-Hollisauthor=Y.+Tanauthor=M.+B.+Dennewitzauthor=G.+R.+Adamiauthor=R.+H.+Costa&title=Increased+Hepatic+Forkhead+Box+M1B+%28FoxM1B%29+Levels+in+Old-Aged+Mice+Stimulated+Liver+Regeneration+through+Diminished+P27Kip1+Protein+Levels+and+Increased+Cdc25B+Expression&doi=10.1074%2Fjbc.M207510200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Hepatic Forkhead Box M1B (FoxM1B) Levels in Old-aged Mice Stimulated Liver Regeneration through Diminished p27Kip1 Protein Levels and Increased Cdc25B Expression</span></div><div class="casAuthors">Wang, Xinhe; Krupczak-Hollis, Katherine; Tan, Yongjun; Dennewitz, Margaret B.; Adami, Guy R.; Costa, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">44310-44316</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Recent liver regeneration studies indicate that maintaining hepatic Forkhead Box M1B (FoxM1B) expression in 12-mo-old (old-aged) Transthyretin-FoxM1B transgenic mice increases hepatocyte proliferation and expression of cell cycle regulatory genes.  Because these transgenic CD-1 mice maintain FoxM1B levels during the aging process, we conducted the current study to det. whether adenovirus delivery of the FoxM1B gene (AdFoxM1B) is sufficient to stimulate liver regeneration in old-aged Balb/c mice.  Here we show that AdFoxM1B infection of old-aged mice caused a significant increase in FoxM1B expression, hepatocyte DNA replication, and mitosis following partial hepatectomy.  This stimulation in hepatocyte S-phase progression was assocd. with diminished protein expression and perinuclear localization of cyclin-dependent kinase (Cdk) inhibitor p27Kip1 (p27) protein following partial hepatectomy.  In contrast, old-aged mice infected with control virus displayed high hepatocyte levels of p27 protein, which had been localized to the nucleus prior to S-phase.  Furthermore, we found that restoring FoxM1B expression did not influence p27 mRNA levels, and this new finding implicates FoxM1B in regulation of p27 protein levels.  Likewise, AdFoxM1B-infected regenerating livers displayed elevated S-phase levels of Cdk2 kinase activity compared with old-aged mice infected with control virus.  Furthermore, restoring FoxM1B expression in old-aged mice caused elevated levels of Cyclin B1, Cyclin B2, Cdc25B, Cdk1, and p55CDC mRNA as well as stimulating Cdc25B nuclear localization during liver regeneration, all of which are required for mitosis.  These studies indicated that an acute delivery of the FoxM1B gene in old-aged mice is sufficient to re-establish proliferation of regenerating hepatocytes, suggesting that FoxM1B can be used for therapeutic intervention to alleviate the redn. in cellular proliferation obsd. in the elderly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpof6jVzwCPnLVg90H21EOLACvtfcHk0lhzOKSXuZNxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1aktL4%253D&md5=75897091171110f57381f42608e4932f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207510200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207510200%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKrupczak-Hollis%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DDennewitz%26aufirst%3DM.%2BB.%26aulast%3DAdami%26aufirst%3DG.%2BR.%26aulast%3DCosta%26aufirst%3DR.%2BH.%26atitle%3DIncreased%2520Hepatic%2520Forkhead%2520Box%2520M1B%2520%2528FoxM1B%2529%2520Levels%2520in%2520Old-Aged%2520Mice%2520Stimulated%2520Liver%2520Regeneration%2520through%2520Diminished%2520P27Kip1%2520Protein%2520Levels%2520and%2520Increased%2520Cdc25B%2520Expression%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D44310%26epage%3D44316%26doi%3D10.1074%2Fjbc.M207510200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamurcu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">FOXM1 Regulates Expression of Eukaryotic Elongation Factor 2 Kinase and Promotes Proliferation, Invasion and Tumorgenesis of Human Triple Negative Breast Cancer Cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">16619</span>– <span class="NLM_lpage">16635</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.18632%2Foncotarget.7672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=26918606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A280%3ADC%252BC28jks1ehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=16619-16635&author=Z.+Hamurcuauthor=A.+Ashourauthor=N.+Kahramanauthor=B.+Ozpolat&title=FOXM1+Regulates+Expression+of+Eukaryotic+Elongation+Factor+2+Kinase+and+Promotes+Proliferation%2C+Invasion+and+Tumorgenesis+of+Human+Triple+Negative+Breast+Cancer+Cells&doi=10.18632%2Foncotarget.7672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells</span></div><div class="casAuthors">Hamurcu Zuhal; Ashour Ahmed; Kahraman Nermin; Ozpolat Bulent; Hamurcu Zuhal; Hamurcu Zuhal; Ozpolat Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">16619-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K), an emerging molecular target for cancer therapy, contributes to cancer proliferation, cell survival, tumorigenesis, and invasion, disease progression and drug resistance.  Although eEF2K is highly up-regulated in various cancers, the mechanism of gene regulation has not been elucidated.  In this study, we examined the role of Forkhead Box M1 (FOXM1) proto-oncogenic transcription factor in triple negative breast cancer (TNBC) cells and the regulation of eEF2K.  We found that FOXM1 is highly upregulated in TNBC and its knockdown by RNA interference (siRNA) significantly inhibited eEF2K expression and suppressed cell proliferation, colony formation, migration, invasion and induced apoptotic cell death, recapitulating the effects of eEF2K inhibition.  Knockdown of FOXM1 inhibited regulators of cell cycle, migration/invasion and survival, including cyclin D1, Src and MAPK-ERK signaling pathways, respectively.  We also demonstrated that FOXM1 (1B and 1C isoforms) directly binds to and transcriptionally regulates eEF2K gene expression by chromatin immunoprecipitation (ChIP) and luciferase gene reporter assays.  Furthermore, in vivo inhibition of FOXM1 by liposomal siRNA-nanoparticles suppressed growth of MDA-MB-231 TNBC tumor xenografts in orthotopic models.  In conclusion, our study provides the first evidence about the transcriptional regulation of eEF2K in TNBC and the role of FOXM1 in mediating breast cancer cell proliferation, survival, migration/invasion, progression and tumorgenesis and highlighting the potential of FOXM1/eEF2K axis as a molecular target in breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnE1pTgfQWEySm0e6ZOaemfW6udTcc2eZWlHso4bSUK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jks1ehuw%253D%253D&md5=01078417f171868a3f71be29a9fcca60</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7672%26sid%3Dliteratum%253Aachs%26aulast%3DHamurcu%26aufirst%3DZ.%26aulast%3DAshour%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DFOXM1%2520Regulates%2520Expression%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520and%2520Promotes%2520Proliferation%252C%2520Invasion%2520and%2520Tumorgenesis%2520of%2520Human%2520Triple%2520Negative%2520Breast%2520Cancer%2520Cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D16619%26epage%3D16635%26doi%3D10.18632%2Foncotarget.7672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanlikilicer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhlis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Aguayo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Dual Suppressive Effect of MiR-34A on the FOXM1/EEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4225</span>– <span class="NLM_lpage">4241</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F1078-0432.CCR-17-1959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29748184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVahs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4225-4241&author=R.+Bayraktarauthor=C.+Ivanauthor=E.+Bayraktarauthor=P.+Kanlikilicerauthor=N.+N.+Kabilauthor=N.+Kahramanauthor=H.+A.+Mokhlisauthor=D.+Karakasauthor=C.+Rodriguez-Aguayoauthor=A.+Arslanauthor=J.+Shengauthor=S.+Wongauthor=G.+Lopez-Beresteinauthor=G.+A.+Calinauthor=B.+Ozpolat&title=Dual+Suppressive+Effect+of+MiR-34A+on+the+FOXM1%2FEEF2-Kinase+Axis+Regulates+Triple-Negative+Breast+Cancer+Growth+and+Invasion&doi=10.1158%2F1078-0432.CCR-17-1959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Dual suppressive effect of miR-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion</span></div><div class="casAuthors">Bayraktar, Recep; Ivan, Cristina; Bayraktar, Emine; Kanlikilicer, Pinar; Kabil, Nashwa N.; Kahraman, Nermin; Mokhlis, Hamada A.; Karakas, Didem; Rodriguez-Aguayo, Cristian; Arslan, Ahmet; Sheng, Jianting; Wong, Stephen; Lopez-Berestein, Gabriel; Calin, George A.; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4225-4241</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent studies indicated that dysregulation of noncoding RNAs (ncRNA) such as miRNAs is involved in pathogenesis of various human cancers.  However, the mol. mechanisms underlying miR-34a are not fully understood in triple-neg. breast cancer (TNBC).  We performed in vitro functional assays on TNBC cell lines to investigate the role of miR-34a in FOXM1/eEF2K signaling axis.  TNBC tumor xenograft models were used for in vivo therapeutic delivery of miR-34a.  In this study, we investigated the role of p53-driven ncRNA miR-34a and found that miR-34a is assocd. with significantly longer patient survival in TNBC and inversely correlated with levels of proto-oncogenic eEF2K, which was assocd. with significantly shorter overall patient survival.  We showed that miR-34a directly binds to the 3'-untranslated region of eEF2K and FOXM1 mRNAs and suppresses their expression, leading to inhibition of TNBC cell proliferation, motility, and invasion.  Notably, restoring miR-34a expression recapitulated the effects of inhibition of eEF2K and FOXM1, the transcription factor for eEF2K and the direct target of p53, in TNBC cell lines, whereas overexpression of eEF2K and FOXM1 rescued the effects and signaling pathways mediated by miR-34a.  Moreover, in vivo therapeutic delivery of miR-34a nanoparticles by systemic i.v. administration delayed tumor growth of two different orthotopic TNBC tumor xenograft models by inhibiting eEF2K and FOXM1, intratumoral proliferation and angiogenesis, and inducing apoptosis.  Overall, our findings provide new insights into the tumor suppressor role of miR-34a by dual-targeting of FOXM1/eEF2K signaling axis and suggest that miR-34a-based gene therapy may be a potential therapeutic strategy in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxfq_aB9mBmLVg90H21EOLACvtfcHk0ljn14JMBOH9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVahs7Y%253D&md5=12d48c9e740094b5dc49fccffa995349</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1959%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DKanlikilicer%26aufirst%3DP.%26aulast%3DKabil%26aufirst%3DN.%2BN.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DMokhlis%26aufirst%3DH.%2BA.%26aulast%3DKarakas%26aufirst%3DD.%26aulast%3DRodriguez-Aguayo%26aufirst%3DC.%26aulast%3DArslan%26aufirst%3DA.%26aulast%3DSheng%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DCalin%26aufirst%3DG.%2BA.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DDual%2520Suppressive%2520Effect%2520of%2520MiR-34A%2520on%2520the%2520FOXM1%252FEEF2-Kinase%2520Axis%2520Regulates%2520Triple-Negative%2520Breast%2520Cancer%2520Growth%2520and%2520Invasion%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D4225%26epage%3D4241%26doi%3D10.1158%2F1078-0432.CCR-17-1959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vicent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Picazo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Corchón, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Algarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montuenga, L. M.</span></span> <span> </span><span class="NLM_article-title">ERK 1/2 Is Activated in Non-Small-Cell Lung Cancer and Associated with Advanced Tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1052</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fsj.bjc.6601644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=14997206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslWrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=1047-1052&author=S.+Vicentauthor=J.+M.+L%C3%B3pez-Picazoauthor=G.+Toledoauthor=M.+D.+Lozanoauthor=W.+Torreauthor=C.+Garcia-Corch%C3%B3nauthor=C.+Queroauthor=J.+C.+Soriaauthor=S.+Mart%C3%ADn-Algarraauthor=R.+G.+Manzanoauthor=L.+M.+Montuenga&title=ERK+1%2F2+Is+Activated+in+Non-Small-Cell+Lung+Cancer+and+Associated+with+Advanced+Tumours&doi=10.1038%2Fsj.bjc.6601644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours</span></div><div class="casAuthors">Vicent, S.; Lopez-Picazo, J. M.; Toledo, G.; Lozano, M. D.; Torre, W.; Garcia-Corchon, C.; Quero, C.; Soria, J-C.; Martin-Algarra, S.; Manzano, R. G.; Montuenga, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1047-1052</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the ERK1/2 pathway is involved in malignant transformation both in vitro and in vivo.  Little is known about the role of activated ERK1/2 in non-small cell lung cancer (NSCLC).  The purpose of this study was to characterize the extent of the activation of ERK1/2 by immunohistochem. in patients with NSCLC, and to det. the relationship of ERK1/2 activation with clinicopathol. variables.  Specimens from 111 patients with NSCLC (stages I-IV) were stained for P-ERK.  Staining for epidermal growth factor receptor (EGFR) and Ki-67 was also performed.  In all, 34% of the tumor specimens showed activation for ERK1/2, while normal lung epithelial tissue was consistently neg.  There was a strong statistical correlation between nuclear and cytoplasmic P-ERK staining and advanced stages (P<0.05 and P<0.001, resp.), metastatic hilar or mediastinal lymph nodes (P<0.01, P<0.001), and higher T stages (P<0.01, P<0.001).  We did not find correlation of nuclear or cytoplasmic P-ERK staining with either EGFR expression or Ki-67 expression.  Total ERK1/2 expression was evaluated with a specific ERK1/2 antibody and showed that P-ERK staining was not due to ERK overexpression but rather to hyperactivation of ERK1/2.  Patients with a pos. P-ERK cytoplasmic staining had a significant lower survival (P<0.05).  However, multivariate anal. did not show significant survival difference.  Our study indicates that nuclear and cytoplasmic ERK1/2 activation pos. correlates with stage, T and lymph node metastases, and thus, is assocd. with advanced and aggressive NSCLC tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDzCC8cfDByrVg90H21EOLACvtfcHk0ljn14JMBOH9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslWrsbw%253D&md5=62ddfb9aadeb5d8d7086f6eb7cf0656b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601644%26sid%3Dliteratum%253Aachs%26aulast%3DVicent%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez-Picazo%26aufirst%3DJ.%2BM.%26aulast%3DToledo%26aufirst%3DG.%26aulast%3DLozano%26aufirst%3DM.%2BD.%26aulast%3DTorre%26aufirst%3DW.%26aulast%3DGarcia-Corch%25C3%25B3n%26aufirst%3DC.%26aulast%3DQuero%26aufirst%3DC.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DManzano%26aufirst%3DR.%2BG.%26aulast%3DMontuenga%26aufirst%3DL.%2BM.%26atitle%3DERK%25201%252F2%2520Is%2520Activated%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%2520and%2520Associated%2520with%2520Advanced%2520Tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26spage%3D1047%26epage%3D1052%26doi%3D10.1038%2Fsj.bjc.6601644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bircan, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbuz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pataer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdogan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Elongation Factor-2 Kinase (EEF-2K) Expression Is Associated with Poor Patient Survival and Promotes Proliferation, Invasion and Tumor Growth of Lung Cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.07.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.lungcan.2018.07.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30268477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A280%3ADC%252BB3czktV2luw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=31-39&author=H.+A.+Bircanauthor=N.+Gurbuzauthor=A.+Pataerauthor=A.+Canerauthor=N.+Kahramanauthor=E.+Bayraktarauthor=R.+Bayraktarauthor=M.+A.+Erdoganauthor=N.+Kabilauthor=B.+Ozpolat&title=Elongation+Factor-2+Kinase+%28EEF-2K%29+Expression+Is+Associated+with+Poor+Patient+Survival+and+Promotes+Proliferation%2C+Invasion+and+Tumor+Growth+of+Lung+Cancer&doi=10.1016%2Fj.lungcan.2018.07.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer</span></div><div class="casAuthors">Bircan Haci Ahmet; Gurbuz Nilgun; Pataer Apar; Caner Ayse; Kahraman Nermin; Bayraktar Emine; Bayraktar Recep; Erdogan Mumin Alper; Kabil Nashwa; Ozpolat Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Lung cancer is the leading cause of cancer related deaths in worldwide.  Despite recent advances in treatment options, patient survival has not improved substantially due to lack of commonly expressed molecular targets and effective targeted therapeutics.  Thus, better understanding of the biology of lung cancer and identification of novel therapeutic targets are urgently needed for development of highly effective molecularly targeted therapies.  MATERIALS AND METHODS:  Viability, proliferation and metastatic ability of lung cancer cells were evaluated using methylthiazoltetrazolium (MTT), colony formation and matrigel invasion assays, respectively.  Western blotting, RT-PCR, and gene knockdown by siRNA transfections were carried out to investigate the effects of eEF-2K on lung cancer cells.  Athymic Nu/Nu mice were treated with liposomal eEF-2KeEF-2K or control siRNA and tumor growth was evaluated in tumor xenograft models of lung cancer.  RESULTS AND DISCUSSION:  Here, we report that Eukaryotic Elongation Factor-2 kinase (eEF-2K), a member of an atypical alpha kinases family, is significantly upregulated in lung cancer cell lines and its expression is associated with shorter overall patient survival in lung cancer.  Inhibition eEF-2K expression by siRNA or a chemical inhibitorsignificantly suppressed lung cancer cell proliferation, colony formation, survival, migration/invasion and tumorigenesis by inhibiting cyclin D1, Src and Mitogen-Activated Protein Kinases/Extracellular Signal-Regulated Kinase (MAPK/ERK) signaling.  In vivo targeting of eEF-2K by systemically injected nanoliposomal eEF-2K siRNA resulted in a significant inhibition of lung cancer tumor xenografts in nude mice.  Our results suggest, for the first time, that expression of eEF-2K is associated with poor patient prognosis and involved in regulation of critical pathways, including Src and MAPK/ERK and cyclin D1, promoting tumor growth and progression, and thus may be a novel potential therapeutic target in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQh6lCdjmngrhgd2Wuil24tfW6udTcc2eaoXeSc82wEX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czktV2luw%253D%253D&md5=f5be504835970740ac9449ae852c697c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.07.027%26sid%3Dliteratum%253Aachs%26aulast%3DBircan%26aufirst%3DH.%2BA.%26aulast%3DGurbuz%26aufirst%3DN.%26aulast%3DPataer%26aufirst%3DA.%26aulast%3DCaner%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DErdogan%26aufirst%3DM.%2BA.%26aulast%3DKabil%26aufirst%3DN.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DElongation%2520Factor-2%2520Kinase%2520%2528EEF-2K%2529%2520Expression%2520Is%2520Associated%2520with%2520Poor%2520Patient%2520Survival%2520and%2520Promotes%2520Proliferation%252C%2520Invasion%2520and%2520Tumor%2520Growth%2520of%2520Lung%2520Cancer%26jtitle%3DLung%2520Cancer%26date%3D2018%26volume%3D124%26spage%3D31%26epage%3D39%26doi%3D10.1016%2Fj.lungcan.2018.07.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dehm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonham, K.</span></span> <span> </span><span class="NLM_article-title">SRC Gene Expression in Human Cancer: The Role of Transcriptional Activation</span>. <i>Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1139/o03-077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1139%2Fo03-077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=15060621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2004&pages=263-274&author=S.+M.+Dehmauthor=K.+Bonham&title=SRC+Gene+Expression+in+Human+Cancer%3A+The+Role+of+Transcriptional+Activation&doi=10.1139%2Fo03-077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">SRC gene expression in human cancer: The role of transcriptional activation</span></div><div class="casAuthors">Dehm, Scott M.; Bonham, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">BCBIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0829-8211</span>.
    
            (<span class="NLM_cas:orgname">National Research Council of Canada</span>)
        </div><div class="casAbstract">A review.  Human pp60c-Src (or c-Src) is a 60 kDa non-receptor tyrosine kinase encoded by the SRC gene and is the cellular homolog to the potent transforming v-Src viral oncogene.  C-Src functions at the hub of a vast array of signal transduction cascades that influence cellular proliferation, differentiation, motility, and survival.  C-Src activation has been documented in upwards of 50% of tumors derived from the colon, liver, lung, breast, and pancreas.  Therefore, a major focus has been to understand the mechanisms of c-Src activation in human cancer.  Early studies concd. on post-translational mechanisms that lead to increased c-Src kinase activity, which often correlated with overexpression of c-Src protein.  More recently, the discovery of an activating SRC mutation in a small subset of advanced colon tumors has been reported.  In addn., elevated SRC transcription has been identified as yet another mechanism contributing significantly to c-Src activation in a subset of human colon cancer cell lines.  Interestingly, histone deacetylase (HDAC) inhibitors, agents with well-documented anti-cancer activity, repress SRC transcription in a wide variety of human cancer cell lines.  Anal. of the mechanisms behind HDAC inhibitor mediated repression could be utilized in the future to specifically inhibit SRC gene expression in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi4CZWd0vRL7Vg90H21EOLACvtfcHk0ljO5qx-qbMbVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFChsb8%253D&md5=3693d1b64959feb8218339c72e2c7b25</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1139%2Fo03-077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fo03-077%26sid%3Dliteratum%253Aachs%26aulast%3DDehm%26aufirst%3DS.%2BM.%26aulast%3DBonham%26aufirst%3DK.%26atitle%3DSRC%2520Gene%2520Expression%2520in%2520Human%2520Cancer%253A%2520The%2520Role%2520of%2520Transcriptional%2520Activation%26jtitle%3DBiochem.%2520Cell%2520Biol.%26date%3D2004%26volume%3D82%26spage%3D263%26epage%3D274%26doi%3D10.1139%2Fo03-077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanlikilicer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguztuzun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulasli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">MicroRNA 603 Acts as a Tumor Suppressor and Inhibits Triplenegative Breast Cancer Tumorigenesis by Targeting Elongation Factor 2 Kinase</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11641</span>– <span class="NLM_lpage">11658</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.18632%2Foncotarget.14264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28036267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A280%3ADC%252BC1c7gs1eisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=11641-11658&author=R.+Bayraktarauthor=M.+Pichlerauthor=P.+Kanlikilicerauthor=C.+Ivanauthor=E.+Bayraktarauthor=N.+Kahramanauthor=B.+Aslanauthor=S.+Oguztuzunauthor=M.+Ulasliauthor=A.+Arslanauthor=G.+Calinauthor=G.+Lopez-Beresteinauthor=B.+Ozpolat&title=MicroRNA+603+Acts+as+a+Tumor+Suppressor+and+Inhibits+Triplenegative+Breast+Cancer+Tumorigenesis+by+Targeting+Elongation+Factor+2+Kinase&doi=10.18632%2Foncotarget.14264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase</span></div><div class="casAuthors">Bayraktar Recep; Kanlikilicer Pinar; Ivan Cristina; Bayraktar Emine; Kahraman Nermin; Aslan Burcu; Calin George; Lopez-Berestein Gabriel; Ozpolat Bulent; Bayraktar Recep; Bayraktar Emine; Ulasli Mustafa; Arslan Ahmet; Pichler Martin; Ivan Cristina; Calin George; Lopez-Berestein Gabriel; Ozpolat Bulent; Oguztuzun Serpil</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">11641-11658</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by the absence of defined molecular targets, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and is associated with high rates of relapse and distant metastasis despite surgery and adjuvant chemotherapy.  The lack of effective targeted therapies for TNBC represents an unmet therapeutic challenge.  Eukaryotic elongation factor 2 kinase (eEF2K) is an atypical calcium/calmodulin-dependent serine/threonine kinase that promotes TNBC tumorigenesis, progression, and drug resistance, representing a potential novel molecular target.  However, the mechanisms regulating eEF2K expression are unknown.  Here, we report that eEF2K protein expression is highly up-regulated in TNBC cells and patient tumors and it is associated with poor patient survival and clinical outcome.  We found that loss/reduced expression of miR-603 leads to eEF2K overexpression in TNBC cell lines.  Its expression results in inhibition of eEF2K by directly targeting the 3-UTR and the inhibition of tumor cell growth, migration and invasion in TNBC.  In vivo therapeutic gene delivery of miR-603 into TNBC xenograft mouse models by systemic administration of miR-603-nanoparticles led to a significant inhibition of eEF2K expression and tumor growth, which was associated with decreased activity of the downstream targets of eEF2K, including Src, Akt, cyclin D1 and c-myc.  Our findings suggest that miR-603 functions as a tumor suppressor and loss of miR-603 expression leads to increase in eEF2K expression and contributes to the growth, invasion, and progression of TNBC.  Taken together, our data suggest that miR-603-based gene therapy is a potential strategy against TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-_T1YwZchiaNc3HjJRoFAfW6udTcc2eaoXeSc82wEX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7gs1eisA%253D%253D&md5=629328be6dd8244a4b8183d7c0b1bf18</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14264%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DPichler%26aufirst%3DM.%26aulast%3DKanlikilicer%26aufirst%3DP.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DAslan%26aufirst%3DB.%26aulast%3DOguztuzun%26aufirst%3DS.%26aulast%3DUlasli%26aufirst%3DM.%26aulast%3DArslan%26aufirst%3DA.%26aulast%3DCalin%26aufirst%3DG.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DMicroRNA%2520603%2520Acts%2520as%2520a%2520Tumor%2520Suppressor%2520and%2520Inhibits%2520Triplenegative%2520Breast%2520Cancer%2520Tumorigenesis%2520by%2520Targeting%2520Elongation%2520Factor%25202%2520Kinase%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D11641%26epage%3D11658%26doi%3D10.18632%2Foncotarget.14264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhlis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Thymoquinone Inhibits Cell Proliferation, Migration, and Invasion by Regulating the Elongation Factor 2 Kinase (EEF-2K) Signaling Axis in Triple-Negative Breast Cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1007/s10549-018-4847-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1007%2Fs10549-018-4847-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29971628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yksLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2018&pages=593-605&author=N.+Kabilauthor=R.+Bayraktarauthor=N.+Kahramanauthor=H.+A.+Mokhlisauthor=G.+A.+Calinauthor=G.+Lopez-Beresteinauthor=B.+Ozpolat&title=Thymoquinone+Inhibits+Cell+Proliferation%2C+Migration%2C+and+Invasion+by+Regulating+the+Elongation+Factor+2+Kinase+%28EEF-2K%29+Signaling+Axis+in+Triple-Negative+Breast+Cancer&doi=10.1007%2Fs10549-018-4847-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer</span></div><div class="casAuthors">Kabil, Nashwa; Bayraktar, Recep; Kahraman, Nermin; Mokhlis, Hamada A.; Calin, George A.; Lopez-Berestein, Gabriel; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">593-605</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background/purpose: Triple-neg. breast cancer (TNBC) is the most aggressive and chemoresistant subtype of breast cancer.  Therefore, new mol. targets and treatments need to be developed to improve poor patient prognosis and survival.  We have previously shown that eukaryotic elongation factor 2 kinase (eEF-2K) is highly expressed in TNBC cells, is assocd. with poor patient survival and prognosis, and promotes cell proliferation, migration, and invasion.  In vivo targeting of eEF-2K significantly reduces the tumor growth of orthotopic TNBC xenograft mouse models, suggesting that eEF-2K may serve as a potential novel therapeutic target.  Methods/results: In the current study, we identified thymoquinone (TQ), an active ingredient of Nigella sativa, as a potential safe and effective eEF-2K inhibitor in TNBC.  We demonstrated for the first time that TQ inhibits the protein and mRNA expression of eEF-2K, as well as the clin. relevant downstream targets, including Src/FAK and Akt, and induces the tumor suppressor miR-603, in response to NF-kB inhibition.  This effect was assocd. with a significant decrease in the proliferation, colony formation, migration, and invasion of TNBC cells.  Furthermore, systemic in vivo injection of TQ (20 and 100 mg/kg) significantly reduced the growth of MDA-MB-231 tumors and inhibited the eEF-2K expression in an orthotopic tumor model in mice.  Conclusion: Our study provides first evidence that TQ treatment inhibits cell proliferation, migration/invasion, and tumor growth, in part through the inhibition of eEF-2K signaling in TNBC.  Thus, our findings suggest that systemic TQ treatment may be used as a targeted therapeutic strategy for the inhibition of eEF-2K in TNBC tumor growth and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8kyxIVXtRLVg90H21EOLACvtfcHk0ljIu88Rrh5vhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yksLbL&md5=0bbf638cfefa85c33f9c4bc4f8c492c8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs10549-018-4847-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-018-4847-2%26sid%3Dliteratum%253Aachs%26aulast%3DKabil%26aufirst%3DN.%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DMokhlis%26aufirst%3DH.%2BA.%26aulast%3DCalin%26aufirst%3DG.%2BA.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DThymoquinone%2520Inhibits%2520Cell%2520Proliferation%252C%2520Migration%252C%2520and%2520Invasion%2520by%2520Regulating%2520the%2520Elongation%2520Factor%25202%2520Kinase%2520%2528EEF-2K%2529%2520Signaling%2520Axis%2520in%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2018%26volume%3D171%26spage%3D593%26epage%3D605%26doi%3D10.1007%2Fs10549-018-4847-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Elongation Factor 2 Kinase Promotes Angiogenesis in Hepatocellular Carcinoma via PI3K/Akt and STAT3</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1002/ijc.32560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1002%2Fijc.32560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=31286509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWgtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=1383-1395&author=Y.+Zhouauthor=Y.+Liauthor=S.+Xuauthor=J.+Luauthor=Z.+Zhuauthor=S.+Chenauthor=Y.+Tanauthor=P.+Heauthor=J.+Xuauthor=C.+G.+Proudauthor=J.+Xieauthor=K.+Shen&title=Eukaryotic+Elongation+Factor+2+Kinase+Promotes+Angiogenesis+in+Hepatocellular+Carcinoma+via+PI3K%2FAkt+and+STAT3&doi=10.1002%2Fijc.32560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3</span></div><div class="casAuthors">Zhou, Ying; Li, Yaoting; Xu, Shihao; Lu, Jing; Zhu, Ziyi; Chen, Shaoli; Tan, Yuan; He, Peng; Xu, Jin; Proud, Christopher G.; Xie, Jianling; Shen, Kaikai</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1383-1395</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is an aggressive malignancy with increasing mortality in China.  Angiogenesis is crucial for tumor formation, development and metastasis in HCC.  Previous studies indicated that high expression levels of elongation factor 2 kinase (eEF2K), a protein kinase that neg. regulates the elongation stage of translation, were assocd. with poor prognosis of HCC.  This study show that pharmacol. inhibition or knockdown of eEF2K in highly metastatic liver cancer cells inhibits their colony forming and migratory capacities, as well as reducing their invasiveness.  Importantly, knocking down eEF2K by lentiviral directed shRNA prevented tumor growth and angiogenesis of HCC in mice.  Silencing of eEF2K in endothelial cells (HUVECs) led to a redn. in vascularization, evidenced by a decrease in capillary-like structures in the matrigel.  Notably, knocking down eEF2K reduced the expression of angiogenesis-related growth factors in liver cancer cells and the expression of growth factor receptors on HUVECs, and thus restricted signaling crosstalk that promotes angiogenesis between HCC cells and endothelial cells.  This study also showed that silencing of eEF2K effectively reduced protein levels of SP1/KLF5 transcription factors and hence decreased the levels of bound SP1/KLF5 to the VEGF promoter, resulted in a decrease in VEGF mRNA expression.  Knocking down eEF2K also led to a striking decrease in the phosphorylation of PI3K/Akt and STAT3, indicating inactivation of these tumorigenic pathways.  Taken together, our data suggest that eEF2K contributes to angiogenesis and tumor progression in HCC via SP1/KLF5-mediated VEGF expression, as well as the subsequent stimulation of PI3K/Akt and STAT3 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG91ZjVeu0FrVg90H21EOLACvtfcHk0ljIu88Rrh5vhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWgtrjO&md5=344cdf63f7bcc4cd5919ed2b73564a6f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fijc.32560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32560%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26atitle%3DEukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520Promotes%2520Angiogenesis%2520in%2520Hepatocellular%2520Carcinoma%2520via%2520PI3K%252FAkt%2520and%2520STAT3%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2020%26volume%3D146%26spage%3D1383%26epage%3D1395%26doi%3D10.1002%2Fijc.32560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, C.</span></span> <span> </span><span class="NLM_article-title">β-Cryptoxanthin Induced Anti-Proliferation and Apoptosis by G0/G1 Arrest and AMPK Signal Inactivation in Gastric Cancer</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>859</i></span>,  <span class="NLM_fpage">172528</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2019.172528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ejphar.2019.172528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=31288004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGns7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=859&publication_year=2019&pages=172528&author=M.+Gaoauthor=F.+Dangauthor=C.+Deng&title=%CE%B2-Cryptoxanthin+Induced+Anti-Proliferation+and+Apoptosis+by+G0%2FG1+Arrest+and+AMPK+Signal+Inactivation+in+Gastric+Cancer&doi=10.1016%2Fj.ejphar.2019.172528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">β-Cryptoxanthin induced anti-proliferation and apoptosis by G0/G1 arrest and AMPK signal inactivation in gastric cancer</span></div><div class="casAuthors">Gao, Meili; Dang, Fan; Deng, Chun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">859</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172528</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A β-Cryptoxanthin has been assocd. with reduced-risk of some cancers.  However, the mechanisms of β-cryptoxanthin still remain unclearly understood in gastric cancer (GC).  In this study, we examd. the effect of β-cryptoxanthin on AMPK signal in human gastric cancer cells.  AGS and SGC-7901 cells were treated with β-cryptoxanthin (0-40μM) and AGS cells were injected in BALB/c (nu/nu) mice to analyze the effect of β-cryptoxanthin on GC.  We found that β-cryptoxanthin induced inhibitory effect on the cell viability in a time- and concn.-dependent manner.  The no. of migrated cells and protein levels of matrix metalloproteinase (MMP) -2 and MMP-9 were obviously decreased.  β-Cryptoxanthin treatment induced G0/G1 arrest, and reduced the expression of Cyclin E, Cyclin D1, cyclin-dependent kinases (CDK) of CDK4 and CDK6, and increased the expression of p53 and p21 in the two GC cells.  Addnl., β-cryptoxanthin induced apoptosis and increased the expression of cleaved caspase-3, -8, -9 as well as cytochrome C (cyt C).  β-Cryptoxanthin induced AMP-activated protein kinase (AMPK) signal inactivation by the down-regulation of protein kinase A (PKA), p-AMPK, eukaryotic elongation factor 2 kinase (eEF2k).  Furthermore, β-cryptoxanthin inhibited tumor growth through suppressing the tumor vol. and wt., inducing apoptotic cells.  Besides, β-cryptoxanthin induced significant redns. of vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).  In conclusion, our data provide the novel evidence to understand the mechanism of anti-pcancer of β-cryptoxanthin and indicate that β-cryptoxanthin can serve as a promising chemopreventive agent against gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKVdtY9022bVg90H21EOLACvtfcHk0liZiqItbhRcVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGns7rE&md5=baa2786739dc745b0d159b44586cb5c6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2019.172528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2019.172528%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DDang%26aufirst%3DF.%26aulast%3DDeng%26aufirst%3DC.%26atitle%3D%25CE%25B2-Cryptoxanthin%2520Induced%2520Anti-Proliferation%2520and%2520Apoptosis%2520by%2520G0%252FG1%2520Arrest%2520and%2520AMPK%2520Signal%2520Inactivation%2520in%2520Gastric%2520Cancer%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D859%26spage%3D172528%26doi%3D10.1016%2Fj.ejphar.2019.172528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakhill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">The EEF2 Kinase-Induced STAT3 Inactivation Inhibits Lung Cancer Cell Proliferation by Phosphorylation of PKM2</span>. <i>Cell Commun. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi"> DOI: 10.1186/s12964-020-0528-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1186%2Fs12964-020-0528-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=32054489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVGhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=25&author=M.+Xiaoauthor=J.+Xieauthor=Y.+Wuauthor=G.+Wangauthor=X.+Qiauthor=Z.+Liuauthor=Y.+Wangauthor=X.+Wangauthor=A.+Hoqueauthor=J.+Oakhillauthor=C.+G.+Proudauthor=J.+Li&title=The+EEF2+Kinase-Induced+STAT3+Inactivation+Inhibits+Lung+Cancer+Cell+Proliferation+by+Phosphorylation+of+PKM2&doi=10.1186%2Fs12964-020-0528-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The eEF2 kinase-induced STAT3 inactivation inhibits lung cancer cell proliferation by phosphorylation of PKM2</span></div><div class="casAuthors">Xiao, Min; Xie, Jianling; Wu, Yu; Wang, Genzhu; Qi, Xin; Liu, Zailiang; Wang, Yuying; Wang, Xuemin; Hoque, Ashfaqul; Oakhill, Jon; Proud, Christopher G.; Li, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Cell Communication and Signaling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">CCSEC6</span>;
        ISSN:<span class="NLM_cas:issn">1478-811X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Abstr.: Background: Eukaryotic elongation factor-2 kinase (eEF2K) is a Ca 2+ /calmodulin (CaM)-dependent protein kinase that inhibits protein synthesis.  However, the role of eEF2K in cancer development was reported paradoxically and remains to be elucidated.  Methods: Herein, A549 cells with eEF2K depletion or overexpression by stably transfected lentivirus plasmids were used in vitro and in vivo study.  MTT and colony assays were used to detect cell proliferation and growth.  Results: We demonstrated that eEF2K inhibited lung cancer cells proliferation and affected the inhibitory effects of EGFR inhibitor gefitinib.  Mechanistically, we showed that eEF2K formed a complex with PKM2 and STAT3, thereby phosphorylated PKM2 at T129, leading to reduced dimerization of PKM2.  Subsequently, PKM2 impeded STAT3 phosphorylation and STAT3-dependent c-Myc expression. eEF2K depletion promoted the nuclear translocation of PKM2 and increased aerobic glycolysis reflected by increased lactate secretion and glucose.  Conclusions: Our findings define a novel mechanism underlying the regulation of cancer cell proliferation by eEF2K independent of its role in protein synthesis, disclosing the diverse roles of eEF2K in cell biol., which lays foundation for the development of new anticancer therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhD9KBFSLrcLVg90H21EOLACvtfcHk0liZiqItbhRcVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVGhtLY%253D&md5=1265794a975ac8d45c0d50ee5bc089a5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2Fs12964-020-0528-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12964-020-0528-y%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHoque%26aufirst%3DA.%26aulast%3DOakhill%26aufirst%3DJ.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DThe%2520EEF2%2520Kinase-Induced%2520STAT3%2520Inactivation%2520Inhibits%2520Lung%2520Cancer%2520Cell%2520Proliferation%2520by%2520Phosphorylation%2520of%2520PKM2%26jtitle%3DCell%2520Commun.%2520Signaling%26date%3D2020%26volume%3D18%26spage%3D25%26doi%3D10.1186%2Fs12964-020-0528-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gschwendt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kittstein, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, F.</span></span> <span> </span><span class="NLM_article-title">Elongation Factor-2 Kinase: Effective Inhibition by the Novel Protein Kinase Inhibitor Rottlerin and Relative Insensitivity towards Staurosporine</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(94)80121-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2F0014-5793%2894%2980121-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=8307162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFOgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=1994&pages=85-88&author=M.+Gschwendtauthor=W.+Kittsteinauthor=F.+Marks&title=Elongation+Factor-2+Kinase%3A+Effective+Inhibition+by+the+Novel+Protein+Kinase+Inhibitor+Rottlerin+and+Relative+Insensitivity+towards+Staurosporine&doi=10.1016%2F0014-5793%2894%2980121-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Elongation factor-2 kinase: effective inhibition by the novel protein kinase inhibitor rottlerin and relative insensitivity towards staurosporine</span></div><div class="casAuthors">Gschwendt, Michael; Kittstein, Walter; Marks, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-8</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">The elongation factor-2 (eEF-2) is selectively phosphorylated by the eEF-2 kinase (calmodulin-dependent kinase III).  This phosphorylation can be inhibited by calmodulin antagonists, such as CGS 9343B (IC50 = 4 μM).  The novel protein kinase inhibitor rottlerin is shown to suppress eEF-2 phosphorylation with an IC50 of 5.3 μM.  By contrast, the eEF-2 kinase is rather resistant towards the potent but non-selective protein kinase inhibitor staurosporine (IC50 > 50 μM) and thus can be differentiated from most other protein kinases that are suppressed by staurosporine in the nM range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcka0nTmZgk7Vg90H21EOLACvtfcHk0liZiqItbhRcVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFOgtr4%253D&md5=98b0abf8a08408167ea63200aab9731d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2980121-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252980121-5%26sid%3Dliteratum%253Aachs%26aulast%3DGschwendt%26aufirst%3DM.%26aulast%3DKittstein%26aufirst%3DW.%26aulast%3DMarks%26aufirst%3DF.%26atitle%3DElongation%2520Factor-2%2520Kinase%253A%2520Effective%2520Inhibition%2520by%2520the%2520Novel%2520Protein%2520Kinase%2520Inhibitor%2520Rottlerin%2520and%2520Relative%2520Insensitivity%2520towards%2520Staurosporine%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D338%26spage%3D85%26epage%3D88%26doi%3D10.1016%2F0014-5793%2894%2980121-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caivano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1042/bj3510095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1042%2Fbj3510095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10998351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=95-105&author=S.+P.+Daviesauthor=H.+Reddyauthor=M.+Caivanoauthor=P.+Cohen&title=Specificity+and+Mechanism+of+Action+of+Some+Commonly+Used+Protein+Kinase+Inhibitors&doi=10.1042%2Fbj3510095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span></div><div class="casAuthors">Davies, Stephen P.; Reddy, Helen; Caivano, Matilde; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 28 com. available compds. reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examd. against a large panel of protein kinases.  The compds. KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based expts. are likely to be erroneous.  Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency.  LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase.  The compds. with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190.  U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.  Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one addnl. protein kinase.  Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure.  The authors propose guidelines for the use of protein kinase inhibitors in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs5LPDkzaGrVg90H21EOLACvtfcHk0liZiqItbhRcVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D&md5=e14eb47a52dc43afca7373c276b2d147</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1042%2Fbj3510095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3510095%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DReddy%26aufirst%3DH.%26aulast%3DCaivano%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DSpecificity%2520and%2520Mechanism%2520of%2520Action%2520of%2520Some%2520Commonly%2520Used%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26spage%3D95%26epage%3D105%26doi%3D10.1042%2Fbj3510095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R. K.</span></span> <span> </span><span class="NLM_article-title">Rottlerin-Induced Autophagy Leads to the Apoptosis in Breast Cancer Stem Cells: Molecular Mechanisms</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">171</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-12-171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1186%2F1476-4598-12-171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24359639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Wgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=171&author=D.+Kumarauthor=S.+Shankarauthor=R.+K.+Srivastava&title=Rottlerin-Induced+Autophagy+Leads+to+the+Apoptosis+in+Breast+Cancer+Stem+Cells%3A+Molecular+Mechanisms&doi=10.1186%2F1476-4598-12-171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms</span></div><div class="casAuthors">Kumar, Dhruv; Shankar, Sharmila; Srivastava, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171/1-171/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Autophagy is an indispensable lysosomal self-digestion process involved in the degrdn. of aggregated proteins and damaged organelles.  Autophagy is assocd. with the several pathol. processes, including cancer.  Cancer stem cells (CSCs) play significant roles in cancer initiation, progression and drug resistance.  Recent studies have demonstrated the antitumor activities of plant-derived chemopreventive agent rottlerin (Rott).  However, the mol. mechanism by which Rott induces autophagy in breast CSCs has not been investigated.  Results: The objectives of this study were to examine the mol. mechanism by which Rott induces autophagy which leads to apoptosis in breast CSCs.  Treatment of breast CSCs with Rott for 24 h resulted in a concn. dependent induction of autophagy, followed by apoptosis as measured by flow cytometry.  Electron microscopy confirmed the presence of autophagosomes in Rott treated breast CSCs.  Western blot anal. showed that Rott treatment increased the expression of LC3, Beclin-1 and Atg12 that are accumulated during autophagy.  Prolonged exposure of breast CSCs to Rott caused apoptosis which was assocd. with the suppression of phosphorylated Akt and mTOR, upregulation of phosphorylated AMPK, and downregulation of anti-apoptosis Bcl-2, Bcl-XL, XIAP and cIAP-1.  Knock-down of Atg7 or Beclin-1 by shRNA inhibited Rott-induced autophagy at 24 h.  Our study also demonstrates that pre-treatment of breast CSCs with autophagosome inhibitors 3-methyladenine and Bafilomycin, as well as protein synthesis inhibitor cycloheximide inhibited Rott-induced autophagy and apoptosis.  Rott induces autophagy via extensive cytoplasmic vacuolization in breast CSCs.  Mol. docking results between C2-domain of protein kinase C-delta and Rott indicated that both hydrogen bonding and hydrophobic interactions contributed significantly for ligand binding with min. binding affinity of ≈ 7.5 Kcal/mol.  Although, autophagy inhibitors suppress the formation of cytoplasmic vacuolization and autophagy in breast CSCs, the potency of Rott to induce autophagy and apoptosis might be based on its capability to activate several pathways such as AMPK and proteasome inhibition.  Conclusions: A better understanding of the relationship between autophagy and apoptosis would eventually allow us to discover novel drugs for the treatment of breast cancer by eliminating CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKFUtFnPynvrVg90H21EOLACvtfcHk0ljpygkwMELLsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Wgs78%253D&md5=77358f30a3d6eed30e2dacf0a90738c5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-12-171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-12-171%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DR.%2BK.%26atitle%3DRottlerin-Induced%2520Autophagy%2520Leads%2520to%2520the%2520Apoptosis%2520in%2520Breast%2520Cancer%2520Stem%2520Cells%253A%2520Molecular%2520Mechanisms%26jtitle%3DMol.%2520Cancer%26date%3D2013%26volume%3D12%26spage%3D171%26doi%3D10.1186%2F1476-4598-12-171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koketsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nairn, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span> <span> </span><span class="NLM_article-title">Novel Compounds, “1,3-Selenazine Derivatives” as Specific Inhibitors of Eukaryotic Elongation Factor-2 Kinase</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1475</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1016/S0304-4165(00)00061-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2FS0304-4165%2800%2900061-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVOls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1475&publication_year=2000&pages=207-215&author=S.+I.+Choauthor=M.+Koketsuauthor=H.+Ishiharaauthor=M.+Matsushitaauthor=A.+C.+Nairnauthor=H.+Fukazawaauthor=Y.+Uehara&title=Novel+Compounds%2C+%E2%80%9C1%2C3-Selenazine+Derivatives%E2%80%9D+as+Specific+Inhibitors+of+Eukaryotic+Elongation+Factor-2+Kinase&doi=10.1016%2FS0304-4165%2800%2900061-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Novel compounds, '1,3-selenazine derivatives' as specific inhibitors of eukaryotic elongation factor-2 kinase</span></div><div class="casAuthors">Cho, S. I.; Koketsu, M.; Ishihara, H.; Matsushita, M.; Nairn, A. C.; Fukazawa, H.; Uehara, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1475</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-215</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The inhibitory activities of 5,6-dihydro-4H-1,3-selenazine derivs. on protein kinases were investigated.  In a multiple protein kinase assay using a postnuclear fraction of v-src-transformed NIH3T3 cells, 4-ethyl-4-hydroxy-2-p-tolyl-5,6-dihydro-4H-1,3-selenazine (TS-2) and 4-hydroxy-6-isopropyl-4-methyl-2-p-tolyl-5,6-dihydro-4H-1,3-selenazine (TS-4) exhibited selective inhibitory activity against eukaryotic elongation factor-2 kinase (eEF-2K) over protein kinase A (PKA), protein kinase C (PKC) and protein tyrosine kinase (PTK).  In further expts. using purified kinases, TS-2 (IC50=0.36 μM) and TS-4 (IC50=0.31 μM) inhibited eEF-2K about 25-fold more effectively than calmodulin-dependent protein kinase-I (CaMK-I), and about 6-fold (TS-2) or 33-fold (TS-4) more effectively than calmodulin-dependent protein kinase-II (CaMK-II), resp.  TS-2 and TS-4 showed much weaker inhibitory activity toward PKA and PKC, while TS-4, but not TS-2, moderately inhibited immunopptd. v-src kinase.  TS-2 (10.7-fold) and TS-4 (12.5-fold) demonstrated more potent and more specific eEF-2K inhibitory activity than rottlerin, a previously identified eEF-2K inhibitor.  TS-2 inhibited ATP or eEF-2 binding to eEF-2K in a competitive or non-competitive manner, resp.  In cultured v-src-transformed NIH3T3 cells, TS-2 also decreased phospho-eEF-2 protein level (IC50=4.7 μM) without changing the total eEF-2 protein level.  Taken together, these results suggest that TS-2 and TS-4 are the first identified selective eEF-2K inhibitors and should be useful tools for studying the function of eEF-2K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfsLRua-VEfrVg90H21EOLACvtfcHk0ljpygkwMELLsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVOls7w%253D&md5=3a58d81422a8a354474c4ff51c95fb99</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0304-4165%2800%2900061-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-4165%252800%252900061-1%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BI.%26aulast%3DKoketsu%26aufirst%3DM.%26aulast%3DIshihara%26aufirst%3DH.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DNairn%26aufirst%3DA.%2BC.%26aulast%3DFukazawa%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DY.%26atitle%3DNovel%2520Compounds%252C%2520%25E2%2580%259C1%252C3-Selenazine%2520Derivatives%25E2%2580%259D%2520as%2520Specific%2520Inhibitors%2520of%2520Eukaryotic%2520Elongation%2520Factor-2%2520Kinase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2000%26volume%3D1475%26spage%3D207%26epage%3D215%26doi%3D10.1016%2FS0304-4165%2800%2900061-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span> <span> </span><span class="NLM_article-title">TX-1123: An Antitumor 2-Hydroxyarylidene-4-Cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor Having Low Mitochondrial Toxicity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3257</span>– <span class="NLM_lpage">3265</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(02)00160-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2FS0968-0896%2802%2900160-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=12150871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVemsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=3257-3265&author=H.+Horiauthor=H.+Nagasawaauthor=M.+Ishibashiauthor=Y.+Utoauthor=A.+Hirataauthor=K.+Saijoauthor=K.+Ohkuraauthor=K.+L.+Kirkauthor=Y.+Uehara&title=TX-1123%3A+An+Antitumor+2-Hydroxyarylidene-4-Cyclopentene-1%2C3-Dione+as+a+Protein+Tyrosine+Kinase+Inhibitor+Having+Low+Mitochondrial+Toxicity&doi=10.1016%2FS0968-0896%2802%2900160-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">TX-1123: an antitumor 2-hydroxyarylidene-4-cyclopentene-1,3-dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity</span></div><div class="casAuthors">Hori, Hitoshi; Nagasawa, Hideko; Ishibashi, Masaki; Uto, Yoshihiro; Hirata, Akihiko; Saijo, Kouichi; Ohkura, Kazuto; Kirk, Kenneth L.; Uehara, Yoshimasa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3257-3265</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of 2-hydroxyarylidene-4-cyclopentene-1,3-diones were designed, synthesized, and evaluated with respect to protein tyrosine kinase (PTK) inhibition, mitochondrial toxicity, and antitumor activity.  Our results show that the cyclopentenedione-derived TX-1123 is a more potent antitumor tyrphostin and also shows lower mitochondrial toxicity than the malononitrile-derived AG17, a potent antitumor tyrphostin.  The O-methylation product of TX-1123 (TX-1925) retained its tyrphostin-like properties, including mitochondrial toxicity and antitumor activities.  However, the methylation product of AG17 (TX-1927) retained its tyrphostin-like antitumor activities, but lost its mitochondrial toxicity.  Our comprehensive evaluation of these agents with respect to protein tyrosine kinase inhibition, mitochondrial inhibition, antitumor activity, and hepatotoxicity demonstrates that PTK inhibitors TX-1123 and TX-1925 are more promising candidates for antitumor agents than tyrphostin AG17.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt-bAAuqLXw7Vg90H21EOLACvtfcHk0ljpygkwMELLsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVemsrk%253D&md5=e544ca06e36b48d58c9fc38ec88ea225</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900160-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900160-8%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DH.%26aulast%3DNagasawa%26aufirst%3DH.%26aulast%3DIshibashi%26aufirst%3DM.%26aulast%3DUto%26aufirst%3DY.%26aulast%3DHirata%26aufirst%3DA.%26aulast%3DSaijo%26aufirst%3DK.%26aulast%3DOhkura%26aufirst%3DK.%26aulast%3DKirk%26aufirst%3DK.%2BL.%26aulast%3DUehara%26aufirst%3DY.%26atitle%3DTX-1123%253A%2520An%2520Antitumor%25202-Hydroxyarylidene-4-Cyclopentene-1%252C3-Dione%2520as%2520a%2520Protein%2520Tyrosine%2520Kinase%2520Inhibitor%2520Having%2520Low%2520Mitochondrial%2520Toxicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D3257%26epage%3D3265%26doi%3D10.1016%2FS0968-0896%2802%2900160-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lockman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeder, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostanin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhoite, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baichwal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam Willardsen, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of EEF2-K by Thieno[2,3-b]Pyridine Analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2283</span>– <span class="NLM_lpage">2286</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.bmcl.2010.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=20189382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslGmtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2283-2286&author=J.+W.+Lockmanauthor=M.+D.+Reederauthor=K.+Suzukiauthor=K.+Ostaninauthor=R.+Hoffauthor=L.+Bhoiteauthor=H.+Austinauthor=V.+Baichwalauthor=J.+Adam+Willardsen&title=Inhibition+of+EEF2-K+by+Thieno%5B2%2C3-b%5DPyridine+Analogues&doi=10.1016%2Fj.bmcl.2010.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eEF2-K by thieno[2,3-b]pyridine analogues</span></div><div class="casAuthors">Lockman, Jeffrey W.; Reeder, Matthew D.; Suzuki, Kazuyuki; Ostanin, Kirill; Hoff, Ryan; Bhoite, Leena; Austin, Harry; Baichwal, Vijay; Adam Willardsen, J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2283-2286</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Several series of thieno[2-3-b]pyridine analogs were synthesized and screened for inhibitory activity against eukaryotic elongation factor-2 kinase (eEF2-K).  Modifications around several regions of the lead mols. were made, with a ring fusion adjacent to the nitrogen on the thienopyridine core being crit. for activity.  The most active compd. 34 shows an IC50 of 170 nM against eEF2-K in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfkbsgYtCHIrVg90H21EOLACvtfcHk0ljLShXI1pJXLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslGmtb4%253D&md5=dd50cf5427d106d9e361349de04ca0ad</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DLockman%26aufirst%3DJ.%2BW.%26aulast%3DReeder%26aufirst%3DM.%2BD.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DOstanin%26aufirst%3DK.%26aulast%3DHoff%26aufirst%3DR.%26aulast%3DBhoite%26aufirst%3DL.%26aulast%3DAustin%26aufirst%3DH.%26aulast%3DBaichwal%26aufirst%3DV.%26aulast%3DAdam%2BWillardsen%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520EEF2-K%2520by%2520Thieno%255B2%252C3-b%255DPyridine%2520Analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2283%26epage%3D2286%26doi%3D10.1016%2Fj.bmcl.2010.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. W.</span></span> <span> </span><span class="NLM_article-title">New Sorbicillinoid Derivatives with GLP-1R and EEF2K Affinities from a Sponge-Derived Fungus Penicillium Chrysogenum 581F1</span>. <i>Nat. Prod. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2880</span>– <span class="NLM_lpage">2886</span>, <span class="refDoi"> DOI: 10.1080/14786419.2019.1596099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1080%2F14786419.2019.1596099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30990084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVersbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=2880-2886&author=M.+J.+Caoauthor=T.+Zhuauthor=J.+T.+Liuauthor=L.+Ouyangauthor=F.+Yangauthor=H.+W.+Lin&title=New+Sorbicillinoid+Derivatives+with+GLP-1R+and+EEF2K+Affinities+from+a+Sponge-Derived+Fungus+Penicillium+Chrysogenum+581F1&doi=10.1080%2F14786419.2019.1596099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">New sorbicillinoid derivatives with GLP-1R and eEF2K affinities from a sponge-derived fungus Penicillium chrysogenum 581F1</span></div><div class="casAuthors">Cao, Min-Jia; Zhu, Tao; Liu, Jing-Tang; Ouyang, Liang; Yang, Fan; Lin, Hou-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2880-2886</span>CODEN:
                <span class="NLM_cas:coden">NPRAAT</span>;
        ISSN:<span class="NLM_cas:issn">1478-6419</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Two new sorbicillinoids, 13-hydroxy-dihydrotrichodermolide (I) and 10,11,27,28-tetrahydrotrisorbicillinone C (II), were isolated from the sponge-derived fungus Penicillium chrysogenum 581F1.  Their structures were detd. on the basis of spectroscopic anal.  I and II displayed high affinities to target proteins GLP-1R (diabetes) and eEF2K (cancer) with Kd values of 0.0285μM and 0.0162μM for GLP-1R and 0.118μM and 0.0746μM for eEF2K, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXYwA0lR9hsLVg90H21EOLACvtfcHk0ljLShXI1pJXLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVersbk%253D&md5=66925b12d745b89d53eca16d36cba300</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1080%2F14786419.2019.1596099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14786419.2019.1596099%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DM.%2BJ.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%2BT.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DH.%2BW.%26atitle%3DNew%2520Sorbicillinoid%2520Derivatives%2520with%2520GLP-1R%2520and%2520EEF2K%2520Affinities%2520from%2520a%2520Sponge-Derived%2520Fungus%2520Penicillium%2520Chrysogenum%2520581F1%26jtitle%3DNat.%2520Prod.%2520Res.%26date%3D2020%26volume%3D34%26spage%3D2880%26epage%3D2886%26doi%3D10.1080%2F14786419.2019.1596099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hait, W. N.</span></span> <span> </span><span class="NLM_article-title">Disruption of the EF-2 Kinase/Hsp90 Protein Complex: A Possible Mechanism to Inhibit Glioblastoma by Geldanamycin</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4010</span>– <span class="NLM_lpage">4016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=11358819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVWqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4010-4016&author=J.+Yangauthor=J.+M.+Yangauthor=M.+Iannoneauthor=W.+J.+Shihauthor=Y.+Linauthor=W.+N.+Hait&title=Disruption+of+the+EF-2+Kinase%2FHsp90+Protein+Complex%3A+A+Possible+Mechanism+to+Inhibit+Glioblastoma+by+Geldanamycin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin</span></div><div class="casAuthors">Yang, Jun; Yang, Jin-Ming; Iannone, Marie; Shih, Weichung Joe; Lin, Yong; Hait, William N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4010-4016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glioblastoma multiforme is the most treatment-resistant brain tumor.  Elongation factor-2 (EF-2) kinase (calmodulin kinase III) is a unique protein kinase that is overexpressed in glioma cell lines and in human surgical specimens.  Several mitogens activate this kinase and inhibitors block mitogen activation and produce cell death.  Geldanamycin (GA) is a benzoquinone ansamycin antibiotic that disrupts Hsp90-protein interactions.  Because EF-2 kinase is chaperoned by Hsp90, we investigated the effects of GA on the viability of glioma cells, the expression of EF-2 kinase protein, and the interaction between Hsp90 and EF-2 kinase.  GA was a potent inhibitor of the clonogenicity of four glioma cells lines with IC50s ranging from 1 to 3 nM.  17-Allylamino-17-demethoxygeldanamycin (17-AAG), a less toxic and less potent deriv. of GA, inhibited the clonogenicity of glioma cells with IC50 values of 13 nM in C6 cells and 35 nM in T98G cells.  Treatment of cell lines for 24-48 h of GA or 17-AAG disrupted EF-2-kinase/Hsp90 interactions as measured by coimmunopptn., resulting in a decreased amt. of recoverable kinase in cell lysates.  The ability of GA to inhibit the growth of glioma cells was abrogated by overexpressing EF-2 kinase.  In addn., 17-AAG significantly inhibited the growth of a glioma xenograft in nude mice.  These studies demonstrate for the first time the activity of GAs against human gliomas in vitro and in vivo and suggest that destruction of EF-2 kinase may be an important cytotoxic mechanism of this unique class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-vSj_gRoatLVg90H21EOLACvtfcHk0ljLShXI1pJXLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVWqsbs%253D&md5=892bf41051344cf793533b741de9747a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DIannone%26aufirst%3DM.%26aulast%3DShih%26aufirst%3DW.%2BJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHait%26aufirst%3DW.%2BN.%26atitle%3DDisruption%2520of%2520the%2520EF-2%2520Kinase%252FHsp90%2520Protein%2520Complex%253A%2520A%2520Possible%2520Mechanism%2520to%2520Inhibit%2520Glioblastoma%2520by%2520Geldanamycin%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4010%26epage%3D4016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzy, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hait, W. N.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of an Inhibitor of Eukaryotic Elongation Factor 2 Kinase against Human Cancer Cell Lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6894</span>– <span class="NLM_lpage">6899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=14583488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVGns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=6894-6899&author=S.+Aroraauthor=J.+M.+Yangauthor=T.+G.+Kinzyauthor=R.+Utsumiauthor=T.+Okamotoauthor=T.+Kitayamaauthor=P.+A.+Ortizauthor=W.+N.+Hait&title=Identification+and+Characterization+of+an+Inhibitor+of+Eukaryotic+Elongation+Factor+2+Kinase+against+Human+Cancer+Cell+Lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of an Inhibitor of Eukaryotic Elongation Factor 2 Kinase against Human Cancer Cell Lines</span></div><div class="casAuthors">Arora, Sonia; Yang, Jin-Ming; Kinzy, Terri Goss; Utsumi, Ryutaro; Okamoto, Tadashi; Kitayama, Takashi; Ortiz, Pedro A.; Hait, William N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6894-6899</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent evidence suggests that the machinery of protein synthesis may provide novel targets for anticancer drugs.  For example, aberrations in protein synthesis are commonly encountered in established cancers, and disruption by mutation or overexpression of translation factors can cause cellular transformation.  We previously demonstrated that the activity of eukaryotic elongation factor 2 (eEF-2) kinase was markedly increased in several forms of malignancy and that nonspecific inhibitors of this enzyme promoted cell death.  On the basis of the predicted amino acid sequence of eEF-2 kinase deduced from the cloned cDNA, we hypothesized that inhibitors of prokaryotic histidine kinases might also inhibit the activity of eEF-2 kinase.  We describe herein the screening of a series of imidazolium histidine kinase inhibitors and the identification of an active lead compd., NH125.  NH125 inhibited eEF-2 kinase activity (IC50 = 60 nM) in vitro, blocked the phosphorylation of eEF-2 in intact cells, and showed relative selectivity over other protein kinases: protein kinase C (IC50 = 7.5 μM), protein kinase A (IC50 = 80 μM), and calmodulin-dependent kinase II (IC50 > 100 μM).  NH125 decreased the viability of 10 cancer cell lines with IC50s ranging from 0.7 to 4.7 μM.  Forced overexpression of eEF-2 kinase in a glioma cell line produced 10-fold resistance to NH125.  In conclusion, these results suggest that identification of potent inhibitors of eEF-2 kinase may lead to the development of new types of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEyQVDmEkPp7Vg90H21EOLACvtfcHk0lgcA7So7ACyag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVGns7g%253D&md5=3fc89947782a76d6e522898a57f00aa5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DKinzy%26aufirst%3DT.%2BG.%26aulast%3DUtsumi%26aufirst%3DR.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DKitayama%26aufirst%3DT.%26aulast%3DOrtiz%26aufirst%3DP.%2BA.%26aulast%3DHait%26aufirst%3DW.%2BN.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520an%2520Inhibitor%2520of%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520against%2520Human%2520Cancer%2520Cell%2520Lines%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D6894%26epage%3D6899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishnan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrior, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, K. B.</span></span> <span> </span><span class="NLM_article-title">1-Benzyl-3-Cetyl-2-Methylimidazolium Iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (EEF2): A Cautionary Note on the Anticancer Mechanism of an EEF2 Kinase Inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">43951</span>– <span class="NLM_lpage">43958</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.301291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.M111.301291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=22020937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=43951-43958&author=Z.+Chenauthor=S.+M.+Gopalakrishnanauthor=M.+H.+Buiauthor=N.+B.+Soniauthor=U.+Warriorauthor=E.+F.+Johnsonauthor=J.+B.+Donnellyauthor=K.+B.+Glaser&title=1-Benzyl-3-Cetyl-2-Methylimidazolium+Iodide+%28NH125%29+Induces+Phosphorylation+of+Eukaryotic+Elongation+Factor-2+%28EEF2%29%3A+A+Cautionary+Note+on+the+Anticancer+Mechanism+of+an+EEF2+Kinase+Inhibitor&doi=10.1074%2Fjbc.M111.301291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (eEF2): A CAUTIONARY NOTE ON THE ANTICANCER MECHANISM OF AN eEF2 KINASE INHIBITOR</span></div><div class="casAuthors">Chen, Zehan; Gopalakrishnan, Sujatha M.; Bui, Mai-Ha; Soni, Niru B.; Warrior, Usha; Johnson, Eric F.; Donnelly, Jennifer B.; Glaser, Keith B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">43951-43958</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF2K) relays growth and stress signals to protein synthesis through phosphorylation and inactivation of eukaryotic elongation factor 2 (eEF2). 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) is a widely accepted inhibitor of mammalian eEF2K and an efficacious anti-proliferation agent against different cancer cells.  It implied that eEF2K could be an efficacious anticancer target.  However, eEF2K siRNA was ineffective against cancer cells including those sensitive to NH125.  To test if pharmacol. intervention differs from siRNA interference, we identified a highly selective small mol. eEF2K inhibitor A-484954.  Like siRNA, A-484954 had little effect on cancer cell growth.  We carefully examd. the effect of NH125 and A-484954 on phosphorylation of eEF2, the known cellular substrate of eEF2K.  Surprisingly, NH125 increased eEF2 phosphorylation, whereas A-484954 inhibited the phosphorylation as expected for an eEF2K inhibitor.  Both A-484954 and eEF2K siRNA inhibited eEF2K and reduced eEF2 phosphorylation with little effect on cancer cell growth.  These data demonstrated clearly that the anticancer activity of NH125 was more correlated with induction of eEF2 phosphorylation than inhibition of eEF2K.  Actually, induction of eEF2 phosphorylation was reported to correlate with inhibition of cancer cell growth.  We compared several known inducers of eEF2 phosphorylation including AMPK activators and an mTOR inhibitor.  Interestingly, stronger induction of eEF2 phosphorylation correlated with more effective growth inhibition.  We also explored signal transduction pathways leading to NH125-induced eEF2 phosphorylation.  Preliminary data suggested that NH125-induced eEF2 phosphorylation was likely mediated through multiple pathways.  These observations identified an opportunity for a new multipathway approach to anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGI7DoizNH17Vg90H21EOLACvtfcHk0lgcA7So7ACyag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtbjM&md5=9cb0e962892fe086c0d0ca77b8fa0730</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.301291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.301291%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGopalakrishnan%26aufirst%3DS.%2BM.%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DWarrior%26aufirst%3DU.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonnelly%26aufirst%3DJ.%2BB.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26atitle%3D1-Benzyl-3-Cetyl-2-Methylimidazolium%2520Iodide%2520%2528NH125%2529%2520Induces%2520Phosphorylation%2520of%2520Eukaryotic%2520Elongation%2520Factor-2%2520%2528EEF2%2529%253A%2520A%2520Cautionary%2520Note%2520on%2520the%2520Anticancer%2520Mechanism%2520of%2520an%2520EEF2%2520Kinase%2520Inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D43951%26epage%3D43958%26doi%3D10.1074%2Fjbc.M111.301291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span> <span> </span><span class="NLM_article-title">Farnesyltransferase Inhibitor SCH66336 Induces Rapid Phosphorylation of Eukaryotic Translation Elongation Factor 2 in Head and Neck Squamous Cell Carcinoma Cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">5841</span>– <span class="NLM_lpage">5847</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-3141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F0008-5472.CAN-04-3141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=15994961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlslOqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=5841-5847&author=H.+Renauthor=S.+K.+Taiauthor=F.+Khuriauthor=Z.+Chuauthor=L.+Mao&title=Farnesyltransferase+Inhibitor+SCH66336+Induces+Rapid+Phosphorylation+of+Eukaryotic+Translation+Elongation+Factor+2+in+Head+and+Neck+Squamous+Cell+Carcinoma+Cells&doi=10.1158%2F0008-5472.CAN-04-3141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase Inhibitor SCH66336 Induces Rapid Phosphorylation of Eukaryotic Translation Elongation Factor 2 in Head and Neck Squamous Cell Carcinoma Cells</span></div><div class="casAuthors">Ren, Hening; Tai, Shyh-Kuan; Khuri, Fadlo; Chu, Zuming; Mao, Li</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5841-5847</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Farnesyltransferase inhibitors (FTI) are a class of therapeutic agents designed to target tumors with mutations of the ras oncogene.  However, the biol. effect of FTIs is often independent of ras mutation status, which suggests the existence of addnl. mechanisms.  In this study, we investigated the mol. effects of SCH66336 an FTI, in head and neck squamous cell carcinoma cells using proteomic approaches.  We showed that SCH66336 induced phosphorylation (inactivation) of eukaryotic translation elongation factor 2 (eEF2), an important mol. for protein synthesis, as early as 3 h after SCH66336 administration.  Protein synthesis was subsequently reduced in the cells.  Paradoxically, activation of eEF2 kinase (eEF2K), the only known kinase that regulates eEF2, was obsd. only at 12 h after SCH66336 treatment.  Consistent with this observation, the inhibition of phosphorylated-MEK and phosphorylated-p70S6K, the two key signaling mols. responsible for activation of eEF2K, also occurred at least 12 h after SCH66336 administration.  Our data suggest that inhibition of protein synthesis through inactivation of eEF2 is a novel mechanism of SCH66336 mediated growth inhibition and that this effect is independent of ras-MEK/p70S6K-eEF2K signaling cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuKdDvft_rabVg90H21EOLACvtfcHk0lgcA7So7ACyag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlslOqtr0%253D&md5=1be705ee1ac1baa26ff28313d758748d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3141%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTai%26aufirst%3DS.%2BK.%26aulast%3DKhuri%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DZ.%26aulast%3DMao%26aufirst%3DL.%26atitle%3DFarnesyltransferase%2520Inhibitor%2520SCH66336%2520Induces%2520Rapid%2520Phosphorylation%2520of%2520Eukaryotic%2520Translation%2520Elongation%2520Factor%25202%2520in%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D5841%26epage%3D5847%26doi%3D10.1158%2F0008-5472.CAN-04-3141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comert
Onder, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durdagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ay, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as EEF-2K Inhibitors</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1766</span>– <span class="NLM_lpage">1778</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.9b01083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.9b01083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitl2qt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2020&pages=1766-1778&author=F.+Comert%0AOnderauthor=S.+Durdagiauthor=K.+Sahinauthor=B.+Ozpolatauthor=M.+Ay&title=Design%2C+Synthesis%2C+and+Molecular+Modeling+Studies+of+Novel+Coumarin+Carboxamide+Derivatives+as+EEF-2K+Inhibitors&doi=10.1021%2Facs.jcim.9b01083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors</span></div><div class="casAuthors">Comert Onder, Ferah; Durdagi, Serdar; Sahin, Kader; Ozpolat, Bulent; Ay, Mehmet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1766-1778</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF-2K) is an unusual alpha kinase commonly upregulated in various human cancers, including breast, pancreatic, lung, and brain tumors.  We have demonstrated that eEF-2K is relevant to poor prognosis and shorter patient survival in breast and lung cancers and validated it as a mol. target using genetic methods in related in vivo tumor models.  Although several eEF-2K inhibitors have been published, none of them have shown to be potent and specific enough for translation into clin. trials.  Therefore, development of highly effective novel inhibitors targeting eEF-2K is needed for clin. applications.  However, currently, the crystal structure of eEF-2K is not known, limiting the efforts for designing novel inhibitor compds.  Therefore, using homol. modeling of eEF-2K, we designed and synthesized novel coumarin-3-carboxamides including compds. (I) and (II) and evaluated their activity by performing in silico anal. and in vitro biol. assays in breast cancer cells (structures contained within.  The Mol. Mechanics/Generalized Born Surface Area (MM/GBSA) area results showed that I have interaction energies with eEF-2K better than those of II compds.  Our in vitro results indicated that compds. I were highly effective in inhibiting eEF-2K at 1.0 and 2.5μM concns. compared to compds. II, supporting the in silico findings.  In conclusion, the results of this study suggest that our homol. modeling along with in silico anal. may be effectively used to design inhibitors for eEF-2K.  Our newly synthesized compds. I may be used as novel eEF-2K inhibitors with potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt2bUQbz7aE7Vg90H21EOLACvtfcHk0lh0b1bMqj32Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitl2qt7g%253D&md5=61fbbd9df1f63e4e2a5d32fb2cfc4492</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.9b01083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.9b01083%26sid%3Dliteratum%253Aachs%26aulast%3DComert%2BOnder%26aufirst%3DF.%26aulast%3DDurdagi%26aufirst%3DS.%26aulast%3DSahin%26aufirst%3DK.%26aulast%3DOzpolat%26aufirst%3DB.%26aulast%3DAy%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Molecular%2520Modeling%2520Studies%2520of%2520Novel%2520Coumarin%2520Carboxamide%2520Derivatives%2520as%2520EEF-2K%2520Inhibitors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2020%26volume%3D60%26spage%3D1766%26epage%3D1778%26doi%3D10.1021%2Facs.jcim.9b01083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edupuganti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, C. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitjian, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anslyn, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Pyrido[2,3-d]Pyrimidine-2,4-Dione Derivatives as EEF-2K Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4910</span>– <span class="NLM_lpage">4916</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.06.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.bmc.2014.06.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25047940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyms7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4910-4916&author=R.+Edupugantiauthor=Q.+Wangauthor=C.+D.+J.+Tavaresauthor=C.+A.+Chitjianauthor=J.+L.+Bachmanauthor=P.+Renauthor=E.+V.+Anslynauthor=K.+N.+Dalby&title=Synthesis+and+Biological+Evaluation+of+Pyrido%5B2%2C3-d%5DPyrimidine-2%2C4-Dione+Derivatives+as+EEF-2K+Inhibitors&doi=10.1016%2Fj.bmc.2014.06.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors</span></div><div class="casAuthors">Edupuganti, Ramakrishna; Wang, Qiantao; Tavares, Clint D. J.; Chitjian, Catrina A.; Bachman, James L.; Ren, Pengyu; Anslyn, Eric V.; Dalby, Kevin N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4910-4916</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A small mol. library of pyrido[2,3-d]pyrimidine-2,4-diones was synthesized from 6-amino-1,3-disubstituted uracils, characterized, and screened for inhibitory activity against eukaryotic elongation factor-2 kinase (eEF-2K).  To understand the binding pocket of eEF-2K, structural modifications of the pyrido[2,3-d]pyrimidine were made at three regions.  A homol. model of eEF-2K was created, and compd. I (A-484954, Abbott labs.) was docked in the catalytic domain of eEF-2K.  Compds. I (IC50 = 420 nM) and II (IC50 = 930 nM) are found to be better mols. in this preliminary series of pyrido[2,3-d]pyrimidine analogs.  EEF-2K activity in MDA-MB-231 breast cancer cells is significantly reduced by compd. I, to a lesser extent by compd. II, and is unaffected by thioamide analog.  Similar inhibitory results are obsd. when eEF-2K activity is stimulated by 2-deoxy-D-glucose (2-DOG) treatment, suggesting that compds. I and II are able to inhibit AMPK-mediated activation of eEF-2K to a notable extent.  The results of this work will shed light on the further design and optimization of novel pyrido[2,3-d]pyrimidine analogs as eEF-2K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1DNRahjmvArVg90H21EOLACvtfcHk0lh0b1bMqj32Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyms7vP&md5=cba3bfaa20b7eb1076c3ee6c1afbb956</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.06.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.06.050%26sid%3Dliteratum%253Aachs%26aulast%3DEdupuganti%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DTavares%26aufirst%3DC.%2BD.%2BJ.%26aulast%3DChitjian%26aufirst%3DC.%2BA.%26aulast%3DBachman%26aufirst%3DJ.%2BL.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAnslyn%26aufirst%3DE.%2BV.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Pyrido%255B2%252C3-d%255DPyrimidine-2%252C4-Dione%2520Derivatives%2520as%2520EEF-2K%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4910%26epage%3D4916%26doi%3D10.1016%2Fj.bmc.2014.06.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-W. W.</span></span> <span> </span><span class="NLM_article-title">A High-Throughput Screening Assay for Eukaryotic Elongation Factor 2 Kinase Inhibitors</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2016.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.apsb.2016.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=27818922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A280%3ADC%252BC2snjsFGmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=557-563&author=T.+Xiaoauthor=R.+Liuauthor=C.+G.+Proudauthor=M.-W.+W.+Wang&title=A+High-Throughput+Screening+Assay+for+Eukaryotic+Elongation+Factor+2+Kinase+Inhibitors&doi=10.1016%2Fj.apsb.2016.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput screening assay for eukaryotic elongation factor 2 kinase inhibitors</span></div><div class="casAuthors">Xiao Ting; Liu Rui; Proud Christopher G; Wang Ming-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">557-563</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) inhibitors may aid in the development of new therapeutic agents to combat cancer.  Purified human eEF2K was obtained from an Escherichia coli expression system and a luminescence-based high-throughput screening (HTS) assay was developed using MH-1 peptide as the substrate.  The luminescent readouts correlated with the amount of adenosine triphosphate remaining in the kinase reaction.  This method was applied to a large-scale screening campaign against a diverse compound library and subsequent confirmation studies.  Nine initial hits showing inhibitory activities on eEF2K were identified from 56,000 synthetic compounds during the HTS campaign, of which, five were chosen to test their effects in cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRu2RD154rBG4hLSh9fo81bfW6udTcc2eYJT2JFf3J_5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snjsFGmtQ%253D%253D&md5=163aef48d7062502ec335c4c0dd67b46</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2016.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2016.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DProud%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DM.-W.%2BW.%26atitle%3DA%2520High-Throughput%2520Screening%2520Assay%2520for%2520Eukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520Inhibitors%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2016%26volume%3D6%26spage%3D557%26epage%3D563%26doi%3D10.1016%2Fj.apsb.2016.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span> <span> </span><span class="NLM_article-title">Integrative Bioinformatics and Proteomics-Based Discovery of an EEF2K Inhibitor (Cefatrizine) with ER Stress Modulation in Breast Cancer Cells</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1039/C5MB00848D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1039%2FC5MB00848D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=26776155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=729-736&author=Z.+Yaoauthor=J.+Liauthor=Z.+Liuauthor=L.+Zhengauthor=N.+Fanauthor=Y.+Zhangauthor=N.+Jiaauthor=J.+Lvauthor=N.+Liuauthor=X.+Zhuauthor=J.+Duauthor=C.+Lvauthor=F.+Xieauthor=Y.+Liuauthor=X.+Wangauthor=Z.+Feiauthor=C.+Gao&title=Integrative+Bioinformatics+and+Proteomics-Based+Discovery+of+an+EEF2K+Inhibitor+%28Cefatrizine%29+with+ER+Stress+Modulation+in+Breast+Cancer+Cells&doi=10.1039%2FC5MB00848D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells</span></div><div class="casAuthors">Yao, Zhiqiang; Li, Juntang; Liu, Zhongyu; Zheng, Lu; Fan, Naijun; Zhang, Ying; Jia, Nan; Lv, Jingjing; Liu, Ningning; Zhu, Xiaoshan; Du, Jiangbo; Lv, Ci; Xie, Feng; Liu, Yigang; Wang, Xingke; Fei, Zhou; Gao, Chunfang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">729-736</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF2K), a unique calcium/calmodulin-dependent protein kinase, is well known to regulate apoptosis, autophagy and ER stress in many types of human cancers.  Therefore, eEF2K would be regarded as a promising therapeutic target; however, the eEF2K-regulated mechanism and its targeted inhibitor still remain to be discovered in cancer.  Herein, we constructed a protein-protein interaction (PPI) network of eEF2K and achieved an eEF2K-regulated ER stress subnetwork by bioinformatics prediction.  Then, we found that the differential protein expressions involved in ER stress in the context of si-eEF2K-treated MCF-7 and MDA-MB-436 cells by iTRAQ-based analyses, resp.  Integrated into these aforementioned results, we constructed a core eEF2K-regulated ER stress subnetwork in breast cancer cells.  Subsequently, we screened a series of candidate compds. targeting eEF2K and discovered a novel eEF2K inhibitor (cefatrizine) with an anti-proliferative activity toward breast cancer cells.  Moreover, we found that cefatrizine induced ER stress in both MCF-7 and MDA-MB-436 cells.  Interestingly, we demonstrated that the mechanism of cefatrizine-induced ER stress was in good agreement with our bioinformatics and proteomics-based results.  In conclusion, these results demonstrate that a novel eEF2K inhibitor (cefatrizine) induces ER stress in breast cancer cells by integrating bioinformatics prediction, proteomics analyses and exptl. validation, which would provide a clue for exploring more mechanisms of eEF2K and its targeted inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDQPIGrQ6947Vg90H21EOLACvtfcHk0lhBQaYwjnWM2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGhuw%253D%253D&md5=84c2bbd60d8c71479e98f426db5fbb5b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1039%2FC5MB00848D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MB00848D%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DN.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFei%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DC.%26atitle%3DIntegrative%2520Bioinformatics%2520and%2520Proteomics-Based%2520Discovery%2520of%2520an%2520EEF2K%2520Inhibitor%2520%2528Cefatrizine%2529%2520with%2520ER%2520Stress%2520Modulation%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DMol.%2520BioSyst.%26date%3D2016%26volume%3D12%26spage%3D729%26epage%3D736%26doi%3D10.1039%2FC5MB00848D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Structure-Activity Relationship of a Focused Library of β-Phenylalanine Derivatives as Novel EEF2K Inhibitors with Apoptosis-Inducing Mechanisms in Breast Cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ejmech.2017.11.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29202403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=402-418&author=Y.+Guoauthor=Y.+Zhaoauthor=G.+Wangauthor=Y.+Chenauthor=Y.+Jiangauthor=L.+Ouyangauthor=B.+Liu&title=Design%2C+Synthesis+and+Structure-Activity+Relationship+of+a+Focused+Library+of+%CE%B2-Phenylalanine+Derivatives+as+Novel+EEF2K+Inhibitors+with+Apoptosis-Inducing+Mechanisms+in+Breast+Cancer&doi=10.1016%2Fj.ejmech.2017.11.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer</span></div><div class="casAuthors">Guo, Yongzhi; Zhao, Yuqian; Wang, Guan; Chen, Yi; Jiang, Yingnan; Ouyang, Liang; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">402-418</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca2+/calmudulin-dependent protein kinase, belonging to a small family of an atypical Ser/Thr-protein kinase.  EEF2K has been recently reported to be highly activated or over-expressed in many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target.  In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivs. with assessment of inhibition activity against eEF2K and cytotoxicity.  After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K inhibitor (I) with best eEF2K enzymic activity (IC50 of 5.5 μM) and anti-proliferative activity (MDA-MB-231 cells, IC50 of 12.6 μM, MDA-MB-436 cells, IC50 of 19.8 μM).  Moreover, we found that I could induce cell death via the apoptotic pathways in MDA-MB-231 and MDA-MB-436 cells.  Subsequently, we evaluated its anti-tumor activity and apoptosis-inducing mechanisms in vivo.  These results suggested that I inhibited tumor growth by apoptosis in the xenograft mouse model of breast cancer (MDA-MB-231 and MDA-MB-436).  Collectively, our results demonstrate a novel small-mol. inhibitor targeting eEF2K with mechanism of apoptosis and a therapeutic potential in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHKgIUg85n1LVg90H21EOLACvtfcHk0lhBQaYwjnWM2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FM&md5=d5017cf0b61bbd2cc2962d3ded11dda3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.065%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Structure-Activity%2520Relationship%2520of%2520a%2520Focused%2520Library%2520of%2520%25CE%25B2-Phenylalanine%2520Derivatives%2520as%2520Novel%2520EEF2K%2520Inhibitors%2520with%2520Apoptosis-Inducing%2520Mechanisms%2520in%2520Breast%2520Cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D402%26epage%3D418%26doi%3D10.1016%2Fj.ejmech.2017.11.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine Induces Autophagic Cell Death via EEF2K-AMPK-MTOR-ULK Complex Axis in Triple Negative Breast Cancer</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">e12402</span>, <span class="refDoi"> DOI: 10.1111/cpr.12402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1111%2Fcpr.12402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29094413" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=e12402&author=D.+Sunauthor=L.+Zhuauthor=Y.+Zhaoauthor=Y.+Jiangauthor=L.+Chenauthor=Y.+Yuauthor=L.+Ouyang&title=Fluoxetine+Induces+Autophagic+Cell+Death+via+EEF2K-AMPK-MTOR-ULK+Complex+Axis+in+Triple+Negative+Breast+Cancer&doi=10.1111%2Fcpr.12402"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fcpr.12402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcpr.12402%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DFluoxetine%2520Induces%2520Autophagic%2520Cell%2520Death%2520via%2520EEF2K-AMPK-MTOR-ULK%2520Complex%2520Axis%2520in%2520Triple%2520Negative%2520Breast%2520Cancer%26jtitle%3DCell%2520Proliferation%26date%3D2018%26volume%3D51%26spage%3De12402%26doi%3D10.1111%2Fcpr.12402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y. Di</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D. S.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening and Experimental Validation of EEF2K Inhibitors by Combining Homology Modeling, QSAR and Molecular Docking from FDA Approved Drugs</span>. <i>New J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">19097</span>– <span class="NLM_lpage">19106</span>, <span class="refDoi"> DOI: 10.1039/C9NJ02600B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1039%2FC9NJ02600B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2gt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2019&pages=19097-19106&author=W.+L.+Yeauthor=L.+X.+Zhangauthor=Y.+Di+Guanauthor=W.+W.+Xueauthor=A.+F.+Chenauthor=Q.+Caoauthor=Y.+Chengauthor=D.+S.+Cao&title=Virtual+Screening+and+Experimental+Validation+of+EEF2K+Inhibitors+by+Combining+Homology+Modeling%2C+QSAR+and+Molecular+Docking+from+FDA+Approved+Drugs&doi=10.1039%2FC9NJ02600B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual screening and experimental validation of eEF2K inhibitors by combining homology modeling, QSAR and molecular docking from FDA approved drugs</span></div><div class="casAuthors">Ye, Wen-Ling; Zhang, Liu-Xia; Guan, Yi-Di; Xue, Wei-Wei; Chen, Alex F.; Cao, Qian; Cheng, Yan; Cao, Dong-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">New Journal of Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">19097-19106</span>CODEN:
                <span class="NLM_cas:coden">NJCHE5</span>;
        ISSN:<span class="NLM_cas:issn">1144-0546</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF2K), a calcium/calmodulin-dependent protein kinase, is a potential target for treating cancer. eEF2K can reduce the binding ability of eEF2 to ribosomes by phosphorylating eEF2, thereby inhibiting peptide chain extension and neg. regulating protein synthesis, which provides a cytoprotective mechanism for the development of cancer. eEF2K has been reported to be overexpressed in various types of cancers.  Therefore, it is of high importance to discover new eEF2K inhibitors for cancer therapy.  Here, we proposed a three-step screening strategy to seek eEF2K inhibitors from the FDA approved drug library: homol. modeling of eEF2K protein, SAR-based virtual screening, and docking-based virtual screening.  Based on the screening strategy, 13 drugs with high evaluation scores were purchased to measure their binding affinity (KD) to eEF2K by using the SPR assay.  The assay results suggested that 4 drugs may be potential eEF2K inhibitors, which are Pemetrexed (KD = 0.104 μM), Entecavir (KD = 2.16 μM), calcium levofolinate (KD = 11.7 μM), and Fosbretabulin (KD = 34.5 μM).  To further validate whether these drugs act on eEF2K, Western blot (WB) anal. was performed, which showed that Pemetrexed and Entecavir could inhibit the eEF2K activity.  Furthermore, mol. dynamics (MD) simulation was carried out to further demonstrate the interaction of eEF2K with Pemetrexed, the most bioactive drug.  The specific in vitro/in vivo interaction mechanisms between these drugs and eEF2K are under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofGwzBm2RnzbVg90H21EOLACvtfcHk0lj0oCkUnWjneA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2gt73K&md5=fc20c7884a186c66628594882330f7b4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1039%2FC9NJ02600B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9NJ02600B%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DW.%2BL.%26aulast%3DZhang%26aufirst%3DL.%2BX.%26aulast%3DGuan%26aufirst%3DY.%2BDi%26aulast%3DXue%26aufirst%3DW.%2BW.%26aulast%3DChen%26aufirst%3DA.%2BF.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DD.%2BS.%26atitle%3DVirtual%2520Screening%2520and%2520Experimental%2520Validation%2520of%2520EEF2K%2520Inhibitors%2520by%2520Combining%2520Homology%2520Modeling%252C%2520QSAR%2520and%2520Molecular%2520Docking%2520from%2520FDA%2520Approved%2520Drugs%26jtitle%3DNew%2520J.%2520Chem.%26date%3D2019%26volume%3D43%26spage%3D19097%26epage%3D19106%26doi%3D10.1039%2FC9NJ02600B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span> <span> </span><span class="NLM_article-title">Combined Treatment of Mitoxantrone Sensitizes Breast Cancer Cells to Rapalogs through Blocking EEF-2K-Mediated Activation of Akt and Autophagy</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">948</span>, <span class="refDoi"> DOI: 10.1038/s41419-020-03153-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fs41419-020-03153-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=33144562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlCqur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=948&author=Y.+Guanauthor=S.+Jiangauthor=W.+Yeauthor=X.+Renauthor=X.+Wangauthor=Y.+Zhangauthor=M.+Yinauthor=K.+Wangauthor=Y.+Taoauthor=J.+M.+Yangauthor=D.+Caoauthor=Y.+Cheng&title=Combined+Treatment+of+Mitoxantrone+Sensitizes+Breast+Cancer+Cells+to+Rapalogs+through+Blocking+EEF-2K-Mediated+Activation+of+Akt+and+Autophagy&doi=10.1038%2Fs41419-020-03153-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy</span></div><div class="casAuthors">Guan, Yidi; Jiang, Shilong; Ye, Wenling; Ren, Xingcong; Wang, Xinluan; Zhang, Yi; Yin, Mingzhu; Wang, Kuansong; Tao, Yongguang; Yang, JinMing; Cao, Dongsheng; Cheng, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">948</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Oncogenic activation of the mTOR signaling pathway occurs frequently in tumor cells and contributes to the devastating features of cancer, including breast cancer. mTOR inhibitors rapalogs are promising anticancer agents in clin. trials; however, rapalogs resistance remains an unresolved clin. challenge.  In this study, we found that eEF-2K, which is overexpressed in cancer cells and is required for survival of stressed cells, was involved in the neg.-feedback activation of Akt and cytoprotective autophagy induction in breast cancer cells in response to mTOR inhibitors.  Therefore, disruption of eEF-2K simultaneously abrogates the two crit. resistance signaling pathways, sensitizing breast cancer cells to rapalogs.  Importantly, we identified mitoxantrone, an admitted anticancer drug for a wide range of tumors, as a potential inhibitor of eEF-2K via a structure-based virtual screening strategy.  We further demonstrated that mitoxantrone binds to eEF-2K and inhibits its activity, and the combination treatment of mitoxantrone and mTOR inhibitor resulted in significant synergistic cytotoxicity in breast cancer.  In conclusion, we report that eEF-2K contributes to the activation of resistance signaling pathways of mTOR inhibitor, suggesting a novel strategy to enhance mTOR-targeted cancer therapy through combining mitoxantrone, an eEF-2K inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmZBm2wJhJJbVg90H21EOLACvtfcHk0lj0oCkUnWjneA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlCqur7M&md5=7bb44468fcbef7b2a5f15f3c4938c062</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fs41419-020-03153-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-020-03153-x%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DY.%26atitle%3DCombined%2520Treatment%2520of%2520Mitoxantrone%2520Sensitizes%2520Breast%2520Cancer%2520Cells%2520to%2520Rapalogs%2520through%2520Blocking%2520EEF-2K-Mediated%2520Activation%2520of%2520Akt%2520and%2520Autophagy%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2020%26volume%3D11%26spage%3D948%26doi%3D10.1038%2Fs41419-020-03153-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhola, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bafna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meszoely, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">Kinome-Wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1158%2F0008-5472.CAN-14-2475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=25480943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=405-414&author=N.+E.+Bholaauthor=V.+M.+Jansenauthor=S.+Bafnaauthor=J.+M.+Giltnaneauthor=J.+M.+Balkoauthor=M.+V.+Estradaauthor=I.+Meszoelyauthor=I.+Mayerauthor=V.+Abramsonauthor=F.+Yeauthor=M.+Sandersauthor=T.+C.+Duggerauthor=E.+V.+Allenauthor=C.+L.+Arteaga&title=Kinome-Wide+Functional+Screen+Identifies+Role+of+PLK1+in+Hormone-Independent%2C+ER-Positive+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-14-2475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer</span></div><div class="casAuthors">Bhola, Neil E.; Jansen, Valerie M.; Bafna, Sangeeta; Giltnane, Jennifer M.; Balko, Justin M.; Estrada, Monica V.; Meszoely, Ingrid; Mayer, Ingrid; Abramson, Vandana; Ye, Fei; Sanders, Melinda; Dugger, Teresa C.; Allen, Eliezer V.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">405-414</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings suggest that breast cancers that recur in a hormone-independent form may be sensitive to attack by exptl. small mol. inhibitors that target the mitotic kinase PLK1, the most advanced of which is currently in phase III trials for acute myeloid leukemias.  Estrogen receptor (ER) α-pos. breast cancers initially respond to antiestrogens but eventually become estrogen independent and recur.  ER+ breast cancer cells resistant to long-term estrogen deprivation (LTED) exhibit hormone-independent ER transcriptional activity and growth.  A kinome-wide siRNA screen using a library targeting 720 kinases identified Polo-like kinase 1 (PLK1) as one of the top genes whose downregulation resulted in inhibition of estrogen-independent ER transcriptional activity and growth of LTED cells.  High PLK1 mRNA and protein correlated with a high Ki-67 score in primary ER+ breast cancers after treatment with the aromatase inhibitor letrozole.  RNAi-mediated knockdown of PLK1 inhibited ER expression, estrogen-independent growth, and ER transcription in MCF7 and HCC1428 LTED cells.  Pharmacol. inhibition of PLK1 with volasertib, a small-mol. ATP-competitive PLK1 inhibitor, decreased LTED cell growth, ER transcriptional activity, and ER expression.  Volasertib in combination with the ER antagonist, fulvestrant, decreased MCF7 xenograft growth in ovariectomized mice more potently than each drug alone.  JUNB, a component of the AP-1 complex, was expressed 16-fold higher in MCF7/LTED compared with parental MCF7 cells.  Furthermore, JUNB and BCL2L1 (which encodes antiapoptotic BCL-xL) mRNA levels were markedly reduced upon volasertib treatment in MCF7/LTED cells, while they were increased in parental MCF7 cells.  Finally, JUNB knockdown decreased ER expression and transcriptional activity in MCF7/LTED cells, suggesting that PLK1 drives ER expression and estrogen-independent growth via JUNB.  These data support a crit. role of PLK1 in acquired hormone-independent growth of ER+ human breast cancer and is therefore a promising target in tumors that have escaped estrogen deprivation therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotBYnbgcIjm7Vg90H21EOLACvtfcHk0lj0oCkUnWjneA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWiug%253D%253D&md5=d33d1b9954337951c31a0e316191332b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2475%26sid%3Dliteratum%253Aachs%26aulast%3DBhola%26aufirst%3DN.%2BE.%26aulast%3DJansen%26aufirst%3DV.%2BM.%26aulast%3DBafna%26aufirst%3DS.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DEstrada%26aufirst%3DM.%2BV.%26aulast%3DMeszoely%26aufirst%3DI.%26aulast%3DMayer%26aufirst%3DI.%26aulast%3DAbramson%26aufirst%3DV.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DSanders%26aufirst%3DM.%26aulast%3DDugger%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DE.%2BV.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DKinome-Wide%2520Functional%2520Screen%2520Identifies%2520Role%2520of%2520PLK1%2520in%2520Hormone-Independent%252C%2520ER-Positive%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D405%26epage%3D414%26doi%3D10.1158%2F0008-5472.CAN-14-2475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Polo-like Kinase 1/Eukaryotic Elongation Factor 2 Kinase (PLK1/EEF2K) Dual Inhibitors for Regulating Breast Cancer Cells Apoptosis and Autophagy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ejmech.2017.12.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29288948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Kmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=517-528&author=Z.+Panauthor=Y.+Chenauthor=J.+Liuauthor=Q.+Jiangauthor=S.+Yangauthor=L.+Guoauthor=G.+He&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Polo-like+Kinase+1%2FEukaryotic+Elongation+Factor+2+Kinase+%28PLK1%2FEEF2K%29+Dual+Inhibitors+for+Regulating+Breast+Cancer+Cells+Apoptosis+and+Autophagy&doi=10.1016%2Fj.ejmech.2017.12.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy</span></div><div class="casAuthors">Pan, Zhaoping; Chen, Yujuan; Liu, Jingyan; Jiang, Qinglin; Yang, Shengyong; Guo, Li; He, Gu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Both PLK1 and EEF2K are serine/threonine kinases that play important roles in the proliferation and programmed cell death of various types of cancer.  They are highly expressed in breast cancer tissues.  Based on the multiple-complexes generated pharmacophore models of PLK1 and homol. models of EEF2K, the integrated virtual screening is performed to discover novel PLK1/EEF2K dual inhibitors.  The top ten hit compds. are selected and tested in vitro, and five of them display PLK1 and EEF2K inhibition in vitro.  Based on the docking modes of the most potent hit compd., a series of derivs. are synthesized, characterized and biol. assayed on the PLK1, EEF2K as well as breast cancer cell proliferation models.  Compd. I with satisfied inhibitory potency are shifted to mol. mechanism studies contained mol. dynamics simulations, cell cycles, apoptosis and autophagy assays.  Our results suggested that these novel PLK1/EEF2K dual inhibitors can be used as lead compds. for further development breast cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW3GfRJEilVbVg90H21EOLACvtfcHk0lhxxQD6nnB9pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Kmsw%253D%253D&md5=21a2433b436edc4c3cfae89389fdfd6e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Polo-like%2520Kinase%25201%252FEukaryotic%2520Elongation%2520Factor%25202%2520Kinase%2520%2528PLK1%252FEEF2K%2529%2520Dual%2520Inhibitors%2520for%2520Regulating%2520Breast%2520Cancer%2520Cells%2520Apoptosis%2520and%2520Autophagy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D517%26epage%3D528%26doi%3D10.1016%2Fj.ejmech.2017.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Ablation of Elongation Factor 2 Kinase Enhances Heat-Shock Protein 90 Chaperone Expression and Protects Cells under Proteotoxic Stress</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">7169</span>– <span class="NLM_lpage">7176</span>, <span class="refDoi"> DOI: 10.1074/jbc.AC119.008036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1074%2Fjbc.AC119.008036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30890561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWiu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=7169-7176&author=J.+Xieauthor=P.+Van+Dammeauthor=D.+Fangauthor=C.+G.+Proud&title=Ablation+of+Elongation+Factor+2+Kinase+Enhances+Heat-Shock+Protein+90+Chaperone+Expression+and+Protects+Cells+under+Proteotoxic+Stress&doi=10.1074%2Fjbc.AC119.008036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Ablation of elongation factor 2 kinase enhances heat-shock protein 90 chaperone expression and protects cells under proteotoxic stress</span></div><div class="casAuthors">Xie, Jianling; Van Damm, Petra; Fang, Danielle; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7169-7177</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) neg. regulates the elongation stage of mRNA translation and is activated under different stress conditions to slow down protein synthesis.  One effect of eEF2K is to alter the repertoire of expressed proteins, perhaps to aid survival of stressed cells.  Here, we applied pulsed stable isotope labeling with amino acids in cell culture (SILAC) to study changes in the synthesis of specific proteins in human lung adenocarcinoma (A549) cells in which eEF2K had been depleted by an inducible shRNA.  We discovered that levels of heat-shock protein 90 (HSP90) are increased in eEF2K-depleted human cells as well as in eEF2K-knockout (eEF2K-/-) mouse embryonic fibroblasts (MEFs).  This rise in HSP90 coincided with an increase in the fraction of HSP90 mRNAs assocd. with translationally active polysomes, irresp. of unchanged total HSP90 levels.  These results indicate that blocking eEF2K function can enhance expression of HSP90 chaperones.  In eEF2K-/- mouse embryonic fibroblasts (MEFs), inhibition of HSP90 by its specific inhibitor AUY922 promoted the accumulation of ubiquitinated proteins.  Notably, HSP90 inhibition promoted apoptosis of eEF2K-/- MEFs under proteostatic stress induced by the proteasome inhibitor MG132.  Up-regulation of HSP90 likely protects cells from protein folding stress, arising, for example, from faster rates of polypeptide synthesis due to the lack of eEF2K.  Our findings indicate that eEF2K and HSPs closely cooperate to maintain proper proteostasis and suggest that concomitant inhibition of HSP90 and eEF2K could be a strategy to decrease cancer cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUSdrHKdrom7Vg90H21EOLACvtfcHk0lhxxQD6nnB9pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWiu7vF&md5=884bc4568b694807921b6a4bb4037b46</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.AC119.008036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.AC119.008036%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DAblation%2520of%2520Elongation%2520Factor%25202%2520Kinase%2520Enhances%2520Heat-Shock%2520Protein%252090%2520Chaperone%2520Expression%2520and%2520Protects%2520Cells%2520under%2520Proteotoxic%2520Stress%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D7169%26epage%3D7176%26doi%3D10.1074%2Fjbc.AC119.008036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.-x.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Elongation Factor-2 Kinase Regulates the Cross-Talk between Autophagy and Pyroptosis in Doxorubicin-Treated Human Melanoma Cells in Vitro</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1038/s41401-019-0222-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1038%2Fs41401-019-0222-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30914761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslKktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=1237-1244&author=P.+Yuauthor=H.-y.+Wangauthor=M.+Tianauthor=A.-x.+Liauthor=X.-s.+Chenauthor=X.-l.+Wangauthor=Y.+Zhangauthor=Y.+Cheng&title=Eukaryotic+Elongation+Factor-2+Kinase+Regulates+the+Cross-Talk+between+Autophagy+and+Pyroptosis+in+Doxorubicin-Treated+Human+Melanoma+Cells+in+Vitro&doi=10.1038%2Fs41401-019-0222-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro</span></div><div class="casAuthors">Yu, Pian; Wang, Hai-yan; Tian, Min; Li, Ao-xue; Chen, Xi-sha; Wang, Xin-luan; Zhang, Yi; Cheng, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1237-1244</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF-2K), a neg. regulator of protein synthesis, has been shown to play an important role in modulating autophagy and apoptosis in tumor cells under various stresses.  In this study, we investigated the regulatory role of eEF-2K in pyroptosis (a new form of programmed necrosis) in doxorubicin-treated human melanoma cells.  We found that doxorubicin (0.5-5μmol/L) induced pyroptosis in melanoma cell lines SK-MEL-5, SK-MEL-28, and A-375 with high expression of DFNA5, but not in human breast cancer cell line MCF-7 with little expression of DFNA5.  On the other hand, doxorubicin treatment activated autophagy in the melanoma cells; inhibition of autophagy by transfecting the cells with siRNA targeting Beclin1 or by pretreatment with chloroquine (20μmol/L) significantly augmented pyroptosis, thus sensitizing the melanoma cells to doxorubicin.  We further demonstrated that doxorubicin treatment activated eEF-2K in the melanoma cells, and silencing of eEF-2K blunted autophagic responses, but promoted doxorubicin-induced pyroptotic cell death.  Taken together, the above results demonstrate that eEF-2K dictates the cross-talk between pyroptosis and autophagy in doxorubicin-treated human melanoma cells; suppression of eEF-2K results in inhibiting autophagy and augmenting pyroptosis, thus modulating the sensitivity of melanoma cells to doxorubicin, suggesting that targeting eEF-2K may reinforce the antitumor efficacy of doxorubicin, offering a new insight into tumor chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEj3G3I-UI1rVg90H21EOLACvtfcHk0lhxxQD6nnB9pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslKktLY%253D&md5=26984675c5f05a6628e59b3bbc2bc037</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fs41401-019-0222-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-019-0222-z%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DH.-y.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DA.-x.%26aulast%3DChen%26aufirst%3DX.-s.%26aulast%3DWang%26aufirst%3DX.-l.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DY.%26atitle%3DEukaryotic%2520Elongation%2520Factor-2%2520Kinase%2520Regulates%2520the%2520Cross-Talk%2520between%2520Autophagy%2520and%2520Pyroptosis%2520in%2520Doxorubicin-Treated%2520Human%2520Melanoma%2520Cells%2520in%2520Vitro%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D1237%26epage%3D1244%26doi%3D10.1038%2Fs41401-019-0222-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Inhibiting EEF-2 Kinase-Mediated Autophagy Enhanced the Cytocidal Effect of AKT Inhibitor on Human Nasopharyngeal Carcinoma</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2655</span>– <span class="NLM_lpage">2663</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S169952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.2147%2FDDDT.S169952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30214154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGru77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=2655-2663&author=Y.+Y.+Zhaoauthor=Y.+Tianauthor=L.+Liuauthor=J.+H.+Zhanauthor=X.+Houauthor=X.+Chenauthor=T.+Zhouauthor=Y.+Huangauthor=L.+Zhang&title=Inhibiting+EEF-2+Kinase-Mediated+Autophagy+Enhanced+the+Cytocidal+Effect+of+AKT+Inhibitor+on+Human+Nasopharyngeal+Carcinoma&doi=10.2147%2FDDDT.S169952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma</span></div><div class="casAuthors">Zhao, Yuan-yuan; Tian, Ying; Liu, Lin; Zhan, Jian-hua; Hou, Xue; Chen, Xi; Zhou, Ting; Huang, Yan; Zhang, Li</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2655-2663</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Aim: Our previous research showed that AKT inactivation via small mol. inhibitors did not induce significant apoptosis, but rather markedly increased autophagy in nasopharyngeal carcinoma (NPC).  The purpose of the current study was to det. whether autophagy inhibition can enhance the anticancer efficacy of an AKT inhibitor (MK-2206).  Materials and methods: NPC cell lines CNE-2 (Epstein-Barr virus neg.) and C666-1 (Epstein-Barr virus pos.) were used to conduct the research.  Autophagy induction effects were evaluated via Western blotting.  Eukaryotic elongation factor-2 (eEF-2) kinase was specifically and stably knocked down using shRNA.  The growth and proliferation of the cells were assessed by Cell Counting Kit-8.  In CNE-2 xenograft tumors, the antitumor effects of an AKT inhibitor (MK-2206) combined with an eEF-2 kinase inhibitor (NH125) were tested.  Results: MK-2206 induced eEF-2 kinase-dependent autophagy in NPC cell lines.  Knockdown of eEF-2 kinase using shRNA blunted the autophagy activated by MK-2206.  Compared with treatment with MK-2206 alone, shRNA or NH125 suppressed eEF-2 kinase and increased the growth-inhibitory effect of MK-2206 on the human NPC cell lines.  The synergistic effects of eEF-2 kinase inhibition and MK-2206 were similar to those of the combination of hydroxychloroquine and MK-2206.  Moreover, NH125 showed good synergistic effects with MK-2206 in vivo.  Conclusion: eEF-2 kinase-mediated autophagy induced by AKT inhibition played a protective role in NPC cells.  Inhibition of eEF-2 kinase may be an effective method for increasing the efficacy of an AKT inhibitor such as MK-2206 in NPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroi6eXROUFC7Vg90H21EOLACvtfcHk0lh_gLwLgrK5cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGru77N&md5=3e5fcf3993f95bc0a70df2a902fa35a6</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S169952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S169952%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BY.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DJ.%2BH.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DInhibiting%2520EEF-2%2520Kinase-Mediated%2520Autophagy%2520Enhanced%2520the%2520Cytocidal%2520Effect%2520of%2520AKT%2520Inhibitor%2520on%2520Human%2520Nasopharyngeal%2520Carcinoma%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2018%26volume%3D12%26spage%3D2655%26epage%3D2663%26doi%3D10.2147%2FDDDT.S169952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span> <span> </span><span class="NLM_article-title">Gastric Adenocarcinoma Predictive Long Intergenic Non-Coding RNA Promotes Tumor Occurrence and Progression in Non-Small Cell Lung Cancer via Regulation of the MiR-661/EEF2K Signaling Pathway</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2136</span>– <span class="NLM_lpage">2147</span>, <span class="refDoi"> DOI: 10.1159/000495831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1159%2F000495831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30522114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWrt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=2136-2147&author=H.+Guauthor=J.+Chenauthor=Y.+Songauthor=H.+Shao&title=Gastric+Adenocarcinoma+Predictive+Long+Intergenic+Non-Coding+RNA+Promotes+Tumor+Occurrence+and+Progression+in+Non-Small+Cell+Lung+Cancer+via+Regulation+of+the+MiR-661%2FEEF2K+Signaling+Pathway&doi=10.1159%2F000495831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Gastric Adenocarcinoma Predictive Long Intergenic Non-Coding RNA Promotes Tumor Occurrence and Progression in Non-Small Cell Lung Cancer via Regulation of the miR-661/eEF2K Signaling Pathway</span></div><div class="casAuthors">Gu, Haiting; Chen, Junfeng; Song, Yukang; Shao, Haiyan</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2136-2147</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: Long non-coding RNAs (lncRNAs) play vital roles in carcinogenesis as oncogenes or tumor suppressor genes.  This study explored the biol. function of lncRNA gastric adenocarcinoma predictive long intergenic non-coding RNA (GAPLINC) in human non-small cell lung cancer (NSCLC).  Methods: GAPLINC expression in NSCLC specimens and cell lines was detected by qRT-PCR and Western blot.  The effect of GAPLINC on cell proliferation was investigated using CCK8-assay, colony formation assay, and xenograft model.  The effects of GAPLINC on apoptosis and cell cycle were detd. using flow cytometry.  The mechanism of GAPLINC involved in NSCLC was explored using Western blot, luciferase reporter assay, and RNA fluorescence in situ hybridization.  Results: We found that GAPLINC expression was up-regulated in NSCLC tissues and cell lines.  Overexpression of GAPLINC was assocd. with poor prognosis in patients with NSCLC.  Silencing of GAPLINC significantly inhibited cell proliferation, promoted apoptosis, and induced cell cycle arrest in the G0/G1 phase.  Results from xenograft transplantation showed that GAPLINC silencing inhibited the tumor growth in vivo.  Interestingly, GAPLINC silencing decreased the expression of eukaryotic elongation factor-2 kinase (eEF2K) protein both in vivo and in vitro.  Bioinformatic anal. and luciferase reporter confirmed that miR-661 targeted GAPLINC and eEF2K 3'-UTR and was neg. correlated with the expression of GAPLINC and eEF2K.  Conclusion: Our findings indicate that GAPLINC promotes NSCLC tumorigenesis by regulating miR-661/eEF2K cascade and provide new insights for the pathogenesis underlying NSCLC and potential targets for therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5N70wrpv2srVg90H21EOLACvtfcHk0lh_gLwLgrK5cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWrt7vI&md5=b199620ca03d39f1e866ab69af258639</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1159%2F000495831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000495831%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DShao%26aufirst%3DH.%26atitle%3DGastric%2520Adenocarcinoma%2520Predictive%2520Long%2520Intergenic%2520Non-Coding%2520RNA%2520Promotes%2520Tumor%2520Occurrence%2520and%2520Progression%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520via%2520Regulation%2520of%2520the%2520MiR-661%252FEEF2K%2520Signaling%2520Pathway%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2018%26volume%3D51%26spage%3D2136%26epage%3D2147%26doi%3D10.1159%2F000495831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">EEF-2 Kinase-Targeted MiR-449b Confers Radiation Sensitivity to Cancer Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.canlet.2018.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=29331413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2018&pages=64-74&author=C.+Jiauthor=Q.+H.+Xuauthor=L.+C.+Guoauthor=X.+H.+Wangauthor=Y.+J.+Renauthor=H.+H.+Zhangauthor=W.+D.+Zhuauthor=Z.+J.+Mingauthor=Y.+S.+Yuanauthor=X.+C.+Renauthor=J.+X.+Songauthor=Y.+Chengauthor=J.+M.+Yangauthor=Y.+Zhang&title=EEF-2+Kinase-Targeted+MiR-449b+Confers+Radiation+Sensitivity+to+Cancer+Cells&doi=10.1016%2Fj.canlet.2018.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">eEF-2 Kinase-targeted miR-449b confers radiation sensitivity to cancer cells</span></div><div class="casAuthors">Ji, Cheng; Xu, Qiong Hua; Guo, Ling Chuan; Wang, Xiao Hui; Ren, Yi Jie; Zhang, Hong Han; Zhu, Wei Dong; Ming, Zhi Jun; Yuan, Yun Sheng; Ren, Xing Cong; Song, Jian Xun; Cheng, Yan; Yang, Jin Ming; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64-74</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The roles of microRNA in regulation of various biol. processes and in modulation of therapeutic effects have been widely appreciated.  In this study, we found a pos. correlation between miR-449 b expression and radiation sensitivity in cancer cells and in tumor specimens from patients.  We showed that eEF-2 kinase, a neg. regulator of global protein synthesis, is a target of miR-449 b.  Introducing a miR-449 b mimic into cancer cells led to suppression of eEF-2 kinase expression, leading to increases of protein synthesis and depletion of cellular ATP.  Further, we demonstrated that the miR-449 b mimic rendered the cancer cells more sensitive to ionizing radiation both in vitro (cell culture) and in vivo (animal xenograft model).  Moreover, the radiation sensitivity conferred by miR-449 b could be blunted by cycloheximide, an inhibitor of protein synthesis, or by direct delivery of ATP liposome, supporting eEF-2 kinase as a mediator of the radio-sensitizing effects of miR-449 b.  These results indicate that miR-449 b, which is frequently down-regulated in radio-resistant cancers, may represent a new crit. determinant of radio-sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN1ld40ST8ILVg90H21EOLACvtfcHk0lh_gLwLgrK5cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOnu7g%253D&md5=6dd7545c470bb2317f69323163eb39ec</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DQ.%2BH.%26aulast%3DGuo%26aufirst%3DL.%2BC.%26aulast%3DWang%26aufirst%3DX.%2BH.%26aulast%3DRen%26aufirst%3DY.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%2BH.%26aulast%3DZhu%26aufirst%3DW.%2BD.%26aulast%3DMing%26aufirst%3DZ.%2BJ.%26aulast%3DYuan%26aufirst%3DY.%2BS.%26aulast%3DRen%26aufirst%3DX.%2BC.%26aulast%3DSong%26aufirst%3DJ.%2BX.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DEEF-2%2520Kinase-Targeted%2520MiR-449b%2520Confers%2520Radiation%2520Sensitivity%2520to%2520Cancer%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D418%26spage%3D64%26epage%3D74%26doi%3D10.1016%2Fj.canlet.2018.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhlis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanlikilicer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">NcRNA Therapy with MiRNA-22–3p Suppresses the Growth of Triple-Negative Breast Cancer</span>. <i>Mol. Ther.--Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1016/j.omtn.2021.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.omtn.2021.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=33614241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjs1yiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2021&pages=930-943&author=A.+Gorurauthor=R.+Bayraktarauthor=C.+Ivanauthor=H.+A.+Mokhlisauthor=E.+Bayraktarauthor=N.+Kahramanauthor=D.+Karakasauthor=S.+Karamilauthor=N.+N.+Kabilauthor=P.+Kanlikilicerauthor=B.+Aslanauthor=L.+Tamerauthor=Z.+Wangauthor=V.+Cristiniauthor=G.+Lopez-Beresteinauthor=G.+Calinauthor=B.+Ozpolat&title=NcRNA+Therapy+with+MiRNA-22%E2%80%933p+Suppresses+the+Growth+of+Triple-Negative+Breast+Cancer&doi=10.1016%2Fj.omtn.2021.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer</span></div><div class="casAuthors">Gorur, Aysegul; Bayraktar, Recep; Ivan, Cristina; Mokhlis, Hamada Ahmed; Bayraktar, Emine; Kahraman, Nermin; Karakas, Didem; Karamil, Selda; Kabil, Nashwa N.; Kanlikilicer, Pinar; Aslan, Burcu; Tamer, Lulufer; Wang, Zhihui; Cristini, Vittorio; Lopez-Berestein, Gabriel; Calin, George; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy--Nucleic Acids</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">930-943</span>CODEN:
                <span class="NLM_cas:coden">MTAOC5</span>;
        ISSN:<span class="NLM_cas:issn">2162-2531</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Deregulation of noncoding RNAs, including microRNAs (miRs), is implicated in the pathogenesis of many human cancers, including breast cancer.  Through extensive anal. of The Cancer Genome Atlas, we found that expression of miR-22-3p is markedly lower in triple-neg. breast cancer (TNBC) than in normal breast tissue.  The restoration of miR-22-3p expression led to significant inhibition of TNBC cell proliferation, colony formation, migration, and invasion.  We demonstrated that miR-22-3p reduces eukaryotic elongation factor 2 kinase (eEF2K) expression by directly binding to the 3' untranslated region of eEF2K mRNA.  Inhibition of EF2K expression recapitulated the effects of miR-22-3p on TNBC cell proliferation, motility, invasion, and suppression of phosphatidylinositol 3-kinase/Akt and Src signaling.  Systemic administration of miR-22-3p in single-lipid nanoparticles significantly suppressed tumor growth in orthotopic MDA-MB-231 and MDA-MB-436 TNBC models.  Evaluation of the tumor response, following miR-22-3p therapy in these models using a novel math. model factoring in various in vivo parameters, demonstrated that the therapy is highly effective against TNBC.  These findings suggest that miR-22-3p functions as a tumor suppressor by targeting clin. significant oncogenic pathways and that miR-22-3p loss contributes to TNBC growth and progression.  The restoration of miR-22-3p expression is a potential novel noncoding RNA-based therapy for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeKCFNM1OYs7Vg90H21EOLACvtfcHk0ljql74K1bMj8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjs1yiu70%253D&md5=9566fa8d23b98d6d398303f12d7b2bdc</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.omtn.2021.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.omtn.2021.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DGorur%26aufirst%3DA.%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DMokhlis%26aufirst%3DH.%2BA.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DKarakas%26aufirst%3DD.%26aulast%3DKaramil%26aufirst%3DS.%26aulast%3DKabil%26aufirst%3DN.%2BN.%26aulast%3DKanlikilicer%26aufirst%3DP.%26aulast%3DAslan%26aufirst%3DB.%26aulast%3DTamer%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCristini%26aufirst%3DV.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DCalin%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DNcRNA%2520Therapy%2520with%2520MiRNA-22%25E2%2580%25933p%2520Suppresses%2520the%2520Growth%2520of%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DMol.%2520Ther.--Nucleic%2520Acids%26date%3D2021%26volume%3D23%26spage%3D930%26epage%3D943%26doi%3D10.1016%2Fj.omtn.2021.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shahbazi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulubayram, K.</span></span> <span> </span><span class="NLM_article-title">Modified Gold-Based SiRNA Nanotherapeutics for Targeted Therapy of Triple-Negative Breast Cancer</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1961</span>– <span class="NLM_lpage">1973</span>, <span class="refDoi"> DOI: 10.2217/nnm-2017-0081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.2217%2Fnnm-2017-0081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=28745127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GhtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1961-1973&author=R.+Shahbaziauthor=E.+Asikauthor=N.+Kahramanauthor=M.+Turkauthor=B.+Ozpolatauthor=K.+Ulubayram&title=Modified+Gold-Based+SiRNA+Nanotherapeutics+for+Targeted+Therapy+of+Triple-Negative+Breast+Cancer&doi=10.2217%2Fnnm-2017-0081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Modified gold-based sirna nanotherapeutics for targeted therapy of triple-negative breast cancer</span></div><div class="casAuthors">Shahbazi, Reza; Asik, Elif; Kahraman, Nermin; Turk, Mustafa; Ozpolat, Bulent; Ulubayram, Kezban</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1961-1973</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1748-6963</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aim: In this study, we aimed to therapeutically target eukaryotic elongation factor 2 kinase (eEF-2K) in an in vivo triple-neg. breast cancer (TNBC) tumor model.  Materials & methods: We synthesized a highly monodisperse nanoformulation using polyethylenimine-modified gold nanoparticles (AuNP-PEI) as siRNA delivery vehicle and evaluated gene downregulation.  Results: We found that AuNP-PEI/eEF-2K nanoformulation was highly effective for in vitro and in vivo gene downregulation and showed remarkable antitumor efficacy that was assocd. with eEF-2K knockdown, inhibition of Src and MAPK-ERK signaling pathways in a TNBC orthotopic tumor model.  Conclusion: Our study suggests that eEF-2K plays an important role in TNBC tumorigenesis and its inhibition by AuNP-PEI/eEF-2K siRNA-based nanotherapeutics may be a potential therapeutic strategy for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripOvKyjzSbLVg90H21EOLACvtfcHk0ljql74K1bMj8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GhtbbO&md5=587825bab8fc793fe3fc34f4a36e8a92</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.2217%2Fnnm-2017-0081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm-2017-0081%26sid%3Dliteratum%253Aachs%26aulast%3DShahbazi%26aufirst%3DR.%26aulast%3DAsik%26aufirst%3DE.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DTurk%26aufirst%3DM.%26aulast%3DOzpolat%26aufirst%3DB.%26aulast%3DUlubayram%26aufirst%3DK.%26atitle%3DModified%2520Gold-Based%2520SiRNA%2520Nanotherapeutics%2520for%2520Targeted%2520Therapy%2520of%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DNanomedicine%26date%3D2017%26volume%3D12%26spage%3D1961%26epage%3D1973%26doi%3D10.2217%2Fnnm-2017-0081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poganik, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aye, Y.</span></span> <span> </span><span class="NLM_article-title">On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">3610</span>– <span class="NLM_lpage">3622</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b12608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b12608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVCis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=3610-3622&author=M.+J.+C.+Longauthor=J.+R.+Poganikauthor=Y.+Aye&title=On-Demand+Targeting%3A+Investigating+Biology+with+Proximity-Directed+Chemistry&doi=10.1021%2Fjacs.5b12608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry</span></div><div class="casAuthors">Long, Marcus J. C.; Poganik, Jesse R.; Aye, Yimon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3610-3622</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proximity enhancement is a central chem. tenet underpinning an exciting suite of small-mol. toolsets that have allowed us to unravel many biol. complexities.  The leitmotif of this opus is "tethering"-a strategy in which a multifunctional small mol. serves as a template to bring proteins/biomols. together.  Scaffolding approaches have been powerfully applied to control diverse biol. outcomes such as protein-protein assocn., protein stability, activity, and improve imaging capabilities.  A new twist on this strategy has recently appeared, in which the small-mol. probe is engineered to unleash controlled amts. of reactive chem. signals within the microenvironment of a target protein.  Modification of a specific target elicits a precisely timed and spatially controlled gain-of-function (or dominant loss-of-function) signaling response.  Presented herein is a unique personal outlook conceptualizing the powerful proximity-enhanced chem. biol. toolsets into two paradigms: "multifunctional scaffolding" vs. "on-demand targeting".  By addressing the latest advances and challenges in the established yet constantly evolving multifunctional scaffolding strategies as well as in the emerging on-demand precision targeting (and related) systems, this Perspective is aimed at choosing when it is best to employ each of the two strategies, with an emphasis toward further promoting novel applications and discoveries stemming from these innovative chem. biol. platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6dKG5laUM7Vg90H21EOLACvtfcHk0ljql74K1bMj8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVCis7g%253D&md5=40fa3d02e8de215dd7c596aa7a32af78</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b12608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b12608%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DPoganik%26aufirst%3DJ.%2BR.%26aulast%3DAye%26aufirst%3DY.%26atitle%3DOn-Demand%2520Targeting%253A%2520Investigating%2520Biology%2520with%2520Proximity-Directed%2520Chemistry%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D3610%26epage%3D3622%26doi%3D10.1021%2Fjacs.5b12608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Designing an EEF2K-Targeting PROTAC Small Molecule That Induces Apoptosis in MDA-MB-231 Cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">112505</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1016%2Fj.ejmech.2020.112505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=32717479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVyjur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2020&pages=112505&author=Y.+Liuauthor=Y.+Zhenauthor=G.+Wangauthor=G.+Yangauthor=L.+Fuauthor=B.+Liuauthor=L.+Ouyang&title=Designing+an+EEF2K-Targeting+PROTAC+Small+Molecule+That+Induces+Apoptosis+in+MDA-MB-231+Cells&doi=10.1016%2Fj.ejmech.2020.112505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells</span></div><div class="casAuthors">Liu, Yao; Zhen, Yongqi; Wang, Guan; Yang, Gaoxia; Fu, Leilei; Liu, Bo; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112505</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) is a key α-kinase that neg. regulates the extension step of protein synthesis, which consumes most of the energy and amino acids required for protein synthesis.  Studies have found that eEF2K protein is related to the breast cancer.  However, existing inhibitor effect has not achieved the desired effect in cancer therapy.  Proteolysis target chimeric (PROTAC) technol. is uses proteasome to degrade target protein to achieve the purpose of inhibiting tumor cell growth.  Here, we reported that the use of PROTAC strategy in combining with star eEF2K inhibitor A484954 and its potential derivs.  Consequently, candidate compd. 11l was found to degrade eEF2K and induce apoptosis in human breast carcinoma MDA-MB-231 cells.  Together, these findings demonstrate that our eEF2K-targeting PROTAC small mol. would be a potential new strategy for future breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjwO5jWHiZhLVg90H21EOLACvtfcHk0lii5RwTv6vpwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVyjur7E&md5=76b64831dc135a5c75438b527ee5a8d8</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112505%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDesigning%2520an%2520EEF2K-Targeting%2520PROTAC%2520Small%2520Molecule%2520That%2520Induces%2520Apoptosis%2520in%2520MDA-MB-231%2520Cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D204%26spage%3D112505%26doi%3D10.1016%2Fj.ejmech.2020.112505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devkota, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warthaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edupuganti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, C. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Screens for EEF-2 Kinase</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1177/1087057113505204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1177%2F1087057113505204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24078616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWgsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=445-452&author=A.+K.+Devkotaauthor=M.+Warthakaauthor=R.+Edupugantiauthor=C.+D.+J.+Tavaresauthor=W.+H.+Johnsonauthor=B.+Ozpolatauthor=E.+J.+Choauthor=K.+N.+Dalby&title=High-Throughput+Screens+for+EEF-2+Kinase&doi=10.1177%2F1087057113505204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput screens for eEF-2 kinase</span></div><div class="casAuthors">Devkota, Ashwini K.; Warthaka, Mangalika; Edupuganti, Ramakrishna; Tavares, Clint D. J.; Johnson, William H.; Ozpolat, Bulent; Cho, Eun Jeong; Dalby, Kevin N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">445-452, 8</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">EEF-2 kinase is a potential therapeutic target for breast cancer, gliomas, and depression.  No potent inhibitors of eEF-2K have been reported, and thus development of high-throughput assay systems may expedite the process.  Two high-throughput assays are described for eEF-2K using recombinant, tag-free enzyme purified from bacteria.  The first is a fluorescence-based assay that uses the phosphorylation of a Sox-based peptide substrate by eEF-2K, which results in a 5-fold increase in fluorescence emission, allowing for continuous monitoring of the kinase activity.  The second is a luminescence-based assay that produces a luminescence signal, which correlates with the amt. of ATP remaining in the kinase reaction.  Both assays have been optimized and miniaturized for a 384-well plate format and validated in screens.  In conclusion, we demonstrated that a traditional radiolabeled assay can be readily transferred to universal spectroscopic assays that are robust and will facilitate high-throughput screening of larger size libraries for the identification of small-mol. inhibitors and significantly contribute to the development of therapies for targeting eEF2K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxD6CqjJyXRLVg90H21EOLACvtfcHk0lii5RwTv6vpwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWgsrnF&md5=fb49c1e0a2cda168e1b0ee82e728e3cb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1177%2F1087057113505204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057113505204%26sid%3Dliteratum%253Aachs%26aulast%3DDevkota%26aufirst%3DA.%2BK.%26aulast%3DWarthaka%26aufirst%3DM.%26aulast%3DEdupuganti%26aufirst%3DR.%26aulast%3DTavares%26aufirst%3DC.%2BD.%2BJ.%26aulast%3DJohnson%26aufirst%3DW.%2BH.%26aulast%3DOzpolat%26aufirst%3DB.%26aulast%3DCho%26aufirst%3DE.%2BJ.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26atitle%3DHigh-Throughput%2520Screens%2520for%2520EEF-2%2520Kinase%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2014%26volume%3D19%26spage%3D445%26epage%3D452%26doi%3D10.1177%2F1087057113505204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qadir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sari, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raithatha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Silva, L. G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poorkasreiy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waseem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teh, M.-T. T.</span></span> <span> </span><span class="NLM_article-title">Transcriptome Reprogramming by Cancer Exosomes: Identification of Novel Molecular Targets in Matrix and Immune Modulation</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">97</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1186%2Fs12943-018-0846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=30008265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFektbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=97&author=F.+Qadirauthor=M.+A.+Azizauthor=C.+P.+Sariauthor=H.+Maauthor=H.+Daiauthor=X.+Wangauthor=D.+Raithathaauthor=L.+G.+L.+Da+Silvaauthor=M.+Hussainauthor=S.+P.+Poorkasreiyauthor=I.+L.+Hutchisonauthor=A.+Waseemauthor=M.-T.+T.+Teh&title=Transcriptome+Reprogramming+by+Cancer+Exosomes%3A+Identification+of+Novel+Molecular+Targets+in+Matrix+and+Immune+Modulation&doi=10.1186%2Fs12943-018-0846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptome reprogramming by cancer exosomes: identification of novel molecular targets in matrix and immune modulation</span></div><div class="casAuthors">Qadir, Fatima; Aziz, Mohammad Arshad; Sari, Chrisdina Puspita; Ma, Hong; Dai, Haiyan; Wang, Xun; Raithatha, Dhiresh; Lagreca Da Silva, Lucas Girotto; Hussain, Muhammad; Poorkasreiy, Seyedeh P.; Hutchison, Iain L.; Waseem, Ahmad; Teh, Muy-Teck</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97/1-97/16</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Exosomes are extracellular vesicles released by almost all cell types, including cancer cells, into bodily fluids such as saliva, plasma, breast milk, semen, urine, cerebrospinal fluid, amniotic fluid, synovial fluid and sputum.  Their key function being intercellular communication with both neighboring as well as distant cells.  Cancer exosomes have been shown to regulate organ-specific metastasis.  However, little is known about the functional differences and mol. consequences of normal cells responding to exosomes derived from normal cells compared to those derived from cancer cells.  Methods: Here, we characterised and compared the transcriptome profiles of primary human normal oral keratinocytes (HNOK) in response to exosomes isolated from either primary HNOK or head and neck squamous cell carcinoma (HNSCC) cell lines.  Results: In recipient HNOK cells, we found that regardless of normal or cancer derived, exosomes altered mol. programs involved in matrix modulation (MMP9), cytoskeletal remodelling (TUBB6, FEZ1, CCT6A), viral/dsRNAinduced interferon (OAS1, IFI6), anti-inflammatory (TSC22D3), deubiquitin (OTUD1), lipid metab. and membrane trafficking (BBOX1, LRP11, RAB6A).  Interestingly, cancer exosomes, but not normal exosomes, modulated expression of matrix remodelling (EFEMP1, DDK3, SPARC), cell cycle (EEF2K), membrane remodelling (LAMP2, SRPX), differentiation (SPRR2E), apoptosis (CTSC), transcription/translation (KLF6, PUS7).  We have also identified CEP55 as a potential cancer exosomal marker.  Conclusions: In conclusion, both normal and cancer exosomes modulated unique gene expression pathways in normal recipient cells.  Cancer cells may exploit exosomes to confer transcriptome reprogramming that leads to cancer-assocd. pathologies such as angiogenesis, immune evasion/modulation, cell fate alteration and metastasis.  Mol. pathways and biomarkers identified in this study may be clin. exploitable for developing novel liq.-biopsy based diagnostics and immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeGoFIOFpPCbVg90H21EOLACvtfcHk0lii5RwTv6vpwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFektbk%253D&md5=02961fc9f1f549a1a2246c6ab0554935</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0846-5%26sid%3Dliteratum%253Aachs%26aulast%3DQadir%26aufirst%3DF.%26aulast%3DAziz%26aufirst%3DM.%2BA.%26aulast%3DSari%26aufirst%3DC.%2BP.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRaithatha%26aufirst%3DD.%26aulast%3DDa%2BSilva%26aufirst%3DL.%2BG.%2BL.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DPoorkasreiy%26aufirst%3DS.%2BP.%26aulast%3DHutchison%26aufirst%3DI.%2BL.%26aulast%3DWaseem%26aufirst%3DA.%26aulast%3DTeh%26aufirst%3DM.-T.%2BT.%26atitle%3DTranscriptome%2520Reprogramming%2520by%2520Cancer%2520Exosomes%253A%2520Identification%2520of%2520Novel%2520Molecular%2520Targets%2520in%2520Matrix%2520and%2520Immune%2520Modulation%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D97%26doi%3D10.1186%2Fs12943-018-0846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenchine, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassar, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">EEF2K Enhances Expression of PD-L1 by Promoting the Translation of Its MRNA</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>477</i></span>,  <span class="NLM_fpage">4367</span>– <span class="NLM_lpage">4381</span>, <span class="refDoi"> DOI: 10.1042/BCJ20200697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1042%2FBCJ20200697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=33094805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1amtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2020&pages=4367-4381&author=Y.+Wuauthor=J.+Xieauthor=X.+Jinauthor=R.+V.+Lenchineauthor=X.+Wangauthor=D.+M.+Fangauthor=Z.+D.+Nassarauthor=L.+M.+Butlerauthor=J.+Liauthor=C.+G.+Proud&title=EEF2K+Enhances+Expression+of+PD-L1+by+Promoting+the+Translation+of+Its+MRNA&doi=10.1042%2FBCJ20200697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor-2 kinase enhances expression of PD-L1 by promoting the translation of its mRNA</span></div><div class="casAuthors">Wu, Yu; Xie, Jianling; Jin, Xin; Lenchine, Roman V.; Wang, Xuemin; Fang, Danielle M.; Nassar, Zeyad D.; Butler, Lisa M.; Li, Jing; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">477</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4367-4381</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Emerging advances in cancer therapy have transformed the landscape towards cancer immunotherapy regimens.  Recent discoveries have resulted in the development of clin. immune checkpoint inhibitors that are 'game-changers' for cancer immunotherapy.  Here we show that eEF2K, an atypical protein kinase that neg. modulates the elongation stage of protein synthesis, promotes the synthesis of PD-L1, an immune checkpoint protein which helps cancer cells to escape from immunosurveillance.  Ablation of eEF2K in prostate and lung cancer cells markedly reduced the expression levels of the PD-L1 protein.  We show that eEF2K promotes the assocn. of PD-L1 mRNAs with translationally active polyribosomes and that translation of the PD-L1 mRNA is regulated by a uORF (upstream open reading-frame) within its 5 ' -UTR (5 '-untranslated region) which starts with a non-canonical CUG as the initiation codon.  This inhibitory effect is attenuated by eEF2K thereby allowing higher levels of translation of the PD-L1 coding region and enhanced expression of the PD-L1 protein.  Moreover, eEF2K-depleted cancer cells are more vulnerable to immune attack by natural killer cells.  Therefore, control of translation elongation can modulate the translation of this specific mRNA, one which contains an uORF that starts with CUG, and perhaps others that contain a similar feature.  Taken together, our data reveal that eEF2K regulates PD-L1 expression at the level of the translation of its mRNA by virtue of a uORF in its 5 '-region.  This, and other roles of eEF2K in cancer cell biol. (e.g. in cell survival and migration), may be exploited for the design of future therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZDBV_deQprVg90H21EOLACvtfcHk0lgJD3In-62WXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1amtLbF&md5=993d1f55781c94e0dbabd3e0ba7f1609</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1042%2FBCJ20200697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBCJ20200697%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DLenchine%26aufirst%3DR.%2BV.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DD.%2BM.%26aulast%3DNassar%26aufirst%3DZ.%2BD.%26aulast%3DButler%26aufirst%3DL.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DEEF2K%2520Enhances%2520Expression%2520of%2520PD-L1%2520by%2520Promoting%2520the%2520Translation%2520of%2520Its%2520MRNA%26jtitle%3DBiochem.%2520J.%26date%3D2020%26volume%3D477%26spage%3D4367%26epage%3D4381%26doi%3D10.1042%2FBCJ20200697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, K. W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. H. K.</span></span> <span> </span><span class="NLM_article-title">Silencing of EEF2K (Eukaryotic Elongation Factor-2 Kinase) Reveals AMPK-ULK1-Dependent Autophagy in Colon Cancer Cells</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.4161/auto.29164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.4161%2Fauto.29164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=24955726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFGltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1495-1508&author=C.+M.+Xieauthor=X.+Y.+Liuauthor=K.+W.+Y.+Shamauthor=J.+M.+Y.+Laiauthor=C.+H.+K.+Cheng&title=Silencing+of+EEF2K+%28Eukaryotic+Elongation+Factor-2+Kinase%29+Reveals+AMPK-ULK1-Dependent+Autophagy+in+Colon+Cancer+Cells&doi=10.4161%2Fauto.29164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells</span></div><div class="casAuthors">Xie, Chuan-Ming; Liu, Xiao-Yu; Sham, Kathy W. Y.; Lai, Josie M. Y.; Cheng, Christopher H. K.</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1495-1508</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">EEF2K (eukaryotic elongation factor-2 kinase), also known as Ca2+/calmodulin-dependent protein kinase III, functions in downregulating peptide chain elongation through inactivation of EEF2 (eukaryotic translation elongation factor 2).  Currently, there is a limited amt. of information on the promotion of autophagic survival by EEF2K in breast and glioblastoma cell lines.  However, the precise role of EEF2K in carcinogenesis as well as the underlying mechanism involved is still poorly understood.  In this study, contrary to the reported autophagy-promoting activity of EEF2K in certain cancer cells, EEF2K is shown to neg. regulate autophagy in human colon cancer cells as indicated by the increase of LC3-II levels, the accumulation of LC3 dots per cell, and the promotion of autophagic flux in EEF2K knockdown cells.  EEF2K neg. regulates cell viability, clonogenicity, cell proliferation, and cell size in colon cancer cells.  Autophagy induced by EEF2K silencing promotes cell survival and does not potentiate the anticancer efficacy of the AKT inhibitor MK-2206.  In addn., autophagy induced by silencing of EEF2K is attributed to induction of protein synthesis and activation of the AMPK-ULK1 pathway, independent of the suppression of MTOR activity and ROS generation.  Knockdown of AMPK or ULK1 significantly abrogates EEF2K silencing-induced increase of LC3-II levels, accumulation of LC3 dots per cell as well as cell proliferation in colon cancer cells.  In conclusion, silencing of EEF2K promotes autophagic survival via activation of the AMPK-ULK1 pathway in colon cancer cells.  This finding suggests that upregulation of EEF2K activity may constitute a novel approach for the treatment of human colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonLybXr6EsQ7Vg90H21EOLACvtfcHk0lgJD3In-62WXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFGltLY%253D&md5=5d57a50e2f06d807e9bcae2be80cdecc</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.4161%2Fauto.29164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.29164%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DSham%26aufirst%3DK.%2BW.%2BY.%26aulast%3DLai%26aufirst%3DJ.%2BM.%2BY.%26aulast%3DCheng%26aufirst%3DC.%2BH.%2BK.%26atitle%3DSilencing%2520of%2520EEF2K%2520%2528Eukaryotic%2520Elongation%2520Factor-2%2520Kinase%2529%2520Reveals%2520AMPK-ULK1-Dependent%2520Autophagy%2520in%2520Colon%2520Cancer%2520Cells%26jtitle%3DAutophagy%26date%3D2014%26volume%3D10%26spage%3D1495%26epage%3D1508%26doi%3D10.4161%2Fauto.29164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Gassart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinon, F.</span></span> <span> </span><span class="NLM_article-title">Translating the Anticancer Properties of EEF2K</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1080/15384101.2016.1254974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.1080%2F15384101.2016.1254974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=27830984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOhurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=299-300&author=A.+De%0AGassartauthor=F.+Martinon&title=Translating+the+Anticancer+Properties+of+EEF2K&doi=10.1080%2F15384101.2016.1254974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Translating the anticancer properties of eEF2K</span></div><div class="casAuthors">De Gassart, Aude; Martinon, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-300</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyMnrS4xFNLrVg90H21EOLACvtfcHk0ljPQ65bDz178Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOhurjF&md5=b10bbe7748e6ecb580166fbd8f34e20d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1254974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1254974%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BGassart%26aufirst%3DA.%26aulast%3DMartinon%26aufirst%3DF.%26atitle%3DTranslating%2520the%2520Anticancer%2520Properties%2520of%2520EEF2K%26jtitle%3DCell%2520Cycle%26date%3D2017%26volume%3D16%26spage%3D299%26epage%3D300%26doi%3D10.1080%2F15384101.2016.1254974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Gassart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demaria, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffalon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryazanov, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinon, F.</span></span> <span> </span><span class="NLM_article-title">Pharmacological EEF 2K Activation Promotes Cell Death and Inhibits Cancer Progression</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1484</span>, <span class="refDoi"> DOI: 10.15252/embr.201642194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=10.15252%2Fembr.201642194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=27572820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWmurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=1471-1484&author=A.+De%0AGassartauthor=O.+Demariaauthor=R.+Panesauthor=L.+Zaffalonauthor=A.+G.+Ryazanovauthor=M.+Gillietauthor=F.+Martinon&title=Pharmacological+EEF+2K+Activation+Promotes+Cell+Death+and+Inhibits+Cancer+Progression&doi=10.15252%2Fembr.201642194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological eEF2K activation promotes cell death and inhibits cancer progression</span></div><div class="casAuthors">De Gassart, Aude; Demaria, Olivier; Panes, Rebecca; Zaffalon, Lea; Ryazanov, Alexey G.; Gilliet, Michel; Martinon, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1471-1484</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Activation of the elongation factor 2 kinase (eEF2K) leads to the phosphorylation and inhibition of the elongation factor eEF2, reducing mRNA translation rates.  Emerging evidence indicates that the regulation of factors involved in protein synthesis may be crit. for controlling diverse biol. processes including cancer progression.  Here we show that inhibitors of the HIV aspartyl protease (HIV-PIs), nelfinavir in particular, trigger a robust activation of eEF2K leading to the phosphorylation of eEF2.  Beyond its anti-viral effects, nelfinavir has antitumoral activity and promotes cell death.  We show that nelfinavir-resistant cells specifically evade eEF2 inhibition.  Decreased cell viability induced by nelfinavir is impaired in cells lacking eEF2K.  Moreover, nelfinavir-mediated anti-tumoral activity is severely compromised in eEF2K-deficient engrafted tumors in vivo.  Our findings imply that exacerbated activation of eEF2K is detrimental for tumor survival and describe a mechanism explaining the anti-tumoral properties of HIV-PIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdE4_sM_Sl_rVg90H21EOLACvtfcHk0ljPQ65bDz178Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWmurjN&md5=48b7e8276ee905859484b73af23efac5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.15252%2Fembr.201642194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201642194%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BGassart%26aufirst%3DA.%26aulast%3DDemaria%26aufirst%3DO.%26aulast%3DPanes%26aufirst%3DR.%26aulast%3DZaffalon%26aufirst%3DL.%26aulast%3DRyazanov%26aufirst%3DA.%2BG.%26aulast%3DGilliet%26aufirst%3DM.%26aulast%3DMartinon%26aufirst%3DF.%26atitle%3DPharmacological%2520EEF%25202K%2520Activation%2520Promotes%2520Cell%2520Death%2520and%2520Inhibits%2520Cancer%2520Progression%26jtitle%3DEMBO%2520Rep.%26date%3D2016%26volume%3D17%26spage%3D1471%26epage%3D1484%26doi%3D10.15252%2Fembr.201642194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02218&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02218%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-13%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02218" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0b8eddb211985","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
